0001437749-20-014538.txt : 20200702 0001437749-20-014538.hdr.sgml : 20200702 20200702163259 ACCESSION NUMBER: 0001437749-20-014538 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 92 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sun BioPharma, Inc. CENTRAL INDEX KEY: 0001029125 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870543922 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-239661 FILM NUMBER: 201009901 BUSINESS ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 BUSINESS PHONE: 9524791196 MAIL ADDRESS: STREET 1: 712 VISTA BLVD #305 CITY: WACONIA STATE: MN ZIP: 55387 FORMER COMPANY: FORMER CONFORMED NAME: Cimarron Medical, Inc. DATE OF NAME CHANGE: 20150602 FORMER COMPANY: FORMER CONFORMED NAME: CIMARRON SOFTWARE INC DATE OF NAME CHANGE: 19961217 S-1 1 snbp20200630_s1.htm FORM S-1 snbp20200630_s1.htm

 

As filed with the Securities and Exchange Commission on July 2, 2020

 

Registration No.       

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

SUN BIOPHARMA, INC.

(Exact name of registrant as specified in its charter) 

 

Delaware
(State or other jurisdiction of
incorporation or organization)
 

 

2834
(Primary Standard Industrial
Classification Code Number)
 

 

87-0543922
(I.R.S. Employer
Identification No.)

 

712 Vista Blvd, Suite 305
Waconia, Minnesota 55387
(952) 479-1196

(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)

Susan Horvath
Chief Financial Officer
712 Vista Blvd, Suite 305
Waconia, Minnesota 55387
(952) 479-1196

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to: 

 

W. Morgan Burns
Joshua L. C
olburn
Faegre Drinker Biddle & Reath LLP

90 South Seventh Street
2200 Wells Fargo Center
Minneapolis, Minnesota 55402-3901
Telephone: (612) 766-7000

 

Robert F. Charron
Michael F. Nertney

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas
New York, New York 10105

Telephone: (212) 370-1300

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, check the following box. ☑

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐

Smaller reporting company ☑

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered

 

Proposed Maximum

Aggregate Offering

Price(1)

   

Amount of

Registration Fee

 

Common stock, $0.001 par value per share(2)

  $ 11,500,000     $ 1,492.70  
Underwriter's warrants(3)   $ -     $ -  

Common stock, $0.001 par value per share, underlying underwriter warrants(2)(4)

  $ 632,500     $ 82.10  

TOTAL

  $ 12,132,500     $ 1,574.80  

 


(1)

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) of the Securities Act of 1933, as amended (the “Securities Act”). Includes offering price of shares that the underwriter has the option to purchase to cover over-allotments, if any.

(2)

Pursuant to Rule 416 under the Securities Act, the shares of common stock registered hereby also include an indeterminate number of additional shares of common stock as may from time to time become issuable by reason of stock split, stock dividends, recapitalizations, or other similar transactions.

(3)

Represents warrants granted to the underwriter to purchase shares of common stock in an amount up to 5.0% of the number of shares of common stock sold to the public in this offering. See “Underwriting” contained within this registration statement for information on underwriting arrangements related to this offering. No registration fee pursuant to Rule 457(g) under the Securities Act.

(4)

Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act based on an estimate of the proposed maximum aggregate offering price. The underwriter's warrants are exercisable at a per share exercise price equal to 110% of the public offering price of one share of common stock. As estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(g) of the Securities Act, the proposed maximum offering price of the underwriter's warrants is equal to 110% of $575,000 (5.0% of $11,500,000).

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell securities, and we are not soliciting offers to buy these securities, in any state where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS

SUBJECT TO COMPLETION

DATED JULY 2, 2020

 

         Shares of Common Stock

 


 

This is a firm commitment public offering of          shares of our common stock (assuming a public offering price of $      per share based on the last sale price of our common stock as reported by OTC Markets Group, Inc. on          , 2020). Our common stock is quoted on the OTCQB Venture Market operated by OTC Markets Group, Inc. (“OTCQB”) under the ticker symbol “SNBP.” On July 1, 2020, the last reported sale price of our common stock was $6.00 per share. The price of our common stock as quoted on the OTCQB may not be indicative of the actual offering price. The actual offering price will be determined between us and the underwriter at the time of pricing and may be at a discount to the current market price. We have applied to list the shares of our common stock on the Nasdaq Capital Market under the symbol “SNBP.” No assurance can be given that our application will be approved or that a trading market will develop. Our share price on the OTCQB may not be indicative of the market price on the Nasdaq Capital Market, if we become listed.

 

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading Risk Factors beginning on page  of this prospectus, and under similar headings in any amendments or supplements to this prospectus.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

   

Per Share

   

Total

 

Public offering price

  $       $    

Underwriting discounts and commissions(1)

  $       $    

Proceeds to us, before expenses

  $       $    

 


(1)

In addition, we have agreed to reimburse the underwriter for certain expenses. See “Underwriting”, beginning on page 81 for additional disclosure regarding underwriting discounts, commissions and estimated offering expenses.

 

We have granted a 45-day option to the underwriter to purchase up to           additional shares of common stock from us solely to cover over-allotments, if any.

 

The underwriter expects to deliver the shares on or about          , 2020.

 

Craig-Hallum Capital Group

 

The date of this prospectus is          , 2020

 

 

 

Table of Contents

Page

Prospectus Summary

1

The Offering

6

SUMMARY CONSOLIDATED FINANCIAL DATA

7

Risk Factors

8

CAUTIONARY Note Regarding Forward-Looking Statements

21

Use of Proceeds

22

Price Range of Common Stock

23

CAPITALIZATION

28

DILUTION

30

Dividend Policy

31

Management’s Discussion and Analysis of Financial Condition and Results of Operations

32

Business

42

Management

64

Executive Compensation

69

Security Ownership of Certain Beneficial Owners AND Management

72

DESCRIPTION OF Securities

73

SHARES ELIGIBLE FOR FUTURE SALE

75

UNDERWRITING

77

Legal Matters

85

Experts

85

Where You Can Find More Information

85

FINANCIAL STATEMENTS

F-1

 

You should rely only on the information contained in this prospectus. We have not, and the underwriter has not, authorized anyone to provide you with any information other than that contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not, and the underwriter is not, making an offer of these securities in any jurisdiction where the offer is not permitted.

 

For investors outside the United States: We have not and the underwriter has not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States must inform themselves about, and observe any restrictions relating to, the offering of securities and the distribution of this prospectus outside the United States.

 

This prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We believe that the data obtained from these industry publications and third-party research, surveys and studies are reliable. We are ultimately responsible for all disclosure included in this prospectus.

 

You should rely only on the information contained in this prospectus, as supplemented and amended. We have not authorized anyone to provide you with information that is different. This prospectus may only be used where it is legal to sell these securities. The information in this prospectus may only be accurate on the date of this prospectus.

 

We urge you to read carefully this prospectus, as supplemented and amended, before deciding whether to invest in any of the securities being offered.

 

i

 

Prospectus Summary

 

This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our financial statements and the related notes and the information set forth under the headings Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in each case included elsewhere in this prospectus. Unless otherwise stated or the context requires otherwise, references in this prospectus to Sun BioPharma, the Company, we, us, our and similar references refer to Sun BioPharma, Inc. and its wholly-owned subsidiary, Sun BioPharma Australia Pty Ltd. (SBA).

 

Business Overview

 

We are a clinical-stage biopharmaceutical company focused on developing SBP-101, a proprietary small molecule polyamine metabolic inhibitor delivered subcutaneously for the treatment of patients with pancreatic cancer and other solid tumor cancers. We have an exclusive license to the worldwide rights to this compound from the University of Florida Research Foundation (“UFRF”), and we obtained US Orphan Drug Status for SBP-101 in 2014. In the second quarter of 2020, the Food and Drug Administration (“FDA”) granted Fast Track designation to SBP-101. To date, we have invested approximately $25 million in developing SBP-101, which we are initially targeting as a first-line therapy for metastatic pancreatic ductal adenocarcinoma (“PDA”) in combination with gemcitabine and nab-paclitaxel (“Gem + Nab”), a chemotherapy standard of care. We recently reported positive interim Phase 1a data demonstrating SBP-101 (as first-line therapy in combination with Gem + Nab) was generally well tolerated by PDA patients and presented a 62% objective response rate, which is more than double contemporary response rates for Gem + Nab alone. In addition, 69% of patients experienced a reduction of greater than 75% in CA 19-9 serum levels, a biomarker negatively associated with long-term survival benefit in PDA. We believe SBP-101 represents a novel approach that is differentiated from current programs targeting pancreatic and other solid tumor cancers and, if approved, has the potential to significantly impact clinical outcomes of patients with cancer.

 

Pancreatic cancer is a major unmet medical need. Pancreatic cancer is the number three cause of US cancer deaths according to the National Cancer Institute’s SEER Program. Pancreatic cancer has a 5-year survival rate of just 10%, the lowest rate among major cancers. Current common treatment regimens for PDA, which accounts for approximately 95% of all cases of pancreatic cancer, offer median overall survival of between 8.5 months (Von Hoff 2013) and 11.1 months (Conroy 2011). Only three first-line treatment combinations have been approved by the FDA for pancreatic cancer in the last 25 years, and the two current standard treatment regimens, Gem + Nab and FOLFIRINOX (comprised of leucovorin, fluorouracil, irinotecan, and oxaliplatin), have a 23% objective response rate and 32% objective response rate, respectively, in Phase 3 studies, as compared to SBP-101’s 62% response rate reported in interim Phase 1a results.

 

Polyamines are organic compounds found in nearly all living species and are essential for the growth and function of normal cells. In many cancers, polyamine metabolism is highly upregulated causing hyper-proliferation of tumor cells. Past approaches to polyamine metabolic inhibition as cancer therapy focused on inhibiting synthetic enzymes involved in polyamine metabolism. These approaches produced unwanted toxicity effects or were ineffective because of compensatory mechanisms such as increased extracellular polyamine uptake by tumor cells. SBP-101 is a novel polyamine analogue which is structurally similar to spermine and designed to exploit the self-regulating nature of polyamines. A characteristic of pancreatic cancer is high extracellular uptake of polyamines, and SBP-101 is preferentially taken up by tumor cells, thereby downregulating polyamine synthesis and decreasing further uptake, which inhibits cell proliferation. Moreover, SBP-101 does not trigger a polyamine catabolic cascade and the creation of harmful reactive oxygen species. In addition to PDA, there are many other solid tumors where increased polyamine synthesis has been found. Across all potential indications for SBP-101, we are working to identify biomarkers within cancer patient populations that are associated with aberrant polyamine metabolism and developing proprietary diagnostic tools to better select patients who would benefit from our therapy.

 

1

 

Our Strategy

 

Our goal is to develop and commercialize SBP-101 for the treatment of pancreatic cancer and explore additional potential indications for SBP-101 in other solid tumor types. The key elements of our business strategy to achieve this goal include:

 

 

Leveraging the insights, experience and networks of our management team.

 

 

Advancing our product candidate, SBP-101, as rapidly as possible through clinical development for the treatment of patients with metastatic pancreatic cancer.

 

 

Identify biomarkers within cancer patient populations that are associated with aberrant polyamine metabolism to better select patients who would benefit from our therapy and facilitate the development of SBP-101 for the treatment of other cancer types.

 

 

Evaluate strategic opportunities to accelerate development timelines and maximize the value of our product candidate in collaboration with third parties.

 

Clinical Trials

 

In August 2015, the FDA accepted our Investigational New Drug (“IND”) application for our SBP-101 product candidate. We have completed an initial clinical trial of SBP-101 in patients with previously treated locally advanced or metastatic pancreatic cancer. This was a Phase 1, first-in-human, dose-escalation, safety study. From January 2016 through September 2017, we enrolled twenty-nine patients into six cohorts, or groups, in the dose-escalation phase of the Phase 1 trial. Twenty-four of the patients had received at least two prior chemotherapy regimens. No drug-related serious adverse events occurred during the first four cohorts. In cohort five, serious adverse events (klebsiella sepsis with metabolic acidosis in one patient, renal and hepatic toxicity in one patient, and mesenteric vein thrombosis with metabolic acidosis in one patient) were observed in three of the ten patients, two of whom exhibited progressive disease at the end of their first cycle of treatment and were determined by the Data Safety Monitoring Board (“DSMB”) to have dose-limiting toxicities (“DLTs”). Consistent with the study protocol, the DSMB recommended continuation of the study by expansion of cohort 4, one level below that at which DLTs were observed. Four patients were enrolled in this expansion cohort. One patient developed focal pancreatitis at the site of the primary tumor after 2.3 months, and SBP-101 was considered well tolerated below dose level five. The most common drug related adverse events were nausea, vomiting, diarrhea, injection site pain and abdominal pain, which were mostly mild, grades 1 or 2, and are symptoms common in patients with pancreatic cancer. No drug-related bone marrow toxicity or peripheral neuropathy was observed at any dose level.

 

In addition to being evaluated for safety, 23 of the 29 patients were evaluable for preliminary signals of efficacy prior to or at the eight-week conclusion of their first cycle of treatment using the Response Evaluation Criteria in Solid Tumors version 1.1 (“RECIST”), the current standard for evaluating change in the size of tumors. Eight of the 23 patients (35%) had Stable Disease (“SD”) and 15 of 24 (65%) had Progressive Disease (“PD”). It should be noted that of the 15 patients with PD, six came from cohorts one and two and are considered to have received less than potentially therapeutic doses of SBP-101. We also noted that 28 of the 29 patients had follow-up blood tests measuring the Tumor Marker CA 19-9 associated with pancreatic ductal adenocarcinoma. Eleven of these patients (39%) had reductions in the CA 19-9 levels, as measured at least once after the baseline assessment. Seven of the remaining 17 patients who showed no reduction in CA 19-9 came from cohorts one and two.

 

By cohort, SD occurred in two patients in cohort 3, two patients in cohort 4 and four patients in cohort 5. The best response outcomes and best median survival were observed in the group of patients who received total cumulative doses of approximately 6 mg/kg (cohort 3). Two of four patients (50%) showed SD at week eight. Median survival in this group was 5.9 months, with two patients surviving 8 and 10 months, respectively. By total cumulative dose received, five of 12 patients (42%) who received total cumulative doses between 2.5 mg/kg and 8.0 mg/kg had reductions in the CA19-9 levels, as measured at least once after the baseline assessment. Nine of these patients (67%) exceeded 3 months of overall survival (“OS”), three patients (25%) exceeded 9 months of OS and two patients (17%) exceeded 1 year of OS and were still alive at the end of the study. With the approval of the DSMB, we cancelled the Phase 1b portion of the first-in-human monotherapy study in order to evaluate SBP-101 as a first line, combination chemotherapy in patients with metastatic pancreatic cancer.

 

2

 

We began enrolling patients in our current first-line clinical trial in June of 2018. This second clinical trial is a Phase 1a/1b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel. We are currently conducting the trial at six study sites (four in Australia and two in the United States). In the Phase 1a portion of this trial, we enrolled three cohorts of four to nine patients with increased dosage levels of SBP-101 administered in the second and third cohorts. We completed enrollment in the first three cohorts of Phase 1a in the fourth quarter of 2019, and, based on preliminary safety findings, a 4th cohort began enrollment in January 2020. We completed enrollment in this 4th cohort in February 2020. Demonstration of adequate safety in Phase 1a has enabled Phase 1b exploration of efficacy, in which we plan to enroll a maximum 36 patients using the recommended dosage regimen determined in Phase 1a. We began enrolling in this expansion phase in February of 2020. Additional funding will be required to complete the Phase 1b clinical trial and to plan a randomized phase 2 study. As of December 31, 2019, preliminary efficacy results from evaluable patients in cohorts 2 and 3 (N=13) showed manageable toxicity, an objective response rate of 62% and a disease control rate of 85%, with several patients still ongoing. Approximately 69% of patients (N=16; includes 3 patients who did not receive follow-up scans) had a maximum CA 19-9 decrease greater than 75%. Interim results from the Phase 1b expansion are expected to become available late in the second half of 2020.

 

Recent Developments

 

As we continue to actively advance our clinical programs and discovery and research programs, we are in close contact with the third parties we engage with, who are primarily located in the United States, and are assessing the impact of the COVID-19 pandemic on each of our programs, expected timelines and costs on an ongoing basis. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA’s updated industry guidance for conducting clinical trials issued on March 18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future. In addition, our employees are all telecommuting. The effects of the COVID-19 pandemic could severely impact our business and clinical trials. See “Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic.” for more information regarding the potential impact of the COVID-19 pandemic on our business and operations. We will continue to evaluate the impact of the COVID-19 pandemic on our business and expect to reevaluate the timing of our anticipated preclinical and clinical milestones as we learn more and the impact of the COVID-19 pandemic on our industry becomes more clear.

 

Through the date of this prospectus, we have:

 

 

organized the Company;

 

 

evaluated and secured intellectual property for our core technology;

 

 

completed required pre-clinical steps in the development plan for SBP-101 for pancreatic cancer;

 

 

secured an orphan drug designation from the FDA;

 

 

submitted an investigational new drug (“IND”) application to the FDA in May 2015;

 

 

received an acceptance of an IND application from the FDA in August 2015;

 

 

received acceptance of a Clinical Trial Notification by the Australian Therapeutic Goods Administration in September 2015;

 

 

completed a Phase 1a monotherapy safety study of SBP-101in the treatment of patients with metastatic pancreatic ductal adenocarcinoma;

 

 

completed synthetic process improvement measures expected to be scalable for commercial use and secured intellectual property on this process;

 

 

commenced a second Phase 1a /1b clinical study of SBP-101, a front-line study with SBP-101 given in combination with a current standard of care in patients with pancreatic ductal adenocarcinoma who are previously untreated for metastatic disease; 24 subjects have been enrolled in the Phase 1a portion of the study and we transitioned to enrollment in the Phase 1b portion of the study in February 2020; and

 

 

received Fast Track Designation from the FDA for SBP-101 being developed for first-line treatment of patients with metastatic PDA when administered in combination with gemcitabine and nab-paclitaxel in June 2020.

 

3

 

Risks Associated with Our Business

 

Our business is subject to many significant risks, as more fully described in the section titled “Risk Factors” immediately following this prospectus summary. You should read and carefully consider these risks, together with the risks set forth under the section titled “Risk Factors” and all of the other information in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before deciding whether to invest in our securities. If any of the risks discussed in this prospectus actually occur, our business, financial condition or operating results could be materially and adversely affected. In particular, our risks include, but are not limited to, the following:

 

 

We are a company with limited history for you to evaluate our business which makes it difficult for you to evaluate our historical business and to assess our future viability.

 

 

As a result of our current lack of financial liquidity, we and our auditors have expressed substantial doubt regarding our ability to continue as a “going concern.”

 

 

Our lack of diversification increases the risk of an investment in our Company and our financial condition and results of operations may deteriorate if we fail to diversify.

 

 

We may be unable to obtain the additional capital that is required to execute our business plan, which could restrict our ability to grow.

 

 

Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic.

 

 

Raising additional capital may cause dilution to our stockholders or restrict our operations.

 

 

The market for our product candidate is highly competitive and is subject to rapid scientific change, which could have a material adverse effect on our business, results of operations and financial condition.

 

 

Our product candidate is based on new formulation of an existing technology which has never been approved for the treatment of any cancer and, consequently, is inherently risky. Concerns about the safety and efficacy of our product candidate could limit our future success.

 

 

Clinical trials required for our product candidate are expensive and time-consuming, and their outcome is highly uncertain. If any of our drug trials are delayed or yield unfavorable results, we will have to delay application for or may be unable to obtain regulatory approval for our product candidate.

 

 

Due to our reliance on third-parties to conduct our clinical trials, we are unable to directly control the timing, conduct, expense and quality of our clinical trials, which could adversely affect our clinical data and results and related regulatory approvals.

 

 

Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.

 

 

Our directors, executive officers and significant stockholders have substantial control over us and could limit stockholders’ ability to influence the outcome of key transactions, including changes of control.

 

Implications of Being a Smaller Reporting Company

 

We are a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and have elected to take advantage of certain of the scaled disclosure available to smaller reporting companies.

 

Corporate History

 

Sun BioPharma, Inc. was originally incorporated under the laws of the State of Delaware in September 2011. In 2015, we became a public company by completing a reverse merger transaction (the “Merger”) with a wholly owned subsidiary of Cimarron Medical, Inc., a public company organized under the laws of the State of Utah. Upon completion of the Merger and other separate but contemporaneous transactions by certain of our stockholders, our stockholders collectively owned approximately 99.0% of the post-Merger public company, which was renamed “Sun BioPharma, Inc.” In 2016, we reincorporated under the laws of the State of Delaware via a merger with our operating subsidiary, resulting in our current corporate form.

 

4

 

Corporate Information

 

Our corporate mailing address is 712 Vista Blvd, #305, Waconia, MN 55387. Our telephone number is (952) 479-1196, and our website is www.sunbiopharma.com. The information on our website is not part of this prospectus. We have included our website address as a factual reference and do not intend it to be an active link to our website. The information contained in or connected to our website is not incorporated by reference into, and should not be considered part of, this prospectus.

 

Sun BioPharma™, the Sun BioPharma logo, and other trademarks or service marks of Sun BioPharma, Inc. appearing in this prospectus are our property. Trade names, trademarks, and service marks of other companies appearing in this prospectus are the property of the respective holders.

 

5

 

The Offering

 

Common stock offered by us

          shares of our common stock (or          shares if the underwriter exercises its over-allotment option in full)

   

Over-allotment option

We have granted the underwriter an option for a period of up to 45 days to purchase up to           additional shares of common stock to cover over-allotments, if any.

   

Common stock outstanding before this offering

7,068,308 shares

   

Common stock to be outstanding immediately after this offering

 

          shares (or          shares if the underwriter exercises its over-allotment option in full)

   

Use of proceeds

We estimate that the net proceeds from this offering will be approximately $      million, or approximately $      million if the underwriter exercises its over-allotment option in full, at an assumed public offering price of $      per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering for the continued clinical development of our initial product candidate SBP-101, the repayment of approximately $0.8 million of outstanding indebtedness, and for working capital and other general corporate purposes. See “Use of Proceeds” on page .

   

Underwriter's warrants

The registration statement of which this prospectus is a part also registers for sale common stock issuable upon the exercise of warrants to purchase up to           shares of our common stock to the underwriter as a portion of the underwriting compensation payable to the underwriter in connection with this offering. The warrants will be exercisable at any time, and from time to time, in whole or in part, on the date of issuance and expiring on the five-year anniversary of the effective date of this offering at an exercise price equal to 110% of the public offering price of one share of common stock in this offering. Please see “Underwriting -  Underwriter's Warrants” for a description of these warrants.

   

Risk Factors

You should read the “Risk Factors” section of this prospectus beginning on page  for a discussion of factors to consider carefully before deciding to invest in our securities.

   

OTCQB symbol

“SNBP”

   

Proposed Nasdaq Capital Market trading symbol

We have applied to list our common stock on the Nasdaq Capital Market under the symbol “SNBP.”

 

The number of shares of our common stock outstanding before and after this offering is based on 7,068,308 shares of our common stock outstanding as of June 30, 2020, and excludes:

 

 

1,958,411 shares of common stock issuable upon the exercise of outstanding stock options as of the date of this prospectus at a weighted average exercise price of $6.36 per share;

 

 

1,105,959 additional shares of common stock reserved and available for future issuances under our equity plans;

 

 

3,934,099 shares of common stock issuable upon exercise of stock purchase warrants at a weighted average exercise price of $5.79 per share; and

 

 

shares of common stock issuable upon exercise of the warrants issued to the underwriter at the closing of this offering.

 

Unless otherwise indicated, all information in this prospectus assumes no exercise of the outstanding options or warrants or the conversion of shares issuable pursuant to convertible promissory notes.

 

Except as otherwise stated herein, the information in this prospectus assumes no exercise by the underwriter of its option to purchase up to          additional shares of common stock to cover over-allotments, if any.

 

6

 

SUMMARY CONSOLIDATED FINANCIAL DATA

 

The following selected historical financial information is derived from our consolidated financial statements appearing elsewhere in this prospectus and should be read in conjunction with our consolidated financial statements, including the accompanying notes thereto, beginning on page F-1. Our historical results for any period are not necessarily indicative of results to be expected in any other period, including the full fiscal year ending December 31, 2020. You should read this information together with the sections titled “Capitalization”, “Dilution” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included elsewhere in this prospectus.

 

Summary of Consolidated Statements of Operations
(in thousands, except share and per share amounts)

 

   

Three months ended March 31,

   

Year ended December 31,

 
   

2020

   

2019

   

2019

   

2018

 
   

(unaudited)

   

(unaudited)

                 

Operating Expenses:

                               

General and administrative

  $ 468     $ 303     $ 1,973     $ 2,108  

Research and development

    598       350       2,349       1,783  

Total operating expenses

    1,066       653       4,322       3,891  

Operating loss

    (1,066 )     (653 )     (4,322 )     (3,891 )

Other expense

    (824 )     (999 )     (2,293 )     (2,268 )

Net loss

  $ (1,798 )   $ (1,581 )   $ (6,200 )   $ (5,905 )
                                 

Net loss per share - basic and diluted

  $ (0.27 )   $ (0.31 )   $ (1.09 )   $ (1.27 )

Weighted average shares outstanding - basic and diluted

    7,068,308       5,072,397       5,700,314       4,662,080  

 

Summary Consolidated Balance Sheet Information
(in thousands)

 

   

March 31,

   

December 31,

 
   

2020

   

2019

   

2019

   

2018

 
   

(unaudited)

   

(unaudited)

                 

Cash

  $ 1,296     $ 1,379     $ 2,449     $ 1,405  

Total assets

  $ 2,136     $ 1,911     $ 3,144     $ 1,898  

Total current liabilities

  $ 1,412     $ 2,499     $ 1,759     $ 1,630  

Long-term debt, net

  $     $     $     $  

Stockholders’ equity (deficit)

  $ 724     $ (588 )   $ 1,385     $ 268  

 

7

 

Risk Factors

 

Any investment in our securities involves a high degree of risk. Investors should carefully consider the risks described below and all of the information contained in this prospectus before deciding whether to purchase our securities. Our business, financial condition or results of operations could be materially adversely affected by these risks if any of them actually occur. This prospectus also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks we face as described below and elsewhere in this prospectus.

 

Risks Related to Our Business

 

We are a company with limited operating history for you to evaluate our business.

 

We have a limited operating history for you to consider in evaluating our business and prospects. As such, it is difficult for potential investors to evaluate our business.

 

We have experienced negative cash flows for our operating activities since inception, primarily due to the investments required to develop and commercialize our primary drug candidate, SBP-101. Our financing cash flows historically have been positive due to proceeds from the sale of equity securities and promissory notes issuances. Our net cash used in operating activities was $1.1 million for the three months ended March 31, 2020 and $2.7 million for the year ended December 31, 2019, and we had working capital of $0.7 million and $1.3 million as of the same dates respectively.

 

Our operations are subject to all the risks, difficulties, complications and delays frequently encountered in connection with the formation of any new business, as well as those risks that are specific to the pharmaceutical and biotechnology industries in which we compete. Investors should evaluate us considering the delays, expenses, problems and uncertainties frequently encountered by companies developing markets for new products, services and technologies. We may never overcome these obstacles.

 

As a result of our current lack of financial liquidity, we and our auditors have expressed substantial doubt regarding our ability to continue as a “going concern.”

 

As a result of our current lack of financial liquidity, our auditors’ report for our 2019 financial statements, which is included as part of this report, contains a statement concerning our ability to continue as a “going concern.” Our lack of sufficient liquidity could make it more difficult for us to secure additional financing or enter into strategic relationships on terms acceptable to us, if at all, and may materially and adversely affect the terms of any financing that we may obtain and our public stock price generally.

 

Our continuation as a “going concern” is dependent upon, among other things, achieving positive cash flow from operations and, if necessary, augmenting such cash flow using external resources to satisfy our cash needs. Our plans to achieve positive cash flow primarily include engaging in offerings of securities. Additional potential sources of funds include negotiating up-front and milestone payments on our current and potential future product candidates or royalties from sales of our products that secure regulatory approval and any milestone payments associated with such approved products. These cash sources could, potentially, be supplemented by financing or other strategic agreements. However, we may be unable to achieve these goals or obtain required funding on commercially reasonable terms, or at all, and therefore may be unable to continue as a going concern.

 

Our lack of diversification increases the risk of an investment in our Company and our financial condition and results of operations may deteriorate if we fail to diversify.

 

Our Board of Directors has centered our attention on our drug development activities, which are currently focused on our initial product candidate SBP-101, the polyamine analogue compound we licensed from the UFRF. Our ability to diversify our investments will depend on our access to additional capital and financing sources and the availability and identification of suitable opportunities.

 

8

 

Larger companies have the ability to manage their risk by diversification. However, we lack and expect to continue to lack diversification, in terms of both the nature and geographic scope of our business. As a result, we will likely be impacted more acutely by factors affecting pharmaceutical and biotechnology industries in which we compete than we would if our business were more diversified, enhancing our risk profile. If we cannot diversify our operations, our financial condition and results of operations could deteriorate.

 

We may be unable to obtain the additional capital that is required to execute our business plan, which could restrict our ability to grow.

 

Our current capital and our other existing resources will be sufficient only to provide a limited amount of working capital and will not be sufficient to fund our expected continuing opportunities. We will require additional capital to continue to operate our business.

 

Future acquisitions, research and development and capital expenditures, as well as our administrative requirements, such as clinical trial costs, salaries, insurance expenses and general overhead expenses, as well as legal compliance costs and accounting expenses, will require a substantial amount of additional capital and cash flow. There is no guarantee that we will be able to raise additional capital required to fund our ongoing business on commercially reasonable terms or at all.

 

We intend to pursue sources of additional capital through various financing transactions or arrangements, including collaboration arrangements, debt financing, equity financing or other means. We may not be successful in locating suitable financing transactions on commercially reasonable terms, in the time period required or at all, and we may not obtain the capital we require by other means. If we do not succeed in raising additional capital, our resources will not be sufficient to fund our operations going forward.

 

Any additional capital raised through the sale of equity may dilute the ownership percentage of our stockholders. This could also result in a decrease in the fair market value of our equity securities because our assets would be owned by a larger pool of outstanding equity. The terms of securities we issue in future capital transactions may be more favorable to our new investors, and may include preferences, superior voting rights and the issuance of warrants or other derivative securities which may have a further dilutive effect.

 

Our ability to obtain needed financing may be impaired by such factors as the capital markets, both generally and in the pharmaceutical and other drug development industries in particular, our status as a new enterprise without a significant demonstrated operating history, the limited diversity of our activities and/or the loss of key personnel. If the amount of capital we are able to raise from financing activities is not sufficient to satisfy our capital needs, even to the extent that we reduce our operations, we may be required to cease our operations.

 

We may incur substantial costs in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees, printing and distribution expenses and other costs, which may adversely impact our financial condition.

 

Our business is subject to risks arising from epidemic diseases, such as the COVID-19 pandemic.

 

The recent outbreak of COVID-19, which has been declared by the World Health Organization to be a pandemic, has spread across the globe and is impacting worldwide economic activity. A pandemic, including COVID-19, or other public health epidemic poses the risk that we or our employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to the spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. While it is not possible at this time to estimate the impact that the COVID-19 pandemic could have on our business, the continued spread of COVID-19 and the measures taken by the governments of countries affected could disrupt the supply chain and the manufacture or shipment of both drug substance and finished drug product for our product candidate for preclinical testing and clinical trials and adversely impact our business, financial condition or results of operations. We often attend and present clinical updates at various medical and investor conferences throughout the year. The COVID-19 pandemic has caused, and is likely to continue to cause, cancellations or reduced attendance of these conferences and we may need to seek alternate methods to present clinical updates and to engage with the medical and investment communities. The spread of COVID-19 may also slow potential enrollment of clinical trials and reduce the number of eligible patients for our clinical trials. The COVID-19 pandemic, including related mitigation measures, may also have an adverse impact on global economic conditions which could have an adverse effect on our business and financial condition and our potential to conduct financings on terms acceptable to us, if at all. The extent to which the COVID-19 pandemic impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact.

 

9

 

We may not be able to effectively manage our growth, which may harm our profitability.

 

Our strategy envisions expanding our business. If we fail to effectively manage our growth, our financial results could be adversely affected. Growth may place a strain on our management systems and resources. We must continue to refine and expand our business development capabilities, our systems and processes and our access to financing sources. As we grow, we must continue to hire, train, supervise and manage new employees. We cannot assure you that we will be able to:

 

 

expand our systems effectively or efficiently or in a timely manner;

 

 

allocate our human resources optimally;

 

 

identify and hire qualified employees or retain valued employees; or

 

 

incorporate effectively the components of any business that we may acquire in our effort to achieve growth.

 

If we are unable to manage our growth, our operations and our financial results could be adversely affected by inefficiency, which could diminish our profitability.

 

Our business may suffer if we do not attract and retain talented personnel.

 

Our success will depend in large measure on the abilities, expertise, judgment, discretion, integrity and good faith of our management and other personnel in conducting our business. We have a small management team, and the loss of a key individual or inability to attract suitably qualified staff could materially adversely impact our business. 

 

In January of 2020 Dr. Michael Cullen, our Executive Chairman, President and CEO, announced his intention to resign as CEO of the Company. He intends to continue as the Executive Chairman and is expected to remain an employee of the company focused on drug development. The Board is conducting a search for a new CEO and Dr. Cullen intends to continue to serve as CEO to facilitate a successful transition.

 

Our success depends on the ability of our management, employees, consultants and joint venture partners, if any, to interpret market data correctly and to interpret and respond to economic market and other conditions in order to locate and adopt appropriate investment opportunities, monitor such investments, and ultimately, if required, to successfully divest such investments. Further, no assurance can be given that our key personnel will continue their association or employment with us or that replacement personnel with comparable skills can be found. We will seek to ensure that management and any key employees are appropriately compensated; however, their services cannot be guaranteed. If we are unable to attract and retain key personnel, our business may be adversely affected.

 

The market for our product candidate is highly competitive and is subject to rapid scientific change, which could have a material adverse effect on our business, results of operations and financial condition.

 

The pharmaceutical and biotechnology industries in which we compete are highly competitive and characterized by rapid and significant technological change. We face intense competition from organizations such as pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies. Some of these organizations are pursuing products based on technologies similar to our technology. Other of these organizations have developed and are marketing products or are pursuing other technological approaches designed to produce products that are competitive with our product candidates in the therapeutic effect these competitive products have on the disease targeted by our product candidate. Our competitors may discover, develop or commercialize products or other novel technologies that are more effective, safer or less costly than any that we may develop. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our product candidate.

 

10

 

Many of our competitors are substantially larger than we are and have greater capital resources, research and development staffs and facilities than we have. In addition, many of our competitors are more experienced in drug discovery, development and commercialization, obtaining regulatory approvals and drug manufacturing and marketing.

 

We anticipate that the competition with our product candidate and technology will be based on a number of factors including product efficacy, safety, availability and price. The timing of market introduction of our planned future product candidates and competitive products will also affect competition among products. We expect the relative speed with which we can develop our product candidate, complete the required clinical trials, establish a strategic partner and supply appropriate quantities of the product candidate for late stage trials, if required, to be important competitive factors. Our competitive position will also depend upon our ability to attract and retain qualified personnel, to obtain patent protection in non-U.S. markets, which we currently do not have, or otherwise develop proprietary products or processes and to secure sufficient capital resources for the period between technological conception and commercial sales or out-license to a pharmaceutical partner. If we fail to develop and deploy our proposed product candidate in a successful and timely manner, we will in all likelihood not be competitive.

 

We face significant risks in our product candidate development efforts.

 

Our business depends on the successful development and commercialization of our product candidates. We are currently focused on developing our initial product candidate, SBP-101, for the treatment of PDA and are not permitted to market it in the United States until we receive approval of an NDA from the FDA, or in any foreign jurisdiction until we receive the requisite approvals from such jurisdiction. The process of developing new drugs and/or therapeutic products is inherently complex, unpredictable, time-consuming, expensive and uncertain. We must make long-term investments and commit significant resources before knowing whether our development programs will result in drugs that will receive regulatory approval and achieve market acceptance. A product candidate that appears to be promising at all stages of development may not reach the market for a number of reasons that may not be predictable based on results and data from the clinical program. A product candidate may be found ineffective or may cause harmful side effects during clinical trials, may take longer to progress through clinical trials than had been anticipated, may not be able to achieve the pre-defined clinical endpoints even though clinical benefit may have been achieved, may fail to receive necessary regulatory approvals, may prove impracticable to manufacture in commercial quantities at reasonable cost and with acceptable quality, or may fail to achieve market acceptance.

 

We cannot predict whether or when we will obtain regulatory approval to commercialize our initial product candidate and we cannot, therefore, predict the timing of any future revenues from this or other product candidates, if any. The FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. For example, the FDA:

 

 

could determine that the information provided by us was inadequate, contained clinical deficiencies or otherwise failed to demonstrate the safety and effectiveness of any of our product candidates for any indication;

 

 

may not find the data from clinical trials sufficient to support the submission of an NDA or to obtain marketing approval in the United States, including any findings that the clinical and other benefits of our product candidates outweigh their safety risks;

 

 

may disagree with our trial design or our interpretation of data from preclinical studies or clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our trials;

 

 

may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for the manufacturing of our product candidates;

 

 

may approve our product candidates for fewer or more limited indications than we request, or may grant approval contingent on the performance of costly post-approval clinical trials;

 

 

may change its approval policies or adopt new regulations; or

 

 

may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of our product candidates.

 

11

 

Any failure to obtain regulatory approval of our initial product candidate or future product candidates we develop, if any, would significantly limit our ability to generate revenues, and any failure to obtain such approval for all of the indications and labeling claims we deem desirable could reduce our potential revenues.

 

Our product candidate is based on new formulation of an existing technology which has never been approved for the treatment of any cancer and, consequently, is inherently risky. Concerns about the safety and efficacy of our product candidate could limit our future success.

 

We are subject to the risks of failure inherent in the development of product candidates based on new technologies. These risks include the possibility that any product candidates we create will not be effective, that our current product candidate will be unsafe, ineffective or otherwise fail to receive the necessary regulatory approvals or that our product candidate will be hard to manufacture on a large scale or will be uneconomical to market.

 

Many pharmaceutical products cause multiple potential complications and side effects, not all of which can be predicted with accuracy and many of which may vary from patient to patient. Long term follow-up data may reveal additional complications associated with our product candidate. The responses of potential physicians and others to information about complications could materially affect the market acceptance of our product candidate, which in turn would materially harm our business.

 

Clinical trials required for our product candidate are expensive and time-consuming, and their outcome is highly uncertain. If any of our drug trials are delayed or yield unfavorable results, we will have to delay application for or may be unable to obtain regulatory approval for our product candidate.

 

We must conduct extensive testing of our product candidate before we can obtain regulatory approval to market and sell it. We need to conduct both preclinical animal testing and human clinical trials. Conducting these trials is a lengthy, time-consuming and expensive process. These tests and trials may not achieve favorable results for many reasons, including, among others, failure of the product candidate to demonstrate safety or efficacy, the development of serious or life-threatening adverse events, or side effects, caused by or connected with exposure to the product candidate, difficulty in enrolling and maintaining subjects in the clinical trial, lack of sufficient supplies of the product candidate or comparator drug, and the failure of clinical investigators, trial monitors, contractors, consultants, or trial subjects to comply with the trial protocol. A clinical trial may fail because it did not include a sufficient number of patients to detect the endpoint being measured or reach statistical significance. A clinical trial may also fail because the dose(s) of the investigational drug included in the trial were either too low or too high to determine the optimal effect of the investigational drug in the disease setting. Many clinical trials are conducted under the oversight of Independent Data Monitoring Committees (“IDMCs”). These independent oversight bodies are made up of external experts who review the progress of ongoing clinical trials, including available safety and efficacy data, and make recommendations concerning a trial’s continuation, modification, or termination based on interim, unblinded data. Any of our ongoing clinical trials may be discontinued or amended in response to recommendations made by responsible IDMCs based on their review of such interim trial results.

 

We will need to reevaluate our product candidate if it does not test favorably and either conduct new trials, which are expensive and time consuming, or abandon our drug development program. Even if we obtain positive results from preclinical or clinical trials, we may not achieve the same success in future trials. Many companies in the biopharmaceutical industry have suffered significant setbacks in clinical trials, even after promising results have been obtained in earlier trials. The failure of clinical trials to demonstrate safety and effectiveness for the desired indication could harm the development of our product candidate and our business, financial condition and results of operations may be materially harmed.

 

12

 

The results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results, and our current product candidates may not have favorable results in later studies or trials.

 

Pre-clinical studies and Phase 1 and Phase 2 clinical trials are not primarily designed to test the efficacy of a product candidate in the general population, but rather to test initial safety, to study pharmacokinetics and pharmacodynamics, to study limited efficacy in a small number of study patients in a selected disease population, and to identify and attempt to understand the product candidate’s side effects at various doses and dosing schedules. Success in pre-clinical studies or completed clinical trials does not ensure that later studies or trials, including continuing pre-clinical studies and large-scale clinical trials, will be successful nor does it necessarily predict future results. Favorable results in early studies or trials may not be repeated in later studies or trials, and product candidates in later stage trials may fail to show acceptable safety and efficacy despite having progressed through earlier trials.

 

Due to our reliance on third-parties to conduct our clinical trials, we are unable to directly control the timing, conduct, expense and quality of our clinical trials, which could adversely affect our clinical data and results and related regulatory approvals.

 

We extensively outsource our clinical trial activities and expect to directly perform only a small portion of the preparatory stages for planned trials. We rely on independent third-party contract research organizations (“CROs”) to perform most of our clinical trials, including document preparation, site identification, screening and preparation, pre-study visits, training, program management and bio-analytical analysis. Many important aspects of the services performed for us by the CROs are out of our direct control. If there is any dispute or disruption in our relationship with our CROs, our clinical trials may be delayed. Moreover, in our regulatory submissions, we rely on the quality and validity of the clinical work performed by third-party CROs. If a CRO’s processes, methodologies or results are determined to be invalid or inadequate, our own clinical data and results and related regulatory approvals could be adversely affected or invalidated.

 

Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.

 

In order to manufacture and sell our product candidate, we must comply with extensive international and domestic regulations. In order to sell our product candidate in the United States, approval from the FDA is required. The FDA approval process is expensive and time-consuming. We cannot predict whether our product candidate will be approved by the FDA. Even if our product candidate is approved, we cannot predict the time frame for such approval. Foreign regulatory requirements differ from jurisdiction to jurisdiction and may, in some cases, be more stringent or difficult to obtain than FDA approval. As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. If we cannot demonstrate that our product candidate can be used safely and successfully in a broad enough segment of the indicated patient population for a satisfactory length of time, our product candidate would likely be denied approval by the FDA and the regulatory agencies of foreign governments.

 

We may be unable to formulate or manufacture our product candidate in a way that is suitable for commercial use.

 

Changes in product formulations and manufacturing processes may be required as our product candidate progresses in clinical development and is ultimately commercialized. If we are unable to develop suitable product formulations or manufacturing processes to support large scale clinical testing of our product candidate, we may be unable to supply necessary materials for our clinical trials, which would delay the development of our product candidate. Similarly, if we are unable to supply sufficient quantities of our product candidate or develop product formulations suitable for commercial use, we will not be able to successfully commercialize our product candidate.

 

We lack sales, marketing and distribution capabilities and currently expect to rely on third parties to market and distribute our product candidate, which may harm or delay our commercialization efforts.

 

We currently have no sales, marketing, or distribution capabilities and do not currently intend to develop such capabilities in the foreseeable future. If we are unable to partner with a larger pharmaceutical organization having the expertise and capacity to perform these functions, then we may be unable to sell any product that we develop. We may not be able to enter into any necessary arrangements, including marketing or distribution agreements, on acceptable terms, if at all. Should our strategic partners, if any, be unable to effectively sell our products, then our ability to generate revenues will be significantly harmed.

 

13

 

We may be required to defend lawsuits or pay damages for product liability claims.

 

Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and in the sale of products after regulatory approval. Product liability claims, regardless of their merits, could exceed policy limits, divert management’s attention and adversely affect our reputation and the demand for our product. In any such event, your investment in our securities could be materially and adversely affected.

 

Risks Related to the Regulation of our Business

 

Federal and state pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.

 

The Food and Drug Administration Modernization Act (the “FDMA”), established a public registry of open clinical trials involving drugs intended to treat serious or life-threatening diseases or conditions in order to promote public awareness of and access to these clinical trials. Under the FDMA, pharmaceutical manufacturers and other trial sponsors are required to post the general purpose of these trials, as well as the eligibility criteria, location and contact information of the trials. Failure to comply with any clinical trial posting requirements could expose us to negative publicity, fines and other penalties, all of which could materially harm our business.

 

In recent years, several states, including California, Vermont, Maine, Minnesota, New Mexico and West Virginia have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs and file periodic reports on sales, marketing, pricing and other activities. Similar legislation is being considered in other states. Many of these requirements are new and uncertain, and available guidance is limited. Unless we are in full compliance with these laws, we could face enforcement actions and fines and other penalties and could receive adverse publicity, all of which could harm our business.

 

If the product candidate we develop becomes subject to unfavorable pricing regulations, third party reimbursement practices or healthcare reform initiatives, our ability to successfully commercialize our product candidate may be impaired.

 

Our future revenues, profitability and access to capital will be affected by the continuing efforts of governmental and private third-party payors to contain or reduce the costs of health care through various means. We expect several federal, state and foreign proposals to control the cost of drugs through government regulation. We are unsure of the impact recent health care reform legislation may have on our business or what actions federal, state, foreign and private payors may take in response to the recent reforms. Therefore, it is difficult to predict the effect of any implemented reform on our business. Our ability to commercialize our product candidate successfully will depend, in part, on the extent to which reimbursement for the cost of such product candidate and related treatments will be available from government health administration authorities, such as Medicare and Medicaid in the United States, private health insurers and other organizations. Significant uncertainty exists as to the reimbursement status of newly approved health care products, particularly for indications for which there is no current effective treatment or for which medical care typically is not sought. Adequate third-party coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product research and development. If adequate coverage and reimbursement levels are not provided by government and third-party payors for use of our product candidates, our product candidates may fail to achieve market acceptance and our results of operations will be harmed.

 

14

 

Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.

 

Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA’s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.

 

Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services (“HHS”) released the "American Patients First Blueprint" and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower consumers' out-of-pocket costs. The Trump administration also proposed to establish an “international pricing index” that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate in Medicare Part D and to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills has dramatically increased under the current Congress, and the resulting impact on our business is uncertain and could be material.

 

In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California’s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of lower-priced drugs from outside the United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products.

 

Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting our products’ use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules.

 

Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our products in the United States, but our results of operations may be adversely affected. 

 

15

 

Risks Related to Our Intellectual Property

 

If we are unable to obtain, maintain and enforce our proprietary rights, we may not be able to compete effectively or operate profitably.

 

We are party to a license agreement with UFRF. The patent underlying the licensed intellectual property and those of other biopharmaceutical companies, are generally uncertain and involve complex legal, scientific and factual questions.

 

Our ability to develop and commercialize drugs depends in significant part on our ability to: (i) obtain and/or develop broad, protectable intellectual property; (ii) obtain additional licenses, if required, to the proprietary rights of others on commercially reasonable terms; (iii) operate without infringing upon the proprietary rights of others; (iv) prevent others from infringing on our proprietary rights; and (v) protect our corporate know-how and trade secrets.

 

Patents that we may acquire and those that might be issued in the future, may be challenged, invalidated or circumvented, and the rights granted thereunder may not provide us with proprietary protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies or duplicate any technology we develop. Because of the extensive time required for development, testing and regulatory review of a potential product candidates, it is possible that, before any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thus reducing any advantage of the patent.

 

Because patent applications in the U.S. and many foreign jurisdictions are typically not published until at least 12 months after filing, or in some cases not at all, and because publications of discoveries in the scientific literature often lag behind actual discoveries, neither we nor our licensors can be certain that either we or our licensors were the first to make the inventions claimed in issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in these patent applications.

 

Additionally, UFRF previously elected to seek protection for certain elements of the licensed technology only in the United States, and the time to file for international patent protection has expired. This limits the strength of the Company’s intellectual property position in certain markets and could affect the overall value of the Company to a potential corporate partner.

 

We may be exposed to infringement or misappropriation claims by third parties, which, if determined adversely to us, could cause us to pay significant damage awards.

 

There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. We may become a party to various types of patent litigation or other proceedings regarding intellectual property rights from time to time even under circumstances where we are not using and do not intend to use any of the intellectual property involved in the proceedings.

 

The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation or proceedings more effectively than we will be able to because our competitors may have substantially greater financial resources. If any patent litigation or other proceeding is resolved against us, we or our collaborators may be enjoined from developing, manufacturing, selling or importing our drugs without a license from the other party and we may be held liable for significant damages. We may not be able to obtain any required license(s) on commercially acceptable terms or at all.

 

Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.

 

16

 

Obtaining and maintaining our patent protection depends upon compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

 

The United States Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case.

 

Confidentiality agreements with employees and others may not adequately prevent disclosure of our know-how, trade secrets and other proprietary information and may not adequately protect our intellectual property, which could impede our ability to compete.

 

Because we operate in the highly technical field of medical technology development, we rely in part on trade secret protection in order to protect our proprietary trade secrets and unpatented know-how. However, trade secrets are difficult to protect, and we cannot be certain that others will not develop the same or similar technologies on their own. We have taken steps, including entering into confidentiality agreements with all of our employees, consultants and corporate partners to protect our trade secrets and unpatented know-how. These agreements generally require that the other party keep confidential and not disclose to third parties any confidential information developed by the party or made known to the party by us during the course of the party’s relationship with us. We also typically obtain agreements from these parties which provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets or know-how is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets or know-how. The failure to obtain or maintain trade secret protection could adversely affect our competitive position.

 

We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

 

As is common in the biotechnology industry, we employ individuals who were previously employed at other biotechnology companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.

 

Risks Related to this Offering and Ownership of our Common Stock

 

Our directors, executive officers and significant stockholders have substantial control over us and could limit stockholders’ ability to influence the outcome of key transactions, including changes of control.

 

As of December 31, 2019, our directors and executive officers beneficially owned 24.5% of our common stock and together may be able to influence significantly all matters requiring approval by our stockholders. As of the same date, one holder of greater than five percent of our common stock beneficially owned 11.6% of our common stock and would, along with certain other shareholders, be able to influence significantly all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other significant corporate transactions. The stockholders may have interests that differ from other stockholders, and they may vote in a way with which other stockholders disagree and that may be adverse to the interests of other stockholders. The concentration of ownership of our common stock may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our Company, and may affect the market price of our common stock. This concentration of ownership of our common stock may also have the effect of influencing the completion of a change in control that may not necessarily be in the best interests of all of our stockholders.

 

17

 

Our common stock is eligible for quotation on the over-the-counter-market but not listed on any national securities exchange.

 

Our shares of common stock are eligible for quotation on the OTCQB tier of the over-the-counter markets under the symbol “SNBP.” Despite eligibility for quotation, no assurance can be given that any market for our common stock will develop or, if one develops, that it will be maintained for any period of time. Quotation on the over-the-counter markets is generally understood to be a less active, and therefore less liquid, trading market than other types of markets such as a national securities exchange. In comparison to a listing on a national securities exchange, quotation on the over-the-counter markets is expected to have an adverse effect on the liquidity of shares of our common stock, both in terms of the number of shares that can be bought and sold at a given price, but also through delays in the timing of transactions and reduction in analyst and media coverage. This may result in lower prices for our common stock than might otherwise be obtained and could also result in a larger spread between the bid and ask prices for our common stock.

 

Our common stock may be a “penny stock,” which may make it difficult to sell shares of our common stock.

 

Our common stock has from time to time been categorized as a “penny stock” as defined in Rule 3a51-1 of the Exchange Act and may be subject to the requirements of Rule 15g-9 of the Exchange Act. Under this rule, broker-dealers who sell penny stocks must, among other things, provide purchasers of these stocks with a standardized risk-disclosure document prepared by the SEC. Under applicable regulations, unless it becomes listed on a national securities exchange, including pursuant to our pending application to list our common stock on the Nasdaq Capital Market, our common stock will generally remain a “penny stock” until such time as its per-share price is $5.00 or more (as determined in accordance with SEC regulations), or until we meet certain net asset or revenue thresholds. These thresholds include the possession of net tangible assets (i.e., total assets less intangible assets and liabilities) in excess of $2 million or average revenues equal to at least $6 million for each of the last three years.

 

The penny-stock rules significantly limit the liquidity of securities in the secondary market, and many brokers choose not to participate in penny-stock transactions. As a result, there is generally less trading in penny stocks. If you become a holder of our common stock, you may not always be able to resell shares of our common stock in a public broker’s transaction, if at all, at the times and prices that you feel are fair or appropriate.

 

If you purchase shares of common stock in this offering, you will incur immediate and substantial dilution in the book value of the shares of our common stock.

 

The proposed public offering price of the shares of our common stock is substantially higher than the net tangible book value per share of our common stock. Investors purchasing shares of common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing shares of common stock in this offering will incur immediate dilution of $             per share, based on an assumed public offering price of $             per share. Further, investors purchasing shares of common stock in this offering will contribute approximately         % of the total amount invested by shareholders since our inception, but will own, as a result of such investment, only approximately       % of the shares of common stock outstanding immediately following this offering. As a result of the dilution to investors purchasing shares of common stock in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. Further, because we may need to raise additional capital to fund our anticipated level of operations, we may in the future sell substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of equity or equity-linked securities, together with the exercise of outstanding options and any additional shares issued in connection with acquisitions, if any, may result in further dilution to investors.

 

Trading in our common stock has been minimal and investors may not be able to sell as much stock as they want at prevailing prices.

 

As of June 30, 2020, the 30-day average daily trading volume in our common stock was less than 500 shares as reported by OTC Markets Group Inc. If trading in our stock continues at that level, it may be difficult for investors to sell or buy substantial quantities of shares in the public market at any given time at prevailing prices as significant price movement can be caused trading a relatively small number of shares. Accordingly, the market price for shares of our common stock may be made more volatile because of the relatively low volume of trading in our common stock. We cannot guarantee that a more liquid market for our common stock will develop.

 

18

 

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and cause investors to lose part or all of their investment.

 

If our stockholders sell substantial amounts of our common stock in the public market or upon the expiration of any statutory holding period under Rule 144, or upon expiration of lock-up periods applicable to outstanding shares, or issued upon the exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an “overhang” and in anticipation of which the market price of our common stock could fall. The existence of an overhang, whether sales have occurred or are occurring, also could make our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate more difficult.

 

Securities analysts may not initiate coverage or continue to cover our common stock, and this may have a negative impact on the market price of our common stock.

 

Common stock prices are often significantly influenced by the research and reports that securities analysts publish about companies and their business. We do not have any control over these analysts. There is no guarantee that securities analysts will cover our common stock. If securities analysts do not cover our common stock, the lack of research coverage may adversely affect the market price of our common stock. If our common stock is covered by securities analysts and our stock is downgraded, our stock price will likely decline. If one or more of these analysts ceases to cover us or fails to publish regular reports on us, we can lose visibility in the financial markets, which can cause our stock price or trading volume to decline.

 

We have broad discretion in the use of the net proceeds from this offering, and our use of those proceeds may not yield a favorable return on investment.

 

We intend to use the net proceeds from this offering for the continued clinical development of our initial product candidate SBP-101 and for working capital and other general corporate purposes. However, our management has broad discretion of how these proceeds are used and could spend the proceeds in ways with which you may not agree. In addition, we may not use the proceeds from this offering effectively or in a manner that increases our market value or results in revenue. We have not established a timetable for the effective deployment of the proceeds, and we cannot predict how long it will take to deploy the proceeds.

 

Raising additional capital may cause dilution to our stockholders or restrict our operations.

 

To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholders’ ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect their rights as stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends. Any of these events could adversely affect our ability to achieve our product development and commercialization goals and harm our business. We do not anticipate any adverse effects stemming from the lack of available credit facilities at this time.

 

Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable.

 

Provisions of our certificate of incorporation and bylaws and applicable provisions of Delaware law may make it more difficult or prevent a third party from acquiring control of us without the approval of our Board of Directors. These provisions:

 

 

set limitations on the removal of directors;

 

 

limit who may call a special meeting of stockholders;

 

 

establish advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon at stockholder meetings;

 

 

do not permit cumulative voting in the election of our directors, which would otherwise permit less than a majority of stockholders to elect directors;

 

 

establish a classified board of directors limiting the number of directors that are elected each year; and

 

 

provide our Board of Directors the ability to designate the terms of and issue preferred stock without stockholder approval.

 

19

 

In addition, Section 203 of the Delaware General Corporation Law generally limits our ability to engage in any business combination with certain persons who own 15% or more of our outstanding voting stock or any of our associates or affiliates who at any time in the past three years have owned 15% or more of our outstanding voting stock unless our Board of Directors has pre-approved the acquisitions that lead to such ownership. These provisions may have the effect of entrenching our management team and may deprive stockholders of the opportunity to sell their shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock.

 

If we issue preferred stock, the rights of holders of our common stock and the value of such common stock could be adversely affected.

 

Our Board of Directors is authorized to issue classes or series of preferred stock, without any action on the part of the stockholders. The Board of Directors also has the power, without stockholder approval, to set the terms of any such classes or series of preferred stock, including voting rights, dividend rights and preferences over the common stock with respect to dividends or upon the liquidation, dissolution or winding-up of our business and other terms. If we issue preferred stock in the future that has a preference over the common stock with respect to the payment of dividends or upon liquidation, dissolution or winding-up, or if we issue preferred stock with voting rights that dilute the voting power of the common stock, the rights of holders of the common stock or the value of the common stock would be adversely affected.

 

The protection provided by the federal securities laws relating to forward-looking statements does not currently apply to us. The lack of this protection could harm us in the event of an adverse outcome in a legal proceeding relating to forward-looking statements made by us.

 

Although federal securities laws provide a safe harbor for forward-looking statements made by a public company that files reports under the federal securities laws, this safe harbor is not available to certain issuers, including penny stock issuers. To the extent our common stock is considered a penny stock, we will not be eligible for the statutory safe harbor included in the Exchange Act of 1934. As a result, we will not have the benefit of this statutory safe harbor protection in the event of certain legal actions based upon forward-looking statements. The lack of this protection in a contested proceeding could harm our financial condition and, ultimately, the value of our common stock.

 

We have identified a significant deficiency in internal control over financial reporting, if we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected.

 

We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish those controls, or any failure of those controls once established, could adversely impact our public disclosures regarding our business, financial condition or results of operations. Any failure of these controls could also prevent us from maintaining accurate accounting records and discovering accounting errors and financial fraud.

 

In the course of completing its assessment of internal control over financial reporting as of December 31, 2019, management did not identify any material weaknesses but did identify a significant deficiency in the number of personnel available to serve the Company’s accounting function, specifically management believes that we may not be able to adequately segregate responsibility over financial transaction processing and reporting. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting, that is less severe than a material weakness yet important enough to merit attention by those responsible for oversight of the Company’s financial reporting. Although we are unable to remediate the significant deficiency with current personnel, we are mitigating its potential impact, primarily through greater involvement of senior management in the review and monitoring of financial transaction processing and reporting.

 

In addition, management’s assessment of internal controls over financial reporting may identify additional weaknesses and conditions that need to be addressed or other potential matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting or disclosure of management’s assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.

 

20

 

CAUTIONARY Note Regarding Forward-Looking Statements

 

This prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this report. These factors include:

 

 

the fact that we are a company with limited operating history for you to evaluate our business;

 

 

our lack of diversification and the corresponding risk of an investment in our Company;

 

 

potential deterioration of our financial condition and results due to failure to diversify;

 

 

our ability to obtain additional capital, on acceptable terms or at all, required to implement our business plan;

 

 

progress and success of our Phase 1 clinical trial;

 

 

our ability to demonstrate safety and effectiveness of our product candidate;

 

 

our ability to obtain regulatory approvals for our product candidate in the United States, the European Union or other international markets;

 

 

the market acceptance and future sales of our product candidate;

 

 

the cost and delays in product development that may result from changes in regulatory oversight applicable to our product candidate;

 

 

the rate of progress in establishing reimbursement arrangement with third-party payors;

 

 

the effect of competing technological and market developments;

 

 

the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and

 

 

other risk factors included under the caption “Risk Factors” starting on page of this prospectus.

 

You should read the matters described in “Risk Factors” and the other cautionary statements made in this prospectus as being applicable to all related forward-looking statements wherever they appear in this prospectus. We cannot assure you that the forward-looking statements in this prospectus will prove to be accurate and therefore prospective investors are encouraged not to place undue reliance on forward-looking statements. You should read this prospectus completely. Other than as required by law, we undertake no obligation to update or revise these forward-looking statements, even though our situation may change in the future.

 

We caution investors not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described under the caption “Risk Factors” of this prospectus, as well as others that we may consider immaterial or do not anticipate at this time. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions that we might make or by known or unknown risks and uncertainties, including those described in under the caption “Risk Factors” of this prospectus. The risks and uncertainties described under the caption “Risk Factors” of this prospectus are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our financial results or condition, may emerge from time to time. We assume no obligation to update forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise investors to consult any further disclosures we may make on related subjects in our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that we file with or furnish to the U.S. Securities and Exchange Commission (the “SEC”).

 

21

 

Use of Proceeds

 

We estimate that the net proceeds from our issuance and sale of shares of our common stock in this offering will be approximately $      million, assuming a public offering price of $      per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us in this offering. If the underwriter exercises its over-allotment option in full, we estimate that the net proceeds from this offering will be approximately $      million.

 

A $1.00 increase or decrease in the assumed public offering price of $      per share would increase or decrease the net proceeds from this offering by approximately $      million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 100,000 shares in the number of shares of common stock offered would increase (decrease) our proceeds by approximately $         , assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

We intend to use the net proceeds from this offering as follows:

 

 

for the continued clinical development of our initial product candidate SBP-101;

 

 

for the repayment of approximately $0.8 million of principal and accrued interest due on outstanding indebtedness (See “Indebtedness” under “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources” on page ); and

 

 

the remainder for working capital, business development and other general corporate purposes.

 

Our expected use of net proceeds from this offering represents our intentions based on our present plans and business conditions, which could change as our plans and business conditions evolve. The amount and timing of our actual expenditures will depend on numerous factors, including the timing and success of clinical studies or clinical studies we may commence in the future, the timing of regulatory submissions and the feedback from regulatory authorities. As a result, our management will have broad discretion over the use of the net proceeds from this offering. Pending our use of the net proceeds from this offering, we may temporarily invest the net proceeds in investment-grade, interest-bearing securities.

 

We anticipate that the net proceeds from this offering together with our existing cash and cash equivalents will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through the middle of 2022. We currently estimate that these funds will enable us to complete a dose-escalation study of SBP-101 in combination with the current standard of care treatment for patients with pancreatic ductile adenocarcinoma. We are also currently evaluating the appropriate timing and form of the next clinical trial to be initiated at the completion of the Phase 1b expansion of the current study. It is expected to be a randomized phase 2 trial for patients with metastatic PDA. Additional clinical trials will likely be required for FDA or other similar approvals if the results of the current clinical trial of our SBP-101 product candidate remain positive. The cost and timing of additional clinical trials are highly dependent on the nature and size of the trials. However, it is estimated that the next steps in the approval process could cost between $20 and $40 million.

 

Predicting the cost necessary to develop product candidates can be difficult and we anticipate that we will need additional funds to conduct a larger randomized trial of the type generally required for obtaining regulatory approval to commercialize a drug. We have based these estimates on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.

 

22

 

Price Range of Common Stock

 

Our common stock became quoted on the over-the-counter markets in 2015 under the symbol “SNBP” and it has been quoted on the OTCQB Venture Market, administered by OTC Markets Group, Inc., since 2016. Despite eligibility for quotation, no assurance can be given that any market for our common stock will develop or be maintained. We have applied to list our common stock on the Nasdaq Capital Market under the same symbol. No assurance can be given that our application will be approved or that a trading market will develop. Our share price on the OTCQB may not be indicative of the market price on the Nasdaq Capital Market, if we become listed. If an “established trading market” ever develops in the future, the sale of shares of our common stock that are deemed to be “restricted securities” pursuant to Rule 144 of the SEC by members of management or others may have a substantial adverse impact on any such market.

 

Set forth below are the high and low bid prices for our common stock for the first quarter of 2020 and each quarter of 2019 and 2018 for which data is available. These bid prices were obtained from OTC Markets Group Inc. All prices listed below reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not represent actual transactions.

 

Fiscal 2020

 

High

   

Low

 

Second Quarter (through June 30, 2020)

  $ 5.25     $ 4.40  

First Quarter

  $ 5.20     $ 4.20  

 

Fiscal 2019

 

High

   

Low

 

Fourth Quarter

  $ 5.82     $ 4.00  

Third Quarter

  $ 5.25     $ 2.25  

Second Quarter

  $ 3.00     $ 2.00  

First Quarter

  $ 3.50     $ 2.10  

 

Fiscal 2018

 

High

   

Low

 

Fourth Quarter

  $ 4.00     $ 3.25  

Third Quarter

  $ 5.75     $ 3.55  

Second Quarter

  $ 7.50     $ 5.00  

First Quarter

  $ 9.00     $ 4.75  

 

On July 1, 2020, the last reported sale price of our common stock on the OTCQB was $6.00 per share. As of the same date, we had 283 holders of record of our common stock.

 

Equity Compensation Plan Information

 

The following table provides information as of December 31, 2019 regarding outstanding grants and shares available for grant under our equity compensation plans.

 

Plan Category

 

Number of securities to be

issued upon exercise of

outstanding options,

warrants and rights

   

Weighted-average exercise

price of outstanding options,

warrants and rights

   

Number of securities

remaining available for

future issuance under

equity compensation plans

 

Equity compensation plans approved by security holders(1)

    1,744,811 (2)   $ 6.526       19,549  

Equity compensation plans not approved by security holders

                 

Total

    1,744,811               19,549  

 

 


(1) Consists of the 2011 Stock Option Plan and 2016 Omnibus Incentive Plan, each described in more detail below.

(2)

Represents 1,480,451 shares underlying common stock options under the 2016 Plan and 246,360 shares underlying common stock options under the 2011 Plan. We ceased issuing awards under the 2011 Plan upon stockholder approval of the 2016 Plan in 2016.

 

 

23

 

2011 Stock Option Plan

 

The Sun BioPharma, Inc. 2011 Stock Option Plan (the “2011 Plan”) was adopted by our Board of Directors in 2011 and subsequently approved by our stockholders in 2012. Upon the initial stockholder approval of the 2016 Plan, our Board of Directors ceased making grants under the 2011 Plan, although awards outstanding under the 2011 Plan will remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the 2011 Plan have a maximum term of ten years and generally vest over zero to two years for employees. As of June 30, 2020, options to purchase 264,360 shares of common stock remained outstanding under the 2011 Plan with a weighted average price of $2.86 per share.

 

2016 Omnibus Incentive Plan

 

The Sun BioPharma, Inc. 2016 Omnibus Incentive Plan was initially adopted by our Board of Directors in March 2016 and approved by our stockholders in May 2016. It was amended and restated by our Board of Directors in April 2020 and approved by our stockholders in May 2020 (as amended, the “2016 Plan”). The 2016 Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2016 Plan at no less than the fair market value of the underlying common stock as of the date of grant. Options granted under the Plan have a maximum term of ten years. Under the 2016 Plan, a total of 2,800,000 shares of common stock were initially reserved for issuance. As of June 30, 2020 options to purchase 1,694,051 shares of our common stock were outstanding under the 2016 Plan with a weighted average price of $6.90 per share. A total of 1,105,949 shares of common stock remained available for future grants under the 2016 Plan as of the same date, subject to the evergreen provision described under “Shares Available” below.

 

Purpose

 

The purpose of the 2016 Plan is to promote the interests of our Company and our stockholders by providing key personnel of our Company and our affiliates with an opportunity to acquire a proprietary interest in the Company and thereby develop a stronger incentive to put forth maximum effort for the continued success and growth of our Company and our affiliates. In addition, the opportunity to acquire a proprietary interest in our Company will aid in attracting and retaining key personnel of outstanding ability. The 2016 Plan is also intended to provide non-employee directors of the Company with an opportunity to acquire a proprietary interest in the Company, to compensate non-employee directors for their contributions to the Company and to aid in attracting and retaining non-employee directors.

 

Administration

 

The 2016 Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”). The Committee has the authority to adopt, revise and waive rules relating to the 2016 Plan and to determine the timing and identity of participants, the amount of any awards and other terms and conditions of awards. The Committee may delegate its responsibilities under the 2016 Plan to one or more of its members or to one or more directors or executive officers of the Company with respect to the selection and grants of awards to employees of the Company who are not deemed to be officers, directors or 10% stockholders of the Company under applicable federal securities laws. The Board of Directors will perform the duties and have the responsibilities of the Committee with respect to awards made to non-employee directors.

 

Eligibility

 

All employees of our Company and our affiliates, non-employee directors of our Company and any consultant or advisor who is a natural person and provides services to us or our affiliates are eligible to receive awards under the 2016 Plan at the discretion of the Committee or the Board, as applicable. No awards may be granted under the 2016 Plan in conjunction with a capital-raising transaction or the promotion or maintenance of a market for our securities. Incentive stock options under the 2016 Plan may be awarded to employees of the Company. As of April 3, 2020, there were approximately 9 total employees and non-employee directors. Such employees, directors and others who currently or may in the future provide services to us and our affiliates may be considered for the grant of awards under the 2016 Plan at the discretion of the Committee or the Board, as applicable.

 

24

 

Shares Available

 

The total number of shares of Company Common Stock available for distribution under the 2016 Plan is 2,800,000, subject to adjustment for future stock splits, stock dividends and similar changes in the capitalization of the Company. In addition, the 2016 Plan provides that the number of shares of Common Stock available for issuance under the 2016 Plan will increase on January 1 of each year beginning in 2021 and ending on January 1, 2025 in an amount equal to the lesser of (i) 20% of the total number of Fully Diluted Shares (as defined in the 2016 Plan) as of December 31 of the immediately preceding calendar year and (ii) such lesser number of shares as may be determined by the Board of Directors or the Committee prior to January 1st of any calendar year. The shares of our Common Stock covered by the 2016 Plan may be treasury shares or authorized but unissued shares.

 

Any shares subject to an award under the 2016 Plan that expires, is cancelled or forfeited or is settled for cash shall, to the extent of such expiration, cancellation, forfeiture or cash settlement, remain in the pool of shares available for grant under the 2016 Plan. The following shares will, however, continue to be charged against the foregoing maximum share limitations and will not again become available for grant: (i) shares tendered by the participant or withheld by us in payment of the purchase price of an Option, (ii) shares tendered by the participant or withheld by us to satisfy any tax withholding obligation with respect to an Option of SAR, (iii) shares subject to a SAR that are not issued in connection with the settlement of the SAR upon its exercise and (iv) shares repurchased by us with proceeds received from the exercise of a stock option issued under the 2016 Plan.

 

Types of Awards

 

The 2016 Plan allows us to grant stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units and other stock-based awards. The Committee may provide that the vesting or payment of any award will be subject to the attainment of certain performance objectives established by the Committee, in addition to completion by the plan participant of a specified period of service. The Committee may amend the terms of any award previously granted, but no amendment may materially impair the rights of any participant with respect to an outstanding award without the participant’s consent, unless such amendment is necessary to comply with applicable laws or stock exchange rules.

 

Stock Options

 

Stock options granted under the 2016 Plan may be either incentive stock options (“ISOs”), which are specifically designated as such for purposes of compliance with Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), or non-statutory stock options (“NSOs”). Options will vest as determined by the Committee, subject to statutory limitations regarding the maximum term of ISOs and the maximum value of ISOs that by vest in a single year. The exercise price of options may not be less than the fair market value of our Common Stock on the date of grant, which, if our shares or not readily tradable on an established securities market will be determined by the Committee as the result of a reasonable application of a reasonable valuation method that satisfies the requirements of Section 409A of the Code. The exercise price must be paid in full at the time of exercise and may be paid in cash or such other manner as permitted by the Committee, including by withholding shares issuable upon exercise or by delivery of shares already owned by a participant. Although not necessarily indicative of fair market value, the most recent sale price of a share of our common stock on the over the counter markets, which sale occurred on April 1, 2020, was $5.25 per share.

 

Stock Appreciation Rights

 

SARs provide for payment to the participant of all or a portion of the excess of the fair market value of a specified number of shares of our Common Stock on the date of exercise over a specified exercise price, which may not be less than the fair market value of our Common Stock on the date of grant. Payment may be made in cash or shares of our Common Stock or a combination of both, as determined by the Committee.

 

25

 

Restricted Stock

 

Restricted stock awards are awards of shares of our Common Stock that are subject to vesting conditions, and the corresponding lapse or waiver of forfeiture conditions and other restrictions, based on such factors and occurring over such period of time as the Committee may determine.

 

Restricted Stock Units

 

Restricted stock units provide a participant with the right to receive, in cash or shares of our Common Stock or a combination of both, the fair market value of a specified number of shares of our Common Stock, and will be subject to such vesting and forfeiture conditions and other restrictions as the Committee determines.

 

Other Stock-Based Awards

 

The Committee may grant other awards under the 2016 Plan that are valued by reference to and/or payable in whole or in part in shares of our Common Stock.

 

Terms of Awards and Plan Provisions

 

Substitute Awards

 

Awards may be granted under the 2016 Plan in substitution for awards granted by another entity acquired by our company or with which our company combines. The terms and conditions of these substitute awards will be comparable to the terms of the awards replaced and may therefore differ from the terms and conditions otherwise set forth in the 2016 Plan. Shares subject to substitute awards will not count against the 2016 Plan share reserve.

 

Repricing of Awards

 

The Committee may not reduce the exercise price of stock options or SARs granted under the 2016 Plan, exchange outstanding stock options or SARs with new stock options or SARs with a lower exercise price or a new full value award, repurchase underwater stock options or SARs or take any other action that would constitute a “repricing,” unless such action is first approved by our stockholders.

 

Transferability of Awards

 

Except as noted below, during the lifetime of a person to whom an award is granted, only that person, or that person’s legal representative, may exercise an option or SAR, or receive payment with respect to performance units or any other award. No award may be sold, assigned, transferred, exchanged or otherwise encumbered other than to a successor in the event of a participant’s death or pursuant to a qualified domestic relations order. However, the Committee may provide that awards, other than incentive stock options, may be transferable to members of the participant’s immediate family or to one or more trusts for the benefit of such family members or partnerships in which such family members are the only partners, if the participant does not receive any consideration for the transfer.

 

Termination of Service

 

Unless otherwise provided in an award agreement, upon termination of a participant’s service with us, all unvested and unexercisable portions of the participant’s outstanding awards will immediately be forfeited. If a participant’s service with us terminates other than for cause (as defined in the 2016 Plan), death or disability, the vested and exercisable portions of the participant’s outstanding stock options and SARs generally will remain exercisable for 90 days after termination. If a participant’s service terminates due to death or disability, the vested and exercisable portions of the participant’s outstanding stock options and SARs generally will remain exercisable for one year after termination. Upon termination for cause, all unexercised stock options and SARs will be forfeited.

 

26

 

Withholding

 

The 2016 Plan permits us to withhold from cash awards, and to require a participant receiving Common Stock under the 2016 Plan to pay us in cash, an amount sufficient to cover any required withholding taxes. In lieu of cash, the Committee may permit a participant to cover withholding obligations through a reduction in the number of shares delivered to such participant or a surrender of shares then owned by the participant.

 

Change in Control

 

If a change in control (as defined in the 2016 Plan) that involves a corporate transaction (as defined in the 2016 Plan) occurs and any outstanding award is continued, assumed or replaced by our Company or the surviving or successor entity in connection with such change in control, and if within 12 months after the change in control a participant’s employment or other service is terminated without cause or with good reason (as defined in the 2016 Plan), then (i) each of the participant’s outstanding options and SARs will become exercisable in full, and (ii) each of the participant’s unvested full value awards will fully vest. If any outstanding award is not continued, assumed or replaced in connection with such change in control, then the same consequences as specified in the previous sentence with respect to a termination of employment or other service will occur in connection with a change in control unless and to the extent the Committee elects to terminate such award in exchange for a payment in an amount equal to the intrinsic value of the award (or, if there is no intrinsic value, the award may be terminated without payment). The Committee may, in its discretion, take such other action as it deems appropriate with respect to outstanding awards for a change in control not involving a corporate transaction or may generally provide for different circumstances upon any change in control in an individual award agreement.

 

Adjustment of Awards

 

In the event of an equity restructuring, such as a stock dividend or stock split, that affects the per share value of our Common Stock, the Committee will make appropriate adjustment to: (i) the number and kind of securities reserved for issuance under the 2016 Plan, (ii) the number and kind of securities subject to outstanding awards under the 2016 Plan, (iii) the exercise price of outstanding options and SARs, and (iv) any maximum limitations prescribed by the 2016 Plan as to grants of certain types of awards. The Committee may also make similar adjustments in the event of any other change in our company’s capitalization, including a merger, consolidation, reorganization or liquidation.

 

Amendment and Termination

 

The 2016 Plan has a term of ten years from its effective date, or the earlier termination of the 2016 Plan by our Board of Directors. Our Board may amend the 2016 Plan at any time, but no amendment may materially impair the rights of any participant with respect to outstanding awards without the participant’s consent. Stockholder approval of any amendment of the 2016 Plan will be obtained if required by applicable law or the rules of any securities exchange on which our Common Stock may then be listed. Awards that are outstanding on the 2016 Plan’s termination date will remain in effect in accordance with the terms of the 2016 Plan and the applicable award agreements.

 

27

 

CAPITALIZATION

 

The following table presents a summary of our cash and cash equivalents and capitalization as of March 31, 2020:

 

 

on an actual basis;

 

 

on an as adjusted basis to give effect to the issuance and sale of        shares of our common stock and warrants to purchase up to        shares of our common stock in this offering at the assumed public offering price of $            per share less underwriting discounts and commissions and estimated offering expenses payable by us; and

 

 

on an as adjusted basis to give effect to (i) the issuance and sale of        shares of our common stock and warrants to purchase up to                  shares of our common stock in this offering at the assumed public offering price of $            per share less underwriting discounts and commissions and estimated offering expenses payable by us and (ii) the conversion of outstanding convertible promissory notes.

 

The unaudited as adjusted information below is prepared for illustrative purposes only and our capitalization following the completion of this offering will be adjusted based on the actual public offering price and other terms of this offering determined at pricing and whether or not the convertible promissory notes are converted. You should read the following table in conjunction with “Summary Consolidated Financial Data”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the historical financial statements and related notes thereto included elsewhere in this prospectus. 

 

(in thousands)

 

Actual as of

March 31, 2020

(unaudited)

   

Offering

Adjustment

   

Pro Forma as

Adjusted for

Offering

 

Cash

  $ 1,296     $       $    

Common stock, $0.001 par value, 100,000,000 shares authorized; 6,631,308 shares issued and outstanding, and outstanding, pro forma; shares issued and outstanding, pro forma as adjusted

    7                  

Additional paid-in capital

    42,671                  

Accumulated deficit

    (43,056 )                

Accumulated comprehensive income

    1,102                  

Total stockholders’ equity

    724                  

Total capitalization

  $ 1,826     $       $    

 

Each $1.00 (decrease) in the assumed public offering price of $      per share would increase (decrease) each of cash, additional paid-in capital, total shareholders’ equity and total capitalization by approximately $           , assuming the number of shares of common stock and warrants offered, as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses. Similarly, each increase (decrease) of 100,000 shares in the number of shares of common stock and warrants offered would increase (decrease) cash, additional paid-in capital, total shareholders’ equity and total capitalization by approximately $            , assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

 

28

 

The number of shares of our common stock outstanding before and after this offering is based on 6,631,308 shares of our common stock outstanding as of March 31, 2020, and excludes:

 

 

1,745,811 shares of common stock issuable upon the exercise of outstanding stock options as of March 31, 2020 at a weighted average exercise price of $6.52 per share;

 

 

1,318,549 additional shares of common stock reserved and available for future awards under our 2016 Stock Option Plan, as amended and restated;(1)

 

 

3,497,099 shares of common stock issuable upon exercise of stock purchase warrants as of March 31, 2020 at a weighted average exercise price of $5.76 per share; and

 

 

        shares of common stock issuable upon exercise of the warrants issued to the underwriter at the closing of this offering.

 

 


(1) The 2016 Omnibus Incentive Plan was last amended effective April 9, 2020 and was last approved by stockholders in May 2020. The amendment, among other things, increased the shares of common stock available for issuance under the plan by 1,300,000 shares.

 

29

 

DILUTION

 

If you purchase shares in this offering your interest will be diluted immediately to the extent of the difference between the assumed public offering price of $      per and the as adjusted net tangible book value per share of our common stock immediately following this offering. Net tangible book value dilution per share to new investors represents the difference between the amount per share paid by purchasers in this offering and the as adjusted net tangible book value per share of common stock immediately after completion of this offering.

 

Our net tangible book value as of March 31, 2020 was approximately $724,000, or approximately $0.11 per share. Net tangible book value per share represents our total tangible assets less total tangible liabilities, excluding goodwill and customer relationship intangibles, divided by the number of shares of common stock outstanding as of March 31, 2020. The Company had no intangible assets as of the same date.

 

After giving effect to the sale of shares of our common stock in this offering at an assumed public offering price of $      per share, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of March 31, 2020, would have been $          million, or $      per share. This represents an immediate increase in as adjusted net tangible book value of approximately $      per share to our existing stockholders, and an immediate dilution of $      per share to purchasers of shares in this offering, as illustrated in the following table:

 

Assumed public offering price per share

          $    

Net tangible book value per share as of March 31, 2020

  $ 0.11          

Increase per share attributable to new investors

  $            

As adjusted net tangible book value per share after this offering

          $    

Dilution per share to new investors in the offering

          $    

 

If the underwriter exercises its over-allotment option in full, the as adjusted net tangible book value will increase to $      per share, representing an immediate dilution of $      per share to new investors, assuming that the assumed public offering price remains the same and after deducting underwriting discounts and commissions and the estimated offering expenses payable by us.

 

A $1.00 increase or decrease in the assumed public offering price of $      per share would increase or decrease the net proceeds from this offering by approximately $      million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions. Similarly, each increase (decrease) of 100,000 shares in the number of shares of common stock offered would increase (decrease) our proceeds by approximately $            , assuming the assumed public offering price remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

 

30

 

The number of shares of our common stock outstanding before and after this offering is based on 6,631,308 shares of our common stock outstanding as of March 31, 2020, and excludes:

 

 

1,745,811 shares of common stock issuable upon the exercise of outstanding stock options as of March 31, 2020 at a weighted average exercise price of $6.52 per share;

 

 

1,318,549 additional shares of common stock reserved and available for future issuances under our 2016 Stock Option Plan, as amended and restated;[1]

 

 

3,497,099 shares of common stock issuable upon exercise of stock purchase warrants as of March 31, 2020 at a weighted average exercise price of $5.76 per share; and

 

 

shares of common stock issuable upon exercise of the warrants issued to the underwriter at the closing of this offering.

 

Dividend Policy 

 

We have never declared or paid cash dividends on our capital stock. Following the completion of this offering, we intend to retain our future earnings, if any, to finance the further development and expansion of our business and do not expect to pay cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our Board of Directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, outstanding indebtedness, plans for expansion and restrictions imposed by lenders, if any.

 

 


(1) The 2016 Omnibus Incentive Plan was last amended effective April 9, 2020 and was last approved by stockholders in May 2020. The amendment, among other things, increased the shares of common stock available for issuance under the plan by 1,300,000 shares.

 

31

 

Management’s Discussion and Analysis of
Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements included elsewhere in this prospectus. This discussion contains forward-looking statements, which are based on our assumptions about the future of our business. Our actual results could differ materially from those contained in the forward-looking statements. Please read Cautionary Note Regarding Forward-Looking Statements included elsewhere in this prospectus for additional information regarding forward-looking statements used in this prospectus.

 

Overview

 

Sun BioPharma, Inc. and its wholly-owned subsidiary, Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer and for a second indication in chronic pancreatitis. We have exclusively licensed worldwide rights to this compound, which has been designated as SBP-101, from UFRF.

 

In August 2015, the Food and Drug Administration (“FDA”) accepted our Investigational New Drug (“IND”) application for our SBP-101 product candidate. We have completed an initial clinical trial of SBP-101 in patients with previously treated locally advanced or metastatic pancreatic cancer. This was a Phase 1, first-in-human, dose-escalation, safety study. From January 2016 through September 2017, we enrolled 29 patients into six cohorts, or groups, in the dose-escalation phase of this Phase 1 trial. Twenty-four of the patients received at least two prior chemotherapy regimens. No drug-related serious adverse events occurred during the first four cohorts. In cohort five, serious adverse events (klebsiella sepsis with metabolic acidosis in one patient, renal and hepatic toxicity in one patient, and mesenteric vein thrombosis with metabolic acidosis in one patient) were observed in three of the ten patients, two of whom exhibited progressive disease at the end of their first cycle of treatment and were determined by the Data Safety Monitoring Board (“DSMB”) to be dose-limiting toxicities (“DLTs”). Consistent with the study protocol, the DSMB recommended continuation of the study by expansion of cohort 4, one level below that at which DLTs were observed. Four patients were enrolled in this expansion cohort. One patient developed focal pancreatitis at the site of the primary tumor after 2.3 months, but otherwise SBP-101 was considered well tolerated below dose level five. The most common drug related adverse events were nausea, vomiting, diarrhea, injection site pain and abdominal pain, which were mostly mild, grades 1 or 2, and are symptoms common in patients with pancreatic cancer. No drug-related bone marrow toxicity or peripheral neuropathy was observed at any dose level.

 

In addition to being evaluated for safety, 23 of the 29 patients were evaluable for preliminary signals of efficacy prior to or at the eight-week conclusion of their first cycle of treatment using the Response Evaluation Criteria in Solid Tumors (“RECIST”), the current standard for evaluating changes in the size of tumors. Eight of the 23 patients (35%) had Stable Disease (“SD”) and 15 of 24 (65%) had Progressive Disease (“PD”). It should be noted that of the 15 patients with PD, six came from cohorts 1 and 2 and are considered to have received less than potentially therapeutic doses of SBP-101. We also noted that 28 of the 29 patients had follow-up blood tests measuring the Tumor Marker CA 19-9 associated with pancreatic ductal adenocarcinoma. Eleven of these patients (39%) had reductions in the CA 19-9 levels, as measured at least once after the baseline assessment. Seven of the remaining 17 patients who showed no reduction in CA 19-9 came from cohorts one and two.

 

By cohort, stable disease occurred in two patients in cohort 3, two patients in cohort 4 and four patients in cohort 5. The best response outcomes and best median survival were observed in the group of patients who received total cumulative doses of approximately 6 mg/kg (cohort 3). Two of four patients (50%) showed SD at week eight. Median survival in this group was 5.9 months, with two patients surviving 8 and 10 months, respectively. By total cumulative dose received, 5 of 12 patients (42%) who received total cumulative doses between 2.5 mg/kg and 8.0 mg/kg had reductions in the CA19-9 levels, as measured at least once after the baseline assessment. Nine of these patients (67%) exceeded 3 months of overall survival (“OS”), three patients (25%) exceeded 9 months of OS and two patients (17%) exceeded 1 year of OS and were still alive at the end of the study. This study was conducted at clinical sites in both Australia and the United States. With the approval of the DSMB, we cancelled the Phase 1b portion of the first-in-human monotherapy study in order to evaluate SBP-101 as front line, combination chemotherapy in pancreatic cancer patients.

 

32

 

We began enrolling patients in our second clinical trial in June of 2018. This second clinical trial is a Phase 1a/1b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel. We are currently conducting the trial at six study sites (four in Australia and two in the United States). In the Phase 1a portion of this trial, we have completed enrollment in the fourth quarter of 2019 of three cohorts of four to nine patients with increased dosage levels of SBP-101 administered in the second and third cohorts and completed enrollment in February of 2020 in a fourth cohort to explore an alternate dosing schedule. Demonstration of adequate safety in Phase 1a allowed us to promptly begin enrollment in February 2020 in the Phase 1b exploration of efficacy. We plan to enroll up to 36 patients using the recommended dosage level and schedule determined in Phase 1a. Early results from the Phase 1b expansion could become available in the second half of 2020.

 

We estimate that completion of our Phase 1b clinical trial in PDA will require additional funding of up to 4.0 million.

 

The Company completed enrollment of the fourth cohort in the quarter ended March 31, 2020, this cohort is evaluating an alternative dosing schedule for the administration of SBP 101. Enrollment in the expansion (1b) phase of the trial began immediately after enrollment in the fourth cohort. Due to the COVID-19 pandemic, enrollment efforts were paused in early April and resumed in late May. All subjects enrolled at the time of the pause continued to be treated. Promising interim results were presented in a poster presentation at ASCO-GI; the poster contained data as of January 4, 2020 in the response-evaluable subjects in cohorts 2 and 3 (N=13). The conclusions at that time reflected (i) an objective response rate of 62%; 4 PRs were observed after 2 cycles of therapy and 4 PRs were observed after 4 cycles of therapy and (ii) a disease control rate (“DCR”) of 85% by RECIST criteria (at least SD for ≥ 16 weeks); 4 subjects had not reached week 16 scans.

 

Additional clinical trials will be required for FDA or other country approvals if the results of the front-line clinical trial of our SBP-101 product candidate justify continued development.

 

In June of 2020, the FDA designated a Fast Track development program to the investigation of SBP-101 for first-line treatment of patients with metastatic PDA when administered in combination with gemcitabine and nab-paclitaxel.

 

We are currently evaluating the appropriate timing and form of the next clinical trial to be initiated at the completion of the Phase 1b expansion of the current study. It is expected to be a randomized phase 2 trial for patients with metastatic PDA. Additional clinical trials will likely be required for FDA or other similar approvals if the results of the current clinical trial of our SBP-101 product candidate remain positive. The cost and timing of additional clinical trials are highly dependent on the nature and size of the trials. However, it is estimated that the next steps in the approval process could cost between $20 and $40 million.

 

Financial Overview 

 

We have incurred losses of $42.6 million since inception. For the three months ended March 31, 2020, we incurred a net loss of $1.8 million. We also incurred negative cash flows from operating activities of $1.1 million for this period.

 

For the year ended December 31, 2019, we incurred a net loss of $6.2 million, which includes a non-cash charge of $2.1 million related to the amortization of the debt discount on $2.1 million of convertible notes which converted to common stock during the year. We expect to continue to incur substantial losses, which will generate negative net cash flows from operating activities, as we continue to pursue research and development activities and commercialize our SBP-101 product candidate.

 

Our cash was approximately $1.3 million and $2.4 million as of March 31, 2020 and December 31, 2019, respectively. A decrease of $1.1 million in cash for the three months ended March 31, 2020 was primarily due to negative cash flow from operations. Other than the temporary pause in enrollment in our current clinical trial, the Company has not experienced any significant disruptions to our operations as the result of the COVID-19 pandemic. We anticipate resuming enrollment as soon as conditions allow. The Company was not required to change management practices as it was decentralized prior to the current pandemic.

 

33

 

In May and June of 2020, we issued an aggregate of 437,000 shares of our common stock and warrants to purchase up to the same aggregate number of additional shares of common stock pursuant to closings under securities purchase agreements. Total proceeds from the sales of common stock and warrants was approximately $1.7 million, of which approximately $90,000 was received from officers and directors of the Company. The warrants issued under these purchase agreements are exercisable for a period of five years from the date of issuance at an initial exercise price of $6.00 per share.

 

We will need additional funds to continue our operations and execute our business plan, including completing our current Phase 1a /1b clinical trial, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets. We historically have financed our operations principally from the sale of convertible debt and equity securities. While we have been successful in the past in obtaining the necessary capital to support our operations and we are likely to seek additional financing through similar means, there is no assurance that we will be able to obtain additional financing under commercially reasonable terms and conditions, or at all. This risk would increase if our clinical data is not positive or if economic or market conditions deteriorate.

 

If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions which may include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-101 product candidate, license to third parties the rights to commercialize our SBP-101 product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.

 

Key Components of Our Results of Operations 

 

General and Administrative Expenses

 

Our selling, general and administrative expenses consist primarily of salaries, benefits and other costs, including stock-based compensation, for our executive and administrative personnel; legal and other professional fees; travel, insurance and other corporate costs.

 

Research and Development Expenses 

 

Since our inception, we have focused our activities on the development of SBP-101, our initial product candidate, for the treatment of pancreatic cancer. We expense both internal and external research and development costs as incurred. Research and development costs include expenses incurred in the conduct of our human clinical trials, for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-101 compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-101 product candidate; personnel costs, including salaries, benefits and stock-based compensation; and costs to license and maintain our licensed intellectual property. During 2019 and 2018, research and development expenditures were focused primarily on costs related to the execution our current Phase 1a /1b front line clinical trial.

 

We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with any certainty the costs we will incur and the timelines we will require in the continued development of our initial product candidate for pancreatic cancer and our other potential pipeline programs. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. Our future research and development expenses will depend on the preclinical and clinical success of each product candidate that we develop, as well as ongoing assessments of the commercial potential of such product candidates. In addition, we cannot forecast whether our current or future product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.

 

34

 

Completion of clinical trials may take several years or more, and the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:

 

 

per patient trial costs;

 

 

the number of trials required for approval;

 

 

the number of sites included in the trials;

 

 

the number of patients that participate in the trials;

 

 

the length of time required to enroll suitable patients;

 

 

the number of doses that patients receive;

 

 

the drop-out or discontinuation rates of patients;

 

 

the duration of patient follow-up;

 

 

potential additional safety monitoring or other studies requested by regulatory agencies;

 

 

the number and complexity of analyses and tests performed during the trial;

 

 

the phase of development of the product candidate; and

 

 

the efficacy and safety profile of the product candidate.

 

Our expenses related to clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with multiple clinical trial sites and for contract research organizations, (“CRO”), which administer clinical trials on our behalf. The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee or unit price. Payments under the contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. Expenses related to clinical trials generally are accrued based on contracted amounts and the achievement of milestones, such as number of patients enrolled. If timelines or contracts are modified based upon changes to the clinical trial design or scope of work to be performed, we modify our estimates of accrued expenses accordingly.

 

We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license. 

 

Other Income (Expense) 

 

Other income (expense) consists of interest income, cash and non-cash interest expense and transaction gains and losses resulting from transactions denominated in other than our functional currency.

 

Critical Accounting Policies and Estimates 

 

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. On an ongoing basis, we evaluate these estimates and judgments, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these estimates.

 

35

 

While our significant accounting policies are more fully described in Note 4 to our Consolidated Financial Statements for the period ended December 31, 2019 appearing elsewhere in this prospectus, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.

 

Stock-Based Compensation

 

In accounting for share-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Calculating share-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period.

 

The fair values of share-based awards are estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of share-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.

 

We grant options to employees and non-employees, including our directors. Grants made to new employees are awarded on a case by case basis. Option grants to employees generally vest annually over three years from the date of grant. Options granted to our non-employee directors generally vest over one-year from the date of grant. Options granted to other non-employees generally vest over three years. Options issued to employees and non-employees generally have a maximum term of ten years.

 

Option grants to non-employees have been made in conjunction with their service as advisors to us. Certain of these advisors have also purchased shares of stock in our private placement offerings, but none beneficially own 5% or more of our outstanding common stock.

 

Research and development costs

 

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from CROs. Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

 

36

 

Results of Operations 

 

Comparison of the three months ended March 31, 2020 to the three months ended March 31, 2019:

 

(in thousands)

 

Three Months Ended March 31,

 
   

2020

   

2019

   

 

 
   

(unaudited)

   

(unaudited)

    Percent Change  

Operating expenses:

                       

General and administrative

  $ 468     $ 303       54.5 %

Research and development

    598       350       70.9 %

Total operating expenses

    1,066       653       63.2 %
                         

Other income (expense), net

    (824 )     (999 )     -17.5 %

Income tax benefit

    92       71       29.6 %
                         

Net loss

  $ (1,798 )   $ (1,581 )     13.7 %

 

Research and development (“R&D”) and general and administrative (“G&A”) expenses include non-cash share-based compensation expense because of our issuance of stock options. We expense the fair value of equity awards over their vesting periods. The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. The awards granted through March 31, 2020 vest upon performance and time-based conditions. We expect to record additional non-cash share-based compensation expense in the future, which may be significant.

 

The following table summarizes the stock-based compensation expense in our statements of comprehensive loss for the three months ended March 31, 2020 and March 31, 2019 (in thousands):

 

   

Three months ended March 31,

 
   

2020

   

2019

 
   

(unaudited)

   

(unaudited)

 

General and administrative

  $ 99       10  

Research and development

    13        

Total share-based compensation

  $ 112       10  

 

General and administrative expense

 

Our G&A expenses increased 54.5% to $468,000 in the first quarter of 2020 up from $303,000 in the first quarter of 2019. The increase is due in part to increased salary costs as employees had taken a voluntary reduction of salaries for a part of the first quarter of 2019; increased stock compensation expense, legal expenses made up the remaining increase.

 

Research and development expense

 

Our R&D expenses increased 70.9% to $598,000 in the first quarter of 2020 up from $350,000 in the first quarter of 2019 the increase is due primarily to increased clinical trial costs in the first quarter of 2020.

 

Other income (expense), net

 

Other expense, net, was $824,000 and $999,000 for the three months ended March 31, 2020 and 2019, respectively. The net expense in the quarter ended March 31, 2020 is composed primarily of a foreign currency exchange loss on the intercompany receivable balance. The net expense in the quarter ended March 31, 2019 is primarily the amortization of debt discount on convertible notes sold in December 2018 and January 2019, all of which converted into equity securities in 2019.

 

37

 

Income tax benefit

 

Income tax benefit increased to $92,000 for the three months ended March 31, 2020 up from $71,000 during the three months ended March 31, 2019. Our income tax benefit is derived primarily from refundable tax credits associated with our R&D activities conducted in Australia and was increased due to increased eligible R&D activities in the first three months of 2020 versus the first three months of 2019.

 

Comparison of the Year Ended December 31, 2019 to the Year Ended December 31, 2018

 

(in thousands)

 

Year Ended December 31,

   

 

 
   

2019

   

2018

    Percent Change  

Operating expenses:

                       

General and administrative

  $ 1,973     $ 2,108       -6.4 %

Research and development

    2,349       1,783       31.7 %

Total operating expenses

    4,322       3,891       11.1 %
                         

Other expense, net

    (2,293 )     (2,268 )     1.1 %

Income tax benefit

    415       254       63.4 %
                         

Net loss

  $ (6,200 )   $ (5,905 )     5.0 %

 

G&A and R&D expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through December 31, 2019 vest based upon time-based and performance conditions. We expect to record additional non-cash compensation expense in the future, which may be significant. The following table summarizes the stock-based compensation expense in our Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2019 and 2018 (in thousands):

 

(in thousands)

 

Year Ended December 31,

 
   

2019

   

2018

 

General and administrative

  $ 695     $ 1,497  

Research and development

    398       876  

Total stock-based compensation

  $ 1,093     $ 2,373  

 

General and administrative expense

 

G&A expenses decreased 6.4% to $2.0 million in 2019, down from $2.1 million in 2018. The decrease in G&A expenses is primarily the result of fewer staff members in the year offset in part by increased legal fees and franchise tax expense.

 

Research and product development expense

 

R&D expenses increased 31.7% to $2.3 million in 2019, up from $1.8 million in 2018. The increase in R&D expenses resulted primarily from an increase in spending on manufacturing of SBP 101 for use in our clinical studies. As we expand our clinical studies it is expected that R&D will continue to increase.

 

Other expense, net

 

Other expense, net, was $2.3 million for both years ended December 31, 2019 and 2018. In 2019, these expenses were primarily the amortization of the debt discount on the 2018 Notes which converted on June 30, 2019. In 2018, these expenses were primarily the amortization of the debt discount on the 2017 Notes which converted in 2018.

 

38

 

Income tax benefit

 

Income tax benefit increased to $415,000 in 2019, up from $254,000 in 2018. Our income tax benefit is derived primarily from refundable tax incentives associated with our R&D activities conducted in Australia. The current year increase reflects an increase in the costs eligible for the Australian R&D tax incentive.

 

Liquidity and Capital Resources

 

The following table summarizes our liquidity and capital resources as of March 31, 2020 and December 31, 2019 and our cash flow data for the three months ended March 31, 2020 and 2019 and is intended to supplement the more detailed discussion that follows (in thousands):

 

Liquidity and Capital Resources

 

March 31, 2020

(unaudited)

   

December 31, 2019

 

Cash

  $ 1,296     $ 2,449  

Working capital

  $ 679     $ 2,076  

 

Cash Flow Data

 

Three Months Ended March 31,

 
   

2020

(unaudited)

   

2019

(unaudited)

 

Cash provided by (used in):

               

Operating activities

  $ (1,120 )   $ (783 )

Financing activities

    (26 )     758  

Effect of exchange rate changes on cash

    (7 )     (1 )

Net increase (decrease) in cash

  $ (1,153 )   $ (26 )

 

Working Capital

 

Our total cash was $1.3 million and $2.4 million as of March 31, 2020 and December 31, 2019, respectively. We had $1.4 million in current liabilities and working capital of $0.7 million as of March 31, 2020, compared to $1.8 million in current liabilities and a working capital of $1.3 as of December 31, 2019.

 

Cash Flows

 

Net Cash Used in Operating Activities

 

Net cash used in operating activities was $1.1 million in the three months ended March 31, 2020 compared to $0.8 million in the three months ended March 31, 2019. The net cash used in each of these periods primarily reflects the net loss for these periods and is partially offset by the effects of changes in operating assets and liabilities.

 

Net Cash Provided by Financing Activities

 

Net cash used by financing activities was $26,000 for the three months ended March 31, 2020 and net cash provided by financing activities was $0.8 million for the three months ended March 31, 2019. The cash provided for the three months ended March 31, 2019 represents the gross proceeds from the sale of the Notes sold during the quarter.

 

Capital Requirements 

 

As we continue to pursue our operations and execute our business plan, including the completion of our current Phase 1 clinical trial for our initial product candidate, SBP-101, in pancreatic cancer, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets, we expect to continue to incur substantial and increasing losses, which will continue to generate negative net cash flows from operating activities.

 

39

 

Our future capital uses and requirements depend on numerous current and future factors. These factors include, but are not limited to, the following:

 

 

the progress of clinical trials required to support our applications for regulatory approvals, including our Phase 1a /1b clinical trial, a human clinical trial in Australia and the United States;

 

 

the impact of the current COVID-19 pandemic on our ability to monitor and complete enrollment in our current clinical trial;

 

 

our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate;

 

 

our ability to obtain regulatory approval of our SBP-101 product candidate in the United States, the European Union or other international markets;

 

 

the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate;

 

 

the market acceptance and level of future sales of our SBP-101 product candidate;

 

 

the rate of progress in establishing reimbursement arrangements with third-party payors;

 

 

the effect of competing technological and market developments; and

 

 

the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims.

 

Through the date of this prospectus, we have used primarily convertible debt and equity financings to fund our ongoing business operations and short-term liquidity needs, and we expect to continue this practice for the foreseeable future. As of March 31, 2020, we did not have any existing credit facilities under which we could borrow funds.

 

We expect that we will increase our projected expenditures once we have additional capital on hand in order to continue our efforts to grow our business and complete our Phase 1a clinical trial for our SBP-101 product candidate. Accordingly, we expect to make additional expenditures in performing our Phase 1a /1b clinical trial and related support activities. With sufficient capital, we also expect to invest in additional R&D efforts on mechanism of action, biomarkers and secondary indications in other cancer types. The exact amounts and timing of any expenditure may vary significantly from our current intentions. We will need to obtain additional funds to continue our operations and execute our business plans, including completing our current Phase 1 clinical trial, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets. We historically have financed our operations principally from the sale of convertible debt and equity securities. While we have been successful in the past in obtaining the necessary capital to support our operations, and have similar future plans to obtain additional financing, there is no assurance that we will be able to obtain additional financing under commercially reasonable terms and conditions, or at all. This risk would increase if our clinical data is inconclusive or not positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

 

If we are unable to obtain additional financing when needed, we will likely need to reduce our operations by taking actions which may include, among other things, reducing use of outside professional service providers, reducing staff or further reduce staff compensation, significantly modifying or delaying the development of our SBP-101 product candidate, licensing rights to third parties, including the right to commercialize our SBP-101 product candidate for patients with pancreatic cancer, or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.

 

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interests of our current stockholders would be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. Specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any of these events could adversely affect our ability to achieve our regulatory approvals and commercialization goals and harm our business.

 

40

 

Our future success is dependent upon our ability to obtain additional financing, the success of our current Phase 1 clinical trial and required future trials, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, the European Union and other international markets. If we are unable to obtain additional financing when needed, if our Phase 1 clinical trial is not successful, if we do not receive regulatory approval required for future trials or if once these studies are concluded, we do not receive marketing approval for our SBP-101 product candidate, we would not be able to continue as a going concern and would be forced to cease operations. The interim financial statements included in this report have been prepared assuming that we will continue as a going concern and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties.

 

Issuances of Common Stock and Warrants during Second Quarter of 2020

 

In May and June of 2020, we issued an aggregate of 437,000 shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under securities purchase agreements. Total proceeds from the sales of common stock and warrants was approximately $1.7 million, of which approximately $90,000 was received from officers and directors of the Company. The warrants issued under these purchase agreements are exercisable for a period of five years from the date of issuance at an initial exercise price of $6.00 per share.

 

Issuances of Common Stock and Warrants during 2019

 

In August, September, and October of 2019, we issued an aggregate of 909,209 shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under securities purchase agreements. Total proceeds from the sales of common stock and warrants was approximately $3.2 million, of this approximately $240,000 was received from officers and directors of the Company. The warrants issued under these purchase agreements are exercisable for a period of five years from the date of issuance at an initial exercise price of $4.00 per share.

 

Issuances of Convertible Notes during 2019 and 2018 and Conversion of Notes in 2019

 

In December of 2018 and January of 2019, we sold convertible promissory notes (the “2018 Notes”) and warrants to purchase common stock for gross proceeds of $2.2 million. The 2018 Notes were scheduled to mature on June 30, 2019 and bore an interest at a rate of 10.0% per year. The 2018 Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (1) June 30, 2019 or (2) the date the Company received gross proceeds of at least $6.0 million from the sale of equity securities (subject to certain exclusions). The stated conversion rate was $3.50 per share. In addition to the 2018 Notes, investors received a Warrant to purchase two shares of common stock for every $3.50 principal amount of 2018 Notes purchased. In total, warrants to purchase up to 1,243,498 shares of common stock were issued in the December and January closings. The exercise price of each warrant is $4.50 per share and they are exercisable until the 5-year anniversary of the dates of issuance. The warrants had a fair market value of $2.5 million upon issuance. After assigning the relative value of the warrants to the proceeds of the notes it was determined that the 2018 Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately $0.9 million. Both the relative value of the warrants and the beneficial conversion feature were recorded as a debt discount which was fully amortized through interest expense over the life of the 2018 Notes. On June 30, 2019, all $2.2 million aggregate principal balance of Notes outstanding plus $105,000 of accrued interest was converted at a conversion rate of $3.50 per share of common stock into 651,758 shares of common stock.

 

Future Capital Requirements

 

We require additional funds to continue our operations and execute our business plan, including completing our current Phase 1 clinical trial, planning for required future trials and pursuing regulatory approvals in the United States, the European Union and other international markets. We historically have financed our operations principally from the sale of convertible debt and equity securities. While we have been successful in the past in obtaining the necessary capital to support our operations and we are likely to seek additional financing through similar means, there is no assurance that we will be able to obtain additional financing under commercially reasonable terms and conditions, or at all. We believe that our existing cash, will be sufficient to fund our operating expenses through third quarter of 2020.

 

41

 

If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions which may include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-101 product candidate, license to third parties the rights to commercialize our SBP-101 product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.

 

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the interests of our current stockholders would be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our current stockholders. If we issue preferred stock, it could affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any of these events could adversely affect our ability to achieve our regulatory approvals and commercialization goals and harm our business.

 

Our future success is dependent upon our ability to obtain additional financing, the success of our current Phase 1a/1b clinical trial and required future trials, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, the European Union and other international markets. If we are unable to obtain additional financing when needed, if our Phase 1 clinical trial is not successful, if we do not receive regulatory approval required future trials or if once these studies are concluded, we do not receive marketing approval for our SBP-101 product candidate, we would not be able to continue as a going concern and would be forced to cease operations. The financial statements included in this report have been prepared assuming that we will continue as a going concern and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties.

 

Indebtedness

 

As of March 31, 2020, we had approximately $0.8 million of indebtedness. Included was a $0.7 million in an unsecured, non-interest-bearing promissory note due at the earlier of December 31, 2020 or the date the Company is listed on a national exchange. Also included was approximately $90,000 in an unsecured loan that accrues interest of 4.125% per year and is scheduled to mature on December 31, 2020. In accordance with the terms of this loan we commenced with monthly payments of $10,000 on May 1, 2018.

 

License Agreement

 

Pursuant to our exclusive license agreement with UFRF, which was last amended on October 4, 2019, we are required to pay royalties ranging from 2.5% to 5% of net sales of licensed products developed from the licensed technology for the shorter of: ten (10) years from the first commercial sale of a licensed product or the period of market exclusivity on a country by country basis. The latest amendment eliminated all future milestone payments. But the Company remains committed to pay an annual license maintenance fee of $10,000.

 

Off-Balance Sheet Arrangements 

 

We have no off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

See Note 4 to the Consolidated Financial Statements for the fiscal year ended December 31, 2019 included herein for a discussion of recent accounting pronouncements.

 

42

 

Business

 

Overview

 

Our product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (“PMI”), a metabolic pathway of critical importance in multiple tumor types. Sun BioPharma initially licensed SBP-101 from UFRF in 2011. SBP-101 showed tumor growth inhibition in preclinical studies of human pancreatic cancer models, demonstrating superior and complementary activity to existing U.S. Food and Drug Administration (“FDA”)-approved chemotherapy agents. SBP-101 has demonstrated encouraging activity against metastatic PDA in clinical trials of patients with pancreatic cancer. The safety results and PMI profile demonstrated in our completed first-in-human safety study provide support for the study of SBP-101 in combination with current standard pancreatic cancer treatment in patients previously untreated for metastatic pancreatic cancer.

 

To facilitate and accelerate the development of this compound for a potential metastatic PDA indication, we have also acquired data and materials related to this technology from other researchers. We believe that SBP-101, if successfully developed, may represent a novel approach that could effectively treat metastatic PDA. Only three first-line treatment combinations, a single maintenance treatment for a subset (3-7%) of patients, and one second-line drug have been approved by the FDA for any types of pancreatic cancers in the last 25 years.

 

In August 2015, the FDA accepted our Investigational New Drug (“IND”) application for our SBP-101 product candidate. We have completed an initial clinical trial of SBP-101 in patients with previously treated locally advanced or metastatic pancreatic cancer. This was a Phase 1, first-in-human, dose-escalation, safety study. From January 2016 through September 2017, we enrolled 29 patients into six cohorts, or groups, in the dose-escalation phase of the Phase 1 trial. Twenty-four of the patients had received at least two prior chemotherapy regimens. No drug-related serious adverse events occurred during the first four cohorts. In cohort five, serious adverse events (klebsiella sepsis with metabolic acidosis in one patient, renal and hepatic toxicity in one patient, and mesenteric vein thrombosis with metabolic acidosis in one patient) were observed in three of the ten patients, two of whom exhibited progressive disease at the end of their first cycle of treatment and were determined by the Data Safety Monitoring Board (“DSMB”) to have dose-limiting toxicities (“DLTs”). Consistent with the study protocol, the DSMB recommended continuation of the study by expansion of cohort 4, one level below that at which DLTs were observed. Four patients were enrolled in this expansion cohort. One patient developed focal pancreatitis at the site of the primary tumor after 2.3 months, and SBP-101 was considered well tolerated below dose level five. The most common drug related adverse events were nausea, vomiting, diarrhea, injection site pain and abdominal pain, which were mostly mild, grades 1 or 2, and are symptoms common in patients with pancreatic cancer. No drug-related bone marrow toxicity or peripheral neuropathy was observed at any dose level.

 

In addition to being evaluated for safety, 23 of the 29 patients were evaluable for preliminary signals of efficacy prior to or at the eight-week conclusion of their first cycle of treatment using the Response Evaluation Criteria in Solid Tumors (“RECIST”), the current standard for evaluating change in the size of tumors. Eight of the 23 patients (35%) had Stable Disease (“SD”) and 15 of 24 (65%) had Progressive Disease (“PD”). It should be noted that of the 15 patients with PD, six came from cohorts one and two and are considered to have received less than potentially therapeutic doses of SBP-101. We also noted that 28 of the 29 patients had follow-up blood tests measuring the Tumor Marker CA 19-9 associated with pancreatic ductal adenocarcinoma. Eleven of these patients (39%) had reductions in the CA 19-9 levels, as measured at least once after the baseline assessment. Seven of the remaining 17 patients who showed no reduction in CA 19-9 came from cohorts one and two.

 

By cohort, SD occurred in two patients in cohort 3, two patients in cohort 4 and four patients in cohort 5. The best response outcomes and best median survival were observed in the group of patients who received total cumulative doses of approximately 6 mg/kg (cohort 3). Two of four patients (50%) showed SD at week eight. Median survival in this group was 5.9 months, with two patients surviving 8 and 10 months, respectively. By total cumulative dose received, five of 12 patients (42%) who received total cumulative doses between 2.5 mg/kg and 8.0 mg/kg had reductions in the CA19-9 levels, as measured at least once after the baseline assessment. Nine of these patients (67%) exceeded 3 months of overall survival (“OS”), three patients (25%) exceeded 9 months of OS and two patients (17%) exceeded 1 year of OS and were still alive at the end of the study. With the approval of the DSMB, we cancelled the Phase 1b portion of the first-in-human monotherapy study in order to evaluate SBP-101 as a first line, combination chemotherapy in pancreatic cancer patients.

 

43

 

We began enrolling patients in our current first-line clinical trial in June of 2018. This second clinical trial is a Phase 1a/1b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel. We are currently conducting the trial at six study sites (four in Australia and two in the United States). In the Phase 1a portion of this trial, we enrolled three cohorts of four to nine patients with increased dosage levels of SBP-101 administered in the second and third cohorts. We completed enrollment in the first three cohorts of Phase 1a in the fourth quarter of 2019, and, based on preliminary safety findings, a 4th cohort began enrollment in January 2020. We completed enrollment in this 4th cohort in February 2020. Demonstration of adequate safety in Phase 1a has enabled Phase 1b exploration of efficacy, in which we plan to enroll a maximum 36 patients using the recommended dosage regimen determined in Phase 1a. We began enrolling in this expansion phase in February of 2020. Additional funding will be required to complete the Phase 1b clinical trial and to plan a randomized phase 2 study. As of December 31, 2019, preliminary efficacy results from evaluable patients in cohorts 2 and 3 (N=13) showed manageable toxicity, an objective response rate of 62% and a disease control rate of 85%, with several patients still ongoing. Interim results from the Phase 1b expansion are expected to become available in the second half of 2020.

 

Through the date of this prospectus, we have:

 

 

organized the Company;

 

 

evaluated and secured intellectual property for our core technology;

 

 

completed required pre-clinical steps in the development plan for SBP-101 for pancreatic cancer;

 

 

secured an orphan drug designation from the FDA;

 

 

submitted an investigational new drug (“IND”) application to the FDA in May 2015;

 

 

received an acceptance of an IND application from the FDA in August 2015;

 

 

received acceptance of a Clinical Trial Notification by the Australian Therapeutic Goods Administration in September 2015;

 

 

completed a Phase 1a monotherapy safety study of SBP-101in the treatment of patients with metastatic pancreatic ductal adenocarcinoma;

 

 

completed synthetic process improvement measures expected to be scalable for commercial use and secured intellectual property on this process;

 

 

commenced a second Phase 1a /1b clinical study of SBP-101, a front-line study with SBP-101 given in combination with a current standard of care in patients with pancreatic ductal adenocarcinoma who are previously untreated for metastatic disease; 24 subjects have been enrolled in the Phase 1a portion of the study and we transitioned to enrollment in the Phase 1b portion of the study in February 2020; and

 

 

received Fast Track Designation from the FDA for SBP-101 in June 2020.

 

Introduction

 

An effective treatment for pancreatic cancer remains a major unmet medical need. Adenocarcinoma of the pancreas, which accounts for approximately 95% of all cases of pancreatic cancer, has a median overall survival of 8 to 11 months in clinical studies of patients with favorable prognostic signs and optimal standard chemotherapy. A recent report from the Pancreatic Cancer Action Network states that pancreatic cancer deaths in the United States have surpassed those from breast cancer and will soon surpass deaths from colorectal cancer to rank number two in US cancer deaths, behind only lung cancer in 2020. The five-year survival rate remains less than 3% for patients diagnosed with metastatic pancreatic cancer and approximately 8.5% across all pancreatic stages, and there has been little significant improvement in survival since gemcitabine was approved in the United States in 1996.

 

44

 

Pancreatic cancer is generally not diagnosed early because the initial clinical signs and symptoms are vague and non-specific. By the time of diagnosis, the cancer is most often locally advanced or metastatic, having spread to regional lymph nodes, liver, lung and/or peritoneum, and is seldom amenable to surgical resection, or removal, with curative intent. Currently, surgical resection offers the only potentially curative therapy, although only approximately 20% of patients are candidates for surgical resection at the time of the diagnosis. Patients who undergo radical surgery still have a limited survival rate, averaging 23 months (Macarulla T, et al Clin Transl Oncol 2017).

 

The prognosis for patients diagnosed with pancreatic cancer is poor and most die from complications related to progression of the disease. The primary treatment for metastatic disease is chemotherapy. Current first-line chemotherapy treatment regimens vary from single agent gemcitabine (FDA approved 1996) and various gemcitabine combinations to the multi-chemotherapy drug combination, FOLFIRINOX, comprised of leucovorin, fluorouracil, irinotecan, and oxaliplatin (Conroy NEJM 2011), frequently supplemented with white blood cell (“WBC”) growth factors. In clinical practice, the FOLFIRINOX regimen is often modified to “FOLFIRINOX Light”, a non-specific term referring to various permutations based on the FOLFIRINOX regimen, but with either lower doses of one or more of the agents, or elimination of one or more of the agents, due to actual or anticipated toxicity. These two standard combination therapies deliver median survival benefits ranging from 7 weeks with gemcitabine and nab-paclitaxel (Von Hoff NEJM 2013) to 4 months FOLFIRINOX (Conroy NEJM 2011) when compared with gemcitabine alone for selected patients with good performance status, meaning that they are in relatively good physical condition at the time of diagnosis. In 2015, the FDA approved Onivyde® (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with a gemcitabine-based chemotherapy. Second line Onivyde is not widely prescribed as indicated because most patients with good performance status who have been previously treated with a gemcitabine-based chemotherapy receive variations of the FOLFIRINOX (which includes generic irinotecan) regimen. On December 27, 2019, the FDA approved olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals LP) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (PDAC), as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Approximately 3% to 7% of individuals with PDAC harbor a BRCA1 or BRCA2 mutation, which are among the most frequently mutated genes in PDAC (Rainone M, et al, An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review. JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]).

 

University research laboratory studies at select dose levels have demonstrated that SBP-101 induces programmed cell death, or “apoptosis,” in the acinar and ductal cells of the pancreas by activation of caspase 3 and poly (adenosine diphosphate-ribose) polymerase (“PARP”) cleavage. In animal models at three independent laboratories, SBP-101, alone or in combination, has demonstrated nearly complete suppression of transplanted human pancreatic cancer, including metastases. SBP-101 has demonstrated both superior and additive efficacy to gemcitabine and nab-paclitaxel in laboratory models of pancreatic cancer. We intend to develop SBP-101 as a unique and novel targeted approach to treating patients with pancreatic cancer, specifically pancreatic ductal adenocarcinoma (“PDA”), administered in combination with existing standard chemotherapy agents. With adequate funding, we also expect to commence evaluation of the potential value of SBP-101 in other chemotherapy combinations.

 

Pancreatic Cancer

 

Pancreatic cancer afflicts approximately 133,000 people in Europe (GLOBOCAN2018, Global Cancer Observatory/World Health Organization), approximately 57,000 people in the United States annually (https://seer.cancer.gov/statfacts/html/pancreas.html), and 270,000 people worldwide – excluding Europe and United States (GLOBOCAN2018). It has been identified as the seventh leading cause of death from cancer in Europe (GLOBOCAN 2018) and the third leading cause of death from cancer in the United States (SEER Cancer Statistics Factsheets 2019). On average PDA represents approximately 95% of all pancreatic cancers diagnosed in given calendar year. Considering that the median overall survival for previously untreated patients with good performance status is between 8.5 months (Von Hoff 2013) and 11.1 months (Conroy 2011) with the two most commonly available treatment regimens, effective treatment for PDA has remained a major unmet medical need.

 

45

 

Pancreatic cancer is generally not diagnosed early because the initial clinical signs and symptoms are vague and non-specific. The most common presenting symptoms include weight loss, epigastric (upper central region of the abdomen) and/or back pain, and jaundice. The back pain is typically dull, constant, and of visceral origin radiating to the back, in contrast to the epigastric pain which is vague and intermittent. Less common symptoms include nausea, vomiting, diarrhea, anorexia, and new onset diabetes or glucose intolerance (Hidalgo 2010).

 

Surgery remains the only treatment option with curative intent, although only about 20% of patients are candidates for surgical resection at the time of the diagnosis. Patients who undergo radical surgery still have a limited survival rate, averaging 23 months (Macarulla T, et al Clin Transl Oncol 2017).

 

For the minority of patients who present with resectable disease, surgery is the treatment of choice. Depending on the location of the tumor the operative procedures may involve cephalic pancreatoduodenectomy, referred to as a “Whipple procedure”, distal pancreatectomy or total pancreatectomy. Pancreatic enzyme deficiency and diabetes are frequent complications of these procedures. Up to 70% of patients with pancreatic cancer present with biliary obstruction that can be relieved by percutaneous or endoscopic stent placement. However, even if the tumor is fully resected, the outcome in patients with pancreatic cancer has been disappointing (Hidalgo 2010, Seufferlein 2012). Post-operative administration of chemotherapy improved progression-free and overall survival in three large randomized clinical trials (Hidalgo 2010), but median post-surgical survival in patients treated in all three trials was similar, only 20-22 months.

 

For patients who present with unresectable, locally advanced or metastatic disease, which represent a majority of PDA patients, management options range from chemotherapy alone to combined forms of treatment with radiation therapy and chemotherapy. However, due to the increased toxicity of combined treatment, randomized trials of such combined regimens have had low enrollment, precluding a firm conclusion as to any advantage of adding radiation to chemotherapy (Hidalgo 2010).

 

Gemcitabine was the first chemotherapeutic agent approved for the treatment of patients with PDA in the modern regulatory era, providing a median survival duration of 5.65 months (Burris 1997). Gemcitabine monotherapy was the standard of care for patients with metastatic pancreatic cancer until combination therapy with gemcitabine plus erlotinib (Tarceva®) was shown to increase median survival by two weeks. This modest benefit was tempered by a significant side effect profile and high cost, limiting its adoption as a standard treatment regimen. Subsequently, the multidrug chemotherapy combination FOLFIRINOX, was shown to provide a median survival benefit of 4.3 months (OS = 11.1 months) over gemcitabine alone (6.8 months), but its significant side effect profile limits the regimen to select patients with a good performance status and often requires supplementation with WBC growth factor therapy. Nab-paclitaxel (Abraxane®) received marketing authorization for use in combination with gemcitabine (FDA approved 2013) after showing an increase in overall survival of seven weeks compared to gemcitabine alone (Von Hoff 2013). Thus, combination therapies have demonstrated a modest survival benefit compared to gemcitabine alone as summarized in the table below (Thota 2014).

 

46

 

Current Treatment Approaches: Survival & Toxicity Profiles Across Three Major Positive Clinical Trials

 

 

Gemcitabine vs. 

Gemcitabine/Erlotinib

Phase 3 trial

ACCORD 11 Trial

Metastatic Pancreatic

Adenocarcinoma Clinical

Trial (MPACT)

 

Gemcitabine

Gemcitabine/

Erlotinib

Gemcitabine

FOLFIRINOX(1)

Gemcitabine

Gemcitabine/

Nab-Paclitaxel

One-Year Survival

17%

23%

20.6%

48.4%

22%

35%

Median Overall Survival

5.91 mo

6.24 mo

6.8 mo

11.1 mo

6.7 mo

8.5 mo

Median Progression-Free Survival

3.55 mo

3.75 mo

3.3 mo

6.4 mo

3.7 mo

5.5 mo

Overall Response Rate

8%

8.6%

9.4%

31.6%

7%

23%

Toxicity

           

Neutropenia

21%

45.7%

27%

38%

Febrile neutropenia

1.2%

5.4%

1%

3%

Thrombocytopenia

3.6%

9.1%

9%

13%

Diarrhea

2%

6%

1.8%

12.7%

1%

6%

Sensory neuropathy

0%

9%

1%

17%

Fatigue

15%

15%

17.8%

23.6%

7%

17%

Rash

6%

1%

Stomatitis

<1%

0%

Infection

17%

16%

Source: Thota R et al., Oncology 2014; Jan 28(1):70–74

 

Other drugs are currently under investigation, but none have received marketing authorization as a first-line treatment of PDA since the approval of Abraxane. Lynparza®, (olaparib) was approved in December 2019 for maintenance therapy of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.

 

Proprietary Technology

 

Function and Characteristics of Polyamines

 

Polyamines are metabolically distinct entities within human cells that bind to and facilitate DNA replication, RNA transcription and processing, and protein (such as pancreatic enzymes) synthesis. Human cells contain three essential and naturally occurring polyamines - putrescine, spermidine, and spermine. Polyamines perform many functions necessary for cellular proliferation, apoptosis and protein synthesis. The critical balance of polyamines within cells is maintained by several enzymes such as ornithine decarboxylase (“ODC”) and spermidine/spermine N1 acetyl transferase (“SSAT”). All of these homeostatic enzymes are short-lived, rapidly inducible intracellular proteins that serve to tightly and continuously regulate native polyamine pools. These enzymes constantly maintain polyamines within a very narrow range of concentration inside the cell.

 

Polyamine Analogues

 

Many tumors, including pancreatic cancer, display an increased uptake rate of polyamines. Polyamine analogues such as SBP-101 are structurally similar to naturally occurring polyamines and are recognized by the cell’s polyamine uptake system, allowing these compounds to gain ready entrance to the cell. We believe that pancreatic acinar cells, because of their extraordinary protein synthesis capacity, exhibit enhanced uptake of polyamines and polyamine analogues such as SBP-101. Because of this preferential uptake by pancreatic acinar cells, polyamine analogues such as SBP-101 disrupt the cell’s polyamine balance and biosynthetic network, and induce programmed cell death, or apoptosis, via processes including caspase 3 activation and poly ADP ribose polymerase (PARP) cleavage. Proof of concept has been demonstrated in multiple human pancreatic cancer models, both in vivo and in vitro, that pancreatic ductal adenocarcinoma exhibits sensitivity to SBP-101.

 


(1) FOLFIRINOX is leucovirin, fluorouracil, irinotecan, and oxaliplatin.

 

47

 

SBP-101

 

SBP-101 is a proprietary polyamine analogue, which we believe accumulates in the acinar cells due to its unique chemical structure. SBP-101 was discovered and extensively studied by Professor Raymond J. Bergeron at the University of Florida College of Pharmacy.

 

Laboratory studies suggest the primary mechanism of action for SBP-101 has been demonstrated to include the enhanced uptake of the compound in the exocrine pancreas. Sufficiently high dosing leads to correspondingly depressed levels of native polyamines, with caspase 3 activation, PARP cleavage and apoptotic destruction (programmed cell death) of the exocrine pancreatic acinar and ductal cells without an inflammatory response. Importantly, pancreatic islet cells, which secrete insulin, are structurally and functionally dissimilar to acinar cells and are not impacted by SBP-101. In animal models at two independent laboratories, SBP-101 has demonstrated significant suppression of transplanted human pancreatic cancer cells, including metastatic pancreatic cancer growth. See “Proof of Principle” below.

 

We believe that SBP-101 exploits the natural affinity of the exocrine pancreas, the liver and kidney, and pancreatic ductal adenocarcinoma cells while leaving the insulin-producing islet cells unharmed. Most current cancer therapies, including chemotherapy, radiation and surgery, are associated with significant side effects that further reduce the patient’s quality of life. However, we believe that the adverse effects of SBP-101 do not overlap with or exacerbate those seen with typical chemotherapy options. The dose-limiting toxicities observed in cohort five of our Phase 1a study, as noted above, were not observed at lower doses and are not expected to overlap with the adverse events of bone marrow suppression and peripheral neuropathy commonly associated with standard chemotherapy. As the endocrine pancreas is expected to be unaffected by SBP-101, no impact on insulin requirement is expected.

 

Proof of Principle

 

SBP-101 has been tested and found effective in reducing pancreatic tumor growth in multiple separate in vivo models of human pancreatic cancer. SBP-101 was used to treat mice subcutaneously implanted with human pancreatic cancer cell line PANC-1 tumor fragments. A dose-response for efficacy was demonstrated with a 26 mg/kg daily injection resulting in near complete suppression of the transplanted tumor.

 

A separate orthotopic xenograft study (direct implant of human tumor cells into the pancreas of the mouse) employed a particularly aggressive human pancreatic cancer cell line, L3.6pl, that is known to metastasize from the pancreas to the liver and the peritoneum in mice. Mice implanted with L3.6pl were treated with SBP-101 and the results were compared with saline-treated control mice, with mice treated with gemcitabine alone (Gemzar®, the then current “gold standard” treatment), and the combination of both drugs. SBP-101 significantly reduced tumor volume compared to gemcitabine alone and the control group, but the combination of SBP-101 and gemcitabine was significantly better than gemcitabine alone as shown in Figure 1.

 

48

 

Figure 1.  L3.6pl Orthotopic Xenograft Study - Mean (+SD) Tumor Volume after Treatment with SBP-101, Gemcitabine (Gemzar®) or Both

 

Source: Study101-Biol-101-001

 

The potential for SBP-101 as an effective therapy for pancreatic cancer has been demonstrated in vivo by separate investigators, in different human pancreatic cancer cell lines and in three different animal models, using SBP-101 synthesized by two different routes, confirming nearly equal, and effective, doses of 25 and 26 mg/kg, respectively.

 

Additionally, when compared in vitro to existing therapies, SBP-101 produced superior results in suppressing growth of pancreatic cancer cells.

 

Development Plan for SBP-101

 

Development of SBP-101 for the pancreatic cancer indication includes a pre-clinical and a clinical phase. The pre-clinical phase, which was substantially completed during 2015, consists of four primary components: chemistry, manufacturing and controls (“CMC”), preclinical (laboratory and animal) pharmacology studies, preclinical toxicology studies, and regulatory submissions in Australia and the United States. In Australia, a Human Research Ethics Committee (“HREC”) application was submitted with subsequent Clinical Trial Notification (“CTN”) to the Therapeutic Goods Administration (“TGA”). Preceding the Australian initiative, a similar, but considerably more extensive, preclinical package has been submitted to and accepted by the FDA in support of an IND application. Our initial clinical trial in previously treated patients with locally advanced or metastatic pancreatic cancer was a Phase 1, first-in-human, dose-escalation, safety study conducted at clinical sites in both Australia and the United States. We engaged expert clinicians who treat pancreatic cancer at major cancer treatment centers in Melbourne and Adelaide, Australia as well as the Mayo Clinic Scottsdale and HonorHealth in Scottsdale, Arizona. These Key Opinion Leaders, with proven performance in pancreatic cancer studies, enthusiastically agreed to participate as investigators for our Phase 1 First-in-Human study.

 

Enrollment in our initial Phase 1 safety trial of SBP-101 in previously treated pancreatic cancer patients commenced in January 2016 and was completed in September 2017. This study was a dose-escalation study with 8-week treatment/observation cycles at each dose level. Results from this trial are discussed in Clinical Development – Pancreatic Cancer below.

 

49

 

We began enrolling patients in our second clinical trial in June of 2018. This second clinical trial is a Phase 1a/1b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel. We are currently conducting the trial at six study sites (four in Australia and two in the United States). In the Phase 1a portion of this trial, we have completed enrollment in the fourth quarter of 2019 of three cohorts of four to nine patients with increased dosage levels of SBP-101 administered in the second and third cohorts and completed enrollment in February of 2020 in a fourth cohort to explore an alternate dosing schedule. Demonstration of adequate safety in Phase 1a allowed us to immediately begin enrollment in February 2020 in the Phase 1b exploration of efficacy. We expect to enroll up to 36 patients using the recommended dosage level and schedule determined in Phase 1a. Early results from the Phase 1b expansion could become available in the second half of 2020.

 

With additional funding SBP-101 may also be explored for neo-adjuvant and/or adjuvant treatment in appropriate patients. There is also preclinical data to suggest that SBP-101 may have potential therapeutic uses for cancers other than pancreatic, but due to the current focus on pancreatic cancer, none have been formally explored.

 

Preclinical Development

 

To enable IND and HREC/CTN submission and as part of our pharmacology work, we conducted plasma and urine assay development and validation in animals, in vitro metabolism studies in liver microsomes and hepatocytes, in vitro interaction studies with hepatic and renal transporters, a protein binding study, animal pharmacokinetic and metabolism/mass balance studies, and human plasma and urine assay development and validation. As a part of the pharmacology evaluation, we conducted an in vitro pharmacology screen profiling assay, a study in six human pancreatic cell lines, and studies in tumor xenograft models in mice using flank transplants of human pancreatic cancer PANC-1 tumor fragments and human pancreatic cancer BxPC-3 tumor fragments as well as human pancreatic cancer cells (L3.6pl) injected orthotopically into the pancreas of nude mice.

 

To meet regulatory requirements and to establish the safety profile of SBP-101, we conducted, in rodents and non-rodents, toxicology dose-ranging studies, IND-enabling GLP (good laboratory practice) toxicology studies, and genetic toxicology studies, including an Ames test. Exploratory studies in mice and rats and a GLP-compliant dog toxicology study have also been completed. The relationship between dose and exposure (pharmacokinetics) has been described for three animal species. We have also completed a preclinical Human Ether-a-go-go-related Gene assay to detect any electrocardiographic QTc interval effects (IKr potassium ion channel testing).

 

In anticipation of the human potential for using SBP-101 in combination therapy with gemcitabine and/or nab-paclitaxel (Abraxane®), we also conducted appropriate nonclinical studies which confirmed the potential value of such combinations, including assessing the comparative efficacy of SBP-101, gemcitabine and nab-paclitaxel in various combinations as shown in Figure 2.

 

50

 

Figure 2. Evaluation of SBP-101 alone and in combination with gemcitabine and nab-paclitaxel in 6 human pancreatic cancer cell lines

 

Source: Baker CB et al Pancreas 2015;44(8) 1350

 

Note that maximum percent growth inhibition (mean ± SE) at 96 hours was observed with 10 µM SBP-101 alone and in combination with gemcitabine and/or nab-paclitaxel in six human pancreatic cancer cell lines.

 

We have met FDA-mandated CMC requirements with a combination of in-house expertise and contractual arrangements. Preparation of anticipated metabolites, impurities and an internal standard, as a prerequisite for analytical studies, were completed through a Sponsored Research Agreement with the University of Florida and a contract manufacturer. We have Service Agreements with Syngene International Ltd. (“Syngene”) for the manufacture and supply of Good Manufacturing Practice (“GMP”)-compliant SBP-101 active pharmaceutical ingredient (“API”) and for the development of synthetic process improvements. Investigational product (IP or clinical trial supply) has been made and tested at Albany Molecular Research Inc. (“AMRI”) in Burlington, MA. Initial lots of GMP-compliant API were prepared by Syngene and released for conversion into supply dosage form. Two clinical trial supply lots have been successfully prepared and released by AMRI. In addition, efforts have continued to refine the synthetic process at Syngene. A new shorter synthetic process has been developed and submitted for patent protection.

 

Pancreatic Cancer IND

 

Our IND application package contained the following:

 

 

Investigator’s Brochure;

 

 

Statement of general investigative plans;

 

 

Proposed Phase 1 pancreatic cancer study protocol;

 

 

Data management and statistical plan;

 

 

CMC data; and

 

 

Pharmacology, absorption, distribution, metabolism and excretion (“ADME”), and toxicology data.

 

51

 

Preparation of the SBP-101 IND for pancreatic cancer required collaboration by our manufacturing, preclinical toxicology, pharmacokinetic and metabolism experts, our regulatory affairs project management, and our in-house clinical expertise. In August 2015, the FDA accepted our application and in January 2016 we commenced patient enrollment in our first Phase 1 clinical trial, which was a safety and tolerability study in patients with previously treated metastatic pancreatic ductal adenocarcinoma.

 

Clinical Development – Pancreatic Cancer

 

Phase 1 Clinical Trial

 

Our initial Phase 1 study in patients with pancreatic cancer commenced the enrollment of patients in January 2016 and enrollment was completed in September 2017. This study was a dose-escalation study with 8-week cycles of treatment/observation at each dose level.

 

A favorable characteristic of the pancreatic action of SBP-101 is the lack of an effect on the normal insulin-producing islet cells. Preservation of islet cell function implies the likely absence of diabetes as a complication of SBP-101 therapy. It is important to note that diabetes is a common co-morbidity in patients with pancreatic cancer, but it is not expected to be an adverse effect of treatment with SBP-101. The potential adverse effect of exocrine pancreatic insufficiency is mitigated by the observation that many patients with pancreatic ductal adenocarcinoma require pancreatic enzyme replacement as a feature of their underlying disease, a complication so common that pancreatic enzyme replacement with one of several commercially available products is typically covered by United States and Australian health care plans. Patients with cystic fibrosis, chronic pancreatitis and pancreatic cancer are the populations most often treated with pancreatic enzyme replacement.

 

Patients in our Phase 1 first-in-human trial underwent regular pancreatic and hepatic enzyme evaluation and obtained periodic chest and abdominal CT follow-up. Patients were also carefully monitored for clinical signs of GI adverse events, but no new onset of exocrine pancreatic insufficiency was attributed to SBP-101 therapy.

 

In August 2015, the FDA accepted our IND application for our SBP-101 product candidate. We have completed an initial clinical trial of SBP-101 in patients with previously treated locally advanced or metastatic pancreatic cancer. This was a Phase 1, first-in-human, dose-escalation, safety study. Between January 2016 and September 2017, we enrolled twenty-nine patients into six cohorts, or groups, in the dose-escalation phase of our Phase 1 trial. Twenty-four of the patients received at least two prior chemotherapy regimens. No drug-related serious adverse events occurred during the first four cohorts. In cohort five, serious adverse events (klebsiella sepsis with metabolic acidosis in one patient, renal and hepatic toxicity in one patient, and mesenteric vein thrombosis with metabolic acidosis in one patient) were observed in three of the ten patients, two of whom exhibited progressive disease at the end of their first cycle of treatment and were determined by the DSMB to be DLTs. Consistent with the study protocol, the DSMB recommended continuation of the study by expansion of cohort 4, one level below that at which DLTs were observed. Four patients were enrolled in this expansion cohort. One patient developed focal pancreatitis at the site of the primary tumor after 2.3 months, but SBP-101 was considered well tolerated below dose level five. The most common drug related adverse events were nausea, vomiting, diarrhea, injection site pain and abdominal pain, which were mostly mild, grades 1 or 2, and are symptoms common in patients with pancreatic cancer. No drug-related bone marrow toxicity or peripheral neuropathy was observed at any dose level.

 

In addition to being evaluated for safety, 23 of the 29 patients were evaluable for preliminary signals of efficacy prior to or at the eight-week conclusion of their first cycle of treatment using the RECIST, the current standard for evaluating changes in the size of tumors. Eight of the 23 patients (35%) had SD and 15 of 24 (65%) had PD. It should be noted that of the 15 patients with PD, six came from cohorts one and two and are considered to have received less than potentially therapeutic doses of SBP-101. We also noted that 28 of the 29 patients had follow-up blood tests measuring the Tumor Marker CA 19-9 associated with pancreatic ductal adenocarcinoma. Eleven of these patients (39%) had reductions in the CA 19-9 levels, as measured at least once after the baseline assessment. Seven of the remaining 17 patients who showed no reduction in CA 19-9 came from cohorts one and two.

 

By cohort, stable disease occurred in two patients in cohort 3, two patients in cohort 4 and four patients in cohort 5. The best response outcomes and best median survival were observed in the group of patients who received total cumulative doses of approximately 6 mg/kg (cohort three). Two of four patients (50%) showed SD at week eight. Median survival in this group was 5.9 months, with two patients surviving 8 and 10 months, respectively. By total cumulative dose received, five of twelve patients (42%) who received total cumulative doses between 2.5 mg/kg and 8.0 mg/kg had reductions in the CA19-9 levels, as measured at least once after the baseline assessment. Nine of these patients (67%) exceeded three months of OS, three patients (25%) exceeded nine months of OS and two patients (17%) exceeded one year of OS and were still alive at the end of the study.

 

52

 

Figure 3. Evaluation of SBP 101 Phase 1Mono-therapy Safety Trial - Median Survival by Cohort

 

 

The absence of adverse events which could potentially overlap with adverse events typically observed in the use of conventional chemotherapeutic agents, supports the case for combination of SBP-101 with conventional chemotherapeutic agents, such as gemcitabine, nab-paclitaxel, or even FOLFIRINOX.

 

Phase 1a/1b Clinical Trial Design (First Line Combination Therapy)

 

Given the life-threatening nature of pancreatic ductal adenocarcinoma, the limited efficacy of current treatment options, and the long history of failures in pancreatic ductal adenocarcinoma developmental therapeutics, we will attempt to evaluate SBP-101 expeditiously as noted below.

 

We began enrolling patients in our current first-line clinical trial in June of 2018. This second clinical trial is a Phase 1a/1b study of the safety, efficacy and pharmacokinetics of SBP-101 administered in combination with two standard-of-care chemotherapy agents, gemcitabine and nab-paclitaxel. We are currently conducting the trial at six study sites (four in Australia and two in the United States). In the Phase 1a portion of this trial, we enrolled in three planned cohorts of four to nine patients with increased dosage levels of SBP-101 administered in the second and third cohorts. We completed enrollment in the 3 planned cohorts of Phase 1a in the fourth quarter of 2019, however, based on preliminary safety findings, a fourth cohort was added to explore an alternate dosing schedule. Enrollment in this 4th cohort was completed in February 2020. Demonstration of adequate safety in Phase 1a has led to a Phase 1b exploration of efficacy, in which we anticipate enrolment of up to thirty-six (36) patients using the recommended dosage level and schedule determined in Phase 1a. We began enrolling in this expansion phase in February 2020. As of December 31, 2019, preliminary efficacy results from evaluable patients in cohorts 2 and 3 (N=13) showed manageable toxicity, an objective response rate of 62% and a disease control rate of 85%, with several patients still ongoing. Early results from the Phase 1b expansion are expected to become available in the second half of 2020.

 

53

 

Figure 4. Evaluation of SBP 101 Phase 1a First-line combo-therapy Safety Trial – Best Response Rate

 

 

Best Response per Subject – Cohorts 2 and 3, N=13. Best response in evaluable subjects was PR in 8 (62%), SD in 5 (38%). Three subjects did not have post baseline scans with RECIST tumor assessments. Source: Kotasek D, Abstract 710, ASCO GI 2020

 

Phase 2 Clinical Trial

 

A randomized Phase 2 study of SBP-101 in combination with two standard chemotherapy agents, gemcitabine and nab-paclitaxel, is expected to follow the Phase 1a/1b safety study providing continued evaluation of safety and efficacy.

 

If we are able to successfully complete all FDA recommended clinical studies, we intend to seek marketing authorization from the FDA, the EMA (European Union), Ministry of Health and Welfare (Japan) and TGA (Australia). The submission fees may be waived when SBP-101 has been designated an orphan drug in each geographic region, as described under “Orphan Drug Status.”

 

Total Development Costs

 

The development of SBP-101 involves a preclinical and a clinical development phase. We have completed our initial preclinical development work for pancreatic cancer and are completing our second Phase 1 clinical trial. Additional clinical trials will be required for FDA or other approvals in foreign jurisdictions if the results of the front-line clinical trial of our SBP-101 product candidate justify continued development. The cost and timing of additional clinical trials is highly dependent on the nature and size of the trials.

 

Orphan Drug Status

 

The Orphan Drug Act (“ODA”) provides special status to drugs which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States, or that affect more than 200,000 persons but for which a manufacturer is not expected to recover the costs of developing and marketing such a drug. Orphan drug designation has the advantage of reducing drug development costs by: (i) streamlining the FDA’s approval process, (ii) providing tax breaks for expenses related to the drug development, (iii) allowing the orphan drug manufacturer to receive assistance from the FDA in funding the clinical testing necessary for approval of an orphan drug, and (iv) facilitating drug development efforts. More significantly, the orphan drug manufacturer’s ability to recover its investment in developing the drug is also greatly enhanced by the FDA granting the manufacturer seven years of exclusive US marketing rights upon approval. Designation of a product candidate as an orphan drug therefore may provide its sponsor with the opportunity to adopt a faster and less expensive pathway to commercializing its product. We obtained US Orphan Drug Status in 2014 and we intend to submit an application for Orphan Drug Status in Europe, Japan and Australia when we have additional clinical data.

 

54

 

Intellectual Property Status

 

We have filed International Patent Application No. PCT/US19/15581 Titled METHODS FOR PRODUCING (6S,15S)-3,8,13,18- TETRAAZAICOSANE-6,15-DIOL. This patent application claims a novel process for the production of SBP-101 and reduces the number of synthetic steps from nineteen to six.

 

Development Project Managers

 

Project managers have been hired or contracted to coordinate all the functions identified in our Development Plan for SBP-101. The personnel responsible for overseeing critical functions of the Development Plan are as follows:

 

Our CMC program is under the direction of Dr. Thomas Neenan, Ph.D., a highly experienced pharmaceutical industry synthetic chemist, who is a founding member of Sun BioPharma, Inc. and our Chief Scientific Officer. Dr. Neenan has commissioned Contract Manufacturing Organizations (“CMOs”), which have improved the process for synthesis of SBP-101, and have produced high-quality compound, chemically identical to that synthesized by Dr. Bergeron at the University of Florida. Dr. Neenan’s completed work includes development, confirmation and documentation of the synthetic chemistry process, analytical purity, reproducibility, stability (shelf-life), degradation products and pharmaceutical formulation and packaging. This work has culminated in adequate supplies of drug to support preclinical work and human clinical trials. Dr. Neenan also leads our preclinical group.

 

Dr. Anthony L. Kiorpes, Ph.D., D.V.M., is a long-term consultant with the Company. Dr. Kiorpes has responsibility for our toxicology program, a role he has assumed previously for many preclinical projects at other companies. His studies have determined single- and multiple-dose safety profiles in rodent and non-rodent species, enabling improved safety monitoring in the design of clinical trials for SBP-101. Dr. Kiorpes’ results have helped management to predict and prevent potential side effects in humans.

 

Dr. Michael T. Cullen, M.D., M.B.A, is our founder and Executive Chairman, President and Chief Executive Officer (“CEO”). Dr. Cullen is an experienced drug development specialist with 10 prior NDA approvals and has led our overall Clinical, Regulatory Affairs and Project Management effort, including timeline and budget management, critical path timeline synchronization, IND/HREC/CTN package submissions, management of industry partner collaborative efforts, initial EU Regulatory Affairs planning, and collaboration on oversight of outsourced CMC efforts. Dr. Cullen has recruited additional experienced and talented staff in the positions of statistical analyses, manufacturing operations, clinical operations, clinical research and non-clinical studies.

 

Dr. Suzanne Gagnon, M.D., is our Chief Medical Officer (“CMO”) and a member of our Board of Directors. Dr. Gagnon is an experienced CMO, having served in that capacity for several private and public companies, including BioPharm/IBAH/Omnicare, ICON, Idis, NuPathe, Luitpold (Daiichi-Sankyo), and Rhone-Poulenc and Rorer (Sanofi) where she helped develop docetaxel, an important chemotherapy agent. Dr. Gagnon assumed the lead in the design and implementation of our clinical trials, recruiting investigators, monitoring the safety of the patients and reporting the findings to the FDA, EMA and TGA, and in medical literature.

 

Dr. Michael J. Walker is an independent consultant for the Company and works as our Director of Pancreatic Research. Dr. Walker is an accomplished, University of Minnesota and UCLA trained pancreatic surgeon, and is currently a part-time instructor at the University of Minnesota School of Medicine. He was also the recipient of an NIH grant to study SBP-101 in collaboration with colleagues at Cedars Sinai Hospital in Los Angeles.

 

55

 

We have engaged Courante Oncology, an experienced clinical Contract Research Organization (“CRO”), to manage clinical operations in the United States, and have engaged Novotech Pty Ltd, another experienced CRO for our Australian operations. These two CROs will provide regulatory documentation for HREC/CTN and Investigational Review Board (“IRB”) submissions, FDA 1571 regulation compliance, and informed consents, as well as clinical study site qualification, contracting and payment, study conduct monitoring, data collection, analysis and reporting.

 

Competition

 

The development and commercialization of new products to treat cancer is intensely competitive and subject to rapid and significant technological change. While we believe that our knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies worldwide. Many of our competitors have significantly greater financial, technical, and human resources. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products before or more successfully than we do.

 

We face competition with respect to our current product candidates and will face competition with respect to future product candidates, from segments of the pharmaceutical, biotechnology and other related markets that pursue approaches to targeting molecular alterations and signaling pathways associated with cancer. Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates. Our competitors may also develop drugs that are more effective, more convenient, less costly, or possessing better safety profiles than our products, and these competitors may be more successful than us in manufacturing and marketing their products.

 

In addition, we may need to develop our product candidates in collaboration with diagnostic companies, and we will face competition from other companies in establishing these collaborations. Our competitors will also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

 

Furthermore, we also face competition more broadly across the market for cost-effective and reimbursable cancer treatments. The most common methods of treating patients with cancer are surgery, radiation and drug therapy, including chemotherapy, immunotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates, if any are approved, may compete with these existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates may be approved as companion treatments and not be competitive with current therapies. Some of these drugs are branded and subject to patent protection, and others are available on a generic basis. Insurers and other third-party payors may also encourage the use of generic products or specific branded products. We expect that if our product candidates are approved, they will be priced at a premium over competitive generic, including branded generic, products. As a result, obtaining market acceptance of, and gaining significant share of the market for, any of our product candidates that we successfully introduce to the market will pose challenges. In addition, many companies are developing new therapeutics and we cannot predict what the standard of care will be as our product candidate progresses through clinical development.

 

SBP-101

 

Commercialization

 

We have not established a sales, marketing or product distribution infrastructure nor have we devoted significant management resources to planning such an infrastructure because our lead product candidate is still in early clinical development. We currently anticipate that we will partner with a larger pharmaceutical organization having the expertise and capacity to perform these functions.

 

56

 

Manufacturing and Suppliers

 

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing as well as for commercial manufacture of any products that we may commercialize. If needed, we intend to engage, by entering into a supply agreement or through another arrangement, third party manufacturers to provide us with additional SBP-101 clinical supply. We identified and qualified manufacturers to provide the active pharmaceutical ingredient and fill-and-finish services for our initial product candidate prior to our submission of an NDA to the FDA and expect to continue utilizing this approach for any future product candidates.

 

Employees

 

As of December 31, 2019, we had five employees, four of whom were full-time employees. We believe that operational responsibilities can be handled by our current employees and independent consultants. We have historically used, and expect to continue to use, the services of independent consultants and contractors to perform various professional services. We believe that this use of third-party service providers enhances our ability to minimize general and administrative expenses.

 

Material Agreements

 

The Standard Exclusive License Agreement (“License Agreement”) dated December 22, 2011, between us and UFRF grants us an exclusive license to the proprietary technology covered by issued United States Patents Nos. US 5,962,533, which expired in February 2016, and US 6,160,022 which expired in July 2019 and Know-How as defined by the License Agreement, with reservations by UFRF for academic or government uses. Under this agreement, we had agreed to pay various royalties, expenses and milestone payments to UFRF. Additionally, pursuant to this agreement, we initially issued to UFRF 80,000 shares of common stock. Anti-dilution protection for UFRF pursuant to this agreement required us to issue additional shares in order for UFRF to maintain its ownership stake at ten percent (10%) of the total number of issued and outstanding shares of our common stock, calculated on a fully diluted basis, until such time as we had received a total of two million dollars ($2,000,000) in exchange for our issuance of equity securities. This requirement was met in 2012, and UFRF is therefore afforded no further anti-dilution protection. Pursuant to this anti-dilution provision, we issued an additional 34,423 shares of common stock to UFRF increasing the total shares of common stock issued to UFRF to 114,423 shares.

 

The License Agreement was amended on December 12, 2016 (the “First Amendment”) and then again on October 3, 2019 (the “Second Amendment”).

 

Under the Second Amendment all minimum royalty payments and milestone payments defined in the License Agreement were eliminated. In addition, the period of payment royalties was changed to be the shorter of (i) ten (10) years from first commercial sale or (ii) the period of market exclusivity on a country by country basis. UFRF may also terminate this license for standard and similar causes such as material breach of the agreement, bankruptcy, failure to pay royalties and other customary conditions.

 

The foregoing description of the material terms of the License Agreement, as amended, is qualified by the full text of the License Agreement, and the Second Amendment, both of which are incorporated herein by reference.

 

Government Regulation

 

FDA Approval Process

 

In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act and other federal and state statutes and regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable US requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

 

57

 

Pharmaceutical product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.

 

Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including the Investigator’s Brochure, information about product chemistry, manufacturing and controls, potential perceived side effects and risks, and a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.

 

A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.

 

Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with federal regulations; (ii) in compliance with good clinical practice (“GCP”), an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well as (iii) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on US patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.

 

The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (“IRB”) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB’s requirements, or may impose other conditions.

 

Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase 1, the initial introduction of the drug into healthy human subjects/patients, the drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence of effectiveness. Phase 2 usually involves trials in a limited patient population to determine the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, pivotal, or Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In many cases the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible. After an NDA is approved, a Phase 4 trial may be undertaken to evaluate safety over a long period of time, quality of life or cost effectiveness.

 

58

 

After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product’s pharmacology, chemistry, toxicology, manufacture, controls and any proposed labeling. The cost of preparing and submitting an NDA is substantial, and the fees are typically increased annually.

 

The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs to encourage timeliness. Most applications for standard review drug products are reviewed within twelve months from submission; most applications for priority review drugs are reviewed within eight months from submission. Priority review can be applied to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. If priority review is achieved, the FDA’s goal is to take action on the application within six months. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an outside advisory committee—typically a panel that includes clinicians and other experts—for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.

 

Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice (“cGMP”), a quality system regulating manufacturing, is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

 

After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included.

 

An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy (“REMS”) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (“ETASU”). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug’s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.

 

Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.

 

Fast Track Designation and Accelerated Approval

 

The FDA is required to facilitate the development, and expedite the review, of drugs that are (1) intended for the treatment of a serious or life-threatening disease or (2) condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the Fast Track program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the product candidate. The FDA must determine if the product candidate qualifies for Fast Track Designation within 60 days of receipt of the sponsor’s request.

 

59

 

Under the Fast Track program and FDA’s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.

 

In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to priority review by FDA.

 

If a submission is granted Fast Track Designation, the sponsor may engage in more frequent interactions with the FDA, and the FDA may review sections of the NDA before the application is complete. This rolling review is available if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable user fees. However, the FDA’s time period goal for reviewing an application does not begin until the last section of the NDA is submitted. Additionally, Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

 

Breakthrough Therapy Designation

 

The FDA is also required to expedite the development and review of the application for approval of drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. Under the Breakthrough Therapy program, the sponsor of a new product candidate may request that the FDA designate the product candidate for a specific indication as a breakthrough therapy. The FDA must determine if the product candidate qualifies for Breakthrough Therapy designation within 60 days of receipt of the sponsor’s request.

 

Orphan Drug Designation and Exclusivity

 

The Orphan Drug Act provides incentives for the development of products intended to treat rare diseases or conditions. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered from sales of the product. If a sponsor demonstrates that a drug is intended to treat a rare disease or condition, the FDA will grant orphan designation for that product for the orphan disease indication, assuming that the same drug has not already been approved for the indication for which the sponsor is seeking orphan designation. If the same drug has already been approved for the indication for which the sponsor is seeking orphan designation, the sponsor must present a plausible hypothesis of clinical superiority in order to obtain orphan designation. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the FDA discloses the identity of the therapeutic agent and its potential orphan use.

 

60

 

Orphan designation may provide manufacturers with benefits such as research grants, tax credits, Prescription Drug User Fee Act (“PDUFA”) application fee waivers and eligibility for orphan drug exclusivity. If a product that has orphan designation subsequently receives the first FDA approval of the active moiety for that disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which for seven years prohibits the FDA from approving another product with the same active ingredient for the same indication, except in limited circumstances. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan drug has exclusivity or obtain approval for the same product but for a different indication for which the orphan drug has exclusivity.

 

In the European Union, orphan drug designation also entitles a party to financial incentives such as reduction of fees or fee waivers and 10 years of market exclusivity is granted following drug or biological product approval. This period may be reduced to 6 years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.

 

Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

 

Post-Approval Requirements

 

Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.

 

Adverse event reporting and submission of periodic reports are required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies, or REMS, and surveillance to monitor the effects of an approved product, or FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, drug manufacture, packaging and labeling procedures must continue to conform to current good manufacturing practices, or cGMPs, after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with FDA subjects’ entities to periodic unannounced inspections by the FDA, during which the Agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.

 

Additional Regulations and Environmental Matters

 

In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, and our activities may implicate the privacy provisions of the Health Insurance Portability and Accountability Act (“HIPAA”) and similar state laws, each as amended.

 

61

 

The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. While we reasonably believe our practices to be in compliance with the Anti-Kickback Statute, our practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.

 

Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (“ACA”) to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (as further discussed below).

 

The Civil Monetary Penalties statute authorizes the imposition of severe financial penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.

 

The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’ marketing of the product for unapproved, and thus non-reimbursable, uses.

 

HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.

 

Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.

 

We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH) and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.

 

62

 

Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians, other specified health care professionals and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians, other specified health care professionals and teaching hospitals and to report annually certain ownership and investment interests held by physicians and other specified health care professionals and their immediate family members. Some states have analogous laws requiring manufacturers to report certain transfers of value to covered individuals and entities.

 

To distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All our activities are potentially subject to federal and state consumer protection and unfair competition laws.

 

If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private “qui tam” actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

 

Coverage and Reimbursement

 

Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, privately managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain, and any changes could have a material impact on drug pricing generally in the United States, including for our product candidates if approved.

 

63

 

Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.

 

The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third- party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

 

Corporate Information

 

Sun BioPharma, Inc. was originally incorporated under the laws of the State of Delaware in September 2011. In 2015, we became a public company by completing a reverse merger transaction (the “Merger”) with a wholly owned subsidiary of Cimarron Medical, Inc., a public company organized under the laws of the State of Utah. Upon completion of the Merger and other separate but contemporaneous transactions by certain of our stockholders, our stockholders collectively owned approximately 99.0% of the post-Merger public company, which was renamed “Sun BioPharma, Inc.” In 2016, we reincorporated under the laws of the State of Delaware via a merger with our operating subsidiary, resulting in our current corporate form.

 

Our website is located at www.SunBioPharma.com. The information contained on or connected to our website is not a part of this report. We have included our website address as a factual reference and do not intend it to be an active link to our website.

 

We make available, free of charge, through our website at www.sunbiopharma.com, materials we file or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act, including our annual report on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and amendments to those reports. These materials are posted to our website as soon as reasonably practicable after we electronically file them with or furnish them to the SEC.

 

The SEC maintains a website that contains reports, proxy and information statements and other information about us and other issuers that file electronically at www.sec.gov.

 

64

 

Management 

 

The name, age and position of each of our directors and executive officers as of the date of this prospectus are as follows:

 

Name

 

Age

 

Position

Michael T. Cullen

 

74

 

Executive Chairman of the Board of Directors, President, Chief Executive Officer and Director

Susan Horvath

 

61

 

Chief Financial Officer and Vice President of Finance

Suzanne Gagnon

 

63

 

Chief Medical Officer and Director

Jeffrey S. Mathiesen

 

59

 

Director

Paul W. Schaffer

 

77

 

Director

D. Robert Schemel

 

65

 

Director

Arthur J. Fratamico

 

54

 

Director

 

Executive Officers

 

Michael T. Cullen, M.D., M.B.A., has served as Executive Chairman of the Board of Directors and as a director of our Company since September 2015. He assumed responsibilities as President and Chief Executive Officer of the Company in October 2018. Dr. Cullen brings 30 years of pharmaceutical experience to our Company, including expertise in working with development-stage companies in planning, designing and advancing drug candidates from preclinical through clinical development. Dr. Cullen co-founded our business in 2011 and had continuously served as Chairman of its Board of Directors since that date. He previously served as Chief Medical Officer from November 2011 to January 2015. Dr. Cullen assumed responsibility as the President and Chief Executive Officer of the Company on October 31, 2018. Dr. Cullen provided due diligence consulting to the pharmaceutical industry from 2009 to 2011, after one year in transition consulting to Eisai Co., Ltd. He developed several oncology drugs as Chief Medical Officer for MGI Pharma Inc. from 2000 to 2008, and previously at G.D. Searle, SunPharm Corporation, and as Vice President for Clinical Consulting at IBAH Inc., the world’s fifth largest contract research organization, where he provided consulting services on business strategy, creating development plans, regulatory matters and designing clinical trials for several development stage companies in the pharmaceutical industry. Dr. Cullen was also a co-founder and Chief Executive Officer of IDD Medical, a pharmaceutical start-up company. Dr. Cullen joined 3M Pharmaceuticals in 1988 and contributed to the development of cardiovascular, rheumatology, pulmonary and immune-response modification drugs. Over the course of his career Dr. Cullen has been instrumental in obtaining the approval of ten drugs, including three (3) since 2004: Aloxi®, Dacogen® and Lusedra®. Board-certified in Internal Medicine, Dr. Cullen practiced from 1977 to 1988 at Owatonna Clinic, Owatonna, MN, where he served as president. Dr. Cullen earned his MD and BS degrees from the University of Minnesota and his MBA from the University of St. Thomas and completed his residency and Board certification in Internal Medicine through the University of North Carolina in Chapel Hill and Wilmington, NC.

 

Susan Horvath has served as our Vice President and Chief Financial Officer since April 2018. Ms. Horvath has held both finance and operating positions within pharmaceutical, healthcare and consumer organizations. In addition to her position with the Company, Ms. Horvath sits on the board of directors and provides financial consulting services for Photonic Pharma, LLC, a privately held company focused on efficiencies in early stage drug discovery. Prior to joining the Sun BioPharma team Ms. Horvath served as Chief Financial Officer of Eyebobs, LLC, a private company focused on eyewear for corrective vision, from December 2016 to January 2018; Vice President and Chief Financial Officer of Tenacious Holdings, Inc. (d/b/a ergodyne) a privately held, safety products company, from January 2014 to December 2016; Chief Financial Officer and Vice President of Human Resources at Healthsense, Inc., a next generation technology (SaaS) and remote monitoring company focused on providing safety and improving quality of life while reducing overall costs of healthcare for seniors and fragile adults, from August 2011 to February 2014; Chief Financial Officer, Vice President of Operations & Human Resources of Hemosphere, Inc., an early commercialization stage medical device company, from July 2008 to December 2010; and Vice President & Team Leader International of CNS, Inc, a publicly traded consumer health care products company focused on the development and marketing of strong consumer brands, from November 2004 to March 2007. Ms. Horvath holds a Bachelor of Science degree in Accounting from the University of Illinois, Champaign, and is a Certified Management Accountant and Certified Public Accountant, inactive.

 

65

 

Other Directors

 

Suzanne Gagnon, M.D., has served as our Chief Medical Officer and as a director of our Company since September 2015. Dr. Gagnon also served as a director of our predecessor entity since June 2015 and as its Chief Medical Officer since January 2015. Previously, Dr. Gagnon served as the Lead Clinical Consultant to the Company. Dr. Gagnon has been the President of Gagnon Consulting LLC since July 2014, consulting on medical, safety and regulatory matters. From 2001 to 2014, Dr. Gagnon served as the Chief Medical Officer for three companies, ICON Clinical Research, Nupathe, Inc. and Idis, Inc. Dr. Gagon is a graduate of Boston University School of Medicine and Boston City Hospital’s Medical Residency Program. We believe that Dr. Gagnon brings exceptional experience in drug development, safety, regulatory matters and executive leadership to the Board of Directors.

 

Jeffrey S. Mathiesen has served as a director of our Company since September 2015. On March 19, 2019 Mr. Mathiesen selected to service as the Vice Chair and lead independent director for the Company. He has served as Advisor to the CEO of Teewinot Life Sciences, a privately held biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids from October 2019 to December 2019, and as Chief Financial Officer from March 2019 to October 2019. Previously he served as Chief Financial Officer of Gemphire Therapeutics Inc., a publicly traded biopharmaceutical company from September 2015 to September 2018. From August 2015 to September 2015 he was a consultant to Gemphire. He served as Chief Financial Officer of Sunshine Heart, Inc., a publicly traded medical device company, from March 2011 to January 2015. From December 2005 to April 2010, Mr. Mathiesen served as Vice President and Chief Financial Officer of Zareba Systems, Inc., a manufacturer and marketer of medical products, perimeter fencing and security systems that was purchased by Woodstream Corporation in April 2010. Mr. Mathiesen has held executive positions with publicly traded companies dating back to 1993, including vice president and chief financial officer positions. Mr. Mathiesen also serves as a director and audit committee chairman of NeuroOne Medical Technologies Corporation, a publicly traded medical device company and served as a director and audit committee chairman of eNeura, Inc., a privately held medical technology company providing therapy for both acute treatment and prevention of migraine from July 2018 to February 2020. Mr. Mathiesen holds a B.S. in Accounting from the University of South Dakota and is also a Certified Public Accountant.

 

Paul W. Schaffer has served as a director since September 2015. Mr. Schaffer had previously served as a director of our predecessor entity since 2014. Mr. Schaffer graduated from Minnesota Pharmacy School in 1966. He owned and operated a compounding pharmacy, Bloomington Drug, for 42 years. Mr. Schaffer is an experienced biotech investor. We believe that Mr. Schaffer brings a wealth of experience in pharmaceutical development and manufacturing to the Board of Directors, as well as knowledge of regulations and issues facing pharmaceutical companies.

 

D. Robert Schemel has served as a director since September 2015. Mr. Schemel had previously served as a director of our predecessor entity since 2012. Mr. Schemel has over 39 years’ experience in the agriculture industry. From 1973-2005, Mr. Schemel owned and operated a farming operation in Kandiyohi County, Minnesota, building a 5,000-acre operation producing corn, soybeans and sugar beets. Mr. Schemel has extensive experience in serving on boards of directors. From 1992-1996 he served as a board member for ValAdCo and then from 1996-2003 he served as the Chairman of the Board for Phenix Biocomposites.

 

Arthur J. Fratamico has served as a director of our Company since December of 2019. He is a registered pharmacist with over 25 years of experience in the pharmaceutical industry and has been the Chief Business Officer at Galera Therapeutics, Inc., a biopharmaceutical company dedicated to discovering and developing novel dismutase mimetics with the goal of transforming cancer radiotherapy, since January 2017. Prior to joining Galera, Mr. Fratamico served as Chief Business Officer of Vitae Pharmaceuticals, Inc., a Nasdaq-listed clinical-stage biotechnology company, from May 2014 until its sale to Allergan in December 2016. Prior to Vitae Pharmaceuticals, he held similar executive roles with a number of biotechnology companies leading their business development efforts, including facilitating the sales of Gemin X Pharmaceuticals, Inc. and MGI Pharma, Inc. In addition to being responsible for numerous licensing transactions and acquisitions, he also directed corporate strategy and managed external corporate communications. He also served in several senior marketing, product planning and new product development positions. Mr. Fratamico earned a bachelor’s degree in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from Drexel University.

 

66

 

Director Independence

 

Our Board of Directors has reviewed the materiality of any relationship that each of our directors has with us, either directly or indirectly. Based on this review, our Board of Directors has determined that Messrs. Mathiesen, Schaffer, Schemel and Fratamico are “independent directors” as defined under the applicable rules of The Nasdaq Stock Market, LLC, which we have voluntarily adopted as our standard for director independence.

 

Committees of the Board of Directors

 

Our Board of Directors has established three standing committees: Audit, Compensation, and Nominating and Governance. The membership of each committee is as follows:

 

 

 

Committees

 

 

Director  

Audit

 

Compensation

 

Nominating and

Governance

 

Independent

Directors

Michael T. Cullen

 

 

 

   

Suzanne Gagnon

 

 

 

   

Jeffrey S. Mathiesen

 

Chair

 

 

Member

 

Paul W. Schaffer

 

Member

 

Member

 

Chair

 

D. Robert Schemel

 

Member

 

Chair

 

 

Arthur J. Fratamico

 

 

Member

 

Member

 

 

 

Audit Committee

 

The Audit Committee’s primary functions, among others, are to: (a) assist the Board of Directors in discharging its statutory and fiduciary responsibilities with regard to audits of the books and records of our Company and the monitoring of its accounting and financial reporting practices; (b) carry on appropriate oversight to determine that our Company and its subsidiaries have adequate administrative and internal accounting controls and that they are operating in accordance with prescribed procedures and codes of conduct; and (c) independently review our Company’s financial information that is distributed to stockholders and the general public. The Audit Committee held five meetings during 2019. The Audit Committee has a charter, which is available on our website at www.sunbiopharma.com.

 

All of the members of the Audit Committee meet the requirements for financial literacy under the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”). Our Board of Directors has determined that Jeffrey S. Mathiesen is qualified to serve as an audit committee financial expert, as that term is defined under the applicable rules of the SEC. Each member of the Audit Committee satisfies the independence requirements of Rule 10A-3(b)(1) of the Securities Exchange Act.

 

Compensation Committee

 

The Compensation Committee reviews and recommends to our Board of Directors all compensation for our executive officers and, on an annual basis, the goals and objectives relevant to the annual compensation of our executive officers in light of their respective performance evaluations. Our Compensation Committee is also responsible for administering our equity incentive plans, including our 2011 Equity Incentive Plan, as amended (the “2011 Plan”) and our 2016 Omnibus Incentive Plan, as amended ( the “2016 Plan”), including approval of individual grants of stock options and other equity-based awards. The Compensation Committee held three meetings during 2019. The Compensation Committee has a charter, which is available on our website at www.sunbiopharma.com.

 

67

 

Nominating and Governance Committee

 

The Nominating and Governance Committee is primarily responsible for identifying individuals qualified to serve as members of our Board of Directors, recommending individuals to our Board of Directors for nomination as directors and committee membership, reviewing the compensation paid to our non-employee directors and recommending adjustments in director compensation, as necessary, in addition to overseeing the annual evaluation of our Board of Directors. The Nominating and Governance Committee held one meeting during 2019. The Nominating and Governance Committee has a charter that is available on our website at www.sunbiopharma.com.

 

Compensation Committee Interlocks and Insider Participation

 

None of the members of the compensation committee nor any director nominee proposed to become a member of the compensation committee is or has at any time during the last completed fiscal year been an officer or employee of our Company. None of our executive officers has served as a member of our Board of Directors or as a member of the compensation or similar committee, of any entity that has one or more executive officers who served on our Board of Directors during the last completed fiscal year.

 

None of the members of the compensation committee is or has at any time during the last completed fiscal year been an officer or employee of our Company. None of our executive officers has served as a member of the Board of Directors, or as a member of the compensation or similar committee, of any entity that has one or more executive officers who served on our Board of Directors or compensation committee during the last completed fiscal year.

 

Director Compensation

 

Directors who are also our employees historically have received no additional cash compensation for serving on our Board of Directors and non-employee directors receive no cash compensation. During 2019, our Company reimbursed non-employee directors for out-of-pocket expenses incurred in connection with attending meetings of our Board of Directors and its committees.

 

Non-Employee Director Compensation for 2019

 

The following table sets forth information concerning annual compensation for our non-employee directors during the year ended December 31, 2019:

 

Name

 

Option Awards(1) ($) 

 

Total ($)

D. Robert Schemel 

 

62,395(2)

 

62,395

Jeffrey S. Mathiesen

 

62,395(3)

 

62,395

Paul W. Schaffer

 

62,395(4)

 

62,395

Arthur J. Fratamico

 

74,992(5)

 

74,992

 


 

(1)

The values of option awards in this table represent the fair value of such awards granted during the fiscal year, as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. The assumptions used to determine the valuation of the awards are discussed in Note 9 to our consolidated financial statements, included in our annual report on Form 10-K for the fiscal year ended December 31, 2019.

 

(2)

Mr. Schemel held options to purchase an aggregate of 54,600 shares as of December 31, 2019.

 

(3)

Mr. Mathiesen held options to purchase an aggregate of 54,600 shares as of December 31, 2019.

 

(4)

Mr. Shaffer held options to purchase an aggregate of 70,600 shares as of December 31, 2019.

 

(5)

Mr. Fratamico held options to purchase an aggregate of 38,300 shares as of December 31, 2019.

 

Effective 2019, the Compensation Committee of the Board of Directors approved a compensation program for our non-employee directors consisting of annual awards of options to purchase common stock. Each non-employee director is eligible to receive an option by dividing a target dollar amount by the Black-Scholes value of a share of our common stock as of the date of grant. The target dollar amount for awards to each such director currently equals equal (i) $35,000 for service as a non-employee director, plus (ii) $5,000 for each committee of which the director is expected to serve as chair.

 

68

 

In May 2019, the Compensation Committee granted to each then-serving non-employee director a one-time grant of an option to purchase a number of shares of our common stock equal to $10,000 divided by the Black-Scholes value of a share of our common stock on the date of grant. Each such option is scheduled to vest in three substantially equal installments on the first, second and third anniversaries of the dates of grant.

 

All options awarded to non-employee directors under the new compensation program will bear an initial exercise price equal to the fair market value of a share of our common stock on the grant date, as determined in accordance with the applicable equity incentive plan, and, once vested, will remain exercisable through the ten-year anniversary of the date of grant.

 

In connection with Mr. Fratamico’s election to the Board of Directors, effective December 19, 2019, the Compensation Committee awarded him two options, one to purchase 6,500 shares, scheduled to vest in full the day before the Annual Meeting and a second to purchase 26,800 shares, 50% of which was exercisable on the date of grant and 25% of which is schedule to vest on the first and second anniversaries of the date of grant. These grants were made consistent with the director compensation program put into place in 2019 and the time remaining prior to the next annual meeting.

 

Changes to Non-Employee Director Compensation for 2020

 

In June 2020, the Nominating and Governance Committee of our Board of Directors adjusted certain components of director compensation. Effective as of June 2020, each non-employee director will receive a recurring monthly cash retainer of $1,000 in addition to annual equity compensation for their service. Also in June 2020, the Compensation Committee of our Board of Directors approved the issuance of options to purchase a number of share of common stock equal to 12,000 for each non-employee director plus 1,700 additional share for service as the chair of a standing committee. Each such option is scheduled to vest in full as of the day before the Company’s next annual meeting of stockholders.

 

69

 

Executive Compensation 

 

The following disclosure focuses on our named executive officers. For fiscal 2019 our “named executive officers” consisted of: Michael T. Cullen and Susan Horvath.

 

Base salaries for each of our named executive officers were initially established based on arm’s-length negotiations with the applicable executive. Our Compensation Committee reviews our executive officers’ salaries annually. When negotiating or reviewing base salaries, the Compensation Committee considers market competitiveness based on the experience of its members, the executive’s expected future contribution to our success and the relative salaries and responsibilities of our other executives.

 

Summary Compensation Table

 

The following table provides information regarding the compensation earned by our named executive officers for fiscal 2019 (collectively referred to as the “Executives”):

 

Name and principal position

 

Fiscal Year

 

Salary
($)

   

Option awards
($)
(1)

   

Total
($)

 

Michael T. Cullen

 

2019

    282,350       377,471       659,821  
Executive Chairman, President and Chief Executive Officer)(2)  

2018

    221,200       491,491       712,691  
                             

Susan Horvath

 

2019

    220,313       181,124       401,436  
 Chief Financial Officer and Vice President of Finance(3)  

2018

    150,000       147,573       297,573  

 

 


(1)

The values of option awards in this table represent the fair value of such awards granted during the fiscal year, as computed in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. The assumptions used to determine the valuation of the awards are discussed in Note 9 to our consolidated financial statements, included in our annual report on Form 10-K for the fiscal year ended December 31, 2019.

(2)

Dr. Cullen was elected to serve in the additional roles of President and Chief Executive Officer on October 31, 2018.

(3)

Ms. Horvath joined the Company on April 17, 2018.

 

Outstanding Equity Awards at December 31, 2019

 

 

     

Option Awards

 Name  

 

 

Grant Date

 

Number of

securities

underlying

unexercised

options (#)

exercisable

   

Number of securities

underlying

unexercised options

(#) unexercisable

   

Option exercise

price ($)

 

Option expiration

Date

Michael T. Cullen

 

3/5/2015

    80,000             3.18  

3/5/2025

   

12/12/2016

    15,000             15.10  

12/12/2026

   

2/27/2018

    100,000             8.10  

2/27/2028

   

5/21/2019

    71,500       84,600 (1)      2.95  

5/21/2029

   

9/24/2019

    30,000             5.00  

9/24/2029

                               

Susan Horvath

 

4/17/2018

    20,000       20,000 (2)      5.75  

4/17/2028

   

5/21/2019

    21,575       36,225 (3)      2.95  

5/21/2029

   

9/24/2019

    25,000             5.00  

9/24/2029

 

 


(1)

Scheduled to vest with respect to 28,200 on May 21st in each of 2020, 2021 and 2022.

(2)

Scheduled to vest with respect to 10,000 on April 17th in each of 2020 and 2021.

(3)

Scheduled to vest with respect to 12,075 on May 21st in each of 2020, 2021 and 2022.

 

70

 

Employment Agreements

 

During 2019, we were party to employment agreements with each of the Executives. In addition to the specific terms summarized below, each Executive is eligible to participate in the other compensation and benefit programs generally available to our employees, including our other executive officers, if any. Each such employment agreement also includes customary non-competition and non-solicitation covenants and a requirement that the Executive execute a supplemental agreement regarding confidentiality and assignment of intellectual property.

 

In accordance with the employment agreements, the base salary of each Executive is reviewed annually by the Compensation Committee of our Board of Directors. Pursuant to the employment agreements, the committee may authorize an increase for the applicable year but may not reduce an Executive’s base salary below its then-current level other than with the Executive’s consent or pursuant to a general wage reduction in respect of substantially all of our executive officers.

 

Executive Chairman, President and Chief Executive Officer

 

Under his employment agreement, as last amended, Dr. Cullen was entitled to receive an initial annualized base salary equal to $288,000. He is eligible to receive an annual performance-based cash bonus with a target amount equal to no less than 45% of his base salary. Payment of the bonus amount will be subject to achievement of metrics to be established by our Board of Directors and Dr. Cullen’s continued employment with the Company through the end of the applicable cash bonus period. Neither our Board of Directors nor its Compensation Committee established such performance criteria for 2019 and therefore no cash bonus was paid.

 

No change was made to Dr. Cullen’s employment agreement as a result of his election to serve in the additional roles of President and Chief Executive Officer in October 2018 until May 21, 2019. On that date the Compensation Committee increased Dr. Cullen’s annualized base salary to $315,000.

 

Chief Financial Officer

 

Under her employment agreement, Ms. Horvath is entitled to receive an initial annualized base salary equal to $225,000. Ms. Horvath also is eligible to receive an annual performance-based cash bonus with a target amount equal to no less than 40% of her base salary. Payment of the bonus amount will be subject to achievement of metrics to be established by our Board of Directors and Ms. Horvath’s continued employment with the Company through the end of the applicable cash bonus period. Neither our Board of Directors nor its Compensation Committee established such performance criteria for 2019 and therefore no cash bonus was paid.

 

Potential Payments Upon Termination or Change-in-Control

 

Under their respective employment agreements, if Dr. Cullen’s or Ms. Horvath’s employment is terminated by us for any reason other than for “cause” (as defined in the applicable employment agreement) or by him or her for “good reason” (as defined in the applicable employment agreement), then he or she will be eligible to receive an amount equal to their respective annualized salary plus an amount equal to a prorated portion of their cash bonus target, if any, for the year in which the termination occurred, in addition to other amounts accrued on or before the date of termination. If any such termination occurs within six months prior or two years after a “change of control” (as defined in the applicable employment agreement), then Dr. Cullen or Ms. Horvath, as applicable, would instead receive an amount equal to his or her respective annualized salary, plus an amount equal to his or her full cash bonus target for the year in which the termination occurred.

 

Certain Relationships and Related Party Transactions

 

The following is a summary of transactions since January 1, 2017 to which our Company has been a party and in which the amount involved exceeded $25,000, which is approximately 1% of the average of our total assets as of the ends of our last two completed fiscal years, and in which any of our directors, executive officers, or beneficial owners of more than 10% of our capital stock had or will have a direct or indirect material interest, other than compensation arrangements that are described under the heading “Executive Compensation: Employment Agreements” and “Director Compensation” above.

 

71

 

Our Chief Medical Officer, Suzanne Gagnon, is also a member of our Board of Directors. We are party to an employment agreement with Dr. Gagnon in substantially the same form as the employment agreements with the Executives described below under the heading “Employment Agreements.” Dr. Gagnon is eligible to participate in the other compensation and benefit programs generally available to our employees. Her employment agreement also includes customary confidentiality, non-competition and non-solicitation covenants. Under her employment agreement as currently in effect, Dr. Gagnon is entitled to receive an initial annualized base salary of $270,000. During 2017, 2018, and 2019, Dr. Gagnon received compensation from the Company amounting to $195,000, $207,700 and $250,100, respectively.

 

In March 2017, Paul W. Schaffer, a director of the Company, purchased $50,000 original principal amount of 2017 Notes.

 

Certain directors and executive officers participated in various debt and equity offerings during the three years ended December 31, 2019. The table below summarizes those securities purchases:

 

Related Person Name and

Position(s)

 

Date of

Investment

 

Securities Purchased

 

Amount

Invested

 

Michael T. Cullen, Executive Chairman President, CEO and Director(1)

 

2/14/2018

 

5,000 Shares of Common Stock and Warrants to Purchase up to 5,000 additional Shares of Common Stock(2)

  $ 25,000  
                 

Paul W. Schaffer, Director

 

5/16/2018

 

5,000 Shares of Common Stock and Warrants to Purchase up to 5,000 additional Shares of Common Stock(2)

  $ 25,000  
                 

Michael T. Cullen, Executive Chairman President, CEO and Director

 

12/31/2018

 

$35,000 principal amount of Convertible Promissory Notes and Warrants to purchase up to 20,000 Shares of Common Stock(3)

  $ 35,000  
                 

Michael T. Cullen, Executive Chairman President, CEO and Director

 

8/30/2019

 

30,000 Shares of Common Stock and Warrants to purchase up to 30,000 additional Shares of Common Stock(4)

  $ 105,000  
                 

Paul W. Schaffer, Director

 

9/20/2019

 

30,000 Shares of Common Stock and Warrants to Purchase up to 30,000 additional Shares of Common Stock(4)

  $ 105,000  
                 

Michael T. Cullen, Executive Chairman President, CEO and Director(1)

 

5/22/2020

 

10,000 Shares of Common Stock and Warrants to Purchase up to 10,000 additional Shares of Common Stock(5)

  $ 40,000  
                 

Paul W. Schaffer, Director

 

6/5/2020

 

10,000 Shares of Common Stock and Warrants to Purchase up to 10,000 additional Shares of Common Stock(5)

  $ 40,000  

 


(1)

As trustee of the Cullen Living Trust Dated April 23, 2009.

(2)

Pursuant to Securities Purchase Agreement. Such warrants are exercisable for a period of three years from the date of issuance at an exercise price of $5.00 per share.

(3)

The Convertible Promissory Notes (“Notes”) were part of a series of notes issued on the same terms as those issued to third parties in December 2018 and January 2019, matured on June 30, 2019 and bore interest at a rate of 10.0% per year in the interim. The Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (1) June 30, 2019 or (2) the date our Company received gross proceeds of at least $6.0 million from the sale of equity securities (subject to certain exclusions). The Notes converted at a stated conversion rate of $3.50 per share subject to downward adjustments, if any, to match the price per share of common stock or any unit containing a share of common stock issued by the Company on or before the date of conversion. The exercise price of each warrant is $4.50 per share and they are exercisable until the 5-year anniversary of the date of issuance. See also Note 6 to our consolidated financial statements, included in our annual report on Form 10-K for the fiscal year ended December 31, 2019.

(4)

Pursuant to Securities Purchase Agreement. Such warrants are exercisable for a period of five years from the date of issuance at an exercise price of $4.00 per share.

(5)

Pursuant to Securities Purchase Agreement. Such warrants are exercisable for a period of five years from the date of issuance at an exercise price of $6.00 per share.

 

 

72

 

Security Ownership of Certain Beneficial Owners AND Management

 

The following table sets forth certain information with respect to the beneficial ownership of our outstanding common stock as of June 30, 2020 by (i) each of our named executive officers identified in the Summary Compensation Table below; (ii) each of our directors; (iii) all of our executive officers, directors and director nominees as a group; and (iv) each other beneficial owner of 5% or more of our outstanding common stock. Ownership percentages are based on 7,068,308 shares of common stock outstanding as of the close of business on the same date. Beneficial ownership is determined in accordance with the rules of the SEC. To our knowledge and subject to applicable community property laws, each of the holders of stock listed below has sole voting and investment power as to the stock owned unless otherwise noted. The table below includes the number of shares underlying rights to acquire common stock that are exercisable within 60 days from June 30, 2020. Except as otherwise noted below, the address for each director or officer listed in the table is c/o Sun BioPharma, Inc., 712 Vista Blvd #305, Waconia, Minnesota 55387.

 

 

 

Shares Beneficially Owned

 
 Name  

Number

   

Percentage

 

Executive Officers and Directors:

               

Michael T. Cullen

    807,271 (a)      10.8 %

Susan Horvath

    125,090 (b)      1.7 %

Suzanne Gagnon

    349,992 (c)      4.8 %

Jeffrey S. Mathiesen

    58,900 (d)      *  

Paul W. Schaffer

    283,985 (e)      4.0 %

D. Robert Schemel

    436,749 (f)      6.1 %

Arthur J. Fratamico

    24,900 (g)      *  

All directors and current executive officers as a group (7 persons)

    2,086,887 (h)      25.6 %
                 

Ryan Gilbertson 2012 Irrevocable Family Trust

8615 Eagle Creek Circle
Savage, MN 55378

    793,564 (i)      10.9 %

 


*

Less than one percent.

(a)

Includes 204,576 shares held by the Cullen Living Trust and 337,200 shares subject to stock options, and 67,500 shares subject to warrants.

(b)

Includes 96,650 shares subject to stock options, and 17,428 shares subject to warrants.

(c)

Includes 8,142 shares held by the Gagnon Family Trust, 297,350 shares subject to stock options and 1,500 shares subject to warrants.

(d)

Includes 52,900 shares subject to options and 3,000 shares subject to warrants.

(e)

Includes 30,685 shares held by the Paul Shaffer Trust, 68,900 shares subject to stock options, 51,756 shares subject to warrants.

(f)

Includes 282,654 shares held by spouse and 52,900 shares subject to stock options and 11,767 shares subject to warrants.

(g)

Includes 24,900 shares subject to stock options.

(h)

Includes 900,300 shares subject to stock options and 140,451 shares subject to warrants.

(i)

Includes 218,455 shares subject to warrants.

 

 

73

 

DESCRIPTION OF Securities

 

The summary of the general terms and provisions of the common stock, par value $0.001 per share (“Common Stock”), of Sun BioPharma, Inc., a Delaware corporation (the “Corporation”), set forth below does not purport to be complete and is subject to and qualified by reference to the Corporation’s Certificate of Incorporation, as amended (the “Certificate”), and Bylaws of the Corporation, as amended (the “Bylaws”). For additional information, please read the Certificate, Bylaws and the applicable provisions of the General Corporation Law of Delaware (the “DGCL”).

 

Authorized Shares

 

The Corporation is authorized to issue up to 110,000,000 shares of capital stock, of which 100,000,000 constitute shares of Common Stock and 10,000,000 constitute shares of preferred stock, par value $0.001 per share (“Preferred Stock”).

 

Common Stock

 

No outstanding shares of common stock is entitled to preference over any other share, and each share is equal to any other share in all respects. Holders of shares of common stock are entitled to one vote for each share held of record at each meeting of shareholders. Holders of shares of common stock are not entitled to any preemptive, subscription, conversion, redemption or sinking fund rights. The absence of preemptive rights could result in a dilution of the interest of shareholders should additional common shares be issued.

 

Subject to any prior rights of any Preferred Stock then outstanding, holders of common stock are entitled to receive dividends in the form of cash, property or shares of capital stock of the Corporation, when and as declared by the board of directors, provided there are sufficient net profits or surplus legally available for that purpose. In any distribution of capital assets, such as liquidation, whether voluntary or involuntary, holders of shares of common stock are entitled to receive pro rata the assets remaining after creditors have been paid in full. All of the issued and outstanding shares of common stock are non-assessable.

 

Anti-Takeover Provisions

 

The Charter Documents and the DGCL contain certain provisions that may discourage an unsolicited takeover of the Company or make an unsolicited takeover of the Company more difficult. The following are some of the more significant anti-takeover provisions that are applicable to the Company:

 

Delaware Anti-Takeover Law

 

In general, Section 203 of the DGCL prohibits a Delaware corporation with a class of voting stock listed on a national securities exchange or held of record by 2,000 or more stockholders from engaging in a Business Combination (as defined below) with an Interested Stockholder (as defined below) for a three-year period following the time that this stockholder becomes an interested stockholder, unless the Business Combination is approved in a prescribed manner. A “Business Combination” includes, among other things, a merger, asset or stock sale or other transaction resulting in a financial benefit to the Interested Stockholder. An “Interested Stockholder” is a person who, together with affiliates and associates, owns, or did own within three years prior to the determination of Interested Stockholder status, 15% or more of the corporation’s voting stock. Under Section 203, a Business Combination between a corporation and an Interested Stockholder is prohibited for three years unless it satisfies one of the following conditions:

 

 

Before the stockholder became an Interested Stockholder, the board of directors approved either the Business Combination or the transaction which resulted in the stockholder becoming an Interested Stockholder;

 

 

Upon consummation of the transaction which resulted in the stockholder becoming an Interested Stockholder, the Interested Stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances; or

 

 

At or after the time the stockholder became an Interested Stockholder, the Business Combination was approved by the board of directors of the corporation and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the Interested Stockholder.

 

74

 

The DGCL permits a corporation to opt out of, or choose not to be governed by, its anti-takeover statute by expressly stating so in its original certificate of incorporation (or subsequent amendment to its certificate of incorporation or bylaws approved by its stockholders). The Certificate does not contain a provision expressly opting out of the application of Section 203 of the DGCL; therefore, the Company is subject to the anti-takeover statute.

 

Requirements for Advance Notification of Stockholder Nominations and Proposals

 

The Bylaws establish advance-notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors.

 

Special Meetings of Stockholders

 

The Certificate and Bylaws provide that a special meeting of stockholders may be called only by the board of directors, the Chairman of the Board or the Chief Executive Officer of the Corporation.

 

Classified Board of Directors

 

The Certificate provides that directors are divided into three classes and elected for staggered terms. At each annual meeting, approximately one third of the directors will be elected to serve a three-year term. Directors serving staggered terms can be removed from office only for cause and only by the affirmative vote of the holders of 75% or more of the outstanding shares of stock then entitled to vote at an election of directors.

 

Authority of the Board of Directors

 

The board of directors has the power to issue any or all of the shares of the Corporation’s capital stock, including the authority to establish one or more series of Preferred Stock and to fix the powers, preferences, rights and limitations of such class or series, without seeking stockholder approval. The board of directors has the authority to adopt and change Bylaws, subject to the right of holders of at least 66.67% of the voting power of all then-outstanding shares entitled to vote generally in the election of directors to adopt, amend or repeal Bylaws.

 

Underwriter's Warrants to be Issued in this Offering

 

We have agreed to issue to Craig-Hallum Capital Group LLC, the underwriter in this offering, warrants to purchase up to 5.0% of the shares of our common stock issued in the offering (exclusive of any shares to be issued pursuant to the exercise of the over-allotment option or the exercise of any warrants sold in this offering). Please see “Underwriting – Underwriter's Warrants” for a description of the warrants we have agreed to issue to the underwriter, subject to the completion of the offering. We expect to enter into a warrant agreement in respect of the Underwriter's Warrants prior to the closing of this offering.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is VStock Transfer, which can be contacted at 18 Lafayette Place, Woodmere, New York, 11598, info@vstocktransfer.com, or +1 (212) 828-8436.

 

75

 

Electronic Distribution

 

This prospectus in electronic format may be made available on websites or through other online services maintained by the underwriter, or by its affiliates. Other than this prospectus in electronic format, the information on the underwriter’s website and any information contained in any other website maintained by the underwriter is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the underwriter in its capacity as underwriter, and should not be relied upon by investors.

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Future sales of substantial amounts of our common stock in the public market, including shares issued upon exercise of outstanding options and warrants, or the anticipation of these sales, could adversely affect prevailing market prices from time to time and could impair our ability to raise equity capital in the future.

 

Upon the closing of this offering, we will have a total of          shares of our common stock outstanding (or          shares if the underwriter exercises its option to purchase additional shares of common stock in full), based on the           shares of our common stock outstanding as of          , 2020. Of these outstanding shares, all of the shares sold in the offering will be freely tradable, except that any shares purchased in this offering by our affiliates, as that term is defined in Rule 144 under the Securities Act, would only be able to be sold in compliance with the limitations described below.

 

Rule 144

 

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements for at least 90 days, a person who is not deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates, is entitled to sell those shares without complying with the manner of sale, volume limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then that person would be entitled to sell those shares upon expiration of the lock-up agreements described below, without complying with any of the requirements of Rule 144.

 

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell upon expiration of the lock-up agreements described below, within any three-month period, a number of shares that does not exceed the greater of:

 

 

1% of the number of shares of our common stock then outstanding, which will equal approximately           shares immediately after this offering; or

 

 

if and when our common stock is listed on the Nasdaq Capital Market, the average weekly trading volume of our common stock on such market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

 

Rule 701

 

Rule 701 generally allows a stockholder who purchased shares of our common stock pursuant to a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public information or holding period provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares pursuant to Rule 701, subject to the market standoff agreements and lock-up agreements described below.

 

76

 

Stock Options and Warrants

 

As of June 30, 2020, options to purchase a total of 1,958,411 shares of common stock were outstanding, which options were vested with respect to 1,594,611 shares. Of the total number of shares of our common stock issuable under these options, approximately      % were subject to contractual lock-up agreements with the underwriter described below, and will become eligible for sale, subject to any applicable limitations of Rule 144, at the expiration of those agreements.

 

As of June 30, 2020, warrants to purchase a total of 3,934,099 shares of common stock at a weighted-average exercise price of $5.79 per share. None of the outstanding warrants or shares issuable upon exercise of the outstanding warrants are currently registered for resale.

 

Lock-Up Agreements

 

We, our officers and directors and each of our stockholders who hold 5% or more of our outstanding common stock expect to enter into lock up agreements with the underwriter prior to the commencement of this offering. See “Underwriting – Lock-up Agreements” for additional information regarding the terms of these agreements. Following the expiration of the lock-up agreements, covered shares will become eligible for sale, subject to any applicable limitations of Rule 144.

 

77

 

UNDERWRITING

 

Craig-Hallum Capital Group LLC is acting as the underwriter of the offering. We have entered into an underwriting agreement dated              , 2020 with the underwriter. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriter and the underwriter has agreed to purchase from us, at the public offering price less the underwriting discount set forth on the cover page of this prospectus, the number of shares of common stock listed next to its name in the following table:

 

Underwriters

 

Number of
Shares

Craig-Hallum Capital Group LLC

 

       

TOTAL

 

         

 

The underwriter is committed to purchase all the shares of common stock offered by us other than those covered by the option to purchase additional shares of common stock described below, if it purchases any shares of common stock. The obligations of the underwriter may be terminated upon the occurrence of certain events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the underwriter's obligations are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the underwriter of officers’ certificates and legal opinions.

 

We have been advised by the underwriter that it proposes to offer the shares directly to the public at the public offering price set forth on the cover page of this prospectus. Any shares sold by the underwriter to securities dealers will be sold at the public offering price less a selling concession not in excess of $       per share.

 

We have agreed to indemnify the underwriter against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriter may be required to make in respect thereof.

 

The underwriter is offering the shares of common stock, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriter reserves the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

 

Over-allotment Option

 

We have granted the underwriter an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus, permits the underwriter to purchase a maximum of           additional shares of common stock (15.0% of the shares sold in this offering) from us to cover over-allotments, if any. If the underwriter exercises all or part of this option, it will purchase shares of common stock covered by the option at the public offering price per share that appears on the cover page of this prospectus, less the underwriting discount. If this option is exercised in full, the total price to the public will be $          and the total net proceeds, before expenses, to us will be approximately $      million.

 

78

 

Discounts, Commissions and Reimbursement

 

The following table shows the public offering price, underwriting discount, non-accountable expense allowance and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriter of the over-allotment option.

 

           

Total(1)

 
   

Per Share

   

Without Over-

Allotment Option

   

With Over-

Allotment Option

 

Public offering price

  $       $       $    

Underwriting discount (7.0%)

  $       $       $    

Proceeds, before expenses, to us(2)

  $       $       $    

 


(1)

Does not include warrants to purchase shares of common stock equal to 5.0% of the number of the common stock sold in the offering to be issued to the underwriter at the closing.

(2)

We have also agreed to reimburse certain expenses of the underwriter relating to the offering in an amount up to $155,000. We have paid an advance of $20,000 to the underwriter, which will be applied against actual out-of-pocket accountable expenses and reimbursed to the Company to the extent any portion thereof is not actually incurred in compliance with FINRA Rule 5110(f)(2)(C).

 

The underwriter proposes to offer the shares of common stock directly to the public at the public offering price set forth on the cover page of this prospectus. In addition, the underwriter may offer some of the common stock to other securities dealers at such price less a concession of $      per share of common stock. After this offering, this offering price and concessions and discounts to brokers and dealers and other selling terms may from time to time be changed by the underwriter.

 

We estimate that the total expenses of this offering, excluding the underwriting discount and expense reimbursements, will be approximately $         .

 

Lock-Up Agreements

 

We, our officers and directors and each of our stockholders who hold 5% or more of our outstanding common stock expect to enter into lock up agreements with the underwriter prior to the commencement of this offering pursuant to which each of these persons or entities, for a period of 180 days from the effective date of the registration statement of which this prospectus forms a part, without the prior consent of the underwriter, agree not to (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; (b) file or cause to be filed any registration statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; or (c) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in (a), (b) or (c) above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise.

 

Underwriter's Warrants

 

We have also agreed to issue to the underwriter or its designees at the closing of this offering, warrants (the “Underwriter’s Warrants”) to purchase a number of shares of common stock equal to 5.0% of the number of shares sold in the offering, including the over-allotment option to the extent it is exercised. The Underwriter’s Warrants will be exercisable at any time and from time to time, in whole or in part, during the five year period commencing on the effective date of this offering. The Underwriter’s Warrants will be exercisable at a price equal to 110.0% of the public offering price per share. The Underwriter’s Warrants have been deemed compensation by the Financial Industry Regulatory Authority, or FINRA, and are therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. Pursuant to FINRA Rule 5110(g), the Underwriter’s Warrants and any shares issued upon exercise thereof will not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person, for a period of 180 days immediately following the date of effectiveness or commencement of sales in this offering, except: (i) the transfer of any security by operation of law or by reason of our reorganization; (ii) the transfer of any security to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii) the transfer of any security if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered; (iv) the transfer of any security that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.

 

79

 

In connection with this offering, on Mach 2, 2020, we issued a warrant to the underwriter to purchase 75,000 shares of our common stock. The warrant expires on March 2, 2025 and has an exercise price of $6.49 per share.

 

The warrant has been deemed compensation by the Financial Industry Regulatory Authority, or FINRA, and is therefore subject to a 180-day lock-up pursuant to Rule 5110(g)(1) of FINRA. Pursuant to FINRA Rule 5110(g), the warrant and any shares issued upon exercise thereof will not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of the securities by any person, for a period of 180 days immediately following the date of effectiveness or commencement of sales in this offering, except: (i) the transfer of any security by operation of law or by reason of our reorganization; (ii) the transfer of any security to any FINRA member firm participating in the offering and the officers or partners thereof, if all securities so transferred remain subject to the lock-up restriction set forth above for the remainder of the time period; (iii) the transfer of any security if the aggregate amount of our securities held by the placement agent or related persons do not exceed 1% of the securities being offered; (iv) the transfer of any security that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund and the participating members in the aggregate do not own more than 10% of the equity in the fund; or (v) the exercise or conversion of any security, if all securities remain subject to the lock-up restriction set forth above for the remainder of the time period.

 

Right of First Refusal

 

For a period of 6 months from the closing of this offering, the underwriter will have an irrevocable right of first refusal to act as lead agent (in the case of a private placement) or as bookrunner (in the case of a public offering), on terms customary to the underwriter.

 

Electronic Offer, Sale and Distribution of Securities

 

A prospectus in electronic format may be made available on the websites maintained by one or more of the underwriter or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The underwriter may agree to allocate a number of shares to selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriter and selling group members that will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us or the underwriter in its capacity as underwriter, and should not be relied upon by investors.

 

80

 

Stabilization

 

In connection with this offering, the underwriter may engage in over-allotment transactions, syndicate-covering transactions, stabilizing transactions, penalty bids and purchases to cover positions created by short sales.

 

  Stabilizing transactions permit bids to purchase securities, so long as the stabilizing bids do not exceed a specified maximum and are engaged in for the purpose of preventing or retarding a decline in the market price of the securities while the offering is in progress.
     
  Over-allotment transactions involve sales by the underwriter of securities in excess of the number of securities the underwriter is obligated to purchase. This creates a syndicate short position, which may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriter is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriter may close out any covered short position by either exercising their over-allotment option or purchasing shares of securities in the open market.
     
  Syndicate covering transactions involve the purchase of securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriter will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which they may purchase securities through the exercise of the over-allotment option. If the underwriter sells more shares of securities than could be covered by the exercise of the over-allotment option, creating a naked short position, the position can be closed out only by buying securities in the open market. A naked short position is more likely to be created if the underwriter is concerned that after pricing there could be downward pressure on the price of the securities in the open market that could adversely affect investors who purchase in this offering.
     
  Penalty bids permit the underwriter to reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased in stabilizing or syndicate covering transactions to cover syndicate short positions.

 

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of our securities. As a result, the price of our securities in the open market may be higher than it would be otherwise in the absence of these transactions.

 

Neither we nor the underwriter makes any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may occur on the Nasdaq Capital Market or on any other trading market. If any of these transactions are commenced, they may be discontinued without notice at any time.

 

Passive Market Making

 

In connection with this offering, the underwriter and selling group members, if any, may engage in passive market making transactions in our common stock in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, then that bid must then be lowered when specified purchase limits are exceeded.

 

81

 

Other Relationships

 

The underwriter and its affiliates may in the future provide, various investment banking, commercial banking, financial advisory, brokerage and other services to us and our affiliates for which services they may in the future receive, customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own accounts and for the accounts of their customers and such investment and securities activities may involve securities and/or instruments of our Company. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

 

OTCQB Quotation

 

Our common stock is quoted on the OTCQB Venture Market operated by OTC Markets Group, Inc. (“OTCQB”) under the ticker symbol “SNBP.” We have applied to have our common stock listed on The Nasdaq Capital Market under the symbol “SNBP”.

 

Offer Restrictions Outside the United States

 

Other than in the United States, no action has been taken by us or the underwriter that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

 

Australia

 

This prospectus is not a disclosure document under Chapter 6D of the Australian Corporations Act, has not been lodged with the Australian Securities and Investments Commission and does not purport to include the information required of a disclosure document under Chapter 6D of the Australian Corporations Act. Accordingly, (1) the offer of the securities under this prospectus is only made to persons to whom it is lawful to offer the securities without disclosure under Chapter 6D of the Australian Corporations Act under one or more exemptions set out in section 708 of the Australian Corporations Act, (2) this prospectus is made available in Australia only to those persons as set forth in clause (1) above, and (3) the offeree must be sent a notice stating in substance that by accepting this offer, the offeree represents that the offeree is such a person as set forth in clause (1) above, and, unless permitted under the Australian Corporations Act, agrees not to sell or offer for sale within Australia any of the securities sold to the offeree within 12 months after its transfer for the offeree under this prospectus.

 

Canada

 

The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

 

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

 

82

 

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriter is not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

 

China

 

The information in this document does not constitute a public offer of the securities, whether by way of sale or subscription, in the People’s Republic of China (excluding, for purposes of this paragraph, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). The securities may not be offered or sold directly or indirectly in the PRC to legal or natural persons other than directly to “qualified domestic institutional investors.”

 

European Economic Area - Belgium, Germany, Luxembourg and the Netherlands

 

The information in this document has been prepared on the basis that all offers of securities will be made pursuant to an exemption under the Directive 2003/71/EC (“Prospectus Directive”), as implemented in Member States of the European Economic Area (each, a “Relevant Member State”), from the requirement to produce a prospectus for offers of securities.

 

An offer to the public of securities has not been made, and may not be made, in a Relevant Member State except pursuant to one of the following exemptions under the Prospectus Directive as implemented in that Relevant Member State:

 

 

to legal entities that are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities;

 

 

to any legal entity that has two or more of (i) an average of at least 250 employees during its last fiscal year; (ii) a total balance sheet of more than €43,000,000 (as shown on its last annual unconsolidated or consolidated financial statements) and (iii) an annual net turnover of more than €50,000,000 (as shown on its last annual unconsolidated or consolidated financial statement);

 

 

to fewer than 100 natural or legal persons (other than qualified investors within the meaning of Article 2(1)I of the Prospectus Directive) subject to obtaining the prior consent of the company or any underwriter for any such offer; or

 

 

in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by the company of a prospectus pursuant to Article 3 of the Prospectus Directive.

 

France

 

This document is not being distributed in the context of a public offering of financial securities (offre au public de titres financiers) in France within the meaning of Article L.411-1 of the French Monetary and Financial Code (Code monétaire et financier) and Articles 211-1 et seq. of the General Regulation of the French Autorité des marchés financiers (“AMF”). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France.

 

This document and any other offering material relating to the securities has not been, and will not be, submitted to the AMF for approval in France and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in France.

 

Such offers, sales and distributions have been and shall only be made in France to (i) qualified investors (investisseurs qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-1 to D.411-3, D. 744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation and/or (ii) a restricted number of non-qualified investors (cercle restreint dinvestisseurs non-qualifiés) acting for their own account, as defined in and in accordance with Articles L.411-2-II-2° and D.411-4, D.744-1, D.754-1 and D.764-1 of the French Monetary and Financial Code and any implementing regulation.

 

83

 

Pursuant to Article 211-3 of the General Regulation of the AMF, investors in France are informed that the securities cannot be distributed (directly or indirectly) to the public by the investors otherwise than in accordance with Articles L.411-1, L.411-2, L.412-1 and L.621-8 to L.621-8-3 of the French Monetary and Financial Code.

 

Ireland

 

The information in this document does not constitute a prospectus under any Irish laws or regulations and this document has not been filed with or approved by any Irish regulatory authority as the information has not been prepared in the context of a public offering of securities in Ireland within the meaning of the Irish Prospectus (Directive 2003/71/EC) Regulations 2005 (the “Prospectus Regulations”). The securities have not been offered or sold, and will not be offered, sold or delivered directly or indirectly in Ireland by way of a public offering, except to (i) qualified investors as defined in Regulation 2(l) of the Prospectus Regulations and (ii) fewer than 100 natural or legal persons who are not qualified investors.

 

Israel

 

The securities offered by this prospectus have not been approved or disapproved by the Israeli Securities Authority (the ISA), or ISA, nor have such securities been registered for sale in Israel. The shares may not be offered or sold, directly or indirectly, to the public in Israel, absent the publication of a prospectus. The ISA has not issued permits, approvals or licenses in connection with the offering or publishing the prospectus; nor has it authenticated the details included herein, confirmed their reliability or completeness, or rendered an opinion as to the quality of the securities being offered. Any resale in Israel, directly or indirectly, to the public of the securities offered by this prospectus is subject to restrictions on transferability and must be effected only in compliance with the Israeli securities laws and regulations.

 

Italy

 

The offering of the securities in the Republic of Italy has not been authorized by the Italian Securities and Exchange Commission (Commissione Nazionale per le Società e la Borsa, “CONSOB”) pursuant to the Italian securities legislation and, accordingly, no offering material relating to the securities may be distributed in Italy and such securities may not be offered or sold in Italy in a public offer within the meaning of Article 1.1(t) of Legislative Decree No. 58 of 24 February 1998 (“Decree No. 58”), other than:

 

 

to Italian qualified investors, as defined in Article 100 of Decree no. 58 by reference to Article 34-ter of CONSOB Regulation no. 11971 of 14 May 1999 (“Regulation no. 1197l”) as amended (“Qualified Investors”); and

 

 

in other circumstances that are exempt from the rules on public offer pursuant to Article 100 of Decree No. 58 and Article 34-ter of Regulation No. 11971 as amended.

 

Any offer, sale or delivery of the securities or distribution of any offer document relating to the securities in Italy (excluding placements where a Qualified Investor solicits an offer from the issuer) under the paragraphs above must be:

 

 

made by investment firms, banks or financial intermediaries permitted to conduct such activities in Italy in accordance with Legislative Decree No. 385 of 1 September 1993 (as amended), Decree No. 58, CONSOB Regulation No. 16190 of 29 October 2007 and any other applicable laws; and

 

 

in compliance with all relevant Italian securities, tax and exchange controls and any other applicable laws.

 

Any subsequent distribution of the securities in Italy must be made in compliance with the public offer and prospectus requirement rules provided under Decree No. 58 and the Regulation No. 11971 as amended, unless an exception from those rules applies. Failure to comply with such rules may result in the sale of such securities being declared null and void and in the liability of the entity transferring the securities for any damages suffered by the investors.

 

84

 

Japan

 

The securities have not been and will not be registered under Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948), as amended (the “FIEL”) pursuant to an exemption from the registration requirements applicable to a private placement of securities to Qualified Institutional Investors (as defined in and in accordance with Article 2, paragraph 3 of the FIEL and the regulations promulgated thereunder). Accordingly, the securities may not be offered or sold, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan other than Qualified Institutional Investors. Any Qualified Institutional Investor who acquires securities may not resell them to any person in Japan that is not a Qualified Institutional Investor, and acquisition by any such person of securities is conditional upon the execution of an agreement to that effect.

 

Portugal

 

This document is not being distributed in the context of a public offer of financial securities (oferta pública de valores mobiliários) in Portugal, within the meaning of Article 109 of the Portuguese Securities Code (Código dos Valores Mobiliários). The securities have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in Portugal. This document and any other offering material relating to the securities have not been, and will not be, submitted to the Portuguese Securities Market Commission (Comissão do Mercado de Valores Mobiliários) for approval in Portugal and, accordingly, may not be distributed or caused to distributed, directly or indirectly, to the public in Portugal, other than under circumstances that are deemed not to qualify as a public offer under the Portuguese Securities Code. Such offers, sales and distributions of securities in Portugal are limited to persons who are “qualified investors” (as defined in the Portuguese Securities Code). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

 

Sweden

 

This document has not been, and will not be, registered with or approved by Finansinspektionen (the Swedish Financial Supervisory Authority). Accordingly, this document may not be made available, nor may the securities be offered for sale in Sweden, other than under circumstances that are deemed not to require a prospectus under the Swedish Financial Instruments Trading Act (1991:980) (Sw. lag (1991:980) om handel med finansiella instrument). Any offering of securities in Sweden is limited to persons who are “qualified investors” (as defined in the Financial Instruments Trading Act). Only such investors may receive this document and they may not distribute it or the information contained in it to any other person.

 

Switzerland

 

The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (“SIX”) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering material relating to the securities may be publicly distributed or otherwise made publicly available in Switzerland.

 

Neither this document nor any other offering material relating to the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority (“FINMA”).

 

This document is personal to the recipient only and not for general circulation in Switzerland.

 

United Arab Emirates

 

Neither this document nor the securities have been approved, disapproved or passed on in any way by the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates, nor have we received authorization or licensing from the Central Bank of the United Arab Emirates or any other governmental authority in the United Arab Emirates to market or sell the securities within the United Arab Emirates. This document does not constitute and may not be used for the purpose of an offer or invitation. No services relating to the securities, including the receipt of applications and/or the allotment or redemption of such shares, may be rendered within the United Arab Emirates by us.

 

85

 

No offer or invitation to subscribe for securities is valid or permitted in the Dubai International Financial Centre.

 

United Kingdom

 

Neither the information in this document nor any other document relating to the offer has been delivered for approval to the Financial Services Authority in the United Kingdom and no prospectus (within the meaning of section 85 of the Financial Services and Markets Act 2000, as amended (“FSMA”)) has been published or is intended to be published in respect of the securities. This document is issued on a confidential basis to “qualified investors” (within the meaning of section 86(7) of FSMA) in the United Kingdom, and the securities may not be offered or sold in the United Kingdom by means of this document, any accompanying letter or any other document, except in circumstances that do not require the publication of a prospectus pursuant to section 86(1) FSMA. This document should not be distributed, published or reproduced, in whole or in part, nor may its contents be disclosed by recipients to any other person in the United Kingdom.

 

Any invitation or inducement to engage in investment activity (within the meaning of section 21 of FSMA) received in connection with the issue or sale of the securities have only been communicated or caused to be communicated and will only be communicated or caused to be communicated in the United Kingdom in circumstances in which section 21(1) of FSMA does not apply to us.

 

In the United Kingdom, this document is being distributed only to, and is directed at, persons (i) who have professional experience in matters relating to investments falling within Article 19(5) (investment professionals) of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005 (“FPO”), (ii) who fall within the categories of persons referred to in Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the FPO or (iii) to whom it may otherwise be lawfully communicated (together “relevant persons”). The investments to which this document relates are available only to, and any invitation, offer or agreement to purchase will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

 

Legal Matters 

 

The validity of the shares of common stock being offered by this prospectus has been passed upon for us by Faegre Drinker Biddle & Reath LLP, Minneapolis, Minnesota. Certain legal matters in connection with this offering will be passed upon for the underwriter by Ellenoff Grossman & Schole LLP, New York, New York.

 

Experts 

 

The financial statements as of December 31, 2019 and 2018 and for the two years in the period ended December 31, 2019 included in this prospectus have been so included in reliance on the report of Cherry Bekaert LLP, an independent registered public accounting firm, appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.

 

Where You Can Find More Information 

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act that registers the distribution of the securities offered under this prospectus. The registration statement, including the attached exhibits and schedules, contains additional relevant information about us and the securities. The rules and regulations of the SEC allow us to omit from this prospectus certain information included in the registration statement.

 

We are subject to the informational requirements of the Securities Exchange Act and are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. Any information we file with the SEC, including the documents incorporated by reference into this prospectus, is also available on the SEC’s website at www.sec.gov. We also make these documents publicly available, free of charge, on our website at www.sunbiopharma.com as soon as reasonably practicable after filing such documents with the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus.

 

86

 

 

Sun BioPharma, Inc.
Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

 

   

March 31, 2020

   

December 31, 2019

 

 

 

(Unaudited)

         
ASSETS                

Current assets:

               

Cash

  $ 1,296     $ 2,449  

Prepaid expenses and other current assets

    389       283  

Income tax receivable

    406       361  

Total current assets

    2,091       3,093  

Other noncurrent assets

    45       51  

Total assets

  $ 2,136     $ 3,144  
                 

LIABILITITES AND STOCKHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable

  $ 271     $ 597  

Accrued expenses

    308       304  

Term debt

    91       116  

Unsecured promissory note payable

    742       742  

Total current liabilities

    1,412       1,759  
                 

Stockholders' equity:

               

Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of March 31, 2020 and December 31 2019

    -       -  

Common stock, $0.001 par value; 100,000,000 authorized; 6,631,308 shares issued and outstanding as of both March 31, 2020 and December 31, 2019

    7       7  

Additional paid-in capital

    42,671       42,331  

Accumulated deficit

    (43,056 )     (41,258 )

Accumulated comprehensive income

    1,102       305  

Total stockholders' equity

    724       1,385  

Total liabilities and stockholders' equity

  $ 2,136     $ 3,144  

 

See accompanying notes to condensed consolidated financial statements.

 

 

F-1

 

Sun BioPharma, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

 (Unaudited)

 

    Three Months Ended March 31,  
   

2020

   

2019

 

Operating expenses:

               

General and administrative

  $ 468     $ 303  

Research and development

    598       350  

Operating loss

    (1,066 )     (653 )
                 

Other (expense) income:

               

Interest expense

    (4 )     (1,033 )

Other(expense) income

    (820 )     34  

Total other expense

    (824 )     (999 )
                 

Loss before income tax benefit

    (1,890 )     (1,652 )
                 

Income tax benefit

    92       71  
                 

Net loss

    (1,798 )     (1,581 )

Foreign currency translation adjustment

    797       (32 )

Comprehensive loss

  $ (1,001 )   $ (1,613 )
                 

Basic and diluted net loss per share

  $ (0.27 )   $ (0.31 )

Weighted average shares outstanding - basic and diluted

    6,631,308       5,072,397  

 

See accompanying notes to condensed consolidated financial statements.

 

F-2

 

Sun BioPharma, Inc.

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(In thousands)

(Unaudited) 

 

   

For the Three Months Ended March 31, 2019

 
   

Common Stock

   

Additional

Paid-In

   

Accumulated

   

Accumulated Other

Comprehensive

   

Total Stockholders'

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Gain (Loss)

   

Equity (Deficit)

 
                                                 
                                                 

Balances as of January 1, 2019

    5,077     $ 5     $ 35,038     $ (35,058 )   $ 283     $ 268  

Beneficial conversion feature on convertible notes payable

    -       -       353       -       -       353  

Warrants issued with sale of convertible notes payable

    -       -       419       -       -       419  

Common stock converted into convertible notes payable

    (7 )     -       (25 )     -       -       (25 )

Stock-based compensation

    -       -       10               -       10  

Net loss

    -       -       -       (1,581 )     -       (1,581 )

Foreign currency translation adjustment

    -       -       -       -       (32 )     (32 )

Balances as of March 31, 2019

    5,070     $ 5     $ 35,795     $ (36,639 )   $ 251     $ (588 )

 

   

For the Three Months Ended March 31, 2020

 
   

Common Stock

   

Additional

Paid-In

   

Accumulated

   

Accumulated Other

Comprehensive

   

Total Stockholders'

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Gain

   

Equity

 

Balances as of January 1, 2020

    6,631     $ 7     $ 42,331     $ (41,258 )   $ 305     $ 1,385  

Warrants issued for future services

    -       -       228       -       -       228  

Stock-based compensation

    -       -       112       -       -       112  

Net loss

    -       -       -       (1,798 )     -       (1,798 )

Foreign currency translation adjustment

    -       -       -       -       797       797  

Balances at March 31, 2020

    6,631     $ 7     $ 42,671     $ (43,056 )   $ 1,102     $ 724  

 

See accompanying notes to condensed consolidated financial statements.

 

F-3

 

Sun BioPharma, Inc.

Condensed Consolidated Statements of Cash Flows
(In thousands)

(Unaudited)

 

   

Three Months Ended March 31,

 
   

2020

   

2019

 

Cash flows from operating activities:

               

Net loss

  $ (1,798 )   $ (1,581 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Stock-based compensation

    112       10  

Amortization of debt discount

    -       974  

Amortization of debt issuance costs

    -       6  

Non-cash interest expense

    -       48  

Changes in operating assets and liabilities:

               

Income tax receivable

    (97 )     (74 )

Prepaid expenses and other current assets

    97       38  

Accounts payable

    546       (193 )

Accrued liabilities

    20       (11 )

Net cash used in operating activities

    (1,120 )     (783 )
                 

Cash flows from financing activities:

               

Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7

    -       810  

Repayment of demand note

    -       (25 )

Repayments of term debt

    (26 )     (27 )

Net cash provided by financing activities

    (26 )     758  
                 

Effect of exchange rate changes on cash

    (7 )     (1 )
                 

Net change in cash

    (1,153 )     (26 )

Cash at beginning of period

    2,449       1,405  

Cash at end of period

  $ 1,296     $ 1,379  
                 

Supplemental disclosure of cash flow information:

               

Cash paid during period for interest

  $ 2     $ 5  
                 

Supplemental disclosure of non-cash transactions:

               

Warrants issued for future services

  $ 228          

Beneficial conversion feature on convertible notes

  $ -     $ 353  

Warrants issued with convertible notes

  $ -     $ 419  

Common stock converted into convertible notes payable

  $ -     $ 25  

 

See accompanying notes to condensed consolidated financial statements.

 

F-4

 

Sun BioPharma, Inc.
Notes to Condensed Consolidated Financial Statements

 

1.     Business

 

Sun BioPharma, Inc. and its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-101, from the University of Florida Research Foundation, Inc. (“UFRF”).

 

2.     Risks and Uncertainties

 

The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures.

 

We have incurred losses of $42.6 million since our inception in 2011. For the three months ended March 31, 2020, we incurred a net loss of $1.8 million, which includes a foreign currency loss of $0.8 million. We also incurred negative cash flows from operating activities of $1.2 million for this period. As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-101, we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of March 31, 2020, we had cash of $1.3 million, working capital of $0.7 million, (current assets less current liabilities) and stockholders’ equity of $0.7 million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities.

 

The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our 2019 financial statements dated March 24, 2020. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-101 product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note 4 titled “Liquidity and Business Plan.”

 

On March 11, 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) a global pandemic and continued widespread infection in the United States is a possibility. Actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-19, including through issuances of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations.  These measures, while intended to protect human life, have led to significantly reduced economic activity. The rapid development and uncertainty of the situation precludes any prediction as to the ultimate impact COVID-19 will have on the Company's business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-19 outbreak in the United States and Australia.  On April 3, 2020, we initiated a temporary pause in the enrollment of new patients in our ongoing clinical trial.  We anticipate resumption of new patient enrollment in Q2 2020 once conditions allow.  We continue to treat patients already enrolled. 

 

3.     Basis of Presentation

 

We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2019 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form 10-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

 

F-5

 

4.     Liquidity and Business Plan

 

We need to obtain additional funds to continue our operations and execute our current business plans. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or not positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.

 

If we are unable to obtain additional financing, we believe that we will need to reduce our operations by taking actions that may include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-101 product candidate, licensing rights to third parties, including the right to commercialize our SBP-101 product candidate for pancreatic cancer, or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.

 

Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-101 product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-101 product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are not successful or if we are unable to obtain marketing approval, we would not be able to continue as a going concern and would be forced to cease operations and liquidate our company.

 

There can be no assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.

 

5.     Summary of Significant Accounting Policies

 

Principles of consolidation

 

The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.

 

Use of estimates

 

The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.

 

Research and development costs

 

Research and development costs include expenses incurred in the conduct of our second Phase 1 human clinical trial, for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-101 compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-101 product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.

 

F-6

 

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

 

All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.

 

We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license.

 

Stock-based compensation

 

In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.

 

The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.

 

Foreign currency translation adjustments

 

The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity (deficit). During the three-month periods ended March 31, 2020 and 2019, any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.

 

Comprehensive loss

 

Comprehensive loss consists of our net loss and the effects of foreign currency translation.

 

Net loss per share

 

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

 

F-7

 

The following table sets forth the potential shares of common stock that were not included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:

 

   

March 31,

 
   

2020

   

2019

 

Employee and non-employee stock options

    1,745,811       1,032,211  

Estimated common shares issuable upon conversion of notes payable and accrued interest

    -       636,234  

Common stock issuable under common stock purchase warrants

    3,497,099       2,509,477  
      5,242,910       4,177,922  

 

6.     Indebtedness

 

Term debt

 

The terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) which was amended in December of 2019 to extend the maturity date from December 31, 2019 to December 31, 2020, remain unchanged as of March 31, 2020.  The fair market value of the warrants issued in 2019 in exchange for modification of the terms is being amortized to interest expense over the remaining term of the loan. The amendment requires the continuation of monthly payments of principal and interest totaling $10,000. The unpaid principal balance at March 31, 2020 was $90,000.

 

Deferred financing costs

 

The following table summarizes the deferred financing costs which are presented as a direct reduction of the carrying amount of their related debt liabilities (in thousands):

 

   

March 31, 2020

   

December 31, 2019

 
   

Term Debt

   

Term Debt

 

Loan principal Amount

  $ 97     $ 126  

Deferred Financing Costs

    51       51  

Accumulated Amortization

    (44 )     (41 )

Unamortized balance

    7       10  

Discount on Debt

    -       -  

Accumulated Amortization

    -       -  

Unamortized balance

    -       -  

Loan carrying amounts, net

  $ 90     $ 116  

 

7.     Stockholders’ Deficit

 

Warrants to purchase common stock issued for future services

 

On February 21, 2020, the Company issued to a service provider a five-year warrant to purchase 75,000 shares of common stock at an exercise price of $6.49 per share. The fair market value of the warrants issued of approximately $228,000 was capitalized and will be charged against future proceeds.

 

F-8

 

Shares of common stock reserved for future issuance were as follows as of March 31, 2020:

 

Stock options outstanding

    1,745,811  

Shares available for grant under equity incentive plan

    18,549  

Common shares issuable under outstanding common stock purchase warrants

    3,497,099  
      5,261,459  

 

8.     Stock-based Compensation

 

2016 Omnibus Incentive Plan

 

The Sun BioPharma, Inc. 2016 Omnibus Incentive Plan (the “2016 Plan”) was adopted by our Board of Directors in March 2016 and approved by our stockholders in May 2016. The 2016 Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2016 Plan at no less than the fair market value of the underlying common stock as of the date of grant. Options granted under the 2016 Plan have a maximum term of ten years. Under the 2016 Plan, a total of 1,500,000 shares of common stock were initially reserved for issuance. As of March 31, 2020, options to purchase 1,481,451shares of common stock were outstanding under the 2016 Plan and 18,549 shares remained available for future awards.

 

2011 Stock Option Plan

 

Our Board of Directors ceased making awards under the Sun BioPharma, Inc. 2011 Stock Option Plan (the “2011 Plan”) upon the receipt of stockholder approval for the 2016 Plan. Awards outstanding under the 2011 Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the 2011 Plan have a maximum term of ten years and generally vest over zero to two years for employees. As of March 31, 2020, options to purchase 264,360 shares of common stock remained outstanding under the 2011 Plan.

 

Stock-based Compensation Expense

 

General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through March 31, 2020 vest based upon time-based and performance conditions. There was approximately $229,000 unamortized stock-based compensation expense related to options granted to employees as of March 31, 2020.

 

Stock-based compensation expense for each of the periods presented is as follows (in thousands):

 

   

Three Months Ended March 31,

 
   

2020

   

2019

 

General and Administrative

    99       10  

Research and Development

    13       -  
      112       10  

 

F-9

 

Details of options granted, exercised, cancelled or forfeited during the three months ended March 31, 2020 follows:

 

   

Shares Available for Grant

   

Shares Underlying Options

 

Balance at January 1, 2020

    19,549       1,744,811  

Granted

    (1,000 )     1,000  

Exercised

    -       -  

Cancelled

    -       -  

Forfeitures

    -       -  
                 

Balance at March 31, 2020

    18,549       1,745,811  

 

Information about stock options outstanding, vested and expected to vest as of March 31, 2020, is as follows:

 

          

Outstanding, Vested and Expected to Vest

   

Options Vested and Excercisable

 

Per Share Exercise Price

 

Shares

   

Weighted Average Remaining Contractual Life (Years)

   

Weighted Average Exercise Price

   

Options Excercisable

   

Weighted Average Remaining Contractual Life (Years)

 
                                             
$0.875 - $1.10     26,360       2.75     $ 1.029       26,360       2.75  
$2.275 - $2.50     38,000       3.87     $ 2.464       38,000       3.87  
$2.95 - $3.70     774,100       8.07     $ 3.040       411,525       7.11  
$4.95 - $8.10     539,300       7.73     $ 6.739       506,500       7.67  
$10.00 - $10.10     54,000       7.30     $ 10.007       54,000       7.30  
$15.10         314,051       6.16     $ 15.100       310,551       6.21  
                                             

Totals

        1,745,811       7.43     $ 6.525       1,346,936       6.94  

 

9. Subsequent Event

 

On May 1, 2020, the Company the Company executed an unsecured promissory note with a lender as a part of the Payroll Protection Program (“PPP”) in the Coronavirus Aid, Relief, and Economic Security Act. Funds totaling approximately $102,000 will be used to support Company payroll. The note may be forgiven in part and bears an interest rate of 1% per annum after a six-month deferment period.

 

F-10

 

 

Sun BioPharma, Inc.
Consolidated Balance Sheets

(In thousands, except share amounts)

 

   

December 31, 2019

   

December 31, 2018

 

ASSETS

               

Current assets:

               

Cash

  $ 2,449     $ 1,405  

Prepaid expenses and other current assets

    283       110  

Income tax receivable

    361       332  

Total current assets

    3,093       1,847  

Other noncurrent assets

    51       51  

Total assets

  $ 3,144     $ 1,898  
                 

LIABILITIES AND STOCKHOLDERS' EQUITY

               

Current liabilities:

               

Accounts payable

  $ 597     $ 1,064  

Accrued expenses

    304       216  

Convertible notes payable, net of debt discounts

    -       64  

Term debt, current portion

    116       286  

Unsecured promissory note payable

    742       -  

Total current liabilities

    1,759       1,630  

Total liabilities

    1,759       1,630  
                 

Stockholders' equity:

               

Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2019 and December 31, 2018

    -       -  

Common stock, $0.001 par value; 100,000,000 authorized; 6,631,308 and 5,077,483 shares issued and outstanding, as of December 31, 2019 and December 31, 2018, respectively

    7       5  

Additional paid-in capital

    42,331       35,038  

Accumulated deficit

    (41,258 )     (35,058 )

Accumulated comprehensive income

    305       283  

Total stockholders' equity

    1,385       268  

Total liabilities and stockholders' equity

  $ 3,144     $ 1,898  

 

See accompanying notes to consolidated financial statements.

 

F-11

 

Sun BioPharma, Inc.

Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)

 

   

Year Ended December 31,

 
   

2019

   

2018

 

Operating expenses:

               

General and administrative

  $ 1,973     $ 2,108  

Research and development

    2,349       1,783  

Operating loss

    (4,322 )     (3,891 )
                 

Other (expense) income:

               

Grant income

    -       54  

Interest expense

    (2,194 )     (1,814 )

Other expense

    (99 )     (508 )

Total other expense

    (2,293 )     (2,268 )
                 

Loss before income tax benefit

    (6,615 )     (6,159 )
                 

Income tax benefit

    415       254  
                 

Net loss

    (6,200 )     (5,905 )

Foreign currency translation adjustment

    22       448  

Comprehensive loss

  $ (6,178 )   $ (5,457 )
                 

Basic and diluted net loss per share

  $ (1.09 )   $ (1.27 )

Weighted average shares outstanding - basic and diluted

    5,700,314       4,662,080  

 

See accompanying notes to consolidated financial statements.

 

F-12

 

Sun BioPharma, Inc.

Consolidated Statements of Stockholders’ Equity (Deficit)

(In thousands)

 

   

Common Stock

   

Additional

Paid-In

   

Accumulated

   

Accumulated Other

Comprehensive

   

Total

Stockholders'

 
   

Shares

   

Amount

   

Capital

   

Deficit

   

Gain (Loss)

   

Equity (Deficit)

 
                                                 
                                                 

Balances as of January 1, 2018

    3,842     $ 4     $ 25,625     $ (29,153 )   $ (165 )   $ (3,689 )

Sale of common stock and warrants

    485       -       2,328       -       -       2,328  

Beneficial conversion feature

    -       -       716       -       -       716  

Conversion of convertible notes payable and accrued interest into common stock and warrants

    751       1       3,257       -       -       3,258  

Warrants issued with sale of convertible notes payable

    -       -       739       -       -       739  

Stock-based compensation

    -       -       2,373       -       -       2,373  

Net loss

    -       -       -       (5,905 )     -       (5,905 )

Foreign currency translation adjustment

    -       -       -       -       448       448  

Balances as of December 31, 2018

    5,078     $ 5     $ 35,038     $ (35,058 )   $ 283     $ 268  

Beneficial conversion feature on convertible notes payable

    -       -       353       -       -       353  

Warrants issued with sale of convertible notes payable

    -       -       419       -       -       419  

Conversion of convertible notes payable and accrued interest into common stock

    651       1       2,280       -       -       2,281  

Common stock converted into convertible notes payable

    (7 )     -       (25 )     -       -       (25 )

Sale of common stock and warrants

    909       1       3,159       -       -       3,160  

Warrants issued in exchange for modification of term debt

    -       -       14       -       -       14  

Stock-based compensation

    -       -       1,093       -       -       1,093  

Net loss

    -       -       -       (6,200 )     -       (6,200 )

Foreign currency translation adjustment

    -       -       -       -       22       22  

Balances as of December 31, 2019

    6,631     $ 7     $ 42,331     $ (41,258 )   $ 305     $ 1,385  

 

See accompanying notes to consolidated financial statements.

 

F-13

 

Sun BioPharma, Inc.

Consolidated Statements of Cash Flows
(In thousands)

 

   

Year Ended December 31,

 
   

2019

   

2018

 

Cash flows from operating activities:

               

Net loss

  $ (6,200 )   $ (5,905 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Stock-based compensation

    1,093       1,279  

Amortization of debt discount

    2,066       1,732  

Amortization of debt issuance costs

    12       9  

Non-cash interest expense

    102       4  

Changes in operating assets and liabilities:

               

Income tax receivable

    (31 )     50  

Prepaid expenses and other current assets

    (174 )     25  

Accounts payable

    301       360  

Accrued liabilities

    92       59  

Net cash used in operating activities

    (2,739 )     (2,387 )
                 

Cash flows from financing activities:

               

Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7 and $5 respectively

    810       1,329  

Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively

    3,160       2,328  

Repayment of demand note

    (25 )     -  

Repayments of term debt

    (161 )     (14 )

Net cash provided by financing activities

    3,784       3,643  
                 

Effect of exchange rate changes on cash

    (1 )     (3 )
                 

Net change in cash

    1,044       1,253  

Cash at beginning of period

    1,405       152  

Cash at end of period

  $ 2,449     $ 1,405  
                 

Supplemental disclosure of cash flow information:

               

Cash paid during period for interest

  $ 14     $ 67  
                 

Supplemental disclosure of non-cash transactions:

               

Beneficial conversion feature on convertible notes

  $ 353     $ 716  

Warrants issued with convertible notes

  $ 419     $ 739  

Warrants issued in exchange for modification of term debt

  $ 14     $ -  

Common stock converted into convertible notes payable

  $ (25 )   $ -  

Conversion of convertible notes payable and accrued interest into common stock and warrants

  $ -     $ 3,258  

Conversion of convertible notes payable and accrued interest into common stock

  $ 2,281     $ -  

Issuance of unsecured promissory note in exchange for vendor accounts payable

  $ 742     $ -  

Options granted in exchange for release from contingent payment obligations

  $ -     $ 1,094  

 

See accompanying notes to consolidated financial statements.

 

F-14

 

Sun BioPharma, Inc.
Notes to Consolidated Financial Statements

 

1.

Business

 

Sun BioPharma, Inc. and its wholly owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-101, from the University of Florida Research Foundation, Inc. (“UFRF”). Sun BioPharma, Inc. was incorporated under the laws of the State of Delaware on September 21, 2011. Sun BioPharma Australia Pty Ltd was established on May 24, 2013 and incorporated under the laws of Australian Securities and Investments Commission.

 

2.

Risks and Uncertainties

 

The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may take many years, and is normally expected to involve substantial expenditures.

 

We have incurred losses of $41.3 million since our inception in 2011. For the year ended December 31, 2019 we incurred a net loss and negative cash flows from operating activities of $6.2 million and $2.7 million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-101. As of December 31, 2019, we had cash of $2.4 million, working capital of $1.3 million and stockholders’ equity of $1.4 million. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities.

 

The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-101, in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.

 

3.

Liquidity and Management Plans

 

We will need to seek additional sources of funds to support our current business plans. We may seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is not positive or economic and market conditions deteriorate.

 

If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that may include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-101 product candidate, license to third parties the rights to commercialize our SBP-101 product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.

 

F-15

 

In closings occurring in August, September and October 2019 the Company sold 909,209 shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately $3.2 million. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $4.00.

 

In closings occurring in December 2018 and January 2019 the Company sold $2.2 million principal amount of unsecured convertible promissory notes (the “Notes”) and warrants to purchase up to 1,243,498 shares of common stock in a private placement to certain investors. On June 30, 2019 the entire principal balance and accrued interest of $105,000 converted into 651,758 shares of common stock per the terms of the Notes at a conversion rate of $3.50. See Note 6 titled “Indebtedness” for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $4.50.

 

Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP-101 product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-101 product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are not successful, if we are unable to obtain marketing approval, we would not be able to continue as a going concern and would be forced to cease operations and liquidate our company.

 

There can be no assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.

 

4.

Summary of Significant Accounting Policies

 

Basis of presentation

 

We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on December 31.

 

Principles of consolidation

 

The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.

 

Use of estimates

 

The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Concentration of credit risk

 

Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits may be in excess of insured limits. The Company has not experienced any losses on its deposits of cash.

 

F-16

 

Beneficial conversion feature

 

For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.

 

Debt issuance costs

 

Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.

 

Research and development costs

 

Research and development costs include expenses incurred in the conduct of our Phase 1 human clinical trials, for third-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-101 compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-101 product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.

 

We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.

 

We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license.

 

Stock-based compensation

 

In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.

 

The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.

 

F-17

 

Income taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of December 31, 2019 and 2018. The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.

 

Foreign currency translation

 

The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2019 and 2018, any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.

 

Grant Income

 

Grant income is derived from a one-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the “Grant Agreement”). The total grant awarded under the Grant Agreement was $225,000 and was used to fund studies of SBP-101 as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of December 31, 2018 the Company has been fully reimbursed under the Grant Agreement.

 

Comprehensive loss

 

Comprehensive loss consists of our net loss and the effects of foreign currency translation.

 

Net loss per share

 

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

 

F-18

 

The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:

 

   

December 31,

 
   

2019

   

2018

 

Employee and non-employee stock options

    1,744,811       1,032,211  

Estimated common shares issuable upon conversion of notes payable and accrued interest

    -       383,947  

Common stock issuable under common stock purchase warrants

    3,422,099       2,035,197  
      5,166,910       3,451,355  

 

Recently Adopted Accounting Pronouncements

 

In June 2018, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2018-07, “Compensation – Stock Compensation (Topic 718).” ASU 2018-07 simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning January 1, 2019. Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.

 

In February 2016, the FASB issued ASU 2016-02, “Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic 842 and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.  For leases with a term of 12 months or less, a lessee is permitted to make an election under which such assets and liabilities would not be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.  This standard was adopted by the Company for the year beginning January 1, 2019. The Company has evaluated the impact of this revised guidance on its financial statements and determined it had no material impact, as the Company has no leasing arrangements with terms greater than one year.

 

5.

Accrued Expenses

 

Accrued expenses consisted of the following (in thousands):

 

   

December 31,

 
   

2019

   

2018

 

Clinical trial and related expenses

  $ 147     $ 42  

Professional services

    125       157  

Other

    32       17  

Total accrued liabilities

  $ 304     $ 216  

 

F-19
 

 

6.

Indebtedness

 

2018 Convertible notes payable

 

In December of 2018 and January of 2019, we sold convertible promissory notes (the “2018 Notes”) and warrants to purchase common stock for gross proceeds of $2.2 million. The 2018 Notes were scheduled to matured on June 30, 2019 and bore an interest at a rate of 10.0% per year. The 2018 Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (1) June 30, 2019 or (2) the date the Company receives gross proceeds of at least $6.0 million from the sale of equity securities (subject to certain exclusions). The stated conversion rate was $3.50 per share. In addition to the 2018 Notes, investors received a Warrant to purchase two shares of common stock for every $3.50 principal amount of 2018 Notes purchased. In total, warrants to purchase up to 1,243,498 shares of common stock were issued in the December and January closings. The exercise price of each warrant is $4.50 per share and they are exercisable until the 5-year anniversary of the dates of issuance. The warrants had a fair market value of $2.5 million upon issuance. After assigning the relative value of the warrants to the proceeds of the notes it was determined that the 2018 Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately $0.9 million. Both the relative value of the warrants and the beneficial conversion feature were recorded as a debt discount which was fully amortized through interest expense over the life of the 2018 Notes. On June 30, 2019, all $2.2 million aggregate principal balance of Notes outstanding plus $105,000 of accrued interest was converted at a conversion rate of $3.50 per share of common stock into 651,758 shares of common stock per the terms of the Notes.

 

2017 Convertible notes payable

 

In 2017 we sold convertible promissory notes (the “2017 Notes”) raising gross proceeds of approximately $3.1 million. The 2017 Notes had been scheduled to mature on December 1, 2018 and bore an interest at a rate of 5.0% per year. Principal and accrued interest on the 2017 Notes was payable at maturity. The 2017 Notes were convertible into shares of common stock or other securities of the Company upon the occurrence of a “qualified financing,” including the sale of equity securities or a strategic partnership, raising gross proceeds of at least $2.0 million on or before the maturity of the 2017 Notes or upon the request of a holder of any 2017 Note at a fixed conversion rate of $10.10 per share. The 2017 Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately $3.0 million, which was recorded as a debt discount and is presented as a direct deduction from the carrying value of the 2017 Notes. The discount was amortized through interest expense over the life of the 2017 Notes.

 

On May 16, 2018, as the result of receiving aggregate gross proceeds exceeding $2.0 million for the sale equity securities, under terms of the 2017 Notes, the Company completed the conversion of previously outstanding debt. Debt totaling approximately $3.1 million and accrued interest totaling approximately $183,000 was converted into 104,463 shares of common stock and 646,279 units (each consisting of a share of common stock and a warrant to purchase one additional share of common stock). The units were available through the 2018 Purchase Agreement. The shares were issued in reliance on the exemption from registration set forth in Section 3(a)(9) of the Securities Act as securities exchanged by an issuer with existing security holders where no commission or other remuneration is paid or given directly or indirectly by the issuer for soliciting such exchange. As of the date of conversion an incremental beneficial conversion feature of $121,000 was recorded as debt discount. Unamortized debt discount totaling $1.0 million was charged to interest expense as of the date of conversion.

 

F-20

 

The following table sets forth the changes in convertible notes payable during the year ended December 31, 2019 (in thousands):

 

   

Convertible Notes Payable

 
   

Principal

   

Accrued Interest

 

Balances at January 1, 2019

  $ 1,359     $ 2  

Aggregate principal value of notes sold

    816       -  

Accrued Interest on notes

    -       103  

Aggregate principal value of notes and accrued interest converted into common stock

    (2,175 )     (105 )
      -       -  

Balances at December 31, 2019

  $ -     $ -  

 

Term debt

 

On October 26, 2012, we entered into an unsecured loan agreement (the “Agreement”) with the Institute for Commercialization of Public Research, Inc. (the “Institute”). Under the terms of the agreement, we borrowed $300,000 at a fixed interest rate of 4.125%. No principal or interest payments were due until the maturity date, October 26, 2017, unless a mandatory repayment event occurred. Effective October 26, 2017, we entered into an amendment to our unsecured loan agreement with the Institute. Under the terms of the amendment, the maturity date of the note was extended to May 1, 2019 with monthly payments of $10,000 beginning on May 1, 2018 with the remaining balance due in full on May 1, 2019. Effective April 5, 2019 the terms of our unsecured loan (the “Term Debt”) payable to the Institute were amended again to extend the maturity date from May 1, 2019 to December 31, 2019. The Institute agreed to the amendment in exchange for a warrant to purchase 5,555 shares of common stock at an exercise price of $4.50. The warrant expires five years from issuance. On December 16, 2019 the Institute again modified the terms of repayment. In exchange for a payment $50,000 payable on December 31, 2019 and a warrant to purchase 5,000 shares of common stock at an exercise price of $4.00 the maturity date of the loan was extended from December 31, 2019 to December 31, 2020. The total fair market value of the warrants issued for both amendments was calculated at $14,000 and was recorded as a discount to the debt, which will be amortized over the remaining period until maturity of the debt. The amendment requires the continuation of monthly payments of principal and interest totaling $10,000 with monthly payments applied first to accrued and unpaid interest. The unpaid principal balance, net of unamortized debt discount, at December 31, 2019 was $116,000.

 

7.

Commitments and Contingencies

 

License agreement

 

On December 22, 2011, we entered into an exclusive license agreement with the University of Florida research Foundation (“UFRF”). This license agreement was amended on first of December 12, 2016 (“First Amendment”) and again on October 3, 2019 (“Second Amendment”). The license agreement requires the Company to pay royalties to UFRF ranging from 2.5% to 5% of net sales of licensed products developed from the licensed technology. The Second Amendment eliminated all minimum annual royalties and modified the duration of royalty payments to the shorter of (1) ten years from first commercial sale of licensed products or (2) the expiration of the period of regulatory exclusivity on a country by country basis. All future milestone payments contemplated in the original agreement were eliminated in the Second Amendment.

 

F-21

 

The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of $10,000. Accordingly, we recorded $10,000 as a license expense in the accompanying 2019 and 2018 Consolidated Statements of Operations and Comprehensive Loss.

 

8.

Stockholders’ Equity (Deficit)

 

2019 Private placement

 

On closings occurring in August, September and October of 2019, we issued an aggregate of 909,209 shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under 2019 Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately $3.2 million, of which $240,000 was received from directors and officers of the Company or its subsidiary. The warrants issued under the 2019 Purchase Agreement will be exercisable for a period of five years from the date of issuance at an exercise price of $4.00 per share See Note 4, titled “Liquidity and Management’s Plans”.

 

2018 Private placement

 

On February 20, 2018, we entered into a Securities Purchase Agreement (the “2018 Purchase Agreement”) with certain accredited investors and completed an initial closing on the same date. Pursuant to the initial closing and two subsequent closings in March and May of 2018, we sold a total of 468,200 shares of common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock. The warrants issued under the 2018 Purchase Agreement will be exercisable for a period of three years from the date of issuance at an exercise price of $5.00 per share. We received aggregate gross proceeds totaling approximately $2.3 million pursuant to private placements under the 2018 Purchase Agreement, of which $125,000 was received from directors and officers of the Company or its subsidiary. As of December 31, 2019, 468,200 warrants remained outstanding.

 

Shares reserved

 

Shares of common stock reserved for future issuance were as follows as of December 31, 2019:

 

Stock options outstanding

    1,744,811  

Shares available for grant under equity incentive plan

    19,549  

Common shares issuable under outstanding common stock purchase warrants

    3,422,099  
      5,186,459  

 

9.

Stock-Based Compensation

 

2016 Omnibus Incentive Plan

 

Stock-based awards are granted under the Sun BioPharma, Inc. 2016 Omnibus Incentive Plan (the “2016 Plan”). The 2016 Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the 2016 Plan at no less than the fair market value of the underlying common stock as of the date of grant. Options granted under the 2016 Plan have a maximum term of ten years. A total of 1,500,000 shares of common stock were initially reserved for issuance under the 2016 Plan. As of December 31, 2019, options to purchase 1,480,451 shares of common stock were outstanding under the 2016 Plan.

 

F-22

 

2011 Stock Option Plan

 

Prior to approval of the 2016 Plan, stock-based awards were granted under the Sun BioPharma, Inc. 2011 Stock Option Plan (the “2011 Plan”). In conjunction with stockholder approval of the 2016 Plan, the Board terminated the 2011 Plan, although awards outstanding under the 2011 Plan will remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the 2011 Plan have a maximum term of ten years and generally vest over zero to two years for employees. As of December 31, 2019, options to purchase 264,360 shares of common stock remained outstanding under the 2011 Plan.

 

We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.

 

A summary of option activity is as follows:

 

   

Shares

Available for

Grant

   

Shares Underlying

Options

   

Weighted

Average

Exercise Price

Per Share

   

Aggregate

Intrinsic Value

 

Balance at January 1, 2018

    1,060,400       733,960     $ 9.79     $ 169,495  

Granted

    (404,000 )     404,000       7.49          

Exercised

    -       (30,000 )     2.20          

Cancelled

    -       -       -          

Forfeitures

    75,749       (75,749 )     7.34          
                                 

Balance at December 31, 2018

    732,149       1,032,211     $ 8.90     $ 56,225  

Granted

    (733,400 )     733,400       3.42          

Exercised

    -       -       -          

Cancelled

    -       -       -          

Forfeitures

    20,800       (20,800 )     15.10          
                                 

Balance at December 31, 2019

    19,549       1,744,811     $ 6.53     $ 1,030,547  

 

A summary of the status of our unvested shares during the year ended and as of December 31, 2019 is as follows:

 

   

Shares Under

Option

   

Weighted Average

Grant Date Fair Value

 
                 

Unvested at December 31, 2018

    42,500     $ 4.83  

Granted

    733,400       2.09  

Vested

    (378,025 )     2.41  

Forefeitures

    -       -  

Unvested at December 31, 2019

    397,875     $ 2.03  

 

F-23

 

Information about stock options outstanding, vested and expected to vest as of December 31, 2019, is as follows:

 

       

Outstanding, Vested and Expected to Vest

   

Options Vested and Excercisable

 

Per Share Exercise Price

 

Shares

   

Weighted Average

Remaining

Contractual Life

(Years)

   

Weighted

Average

Exercise Price

   

Options

Excercisable

   

Weighted Average

Remaining

Contractual Life

(Years)

 
                                             

$0.875

- $1.10     26,360       3.00     $ 1.029       26,360       3.00  

$2.275

- $2.50     38,000       4.12     $ 2.464       38,000       4.12  

$2.95

- $3.70     774,100       8.32     $ 3.040       411,525       7.36  

$4.50

- $8.10     538,300       7.97     $ 6.742       506,500       7.92  

$10.00

- $10.10     54,000       7.55     $ 10.007       54,000       7.55  

$15.10

        314,051       6.41     $ 15.100       310,551       6.46  
                                             

Totals

        1,744,811       7.67     $ 6.526       1,346,936       7.19  

 

As of December 31, 2019, total compensation expense related to unvested employee stock options not yet recognized was $372,000 which is expected to be allocated to expenses over a weighted-average period of 2.4 years.

 

The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended December 31, 2019 and 2018:

 

   

2019

   

2018

 
Common stock fair value   $2.95 - $5.00     $3.50 - $8.10  

Risk-free interest rate

   1.55% - 2.25%      2.30% - 2.94%  

Expected dividend yield

    0         0    

Expected Option life (in years)

   5.00 - 5.50      1.25 - 5.75  

Expected stock price volatility

    72%         72%    

 

Nonemployee stock-based compensation

 

We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”) 2018-07, “Compensation – Stock Compensation (Topic 718). In connection with stock options granted to nonemployees, we recorded $288,000 and $263,000 for nonemployee stock-based compensation during the years ended December 31, 2019 and 2018, respectively.

 

10.

Income Taxes

 

We have incurred net operating losses since inception. We have not reflected the benefit of net operating loss carryforwards in the accompanying financial statements and have established a full valuation allowance against our deferred tax assets.

 

At December 31, 2019 and 2018, the Company had an income tax receivable of $361,000 and $332,000, respectively, comprised of refundable tax incentives related to research and development activities of our subsidiary Sun BioPharma Australia Pty Ltd.

 

Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.

 

F-24

 

The significant components of our deferred tax assets and liabilities are as follows (in thousands):

 

   

December 31,

 

Deferred tax assets (liabilities)

 

2019

   

2018

 
                 

Net operating loss carryforwards

  $ 6,307     $ 4,807  

Research credit carryforwards

    235       235  

Stock-based compensation

    1,230       971  

Other

    72       71  

Deferred tax assets

    7,844       6,084  

Valuation allowance

    (7,844 )     (5,801 )

Deferred tax assets, net of valuation allowance

    -       283  

Beneficial conversion feature, net

    -       (283 )

Deferrred tax liabilities

    -       (283 )
                 

Net deferred tax asset

  $ -     $ -  

 

Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently not likely to be realized and, accordingly, we have provided a full valuation allowance.

 

A reconciliation of the statutory tax rates and the effective tax rates is as follows:

 

   

Year Ended December 31,

 
   

2019

   

2018

 

Statutory rate

    21.0 %     21.0 %

Permanent differences

    (5.9 )     0.1  

Change in effective tax rate

    -       0.6  

Valuation allowance

    (32.4 )     (22.6 )

Foreign research incentives

    5.7       5.7  

Deferred true-up

    16.3       -  

Other

    1.0       0.9  

Effective rate

    5.7 %     5.7 %

 

Net operating losses and tax credit carryforwards as of December 31, 2019, are as follows:

 

   

Amount

(in thousands)

 

Expiration Years

Net operating losses--federal

    12,958  

Expires beginning 2031

2019 net operating loss -- federal

    3,153  

Never expires

Tax credits--federal

    235  

Beginning 2041

 

Utilization of the net operating loss carryforwards and credits may be subject to a substantial annual limitation due to the ownership change limitations provided by the IRC, and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change under Section 382 of the IRC has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change.

 

F-25

 

The Company is subject to taxation in the United States and Australia. Tax returns for the year ended December 31, 2015 and thereafter are subject to examinations by federal and state tax authorities. Tax returns of Sun BioPharma Australia Pty Ltd. for the year ended December 31, 2014 and thereafter are subject to examination by the Australian tax authorities.

 

11.

Subsequent Events

 

On February 21, 2020 the company entered an agreement with an investment banking firm.  A portion of the retainer fee was paid via the issuance of 75,000 5-year warrants.  The fair market value of the warrants issued of approximately $148,000 will be capitalized and charged against future proceeds.

 

F-26

 

 

 

 



 

          Shares of Common Stock

 

 

 

 

 

Sun Biopharma, Inc.

 _________________________ 

 

PRELIMINARY PROSPECTUS

_________________________ 

 

 

  

Craig-Hallum Capital Group 

  

         , 2020

 

 

 




 

 

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS 

 

Item 13.      Other Expenses of Issuance and Distribution.

 

The following table sets forth the costs and expenses, other than the underwriting discounts and commissions and non-accountable expense allowance, payable by Sun BioPharma, Inc. (the “Company”) in connection with the sale of its common stock being registered. All amounts shown are estimates, except the Securities and Exchange Commission (the “Commission”) registration fee and the Financial Industry Regulatory Authority (“FINRA”) filing fee.

 

U.S. Securities and Exchange Commission registration fee

  $ 1,575  

Nasdaq Listing application fee

  $ 50,000  

FINRA filing fee

  $ 2,320  

Accounting fees and expenses

    *  

Legal fees and expenses

  $ 20,000  

Transfer agent and registrar fees

    *  

Printing expenses

    *  

Miscellaneous

    *  

Total

    *  

 


* To be provided by amendment.

 

Item 14.      Indemnification of Directors and Officers.

 

Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify any person made a party to an action by reason of the fact that he or she was a director, executive officer, employee or agent of the corporation or is or was serving at the request of the corporation against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him or her in connection with such action if he or she acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of an action by or in right of the corporation, no indemnification may generally be made in respect of any claim as to which such person is adjudged to be liable to the corporation.

 

The Company’s certificate of incorporation and amended and restated bylaws limit the liability of its directors to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability for any:

 

 

breach of their duty of loyalty to the Company or its stockholders;

 

 

act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

 

 

unlawful payment of dividends or redemption of shares as provided in Section 174 of the Delaware General Corporation Law; or

 

 

transaction from which the directors derived an improper personal benefit.

 

These limitations of liability do not apply to liabilities arising under federal securities laws and do not affect the availability of equitable remedies such as injunctive relief or rescission. The Company’s amended and restated bylaws provide that it will indemnify its directors and executive officers, and may indemnify other officers, employees and other agents, to the fullest extent permitted by law.

 

II-1

 

As permitted by the Delaware General Corporation Law, the Company has entered into indemnification agreements with each of the Company’s directors and executive officers that require the Company to indemnify such persons against expenses, judgments, penalties, fines, settlements and other amounts actually and reasonably incurred, including expenses of a derivative action, in connection with an actual or threatened proceeding if any of the Company’s directors or executive officers may be made a party because he or she is or was one of the Company’s directors. The Company will be obligated to pay such amounts only if the director acted in good faith and in a manner that he or she reasonably believed to be in or not opposed to the Company’s best interests. With respect to any criminal proceeding, the Company will be obligated to pay such amounts only if the director had no reasonable cause to believe his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim for indemnification.

 

Section 145(g) of the Delaware General Corporation Law permits a corporation to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the corporation arising out of his or her actions in connection with their services to the Company, regardless of whether its amended and restated bylaws permit indemnification. The Company has purchased and intends to maintain insurance on behalf of any person who is or was a director or officer against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

 

Item 15.      Recent Sales of Unregistered Securities.

 

On February 21, 2020, the Company issued to the underwriter a five-year warrant to purchase 75,000 shares at an exercise price of $6.49 per share.

 

In closings on May 22, June 5, June 15, and June 22, 2020, the Company sold an aggregate of 437,000 shares of its common stock and warrants to purchase up to 437,000 additional shares of common stock for aggregate gross proceeds of approximately $1.7 million, of which approximately $90,000 was received from officers and directors of the Company. The warrants are exercisable for a period of five years from the date of issuance at an initial exercise price of $6.00 per share.

 

For all of the foregoing transactions, we relied on exemptions from registration set forth in Section 4(a)(2) of the Securities Act, without the use of any general solicitations or advertising to market or otherwise offer the securities for sale and all participants were “accredited investors,” as defined in Rule 501 of Regulation D as promulgated by the SEC under the Securities Act.

 

II-2

 

Item 16.      Exhibits and Financial Statement Schedules.

 

(a) Exhibits

 

Exhibit

No.

 

Description

1.1++

 

Form of Underwriting Agreement

3.1

 

Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed November 15, 2017)

3.2

 

Bylaws (incorporated by reference to Exhibit 3.2 to quarterly report on Form 10-Q for quarter ended June 30, 2016)

4.1++

 

Form of Underwriter's Warrant

5.1++

 

Opinion of Faegre Drinker Biddle & Reath LLP

10.1*

 

2011 Stock Option Plan, as amended through January 1, 2015 (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed September 11, 2015)

10.2*

 

Form of Incentive Stock Option Agreement for awards under 2011 Plan (incorporated by reference to Exhibit 10.2 to current report on Form 8-K filed September 11, 2015)

10.3*

 

Form of Non-Qualified Stock Option Agreement for awards under 2011 Plan (incorporated by reference to Exhibit 10.3 to current report on Form 8-K filed September 11, 2015)

10.4*

 

2016 Omnibus Incentive Plan, as amended and restated as of April 9, 2020 (incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K filed May 26, 2020)

10.5*

 

Form of Incentive Stock Option Agreement for awards under 2016 Plan (incorporated by reference to Exhibit 10.4 to quarterly report on Form 10-Q for quarter ended June 30, 2016)

10.6*

 

Form of Non-Qualified Stock Option Agreement for awards under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.5 to quarterly report on Form 10-Q for quarter ended June 30, 2016)

10.7*

 

Form of Performance-Based Stock Option Agreement for awards under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.7 to annual report on Form 10-K for fiscal year ended December 31, 2016)

10.8**

 

Standard Exclusive License Agreement with University of Florida Research Foundation, Inc., dated December 22, 2011 (incorporated by reference to Exhibit 10.5 to current report on Form 8-K filed September 11, 2015)

10.9

 

Form of First Amendment to License Agreement with University of Florida Research Foundation, Inc. dated December 12, 2016

10.10

 

Second Amendment to License Agreement with University of Florida Research Foundation, Inc., dated October 3, 2019 (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed October 9, 2019)

10.11*

 

Employment Agreement with Michael T. Cullen, dated December 2, 2015 (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed December 4, 2015)

10.12*

 

First Amendment to Employment Agreement with Michael T. Cullen, dated September 12, 2016 (incorporated by reference to Exhibit 10.17 to registration statement on Form S-1filed September 16, 2016)

10.13*

 

Second Amendment to Employment Agreement with Michael T. Cullen, dated October 1, 2017 (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed October 13, 2017)

10.14*

 

Waiver and Third Amendment to Employment Agreement with Michael T. Cullen, effective as of February 27, 2018 (incorporated by reference to Exhibit 10.1 to current report on Form 8-K filed March 5, 2018)

10.15*

 

Employment Agreement with Suzanne Gagnon, dated December 2, 2015 (incorporated by reference to Exhibit 10.9 to annual report on Form 10-K for fiscal year ended December 31, 2015)

10.16*

 

First Amendment to Employment Agreement with Suzanne Gagnon, dated September 12, 2016 (incorporated by reference to Exhibit 10.20 to registration statement on Form S-1 filed September 16, 2016)

10.17*

 

Second Amendment to Employment Agreement with Suzanne Gagnon, dated October 1, 2017 (incorporated by reference to Exhibit 10.4 to current report on Form 8-K filed October 13, 2017)

 

II-3

 

Exhibit

No.

  Description

10.18*

 

Waiver and Third Amendment to Employment Agreement with Suzanne Gagnon, effective as of February 27, 2018 (incorporated by reference to Exhibit 10.4 to current report on Form 8-K filed March 5, 2018)

10.19*

 

Employment Agreement with Susan Horvath, dated April 17, 2018 (incorporated by reference to Exhibit 10.4 to quarterly report on Form 10-Q for quarter ended March 31, 2018)

10.20

 

Seed Capital Accelerator Loan Agreement and Seed Capital Loan Note dated October 26, 2012 (incorporated by reference to Exhibit 10.22 to annual report on Form 10-K for fiscal year ended December 31, 2019)

10.21

 

First Amendment to Seed Capital Accelerator Loan Agreement and Seed Capital Loan Note dated October 13, 2017 (incorporated by reference to Exhibit 10.1 to quarterly report on Form 10-Q for quarter ended March 31, 2019)

10.23

 

Second Amendment to Seed Capital Accelerator Loan Agreement and Seed Capital Loan Note dated April 5, 2019 (incorporated by reference to Exhibit 10.2 to quarterly report on Form 10-Q for quarter ended March 31, 2019

10.24

 

Third Amendment to Seed Capital Accelerator Loan Agreement and Seed Capital Loan Noted dated December 31,2019 (incorporated by reference to Exhibit 10.25 to annual report on Form 10-K for fiscal year ended December 31, 2019)

10.25

 

Form of Common Stock Warrant issued prior to September 2015 (incorporated by reference to Exhibit 4.3 to current report on Form 8-K filed September 11, 2015)

10.26

 

Form of Common Stock Warrant issued June through September 2016 (incorporated by reference to Exhibit 10.2 to current report on Form 8-K filed June 14, 2016)

10.27

 

Form of Common Stock Warrant issued February through May 2018 (incorporated by reference to Exhibit 10.2 to current report on Form 8-K filed February 26, 2018)

10.28

 

Form of Common Stock Warrant issued December 2018 and January 2019 (incorporated by reference to Exhibit 10.3 to current report on Form 8-K filed December 28, 2018)

10.29

 

Common Stock Warrant issued April 2, 2019 (incorporated by reference to Exhibit 10.3 to quarterly report on Form 10-Q for quarter ended March 31, 2019)

10.30

 

Form of Common Stock Warrant issued August through October 2019 (incorporated by reference to Exhibit 10.2 to current report on Form 8-K filed August 29, 2019)

10.31

 

Form of Common Stock Warrant issued May through June 2020 (incorporated by reference to Exhibit 10.2 to current report on Form 8-K file June 11, 2020)

21.1

 

List of Subsidiaries (incorporated by reference to Exhibit 21.1 to annual report on Form 10-K for the fiscal year ended December 31, 2016)

23.1+

 

Consent of Independent Registered Public Accounting Firm

23.2++

 

Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1)

24.1+

 

Powers of Attorney (see signature page)

101+

 

Financial statements for the years ended December 31, 2018 and 2019 and for the three months ended March 31, 2019 and 2020, formatted in XBRL: (i) the Balance Sheets, (ii) the Statements of Operations and Comprehensive Loss, (iii) the Statements of Cash Flows, and (iv) the Notes to Financial Statements.

 


+ Filed herewith

++ To be filed by amendment.

* Management compensatory plan or arrangement required to be filed as an exhibit to this prospectus.

** Portions of exhibit omitted pursuant to order granting confidential treatment issued by the Securities and Exchange Commission.

 

(b) Financial Statement Schedules.

 

All schedules are omitted as the required information is inapplicable or the information is presented in the financial statements or related notes.

 

Schedule II. Valuation and Qualifying Accounts

 

All other schedules are omitted as the required information is inapplicable or the information is presented in the financial statements or related notes.

 

II-4

 

Item 17.      Undertakings.

 

The registrant hereby undertakes:

 

 

(1)

To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

 

(i)

To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

 

(ii)

To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

 

 

(iii)

To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in this registration statement.

 

 

(2)

That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

 

(3)

To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

 

(4)

That, for the purpose of determining liability under the Securities Act to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

 

(5)

That, for the purpose of determining liability under the Securities Act to any purchaser the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective; and for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

 

(6)

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

II-5

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota on this 2nd day of July, 2020.

 

 

 

SUN BIOPHARMA, INC.

 


 

 

By:


 

/s/ Michael T. Cullen

       

Michael T. Cullen

President, Chief Executive Officer and Executive

Chairman

 

Power of Attorney

 

Each person whose signature appears below hereby constitutes and appoints Michael T. Cullen and Susan Horvath, and each of them acting individually, as his true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Registration Statement filed herewith and any and all amendments to said Registration Statement (including post-effective amendments and any related registration statements thereto filed pursuant to Rule 461 and otherwise), and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

         

/s/ Michael T. Cullen

 

President, Chief Executive Officer and Executive Chairman

 

July 2, 2020

Michael T. Cullen

  and Director (Principal Executive Officer)    
         

/s/ Susan Horvath

 

Vice President of Finance, Chief Financial Officer, Treasurer

 

July 2, 2020

Susan Horvath

  and Secretary (Principal Financial and Accounting Officer)    
         

/s/ Arthur J. Fratamico

 

Director

 

July 2, 2020

Arthur J. Fratamico

       
         

/s/ Suzanne Gagnon

 

Director

 

July 2, 2020

Suzanne Gagnon

       
         

/s/ Jeffrey S. Mathiesen

 

Director

 

July 2, 2020

Jeffrey S. Mathiesen

       
         

/s/ Paul Schaffer

 

Director

 

July 2, 2020

Paul W. Schaffer

       
         

/s/ D. Robert Schemel

 

Director

 

July 2, 2020

D. Robert Schemel

       

 

 
EX-23.1 2 ex_192459.htm EXHIBIT 23.1 ex_192459.htm

Exhibit 23.1

 


CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


We hereby consent to the reference to our firm under the caption “Experts” in this Registration Statement on Form S-1 and related prospectus of Sun BioPharma, Inc. and to the inclusion therein of our report, dated March 24, 2020, with respect to the consolidated financial statements of Sun BioPharma, Inc. appearing in its Form 10-K filed March 24, 2020 with the Securities and Exchange Commission.

 

/s/ Cherry Bekaert LLP                            
Tampa, Florida
July 2, 2020

 
EX-101.INS 3 snbp-20200331.xml XBRL INSTANCE DOCUMENT false Q1 2020 S-1 0001029125 false Non-accelerated Filer Sun BioPharma, Inc. true <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-transform:uppercase;"><div style="display: inline; font-weight: bold;">Accrued </div><div style="display: inline; font-weight: bold;">Expenses</div></div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued expenses consisted of the following (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical trial and related expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">147</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">125</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">157</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">304</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div></div> 228000 228000 14000 14000 10000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Beneficial conversion feature</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (&#x201c;BCF&#x201d;) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.</div></div></div> P5Y P3Y 75000 3.50 147000 42000 7000 7000 25000 25000 25000 25000 6000000 105000 105000 183000 3258000 2281000 646279 105000 2000000 2000000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Debt issuance costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.</div></div></div> 283000 0.163 0.057 0.057 -0.059 0.001 225000 54000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Grant Income</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant income is derived from a <div style="display: inline; font-style: italic; font: inherit;">one</div>-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the &#x201c;Grant Agreement&#x201d;). The total grant awarded under the Grant Agreement was <div style="display: inline; font-style: italic; font: inherit;">$225,000</div> and was used to fund studies of SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>the Company has been fully reimbursed under the Grant Agreement.</div></div></div> 900000 353000 353000 716000 48000 102000 4000 2031 3100000 102000 0.025 0.05 P10Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under equity incentive plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">18,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under outstanding common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,497,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,261,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under equity incentive plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under outstanding common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,422,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,186,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Convertible Notes Payable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Principal</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Accrued Interest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at January 1, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Aggregate principal value of notes sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">816</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued Interest on notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">103</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Aggregate principal value of notes and accrued interest converted into common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,175</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(105</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 1000 404000 733400 751000 1000 3257000 3258000 1094000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(in thousands)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 29.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expiration Years</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52.4%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating losses--federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">12,958</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Expires beginning 2031</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019 net operating loss -- federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,153</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Never expires</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credits--federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Beginning 2041</div></div> </td> </tr> </table></div> 2041 1000000 742000 742000 742000 14000 228000 419000 2500000 700000 1300000 597000 1064000 271000 304000 216000 308000 125000 157000 44000 41000 305000 283000 1102000 42331000 35038000 42671000 716000 716000 353000 353000 353000 353000 2373000 2373000 1093000 1093000 10000 10000 112000 112000 419000 739000 739000 419000 419000 419000 288000 263000 99000 10000 13000 112000 10000 974000 2066000 1732000 6000 12000 9000 1745811 1032211 636234 3497099 2509477 5242910 4177922 1744811 1032211 383947 3422099 2035197 5166910 3451355 3144000 1898000 2136000 3093000 1847000 2091000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">p</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">resentation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Our fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31.</div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">3.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of Presentation</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and with the instructions to Form&nbsp;<div style="display: inline; font-style: italic; font: inherit;">10</div>-Q and Regulation S-<div style="display: inline; font-style: italic; font: inherit;">X</div> of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do <div style="display: inline; font-style: italic; font: inherit;">not</div> include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31. </div>The condensed consolidated balance sheet as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>was derived from audited consolidated financial statements but does <div style="display: inline; font-style: italic; font: inherit;">not</div> include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be indicative of the results to be expected for the entire year.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div> 1296000 2449000 1405000 1379000 152000 -1153000 -26000 1044000 1253000 6.49 4 4.50 4.50 4.50 4 4 5 2 1 75000 1243498 5555 5000 468200 3497099 3422099 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">7</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">License agreement</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font: inherit;"> December 22, 2011, </div>we entered into an exclusive license agreement with the University of Florida research Foundation (&#x201c;UFRF&#x201d;). This license agreement was amended on <div style="display: inline; font-style: italic; font: inherit;">first</div> of <div style="display: inline; font-style: italic; font: inherit;"> December 12, 2016 (</div>&#x201c;First Amendment&#x201d;) and again on <div style="display: inline; font-style: italic; font: inherit;"> October 3, 2019 (</div>&#x201c;Second Amendment&#x201d;). The license agreement requires the Company to pay royalties to UFRF ranging from <div style="display: inline; font-style: italic; font: inherit;">2.5%</div> to <div style="display: inline; font-style: italic; font: inherit;">5%</div> of net sales of licensed products developed from the licensed technology. The Second Amendment eliminated all minimum annual royalties and modified the duration of royalty payments to the shorter of (<div style="display: inline; font-style: italic; font: inherit;">1</div>) <div style="display: inline; font-style: italic; font: inherit;">ten</div> years from <div style="display: inline; font-style: italic; font: inherit;">first</div> commercial sale of licensed products or (<div style="display: inline; font-style: italic; font: inherit;">2</div>) the expiration of the period of regulatory exclusivity on a country by country basis. All future milestone payments contemplated in the original agreement were eliminated in the Second Amendment.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of <div style="display: inline; font-style: italic; font: inherit;">$10,000.</div> Accordingly, we recorded <div style="display: inline; font-style: italic; font: inherit;">$10,000</div> as a license expense in the accompanying <div style="display: inline; font-style: italic; font: inherit;">2019</div> and <div style="display: inline; font-style: italic; font: inherit;">2018</div> Consolidated Statements of Operations and Comprehensive Loss.</div></div> 1500000 1500000 1480451 5261459 5186459 0.001 0.001 0.001 100000000 100000000 100000000 6631308 6631308 5077483 6631308 6631308 5077483 7000 5000 7000 -1001000 -1613000 -6178000 -5457000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive loss</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Comprehensive loss consists of our net loss and the effects of foreign currency translation.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">l</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">oss</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Comprehensive loss consists of our net loss and the effects of foreign currency translation.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font: inherit;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on its deposits of cash.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.</div></div></div> 64000 651758 651758 104463 2200000 3100000 2175000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">6.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div><div style="display: inline; font-weight: bold;">Indebtedness</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Term debt</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The terms of our unsecured loan (the &#x201c;Term Debt&#x201d;) payable to the Institute for Commercialization of Public Research, Inc. (the &#x201c;Institute&#x201d;) which was amended in <div style="display: inline; font-style: italic; font: inherit;"> December </div>of <div style="display: inline; font-style: italic; font: inherit;">2019</div> to extend the maturity date from <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>remain unchanged as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020.&nbsp; </div>The fair market value of the warrants issued in <div style="display: inline; font-style: italic; font: inherit;">2019</div> in exchange for modification of the terms is being amortized to interest expense over the remaining term of the loan. The amendment requires the continuation of monthly payments of principal and interest totaling <div style="display: inline; font-style: italic; font: inherit;">$10,000.</div> The unpaid principal balance at <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>was <div style="display: inline; font-style: italic; font: inherit;">$90,000.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Deferred financing costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following table summarizes the deferred financing costs which are presented as a direct reduction of the carrying amount of their related debt liabilities (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 31, 2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Term Debt</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Term Debt</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan principal Amount</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">126</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred Financing Costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Unamortized balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Discount on Debt</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Unamortized balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan carrying amounts, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">116</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">6.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-transform:uppercase;"><div style="display: inline; font-weight: bold;">Indebtedness</div></div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2018</div> </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Convertible notes payable</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> December </div>of <div style="display: inline; font-style: italic; font: inherit;">2018</div> and <div style="display: inline; font-style: italic; font: inherit;"> January </div>of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> we sold convertible promissory notes (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2018</div> Notes&#x201d;) and warrants to purchase common stock for gross proceeds of <div style="display: inline; font-style: italic; font: inherit;">$2.2</div> million. The <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes were scheduled to matured on <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019 </div>and bore an interest at a rate of <div style="display: inline; font-style: italic; font: inherit;">10.0%</div> per year. The <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (<div style="display: inline; font-style: italic; font: inherit;">1</div>) <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019 </div>or (<div style="display: inline; font-style: italic; font: inherit;">2</div>) the date the Company receives gross proceeds of at least <div style="display: inline; font-style: italic; font: inherit;">$6.0</div> million from the sale of equity securities (subject to certain exclusions). The stated conversion rate was <div style="display: inline; font-style: italic; font: inherit;">$3.50</div> per share. In addition to the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes, investors received a Warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">two</div> shares of common stock for every <div style="display: inline; font-style: italic; font: inherit;">$3.50</div> principal amount of <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes purchased. In total, warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">1,243,498</div> shares of common stock were issued in the <div style="display: inline; font-style: italic; font: inherit;"> December </div>and <div style="display: inline; font-style: italic; font: inherit;"> January </div>closings. The exercise price of each warrant is <div style="display: inline; font-style: italic; font: inherit;">$4.50</div> per share and they are exercisable until the <div style="display: inline; font-style: italic; font: inherit;">5</div>-year anniversary of the dates of issuance. The warrants had a fair market value of <div style="display: inline; font-style: italic; font: inherit;">$2.5</div> million upon issuance. After assigning the relative value of the warrants to the proceeds of the notes it was determined that the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately <div style="display: inline; font-style: italic; font: inherit;">$0.9</div> million. Both the relative value of the warrants and the beneficial conversion feature were recorded as a debt discount which was fully amortized through interest expense over the life of the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Notes. On <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019, </div>all <div style="display: inline; font-style: italic; font: inherit;">$2.2</div> million aggregate principal balance of Notes outstanding plus <div style="display: inline; font-style: italic; font: inherit;">$105,000</div> of accrued interest was converted at a conversion rate of <div style="display: inline; font-style: italic; font: inherit;">$3.50</div> per share of common stock into <div style="display: inline; font-style: italic; font: inherit;">651,758</div> shares of common stock per the terms of the Notes.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2017</div> </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Convertible notes payable</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In <div style="display: inline; font-style: italic; font: inherit;">2017</div> we sold convertible promissory notes (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2017</div> Notes&#x201d;) raising gross proceeds of approximately <div style="display: inline; font-style: italic; font: inherit;">$3.1</div> million. The <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes had been scheduled to mature on <div style="display: inline; font-style: italic; font: inherit;"> December 1, 2018 </div>and bore an interest at a rate of <div style="display: inline; font-style: italic; font: inherit;">5.0%</div> per year. Principal and accrued interest on the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes was payable at maturity. The <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes were convertible into shares of common stock or other securities of the Company upon the occurrence of a &#x201c;qualified financing,&#x201d; including the sale of equity securities or a strategic partnership, raising gross proceeds of at least <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million on or before the maturity of the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes or upon the request of a holder of any <div style="display: inline; font-style: italic; font: inherit;">2017</div> Note at a fixed conversion rate of <div style="display: inline; font-style: italic; font: inherit;">$10.10</div> per share. The <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately <div style="display: inline; font-style: italic; font: inherit;">$3.0</div> million, which was recorded as a debt discount and is presented as a direct deduction from the carrying value of the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes. The discount was amortized through interest expense over the life of the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font: inherit;"> May 16, 2018, </div>as the result of receiving aggregate gross proceeds exceeding <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million for the sale equity securities, under terms of the <div style="display: inline; font-style: italic; font: inherit;">2017</div> Notes, the Company completed the conversion of previously outstanding debt. Debt totaling approximately <div style="display: inline; font-style: italic; font: inherit;">$3.1</div> million and accrued interest totaling approximately <div style="display: inline; font-style: italic; font: inherit;">$183,000</div> was converted into <div style="display: inline; font-style: italic; font: inherit;">104,463</div> shares of common stock and <div style="display: inline; font-style: italic; font: inherit;">646,279</div> units (each consisting of a share of common stock and a warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">one</div> additional share of common stock). The units were available through the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Purchase Agreement. The shares were issued in reliance on the exemption from registration set forth in Section <div style="display: inline; font-style: italic; font: inherit;">3</div>(a)(<div style="display: inline; font-style: italic; font: inherit;">9</div>) of the Securities Act as securities exchanged by an issuer with existing security holders where <div style="display: inline; font-style: italic; font: inherit;">no</div> commission or other remuneration is paid or given directly or indirectly by the issuer for soliciting such exchange. As of the date of conversion an incremental beneficial conversion feature of <div style="display: inline; font-style: italic; font: inherit;">$121,000</div> was recorded as debt discount. Unamortized debt discount totaling <div style="display: inline; font-style: italic; font: inherit;">$1.0</div> million was charged to interest expense as of the date of conversion.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">The following table sets forth the changes in convertible notes payable during the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 (</div>in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Convertible Notes Payable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Principal</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Accrued Interest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at January 1, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Aggregate principal value of notes sold</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">816</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued Interest on notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">103</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Aggregate principal value of notes and accrued interest converted into common stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,175</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(105</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Term debt</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On <div style="display: inline; font-style: italic; font: inherit;"> October 26, 2012, </div>we entered into an unsecured loan agreement (the &#x201c;Agreement&#x201d;) with the Institute for Commercialization of Public Research, Inc. (the &#x201c;Institute&#x201d;). Under the terms of the agreement, we borrowed <div style="display: inline; font-style: italic; font: inherit;">$300,000</div> at a fixed interest rate of <div style="display: inline; font-style: italic; font: inherit;">4.125%.</div> <div style="display: inline; font-style: italic; font: inherit;">No</div> principal or interest payments were due until the maturity date, <div style="display: inline; font-style: italic; font: inherit;"> October 26, 2017, </div>unless a mandatory repayment event occurred. Effective <div style="display: inline; font-style: italic; font: inherit;"> October 26, 2017, </div>we entered into an amendment to our unsecured loan agreement with the Institute. Under the terms of the amendment, the maturity date of the note was extended to <div style="display: inline; font-style: italic; font: inherit;"> May 1, 2019 </div>with monthly payments of <div style="display: inline; font-style: italic; font: inherit;">$10,000</div> beginning on <div style="display: inline; font-style: italic; font: inherit;"> May 1, 2018 </div>with the remaining balance due in full on <div style="display: inline; font-style: italic; font: inherit;"> May 1, 2019. </div>Effective <div style="display: inline; font-style: italic; font: inherit;"> April 5, 2019 </div>the terms of our unsecured loan (the &#x201c;Term Debt&#x201d;) payable to the Institute were amended again to extend the maturity date from <div style="display: inline; font-style: italic; font: inherit;"> May 1, 2019 </div>to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>The Institute agreed to the amendment in exchange for a warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">5,555</div> shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$4.50.</div> The warrant expires <div style="display: inline; font-style: italic; font: inherit;">five</div> years from issuance. On <div style="display: inline; font-style: italic; font: inherit;"> December 16, 2019 </div>the Institute again modified the terms of repayment. In exchange for a payment <div style="display: inline; font-style: italic; font: inherit;">$50,000</div> payable on <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and a warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">5,000</div> shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$4.00</div> the maturity date of the loan was extended from <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020. </div>The total fair market value of the warrants issued for both amendments was calculated at <div style="display: inline; font-style: italic; font: inherit;">$14,000</div> and was recorded as a discount to the debt, which will be amortized over the remaining period until maturity of the debt. The amendment requires the continuation of monthly payments of principal and interest totaling <div style="display: inline; font-style: italic; font: inherit;">$10,000</div> with monthly payments applied <div style="display: inline; font-style: italic; font: inherit;">first</div> to accrued and unpaid interest. The unpaid principal balance, net of unamortized debt discount, at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>was <div style="display: inline; font-style: italic; font: inherit;">$116,000.</div></div></div> 1359000 3000000 3.50 3.50 3.50 10.10 300000 97000 126000 103000 0.1 0.05 0.04125 10000 10000 10000 121000 51000 51000 7000 10000 7844000 6084000 0 0 283000 6307000 4807000 72000 71000 235000 235000 1230000 971000 7844000 5801000 283000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8</div></div><div style="display: inline; font-weight: bold;">.</div><div style="display: inline; font-weight: bold;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div><div style="display: inline; font-weight: bold;">S</div><div style="display: inline; font-weight: bold;">tock</div><div style="display: inline; font-weight: bold;">-based</div><div style="display: inline; font-weight: bold;"> Compensation</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2016</div> Omnibus Incentive Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font: inherit;">2016</div> Omnibus Incentive Plan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2016</div> Plan&#x201d;) was adopted by our Board of Directors in <div style="display: inline; font-style: italic; font: inherit;"> March 2016 </div>and approved by our stockholders in <div style="display: inline; font-style: italic; font: inherit;"> May 2016. </div>The <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan at <div style="display: inline; font-style: italic; font: inherit;">no</div> less than the fair market value of the underlying common stock as of the date of grant. Options granted under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">ten</div> years. Under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan, a total of <div style="display: inline; font-style: italic; font: inherit;">1,500,000</div>&nbsp;shares of common stock were initially reserved for issuance. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">1,481,451shares</div> of common stock were outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan and <div style="display: inline; font-style: italic; font: inherit;">18,549</div> shares remained available for future awards.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2011</div> Stock Option Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our Board of Directors ceased making awards under the Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font: inherit;">2011</div> Stock Option Plan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2011</div> Plan&#x201d;) upon the receipt of stockholder approval for the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan. Awards outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">ten</div> years and generally vest over <div style="display: inline; font-style: italic; font: inherit;">zero</div> to <div style="display: inline; font-style: italic; font: inherit;">two</div> years for employees. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">264,360</div> shares of common stock remained outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">-based Compensation</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> Expense</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">General and administrative (&#x201c;G&amp;A&#x201d;) and research and development (&#x201c;R&amp;D&#x201d;) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>vest based upon time-based and performance conditions. There was approximately <div style="display: inline; font-style: italic; font: inherit;">$229,000</div> unamortized stock-based compensation expense related to options granted to employees as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock-based compensation expense for each of the periods presented is as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Three Months Ended March 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and Administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and Development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Details of options granted, exercised, cancelled or forfeited during the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Available for Grant</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Underlying Options</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at March 31, 2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">18,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information about stock options outstanding, vested and expected to vest as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>is as follows:</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%; vertical-align: bottom;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$0.875</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$1.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.275</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$2.50</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.95</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$3.70</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">774,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">411,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.95</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">539,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.73</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.739</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$10.00</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$10.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$15.10</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,551</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Totals</div> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,346,936</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">9</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Stock-</div><div style="display: inline; font-weight: bold;">B</div><div style="display: inline; font-weight: bold;">ased</div><div style="display: inline; font-weight: bold;"> Compensation</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2016</div> Omnibus Incentive Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock-based awards are granted under the Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font: inherit;">2016</div> Omnibus Incentive Plan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2016</div> Plan&#x201d;). The <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan at <div style="display: inline; font-style: italic; font: inherit;">no</div> less than the fair market value of the underlying common stock as of the date of grant. Options granted under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">ten</div> years. A total of <div style="display: inline; font-style: italic; font: inherit;">1,500,000</div>&nbsp;shares of common stock were initially reserved for issuance under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">1,480,451</div> shares of common stock were outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2011</div> Stock Option Plan</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prior to approval of the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan, stock-based awards were granted under the Sun BioPharma, Inc. <div style="display: inline; font-style: italic; font: inherit;">2011</div> Stock Option Plan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2011</div> Plan&#x201d;). In conjunction with stockholder approval of the <div style="display: inline; font-style: italic; font: inherit;">2016</div> Plan, the Board terminated the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan, although awards outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan will remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">ten</div> years and generally vest over <div style="display: inline; font-style: italic; font: inherit;">zero</div> to <div style="display: inline; font-style: italic; font: inherit;">two</div> years for employees. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">264,360</div> shares of common stock remained outstanding under the <div style="display: inline; font-style: italic; font: inherit;">2011</div> Plan.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of option activity is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Available for</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Underlying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Per Share</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic Value</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,060,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,960</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.79</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">169,495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(404,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">404,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(30,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">75,749</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(75,749</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">732,149</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">56,225</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15.10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.53</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,030,547</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A summary of the status of our unvested shares during the year ended and as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Under</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Option</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date Fair Value</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">42,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(378,025</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forefeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">397,875</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2.03</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Information about stock options outstanding, vested and expected to vest as of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019,</div> is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 5%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 16%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$0.875</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$1.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$2.275</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$2.50</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$2.95</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.70</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">774,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">411,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$4.50</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">538,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$10.00</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$10.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$15.10</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,551</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 5%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 4%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 16%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Totals</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.526</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,346,936</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>total compensation expense related to unvested employee stock options <div style="display: inline; font-style: italic; font: inherit;">not</div> yet recognized was <div style="display: inline; font-style: italic; font: inherit;">$372,000</div> which is expected to be allocated to expenses over a weighted-average period of <div style="display: inline; font-style: italic; font: inherit;">2.4</div> years.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018:</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">Common stock fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$2.95</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$3.50</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.55%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.25%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;2.30%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.94%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">0</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">0</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Option life (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;5.00</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.25</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">72%</div></td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">72%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Nonemployee </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">tock-</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">b</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">ased </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">ompensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We account for stock options granted to nonemployees in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">07,</div> &#x201c;Compensation &#x2013; Stock Compensation (Topic <div style="display: inline; font-style: italic; font: inherit;">718</div>). In connection with stock options granted to nonemployees, we recorded <div style="display: inline; font-style: italic; font: inherit;">$288,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$263,000</div> for nonemployee stock-based compensation during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019</div> and <div style="display: inline; font-style: italic; font: inherit;">2018,</div> respectively.</div></div> -0.27 -0.31 -1.09 -1.27 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net loss per share</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company&#x2019;s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have <div style="display: inline; font-style: italic; font: inherit;">not</div> been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the potential shares of common stock that were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt;">March 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">636,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,497,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,509,477</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td></tr></table></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">l</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">oss per </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">hare</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following outstanding potential common shares were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the diluted net loss per share calculations as their effects were <div style="display: inline; font-style: italic; font: inherit;">not</div> dilutive:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">383,947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,422,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,035,197</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,166,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,451,355</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div></div> -7000 -1000 -1000 -3000 0.057 0.057 0.21 0.21 -0.324 -0.226 0.006 0.01 0.009 P2Y146D 229000 372000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign currency translation adjustments</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders&#x2019; equity (deficit). During the <div style="display: inline; font-style: italic; font: inherit;">three</div>-month periods ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9.35pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">urrency </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">t</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">ranslation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (&#x201c;AUD&#x201d;). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018,</div> any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.</div></div></div> 468000 303000 1973000 2108000 -1890000 -1652000 -6615000 -6159000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">10</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Income Taxes</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have incurred net operating losses since inception. We have <div style="display: inline; font-style: italic; font: inherit;">not</div> reflected the benefit of net operating loss carryforwards in the accompanying financial statements and have established a full valuation allowance against our deferred tax assets.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">At <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018,</div> the Company had an income tax receivable of <div style="display: inline; font-style: italic; font: inherit;">$361,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$332,000,</div> respectively, comprised of refundable tax incentives related to research and development activities of our subsidiary Sun BioPharma Australia Pty Ltd.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The significant components of our deferred tax assets and liabilities are as follows (in thousands):</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table cellpadding="0pt" cellspacing="0pt" style="margin-right: auto; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets (liabilities)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,307</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,807</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research credit carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">971</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">71</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,084</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(7,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets, net of valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Beneficial conversion feature, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferrred tax liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently <div style="display: inline; font-style: italic; font: inherit;">not</div> likely to be realized and, accordingly, we have provided a full valuation allowance.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A reconciliation of the statutory tax rates and the effective tax rates is as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Year Ended December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(5.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in effective tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(32.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(22.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign research incentives</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred true-up</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">16.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">0.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Net operating losses and tax credit carryforwards as of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2019,</div> are as follows:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Amount</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(in thousands)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 29.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expiration Years</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52.4%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating losses--federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">12,958</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Expires beginning 2031</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019 net operating loss -- federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,153</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Never expires</div></div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tax credits--federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic; font: inherit;">Beginning 2041</div></div> </td> </tr> </table> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Utilization of the net operating loss carryforwards and credits <div style="display: inline; font-style: italic; font: inherit;"> may </div>be subject to a substantial annual limitation due to the ownership change limitations provided by the IRC, and similar state provisions. We have <div style="display: inline; font-style: italic; font: inherit;">not</div> performed a detailed analysis to determine whether an ownership change under Section&nbsp;<div style="display: inline; font-style: italic; font: inherit;">382</div> of the IRC has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company is subject to taxation in the United States and Australia. Tax returns for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2015 </div>and thereafter are subject to examinations by federal and state tax authorities. Tax returns of Sun BioPharma Australia Pty Ltd. for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2014</div> and thereafter are subject to examination by the Australian tax authorities.</div></div> -92000 -71000 -415000 -254000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income taxes</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018.</div> The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.</div></div></div> 361000 332000 406000 546000 -193000 301000 360000 20000 -11000 92000 59000 97000 74000 31000 -50000 -97000 -38000 174000 -25000 4000 1033000 2194000 1814000 2000 5000 14000 67000 2000 1759000 1630000 3144000 1898000 2136000 1759000 1630000 1412000 116000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Risks and Uncertainties</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font: inherit;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We have incurred losses of <div style="display: inline; font-style: italic; font: inherit;">$42.6</div> million since our inception in <div style="display: inline; font-style: italic; font: inherit;">2011.</div> For the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>we incurred a net loss of <div style="display: inline; font-style: italic; font: inherit;">$1.8</div> million, which includes a&nbsp;foreign currency loss of <div style="display: inline; font-style: italic; font: inherit;">$0.8</div> million. We also incurred negative cash flows from operating activities of <div style="display: inline; font-style: italic; font: inherit;">$1.2</div> million for this period. As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-<div style="display: inline; font-style: italic; font: inherit;">101,</div> we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020, </div>we had cash of <div style="display: inline; font-style: italic; font: inherit;">$1.3</div> million, working capital of <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million, (current assets less current liabilities) and stockholders&#x2019; equity of <div style="display: inline; font-style: italic; font: inherit;">$0.7</div>&nbsp;million. The Company&#x2019;s principal sources of cash have historically included the issuance of convertible debt and equity securities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed<div style="display: inline; font-weight: bold;"> </div>consolidated financial statements do <div style="display: inline; font-style: italic; font: inherit;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our <div style="display: inline; font-style: italic; font: inherit;">2019</div> financial statements dated <div style="display: inline; font-style: italic; font: inherit;"> March 24, 2020. </div>Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note <div style="display: inline; font-style: italic; font: inherit;">4</div> titled &#x201c;Liquidity and Business Plan.&#x201d;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <div style="display: inline; font-style: italic; font: inherit;"> March 11, 2020, </div>the World Health Organization declared the spread of a novel strain of coronavirus (&#x201c;COVID-<div style="display: inline; font-style: italic; font: inherit;">19&#x201d;</div>) a global pandemic and continued widespread infection in the United States is a possibility. Actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-<div style="display: inline; font-style: italic; font: inherit;">19,</div> including through issuances of &#x201c;stay-at-home&#x201d; directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations.&nbsp; These measures, while intended to protect human life, have led to significantly reduced economic activity. The rapid development and uncertainty of the situation precludes any prediction as to the ultimate impact COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> will have on the Company's business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> outbreak in the United States and Australia.&nbsp; On <div style="display: inline; font-style: italic; font: inherit;"> April 3, 2020, </div>we initiated a temporary pause in the enrollment of new patients in our ongoing clinical trial.&nbsp; We anticipate resumption of new patient enrollment in <div style="display: inline; font-style: italic; font: inherit;">Q2</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> once conditions allow.&nbsp; We continue to treat patients already enrolled.&nbsp;</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (&#x201c;FDA&#x201d;) in the United States, the Therapeutic Goods Administration (&#x201c;TGA&#x201d;) in Australia, the European Medicines Agency (&#x201c;EMA&#x201d;) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, <div style="display: inline; font-style: italic; font: inherit;"> may </div>take many years, and is normally expected to involve substantial expenditures.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have incurred losses of <div style="display: inline; font-style: italic; font: inherit;">$41.3</div> million since our inception in <div style="display: inline; font-style: italic; font: inherit;">2011.</div> For the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>we incurred a net loss and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font: inherit;">$6.2</div> million and <div style="display: inline; font-style: italic; font: inherit;">$2.7</div> million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-<div style="display: inline; font-style: italic; font: inherit;">101.</div> As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>we had cash of <div style="display: inline; font-style: italic; font: inherit;">$2.4</div> million, working capital of <div style="display: inline; font-style: italic; font: inherit;">$1.3</div> million and stockholders&#x2019; equity of <div style="display: inline; font-style: italic; font: inherit;">$1.4</div> million. The Company&#x2019;s principal sources of cash have included the issuance of convertible debt and equity securities.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do <div style="display: inline; font-style: italic; font: inherit;">not</div> include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-<div style="display: inline; font-style: italic; font: inherit;">101,</div> in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.</div></div> -26000 758000 3784000 3643000 -1120000 -2739000 -783000 -2387000 -42600000 -1798000 -41300000 -6200000 -1581000 -5905000 -5905000 -6200000 -1581000 -1798000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Adopted</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> Accounting Pronouncement</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2018, </div>the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">07,</div> &#x201c;Compensation &#x2013; Stock Compensation (Topic <div style="display: inline; font-style: italic; font: inherit;">718</div>).&#x201d; ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">07</div> simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019. </div>Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">02,</div> &#x201c;Leases,&#x201d; which created a new Topic, Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.&nbsp; For leases with a term of <div style="display: inline; font-style: italic; font: inherit;">12</div> months or less, a lessee is permitted to make an election under which such assets and liabilities would <div style="display: inline; font-style: italic; font: inherit;">not</div> be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.&nbsp; This standard was adopted by the Company for the year beginning <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019.&nbsp;</div>The Company has evaluated the impact of this revised guidance on its financial statements and determined it had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact, as the Company has <div style="display: inline; font-style: italic; font: inherit;">no</div> leasing arrangements with terms greater than <div style="display: inline; font-style: italic; font: inherit;">one</div> year.</div></div></div> -824000 -999000 -2293000 -2268000 2014 2015 2016 2017 2018 2019 -1066000 -653000 -4322000 -3891000 12958000 3153000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Business</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sun BioPharma, Inc. and its wholly owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and the &#x201c;Company&#x201d;) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-<div style="display: inline; font-style: italic; font: inherit;">101,</div> from the University of Florida Research Foundation, Inc. (&#x201c;UFRF&#x201d;). Sun BioPharma, Inc. was incorporated under the laws of the State of Delaware on <div style="display: inline; font-style: italic; font: inherit;"> September&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">21,</div> <div style="display: inline; font-style: italic; font: inherit;">2011.</div> Sun BioPharma Australia Pty Ltd was established on <div style="display: inline; font-style: italic; font: inherit;"> May 24, 2013 </div>and incorporated under the laws of Australian Securities and Investments Commission.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Sun BioPharma, Inc. and its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and the &#x201c;Company&#x201d;) exist&nbsp;for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-<div style="display: inline; font-style: italic; font: inherit;">101,</div> from the University of Florida Research Foundation, Inc. (&#x201c;UFRF&#x201d;).</div></div> 32000 17000 51000 51000 45000 797000 -32000 22000 448000 448000 22000 -32000 797000 -820000 34000 -99000 -508000 7000 5000 16000 27000 0.001 0.001 0.001 10000000 10000000 10000000 0 0 0 0 0 0 0 0 0 283000 110000 389000 2200000 2200000 810000 810000 1329000 816000 3200000 240000 2300000 125000 3160000 2328000 50000 26000 27000 161000 14000 25000 25000 598000 350000 2349000 1783000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Research and development costs include expenses incurred in the conduct of our <div style="display: inline; font-style: italic; font: inherit;">second</div> Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> human clinical trial, for <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We expense costs associated with obtaining licenses for patented technologies when it is determined there is <div style="display: inline; font-style: italic; font: inherit;">no</div> alternative future use of the intellectual property subject to the license.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs include expenses incurred in the conduct of our Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> human clinical trials, for <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers performing various testing and accumulating data related to our preclinical studies&#x37e; sponsored research agreements&#x37e; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> compound for use in our pre-clinical studies and human clinical trials&#x37e; consulting resources with specialized expertise related to execution of our development plan for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate&#x37e; personnel costs, including salaries, benefits and share-based compensation&#x37e; and costs to license and maintain our licensed intellectual property.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expense costs associated with obtaining licenses for patented technologies when it is determined there is <div style="display: inline; font-style: italic; font: inherit;">no</div> alternative future use of the intellectual property subject to the license.</div></div></div> -41258000 -35058000 -43056000 10000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Clinical trial and related expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">147</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Professional services</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">125</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">157</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">304</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt;">March 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">636,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,497,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,509,477</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,242,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,177,922</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">383,947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,422,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,035,197</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,166,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,451,355</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin-right: auto; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets (liabilities)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,307</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,807</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research credit carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">235</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">971</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">72</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">71</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,084</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(7,844</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(5,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets, net of valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Beneficial conversion feature, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferrred tax liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(283</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Year Ended December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(5.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in effective tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(32.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(22.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Foreign research incentives</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred true-up</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">16.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">0.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Effective rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Three Months Ended March 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and Administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and Development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">112</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Under</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Option</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant Date Fair Value</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">42,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(378,025</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Forefeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">397,875</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 17%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2.03</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%; vertical-align: bottom;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average Remaining Contractual Life (Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$0.875</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$1.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.275</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$2.50</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$2.95</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$3.70</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">774,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">411,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$4.95</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">539,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.73</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.739</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$10.00</td> <td style="width: 1%; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">$10.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$15.10</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.16</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,551</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 6%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Totals</div> </td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,346,936</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 4%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Outstanding, Vested and Expected to Vest</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 16%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">Options Vested and Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per Share Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Excercisable</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Remaining</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Contractual Life</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">(Years)</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 5%;">&nbsp;</td> <td style="width: 4%;">&nbsp;</td> <td style="width: 16%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 12%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$0.875</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$1.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.029</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$2.275</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$2.50</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">38,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$2.95</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.70</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">774,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.32</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">411,525</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$4.50</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">538,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">506,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$10.00</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-left: 9pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">$10.10</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.007</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">54,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">$15.10</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">314,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15.100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">310,551</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 5%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 4%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 16%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 12%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 5%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Totals</div> </td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.526</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,346,936</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Available for Grant</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Underlying Options</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 68%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at March 31, 2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">18,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Available for</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Grant</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Shares Underlying</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Options</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Weighted</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Average</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Exercise Price</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Per Share</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Aggregate</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Intrinsic Value</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,060,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,960</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.79</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">169,495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(404,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">404,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(30,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">75,749</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(75,749</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7.34</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">732,149</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8.90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">56,225</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">733,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(20,800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15.10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6.53</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,030,547</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;">Common stock fair value</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$2.95</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">$3.50</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$8.10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.55%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.25%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;2.30%</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.94%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">0</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">0</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected Option life (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;5.00</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.50</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.25</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 64%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">72%</div></td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">72%</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">March 31, 2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">December 31, 2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Term Debt</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Term Debt</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan principal Amount</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">126</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred Financing Costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Unamortized balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Discount on Debt</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated Amortization</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Unamortized balance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Loan carrying amounts, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">116</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 112000 10000 1093000 1279000 P0Y P2Y P0Y P2Y 0 0 0.72 0.72 0.0155 0.0225 0.023 0.0294 18549 18549 19549 1060400 732149 75749 20800 1000 404000 733400 2.09 169495 56225 1030547 1481451 264360 264360 1744811 1745811 733960 1032211 9.79 8.90 6.53 7.34 15.10 7.49 3.42 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock</div>-based compensation</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when &#x201c;performance&#x201d; has occurred or is probable of occurring.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font: inherit;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the &#x201c;simplified&#x201d; method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">S</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">tock</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">-based compensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when &#x201c;performance&#x201d; has occurred or is probable of occurring.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S.&nbsp;Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font: inherit;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the &#x201c;simplified&#x201d; method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.</div></div></div> 0.875 2.275 2.95 4.95 10 15.10 0.875 2.275 2.95 4.50 10 15.10 26360 38000 411525 506500 54000 310551 1346936 26360 38000 411525 506500 54000 310551 1346936 1745811 1744811 26360 38000 774100 539300 54000 314051 26360 38000 774100 538300 54000 314051 1.10 2.50 3.70 8.10 10.10 1.10 2.50 3.70 8.10 10.10 2.95 5 3.50 8.10 P10Y P10Y P10Y P10Y P5Y P5Y182D P1Y91D P5Y273D 42500 397875 4.83 2.03 378025 2.41 P2Y273D P3Y317D P7Y40D P7Y244D P7Y109D P6Y76D P6Y343D P3Y P4Y43D P7Y131D P7Y335D P7Y200D P6Y167D P7Y69D 1.029 2.464 3.04 6.739 10.007 15.10 6.525 1.029 2.464 3.04 6.742 10.007 15.10 6.526 P2Y273D P3Y317D P8Y25D P7Y266D P7Y109D P6Y58D P7Y156D P3Y P4Y43D P8Y116D P7Y354D P7Y200D P6Y149D P7Y244D 3842000 5078000 6631000 5070000 6631000 90000 116000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Summary of Significant Accounting Policies </div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Research and development costs include expenses incurred in the conduct of our <div style="display: inline; font-style: italic; font: inherit;">second</div> Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> human clinical trial, for <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We expense costs associated with obtaining licenses for patented technologies when it is determined there is <div style="display: inline; font-style: italic; font: inherit;">no</div> alternative future use of the intellectual property subject to the license.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Stock</div>-based compensation</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when &#x201c;performance&#x201d; has occurred or is probable of occurring.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font: inherit;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the &#x201c;simplified&#x201d; method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign currency translation adjustments</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders&#x2019; equity (deficit). During the <div style="display: inline; font-style: italic; font: inherit;">three</div>-month periods ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive loss</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Comprehensive loss consists of our net loss and the effects of foreign currency translation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:18pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net loss per share</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company&#x2019;s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have <div style="display: inline; font-style: italic; font: inherit;">not</div> been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The following table sets forth the potential shares of common stock that were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt;">March 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2020</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">636,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,497,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,509,477</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,242,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,177,922</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,242,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,177,922</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">4.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Basis of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">p</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">resentation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Our fiscal year ends on <div style="display: inline; font-style: italic; font: inherit;"> December 31.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Principles of consolidation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">redit </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">isk</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits <div style="display: inline; font-style: italic; font: inherit;"> may </div>be in excess of insured limits. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on its deposits of cash.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Beneficial conversion feature</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (&#x201c;BCF&#x201d;) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Debt issuance costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Research and development costs</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development costs include expenses incurred in the conduct of our Phase <div style="display: inline; font-style: italic; font: inherit;">1</div> human clinical trials, for <div style="display: inline; font-style: italic; font: inherit;">third</div>-party service providers performing various testing and accumulating data related to our preclinical studies&#x37e; sponsored research agreements&#x37e; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> compound for use in our pre-clinical studies and human clinical trials&#x37e; consulting resources with specialized expertise related to execution of our development plan for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate&#x37e; personnel costs, including salaries, benefits and share-based compensation&#x37e; and costs to license and maintain our licensed intellectual property.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (&#x201c;CROs&#x201d;). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We expense costs associated with obtaining licenses for patented technologies when it is determined there is <div style="display: inline; font-style: italic; font: inherit;">no</div> alternative future use of the intellectual property subject to the license.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">S</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">tock</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">-based compensation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when &#x201c;performance&#x201d; has occurred or is probable of occurring.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S.&nbsp;Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do <div style="display: inline; font-style: italic; font: inherit;">not</div> expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the &#x201c;simplified&#x201d; method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Income taxes</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018.</div> The Company&#x2019;s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9.35pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9.35pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Foreign </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">c</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">urrency </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">t</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">ranslation</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (&#x201c;AUD&#x201d;). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>and <div style="display: inline; font-style: italic; font: inherit;">2018,</div> any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Grant Income</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant income is derived from a <div style="display: inline; font-style: italic; font: inherit;">one</div>-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the &#x201c;Grant Agreement&#x201d;). The total grant awarded under the Grant Agreement was <div style="display: inline; font-style: italic; font: inherit;">$225,000</div> and was used to fund studies of SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>the Company has been fully reimbursed under the Grant Agreement.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Comprehensive </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">l</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">oss</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Comprehensive loss consists of our net loss and the effects of foreign currency translation.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div><div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Net </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">l</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">oss per </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">hare</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following outstanding potential common shares were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the diluted net loss per share calculations as their effects were <div style="display: inline; font-style: italic; font: inherit;">not</div> dilutive:</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">December 31,</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2019</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2018</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,032,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated common shares issuable upon conversion of notes payable and accrued interest</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">383,947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock issuable under common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,422,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,035,197</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,166,910</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,451,355</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"></div></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Recently </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Adopted</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> Accounting Pronouncement</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">s</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2018, </div>the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">07,</div> &#x201c;Compensation &#x2013; Stock Compensation (Topic <div style="display: inline; font-style: italic; font: inherit;">718</div>).&#x201d; ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">07</div> simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019. </div>Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font: inherit;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">02,</div> &#x201c;Leases,&#x201d; which created a new Topic, Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.&nbsp; For leases with a term of <div style="display: inline; font-style: italic; font: inherit;">12</div> months or less, a lessee is permitted to make an election under which such assets and liabilities would <div style="display: inline; font-style: italic; font: inherit;">not</div> be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.&nbsp; This standard was adopted by the Company for the year beginning <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019.&nbsp;</div>The Company has evaluated the impact of this revised guidance on its financial statements and determined it had <div style="display: inline; font-style: italic; font: inherit;">no</div> material impact, as the Company has <div style="display: inline; font-style: italic; font: inherit;">no</div> leasing arrangements with terms greater than <div style="display: inline; font-style: italic; font: inherit;">one</div> year.</div></div></div> 651000 909209 468200 485000 909000 1000 2280000 2281000 2328000 2328000 1000 3159000 3160000 724000 1385000 268000 4000 25625000 -29153000 -165000 -3689000 5000 35038000 -35058000 283000 7000 42331000 -41258000 305000 5000 35795000 -36639000 251000 -588000 7000 42671000 -43056000 1102000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">7</div></div><div style="display: inline; font-weight: bold;">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</div><div style="display: inline; font-weight: bold;">S</div><div style="display: inline; font-weight: bold;">tock</div><div style="display: inline; font-weight: bold;">holders&#x2019; </div><div style="display: inline; font-weight: bold;">Deficit</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Warrants to purchase common stock issued for future services</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">On <div style="display: inline; font-style: italic; font: inherit;"> February 21, 2020, </div>the Company issued to a service provider a <div style="display: inline; font-style: italic; font: inherit;">five</div>-year warrant to purchase <div style="display: inline; font-style: italic; font: inherit;">75,000</div> shares of common stock at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$6.49</div> per share. The fair market value of the warrants issued of approximately <div style="display: inline; font-style: italic; font: inherit;">$228,000</div> was capitalized and will be charged against future proceeds.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Shares </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">of common stock reserved for future issuance were as follows as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, </div><div style="display: inline; font-style: italic; font: inherit;">20</div></div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">20</div></div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">:</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 83%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,745,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under equity incentive plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">18,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under outstanding common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,497,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,261,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Stockholder</div><div style="display: inline; font-weight: bold;">s&#x2019; </div><div style="display: inline; font-weight: bold;">Equity (</div><div style="display: inline; font-weight: bold;">Deficit</div><div style="display: inline; font-weight: bold;">)</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2019</div> Private placement </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On closings occurring in <div style="display: inline; font-style: italic; font: inherit;"> August, </div><div style="display: inline; font-style: italic; font: inherit;"> September </div>and <div style="display: inline; font-style: italic; font: inherit;"> October </div>of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> we issued an aggregate of <div style="display: inline; font-style: italic; font: inherit;">909,209</div> shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under <div style="display: inline; font-style: italic; font: inherit;">2019</div> Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately <div style="display: inline; font-style: italic; font: inherit;">$3.2</div> million, of which <div style="display: inline; font-style: italic; font: inherit;">$240,000</div> was received from directors and officers of the Company or its subsidiary. The warrants issued under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Purchase Agreement will be exercisable for a period of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$4.00</div> per share See Note <div style="display: inline; font-style: italic; font: inherit;">4,</div> titled &#x201c;Liquidity and Management&#x2019;s Plans&#x201d;.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">201</div></div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">8</div></div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"> Private placement </div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">On&nbsp;<div style="display: inline; font-style: italic; font: inherit;"> February 20, 2018, </div>we entered into a Securities Purchase Agreement (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2018</div> Purchase Agreement&#x201d;) with certain accredited investors and completed an initial closing on the same date. Pursuant to the initial closing and <div style="display: inline; font-style: italic; font: inherit;">two</div> subsequent closings in <div style="display: inline; font-style: italic; font: inherit;"> March </div>and <div style="display: inline; font-style: italic; font: inherit;"> May </div>of <div style="display: inline; font-style: italic; font: inherit;">2018,</div> we sold a total of <div style="display: inline; font-style: italic; font: inherit;">468,200</div> shares of common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock. The warrants issued under the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Purchase Agreement will be exercisable for a period of <div style="display: inline; font-style: italic; font: inherit;">three</div> years from the date of issuance at an exercise price of <div style="display: inline; font-style: italic; font: inherit;">$5.00</div> per share. We received aggregate gross proceeds totaling approximately <div style="display: inline; font-style: italic; font: inherit;">$2.3</div> million pursuant to private placements under the <div style="display: inline; font-style: italic; font: inherit;">2018</div> Purchase Agreement, of which <div style="display: inline; font-style: italic; font: inherit;">$125,000</div> was received from directors and officers of the Company or its subsidiary. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">468,200</div> warrants remained outstanding.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Shares </div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">r</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">eserved</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares of common stock reserved for future issuance were as follows as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019:</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 82%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,744,811</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under equity incentive plan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,549</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under outstanding common stock purchase warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,422,099</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">5,186,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">9.</div> Subsequent Event</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> May 1, 2020, </div>the Company the Company executed an unsecured promissory note with a lender as a part of the Payroll Protection Program (&#x201c;PPP&#x201d;) in the Coronavirus Aid, Relief, and Economic Security Act. Funds totaling approximately <div style="display: inline; font-style: italic; font: inherit;">$102,000</div> will be used to support Company payroll. The note <div style="display: inline; font-style: italic; font: inherit;"> may </div>be forgiven in part and bears an interest rate of <div style="display: inline; font-style: italic; font: inherit;">1%</div> per annum after a <div style="display: inline; font-style: italic; font: inherit;">six</div>-month deferment period.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">11</div></div><div style="display: inline; font-weight: bold;">. </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Subsequent Event</div><div style="display: inline; font-weight: bold;">s</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">On <div style="display: inline; font-style: italic; font: inherit;"> February 21, 2020 </div>the company entered an agreement with an investment banking firm.&nbsp; A portion of the retainer fee was paid via the issuance of <div style="display: inline; font-style: italic; font: inherit;">75,000</div> <div style="display: inline; font-style: italic; font: inherit;">5</div>-year warrants.&nbsp; The fair market value of the warrants issued of approximately <div style="display: inline; font-style: italic; font: inherit;">$148,000</div> will be capitalized and charged against future proceeds.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">4.</div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidity and </div><div style="display: inline; font-weight: bold;">Business</div><div style="display: inline; font-weight: bold;"> Plan</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">We&nbsp;need to obtain additional funds to continue our operations and execute our current business plans. We <div style="display: inline; font-style: italic; font: inherit;"> may </div>seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give <div style="display: inline; font-style: italic; font: inherit;">no</div> assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or <div style="display: inline; font-style: italic; font: inherit;">not</div> positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">If we are unable to obtain additional financing, we believe that we will need to reduce our operations by taking actions that <div style="display: inline; font-style: italic; font: inherit;"> may </div>include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate, licensing rights to <div style="display: inline; font-style: italic; font: inherit;">third</div> parties, including the right to commercialize our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate for pancreatic cancer,&nbsp;or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are <div style="display: inline; font-style: italic; font: inherit;">not</div> successful or if we are unable to obtain marketing approval, we would <div style="display: inline; font-style: italic; font: inherit;">not</div> be able to continue as a going concern and would be forced to cease operations and liquidate our company.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">3.</div> </div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Liquidity and Management Plans</div></div> </td> </tr> </table> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We will need to seek additional sources of funds to support our current business plans. We <div style="display: inline; font-style: italic; font: inherit;"> may </div>seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give <div style="display: inline; font-style: italic; font: inherit;">no</div> assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is <div style="display: inline; font-style: italic; font: inherit;">not</div> positive or economic and market conditions deteriorate.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that <div style="display: inline; font-style: italic; font: inherit;"> may </div>include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate, license to <div style="display: inline; font-style: italic; font: inherit;">third</div> parties the rights to commercialize our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">In closings occurring in <div style="display: inline; font-style: italic; font: inherit;"> August, </div><div style="display: inline; font-style: italic; font: inherit;"> September </div>and <div style="display: inline; font-style: italic; font: inherit;"> October 2019 </div>the Company sold <div style="display: inline; font-style: italic; font: inherit;">909,209</div> shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately <div style="display: inline; font-style: italic; font: inherit;">$3.2</div> million. The warrants are exercisable for a period of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance at an initial exercise price of <div style="display: inline; font-style: italic; font: inherit;">$4.00.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In closings occurring in <div style="display: inline; font-style: italic; font: inherit;"> December 2018 </div>and <div style="display: inline; font-style: italic; font: inherit;"> January 2019 </div>the Company sold <div style="display: inline; font-style: italic; font: inherit;">$2.2</div> million principal amount of unsecured convertible promissory notes (the &#x201c;Notes&#x201d;) and warrants to purchase up to <div style="display: inline; font-style: italic; font: inherit;">1,243,498</div> shares of common stock in a private placement to certain investors. On <div style="display: inline; font-style: italic; font: inherit;"> June 30, 2019 </div>the entire principal balance and accrued interest of <div style="display: inline; font-style: italic; font: inherit;">$105,000</div> converted into <div style="display: inline; font-style: italic; font: inherit;">651,758</div> shares of common stock per the terms of the Notes at a conversion rate of <div style="display: inline; font-style: italic; font: inherit;">$3.50.</div> See Note <div style="display: inline; font-style: italic; font: inherit;">6</div> titled &#x201c;Indebtedness&#x201d; for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of <div style="display: inline; font-style: italic; font: inherit;">five</div> years from the date of issuance at an initial exercise price of <div style="display: inline; font-style: italic; font: inherit;">$4.50.</div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-<div style="display: inline; font-style: italic; font: inherit;">101</div> product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are <div style="display: inline; font-style: italic; font: inherit;">not</div> successful, if we are unable to obtain marketing approval, we would <div style="display: inline; font-style: italic; font: inherit;">not</div> be able to continue as a going concern and would be forced to cease operations and liquidate our company.</div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.</div></div> 235000 116000 286000 91000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.</div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of estimates</div></div></div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div> 228000 14000 148000 P5Y P5Y P5Y P5Y P5Y P5Y 6631308 5072397 5700314 4662080 xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001029125 2011-01-01 2019-12-31 0001029125 2011-01-01 2020-03-31 0001029125 srt:MaximumMember snbp:LicensingAgreementWithUniversityOfFloridaResearchFoundationMember 2011-12-22 2011-12-22 0001029125 srt:MinimumMember snbp:LicensingAgreementWithUniversityOfFloridaResearchFoundationMember 2011-12-22 2011-12-22 0001029125 snbp:LicensingAgreementWithUniversityOfFloridaResearchFoundationMember 2011-12-22 2011-12-22 0001029125 snbp:The2017NotesMember 2017-03-17 2017-03-17 0001029125 snbp:The2017NotesMember us-gaap:ConvertibleDebtMember 2017-03-17 2017-03-17 0001029125 2018-01-01 2018-12-31 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-12-31 0001029125 us-gaap:StockCompensationPlanMember 2018-01-01 2018-12-31 0001029125 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001029125 snbp:NonEmployeeStockOptionMember 2018-01-01 2018-12-31 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2018-01-01 2018-12-31 0001029125 srt:MaximumMember 2018-01-01 2018-12-31 0001029125 srt:MinimumMember 2018-01-01 2018-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001029125 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001029125 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001029125 us-gaap:PrivatePlacementMember 2018-01-01 2018-12-31 0001029125 snbp:DirectorsAndOfficersMember 2018-01-01 2018-12-31 0001029125 snbp:AmendedUnsecuredLoanAgreementMember snbp:InstituteMember 2018-05-01 2018-05-01 0001029125 2018-05-16 2018-05-16 0001029125 snbp:ConversionFromDebtToCommonStockMember 2018-05-16 2018-05-16 0001029125 snbp:The2017NotesMember 2018-05-16 2018-05-16 0001029125 snbp:WarrantsInConnectionWith2018ConvertibleNotesPayableMember 2018-12-01 2019-01-31 0001029125 snbp:The2018NotesMember 2018-12-01 2019-01-31 0001029125 snbp:UnsecuredConvertiblePromissoryNotesMember 2018-12-01 2019-01-31 0001029125 2019-01-01 2019-03-31 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-03-31 0001029125 us-gaap:StockCompensationPlanMember 2019-01-01 2019-03-31 0001029125 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001029125 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001029125 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001029125 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001029125 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001029125 2019-01-01 2019-12-31 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-12-31 0001029125 us-gaap:StockCompensationPlanMember 2019-01-01 2019-12-31 0001029125 us-gaap:WarrantMember 2019-01-01 2019-12-31 0001029125 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MaximumMember 2019-01-01 2019-12-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MinimumMember 2019-01-01 2019-12-31 0001029125 snbp:NonEmployeeStockOptionMember 2019-01-01 2019-12-31 0001029125 us-gaap:DomesticCountryMember us-gaap:EarliestTaxYearMember 2019-01-01 2019-12-31 0001029125 us-gaap:ForeignCountryMember us-gaap:AustralianTaxationOfficeMember 2019-01-01 2019-12-31 0001029125 us-gaap:ConvertibleDebtMember 2019-01-01 2019-12-31 0001029125 snbp:LicenseMaintenanceFeeMember snbp:LicensingAgreementWithUniversityOfFloridaResearchFoundationMember 2019-01-01 2019-12-31 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2019-01-01 2019-12-31 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2019-01-01 2019-12-31 0001029125 srt:MaximumMember 2019-01-01 2019-12-31 0001029125 srt:MinimumMember 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange1Member 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange2Member 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange3Member 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange4Member 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange5Member 2019-01-01 2019-12-31 0001029125 snbp:ExercisePriceRange6Member 2019-01-01 2019-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001029125 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001029125 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001029125 snbp:TermDebtMember 2019-04-05 2019-04-05 0001029125 snbp:ConversionFromDebtNotesToCommonStockMember 2019-06-30 2019-06-30 0001029125 snbp:ConversionFromDebtToCommonStockMember 2019-06-30 2019-06-30 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2019-08-01 2019-10-31 0001029125 us-gaap:PrivatePlacementMember 2019-08-01 2019-10-31 0001029125 snbp:DirectorsAndOfficersMember 2019-08-01 2019-10-31 0001029125 snbp:SecondAmendedUnsecuredLoanAgreementMember snbp:InstituteMember 2019-12-16 2019-12-16 0001029125 2020-01-01 2020-03-31 0001029125 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-03-31 0001029125 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001029125 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MaximumMember 2020-01-01 2020-03-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2011StockOptionPlanMember srt:MinimumMember 2020-01-01 2020-03-31 0001029125 snbp:TermDebtMember 2020-01-01 2020-03-31 0001029125 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001029125 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2020-01-01 2020-03-31 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange1Member 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange2Member 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange3Member 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange4Member 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange5Member 2020-01-01 2020-03-31 0001029125 snbp:ExercisePriceRange6Member 2020-01-01 2020-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001029125 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001029125 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001029125 snbp:WarrantsIssuedAsPartialPaymentOfRetainerFeeInConnectionWithInvestmentBankingFirmAgreementMember us-gaap:SubsequentEventMember 2020-02-21 2020-02-21 0001029125 us-gaap:SubsequentEventMember 2020-05-01 2020-05-01 0001029125 snbp:InstituteMember 2012-10-26 0001029125 snbp:The2017NotesMember us-gaap:ConvertibleDebtMember 2017-03-17 0001029125 2017-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001029125 us-gaap:CommonStockMember 2017-12-31 0001029125 us-gaap:RetainedEarningsMember 2017-12-31 0001029125 snbp:WarrantsInConnectionWithDebtConversionMember 2018-05-16 0001029125 snbp:ConversionFromDebtToCommonStockMember 2018-05-16 0001029125 2018-12-31 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2018-12-31 0001029125 us-gaap:ConvertibleDebtMember 2018-12-31 0001029125 srt:MaximumMember 2018-12-31 0001029125 srt:MinimumMember 2018-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001029125 us-gaap:CommonStockMember 2018-12-31 0001029125 us-gaap:RetainedEarningsMember 2018-12-31 0001029125 snbp:WarrantsInConnectionWith2018ConvertibleNotesPayableMember 2019-01-31 0001029125 snbp:The2018NotesMember 2019-01-31 0001029125 snbp:The2018NotesMember us-gaap:ConvertibleDebtMember 2019-01-31 0001029125 2019-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001029125 us-gaap:CommonStockMember 2019-03-31 0001029125 us-gaap:RetainedEarningsMember 2019-03-31 0001029125 snbp:WarrantsInConnectionWithTermDebtMember 2019-04-05 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2019-06-30 0001029125 snbp:ConversionFromDebtNotesToCommonStockMember 2019-06-30 0001029125 snbp:ConversionFromDebtToCommonStockMember 2019-06-30 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2019-10-31 0001029125 snbp:WarrantsInConnectionWithThePrivatePlacementMember 2019-10-31 0001029125 snbp:WarrantsIssuedForBothAmendmentsToTheUnsecuredLoanAgreementMember 2019-12-16 0001029125 snbp:WarrantsIssuedInConnectionWithSecondAmendedUnsecuredLoanAgreementMember 2019-12-16 0001029125 2019-12-31 0001029125 us-gaap:EmployeeStockOptionMember 2019-12-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2019-12-31 0001029125 snbp:WarrantsInConnectionWithSecuritiesPurchaseAgreementMember 2019-12-31 0001029125 snbp:TermDebtMember 2019-12-31 0001029125 us-gaap:DomesticCountryMember 2019-12-31 0001029125 us-gaap:DomesticCountryMember us-gaap:TaxYear2018Member 2019-12-31 0001029125 us-gaap:ConvertibleDebtMember 2019-12-31 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2019-12-31 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2019-12-31 0001029125 srt:MaximumMember 2019-12-31 0001029125 srt:MinimumMember 2019-12-31 0001029125 snbp:ExercisePriceRange1Member 2019-12-31 0001029125 snbp:ExercisePriceRange2Member 2019-12-31 0001029125 snbp:ExercisePriceRange3Member 2019-12-31 0001029125 snbp:ExercisePriceRange4Member 2019-12-31 0001029125 snbp:ExercisePriceRange5Member 2019-12-31 0001029125 snbp:ExercisePriceRange6Member 2019-12-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001029125 us-gaap:CommonStockMember 2019-12-31 0001029125 us-gaap:RetainedEarningsMember 2019-12-31 0001029125 snbp:WarrantsIssuedAsPartialPaymentOfRetainerFeeInConnectionWithInvestmentBankingFirmAgreementMember us-gaap:SubsequentEventMember 2020-02-21 0001029125 snbp:WarrantsIssuedForFutureServicesMember 2020-02-21 0001029125 2020-03-31 0001029125 us-gaap:EmployeeStockOptionMember snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2020-03-31 0001029125 snbp:TermDebtMember 2020-03-31 0001029125 snbp:SunBiopharmaInc2011StockOptionPlanMember 2020-03-31 0001029125 snbp:SunBiopharmaInc2016OmnibusIncentivePlanMember 2020-03-31 0001029125 snbp:ExercisePriceRange1Member 2020-03-31 0001029125 snbp:ExercisePriceRange2Member 2020-03-31 0001029125 snbp:ExercisePriceRange3Member 2020-03-31 0001029125 snbp:ExercisePriceRange4Member 2020-03-31 0001029125 snbp:ExercisePriceRange5Member 2020-03-31 0001029125 snbp:ExercisePriceRange6Member 2020-03-31 0001029125 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001029125 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001029125 us-gaap:CommonStockMember 2020-03-31 0001029125 us-gaap:RetainedEarningsMember 2020-03-31 EX-101.SCH 4 snbp-20200331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 007 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 008 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:calculationLink link:definitionLink link:presentationLink 009 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) link:calculationLink link:definitionLink link:presentationLink 010 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 011 - Statement - Consolidated Statements of Cash Flows (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 1 - Business link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 2 - Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 3 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 4 - Liquidity and Business Plan link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 5 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 6 - Indebtedness link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 7 - Stockholders' Deficit link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 8 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 9 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Business link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Liquidity and Business Plan link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Indebtedness 2 link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Stockholders' Equity (Deficit) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 9 - Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 10 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 11 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 6 - Indebtedness (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 7 - Stockholders' Deficit (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 8 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 5 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 6 - Indebtedness 2 (Tables) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 8 - Stockholders' Equity (Deficit) (Tables) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 9 - Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 10 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 6 - Indebtedness (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 6 - Indebtedness - Schedule of Debt (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 7 - Stockholders' Deficit (Details Textual) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 8 - Stock-based Compensation - Summary of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 8 - Stock-based Compensation - Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 9 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 3 - Liquidity and Business Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 5 - Accrued Expenses - Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 6 - Indebtedness 2 (Details Textual) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 6 - Indebtedness - Changes in Debt (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 8 - Stockholders' Equity (Deficit) (Details Textual) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 9 - Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 9 - Stock-based Compensation - Summary of Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 9 - Stock-based Compensation - Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 10 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 10 - Income Taxes - Income Tax Reconciliation (Details) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note 11 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 5 snbp-20200331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 snbp-20200331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 snbp-20200331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Expected dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 5 - Summary of Significant Accounting Policies Note 6 - Indebtedness Risk-free interest rate Note 7 - Stockholders' Deficit Note 8 - Stock-based Compensation Note 4 - Summary of Significant Accounting Policies Note 5 - Accrued Expenses Note 6 - Indebtedness 2 Note 8 - Stockholders' Equity (Deficit) Income Tax Disclosure [Text Block] Note 9 - Stock-based Compensation Note 10 - Income Taxes Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) License Maintenance Fee [Member] Represents the information pertaining to the license maintenance fee. Expected stock price volatility Note 6 - Indebtedness - Schedule of Debt (Details) Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) Note 8 - Stock-based Compensation - Summary of Option Activity (Details) snbp_DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStock Conversion of convertible notes payable and accrued interest into common stock and warrants Represents the conversion of promissory notes and accrued interest into common stock in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Note 8 - Stock-based Compensation - Options Outstanding (Details) Expected option life (Year) Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Note 5 - Accrued Expenses - Accrued Expenses (Details) Note 6 - Indebtedness - Changes in Debt (Details) Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Beneficial conversion feature on convertible notes Intrinsic Value of Convertible Debt with Conversion Feature Represents the intrinsic value of convertible debt with conversion feature in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Directors and Officers [Member] Represents the information pertaining to the directors and officers. Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 9 - Stock-based Compensation - Options Outstanding (Details) Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Beneficial Conversion Feature, Policy [Policy Text Block] Disclosure of accounting policy for beneficial conversion feature. Note 10 - Income Taxes - Income Tax Reconciliation (Details) Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) Share-based Payment Arrangement, Option, Activity [Table Text Block] Notes To Financial Statements Notes To Financial Statements [Abstract] snbp_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod Granted, shares available for grant (in shares) Represents the number of available shares granted during the period. Foreign currency translation adjustment Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Schedule of Nonvested Share Activity [Table Text Block] Exercise Price Range 5 [Member] Represents the fifth exercise price range. Convertible notes payable, net of debt discounts snbp_DebtConversionOriginalDebtAmountOfAccruedButUnpaidInterest Accrued interest converted into common stock and warrants The value of accrued, but unpaid interest being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Granted, weighted average grant-date fair value (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Vested, weighted average grant-date fair value (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Forfeitures, weighted average grant-date fair value (in dollars per share) The 2017 Notes [Member] Information pertaining to the 2017 Convertible Notes Payable. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, weighted average grant-date fair value (in dollars per share) Unvested, weighted average grant-date fair value (in dollars per share) Term debt, current portion us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Vested, shares under option (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Forfeitures, shares under option (in shares) snbp_DebtInstrumentQualifiedFinancingMinimumProceeds Debt Instrument, Qualified Financing, Minimum Proceeds Represents the minimum amount of proceeds upon the occurrence of Qualified Financing. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares Unvested, shares under option (in shares) Unvested, shares under option (in shares) Balance, weighted average exercise price per share (in dollars per share) Schedule of Debt Activity [Table Text Block] Tabular disclosure of debt activity. Forfeited, weighted average exercise price per share (in dollars per share) Granted, weighted average exercise price per share (in dollars per share) Warrants in Connection with Debt Conversion [Member] Represents the information pertaining to the warrants in connection with the debt conversion. Accrued liabilities Accrued expenses Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Balance, shares underlying options (in shares) Balance, shares underlying options (in shares) Other us-gaap_OtherAccruedLiabilitiesCurrent us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Balance, shares available for grant (in shares) Balance, shares available for grant (in shares) snbp_WarrantsIssuedDuringPeriodValueExchangedForModificationOfDebt Warrants issued in exchange for modification of term debt The value of warrants issued during the period in exchange for the modification of debt held by the entity. Professional services us-gaap_AccruedProfessionalFeesCurrent Supplemental disclosure of non-cash transactions: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) snbp_ProceedsFromConvertibleDebtGross Proceeds from Convertible Debt, Gross The cash inflow from the issuance of a long-term debt instrument, before issuance costs, which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Current liabilities: Supplemental disclosure of cash flow information: us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] Represents company's 2016 Omnibus Incentive Plan stock option plan that permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) snbp_ClassOfWarrantOrRightExpirationTerm Class of Warrant or Right, Expiration Term (Year) Represents the expiration term for warrants. snbp_GrantAgreementTotalGrants Grant Agreement, Total Grants The total amount of grants that will be awarded to an entity to carry out a specific purpose as provided in grant agreement. Share-based Payment Arrangement [Text Block] Grant Income Policy [Policy Text Block] Disclosure of accounting policy for grant income. Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] snbp_DebtInstrumentConvertibleGrossProceedsFromSaleOfEquityTrigger Debt Instrument, Convertible, Gross Proceeds from Sale of Equity Trigger Gross proceeds from sale of equity which is required to trigger the conversion of debt instrument. snbp_DebtConversionAccruedInterestAmount Debt Conversion, Accrued Interest, Amount The amount of the acrrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Award Type [Domain] snbp_DebtConversionConvertedInstrumentUnitsIssued Debt Conversion, Converted Instrument, Units Issued (in shares) The number of units issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period. Basis of Presentation and Significant Accounting Policies [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent, Total Net loss Award Type [Axis] Share-based Payment Arrangement [Member] Warrants Issued for Both Amendments to the Unsecured Loan Agreement [Member] Represents the warrants issued for both amendments to the unsecured loan agreement (the "Agreement"). Convertible Debt Securities [Member] Share-based Payment Arrangement, Option [Member] Warrants Issued in Connection with Second Amended Unsecured Loan Agreement [Member] Represents warrants issued in connection with the unsecured loan agreement (the "Agreement") following its second amendment on December 16, 2019. Second Amended Unsecured Loan Agreement [Member] Represents the amended unsecured loan agreement (the "Agreement") after its second amendment on December 16, 2019. Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Unsecured promissory note payable Carrying value as of the balance sheet date of the portion of long-term, uncollateralized notes payable due within one year or the normal operating cycle, if longer. Non-Employee Stock Option [Member] Share-based payment arrangement to non-employees granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time. Commitments and Contingencies Disclosure [Text Block] Warrants issued in exchange for modification of term debt Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants in exchange for modification of term debt. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Accrued Liabilities [Text Block] The disclosure of accrued liabilities. Convertible Debt [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Loss before income tax benefit us-gaap_IncomeTaxExpenseBenefit Income tax benefit us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Exercise Price Range 6 [Member] Represents the sixth exercise price range. General and administrative Conversion from Debt to Common Stock [Member] Represents the information pertaining to the conversion from debt to common stock snbp_DebtConversionConversionOfPromissoryNotesAndAccruedInterestIntoCommonStockAndWarrants Conversion of convertible notes payable and accrued interest into common stock Represents the conversion of promissory notes and accrued interest into common stock and warrants in a noncash (or part noncash) transaction. "Part noncash" refers to the portion of the transaction not resulting in cash receipts or cash payments in the period. Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares) Represents the number of shares issued during the period related to the conversion of convertible securities into common stock and warrants. snbp_CommonStockConvertedIntoConvertibleNotesPayableShares Common stock converted into convertible notes payable (in shares) Represents number of common stock converted into convertible notes payable. snbp_CommonStockConvertedIntoConvertibleNotesPayableValue Common stock converted into convertible notes payable Common stock converted into convertible notes payable Common stock converted into convertible notes payable Represents the value of common stock converted into convertible notes payable. Conversion of convertible notes payable and accrued interest into common stock and warrants Represents value associated with the conversion of convertible securities into common stock and warrants. Clinical trial and related expenses snbp_ClinicalTrialRelatedLiabilitiesCurrent Amount of expenses incurred but not yet paid of clinical trials, due within one year or the normal operating cycle, if longer. us-gaap_DebtInstrumentIncreaseAccruedInterest Accrued Interest Cash Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash at beginning of period Cash at end of period us-gaap_DebtInstrumentConvertibleConversionPrice1 Debt Instrument, Convertible, Conversion Price (in dollars per share) Share-based compensation expense Share-based Payment Arrangement, Expense us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature Debt Instrument, Convertible, Beneficial Conversion Feature Warrants in Connection with the Private Placement [Member] Represents the information pertaining to the warrants in connection with a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts. Non-cash interest expense Noncash interest expense incurred by the entity during the period. us-gaap_RoyaltyExpense Royalty Expense Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss Use of Estimates, Policy [Policy Text Block] us-gaap_DebtInstrumentPeriodicPayment Debt Instrument, Periodic Payment, Total New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Debt Issuance Costs [Policy Text Block] Disclosure of accounting policy for debt issuance costs. Current Fiscal Year End Date us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Institute [Member] Represents Institute for Commercialization of Public Research, Inc., the lender. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Warrants Issued as Partial Payment of Retainer Fee in Connection with Investment Banking Firm Agreement [Member] Represents warrants issued as partial payment of retainer fee in connection with investment banking firm agreement. Document Period End Date Entity Emerging Growth Company Loan principal Amount Debt Instrument, Face Amount Document Type Interim Period, Costs Not Allocable [Domain] Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Nature of Expense [Axis] Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers Entity Well-known Seasoned Issuer us-gaap_IncreaseDecreaseInIncomeTaxesReceivable Income tax receivable Warrants issued with sale of convertible notes payable Warrants issued with convertible notes Stock-based compensation Beneficial conversion feature Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Sun BioPharma, Inc. 2011 Stock Option Plan [Member] Represents company's stock option plan that permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. Unsecured Convertible Promissory Notes [Member] Related to unsecured convertible promissory notes. Amended Unsecured Loan Agreement [Member] Represents information about the amended unsecured loan agreement. Entity Common Stock, Shares Outstanding (in shares) Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Nature of Operations [Text Block] Conversion of convertible notes payable and accrued interest into common stock Conversion of convertible notes payable and accrued interest into common stock (in shares) us-gaap_TableTextBlock Notes Tables Granted, shares underlying options (in shares) Granted, shares under option (in shares) Forfeitures , shares available for grant (in shares) Forfeited, shares underlying options (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Class of Warrant or Right, Expiration Term (Year) Line of Credit Facility, Lender [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Sale of common stock and warrants (in shares) Stock Issued During Period, Shares, New Issues (in shares) Lender Name [Axis] us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders' equity Sale of common stock and warrants Research and development Accumulated deficit Accumulated comprehensive income Schedule of Short-term Debt [Table Text Block] Operating expenses: Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense Changes in operating assets and liabilities: Amortization of debt issuance costs us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Substantial Doubt about Going Concern [Text Block] Subsequent Event [Member] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] Warrants In Connection with Term Debt [Member] Represents warrants in connection with term debt. Foreign Currency Transactions and Translations Policy [Policy Text Block] us-gaap_ShareBasedCompensation Stock-based compensation Other noncurrent assets Term Debt [Member] Represents information related to term debt. us-gaap_DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued (in shares) Earnings Per Share, Policy [Policy Text Block] us-gaap_DebtConversionOriginalDebtAmount1 Debt Conversion, Original Debt, Amount Aggregate principal value of notes converted into common stock Debt Conversion Description [Axis] Debt Conversion, Name [Domain] Comprehensive Income, Policy [Policy Text Block] Amortization of debt discount Income Tax, Policy [Policy Text Block] Warrants Issued for Future Services [Member] Information pertaining to warrants issued for future services. snbp_WarrantsIssuedForFutureServices Warrants issued for future services The fair value of warrants issued for future services in noncash financing activities. Warrants issued for future services Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants for future services. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. snbp_ProceedsFromPaycheckProtectionProgramUnderCaresAct Proceeds from Paycheck Protection Program Under CARES Act The cash inflow received from loan funding under the Paycheck Protection Program which was established under the Coronavirus Aid, Relief and Economic Security (CARES) Act in March 2020. Research and Development Expense, Policy [Policy Text Block] Conversion from Debt Notes to Common Stock [Member] Represents the information pertaining to the conversion from debt notes to common stock. us-gaap_AssetsCurrent Total current assets Share-based Payment Arrangement [Policy Text Block] Stockholders' Equity Note Disclosure [Text Block] Income tax receivable Income Taxes Receivable, Current Common stock, $0.001 par value; 100,000,000 authorized; 6,631,308 and 5,077,483 shares issued and outstanding, as of December 31, 2019 and December 31, 2018, respectively Warrants in Connection with Securities Purchase Agreement [Member] Represents warrants in conjunction with securities purchase agreement. Adjustments to reconcile net loss to net cash used in operating activities: Common stock, shares authorized (in shares) The 2018 Notes [Member] Represents information related to convertible promissory 2018 notes. Common stock, shares issued (in shares) Common stock, par value (in dollars per share) snbp_WarrantsUponIssuanceFairValue Warrants Upon Issuance, Fair Value Represents the fair value of warrants upon issuance. us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance us-gaap_DeferredTaxAssetsValuationAllowance Valuation allowance Statistical Measurement [Domain] Maximum [Member] Grant income The aggregate amount of income from grants not considered a component of the entity's core operations. Minimum [Member] Warrants In Connection with 2018 Convertible Notes Payable [Member] Represents warrants in connection with 2018 convertible notes payable. us-gaap_DeferredTaxAssetsNet Deferred tax assets, net of valuation allowance Statistical Measurement [Axis] Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2019 and December 31, 2018 Issuance of unsecured promissory note in exchange for vendor accounts payable The issuance of an unsecured promissory note in exchange for vendor accounts payable. snbp_ClassOfWarrantOrRightPrincipalAmountOfEveryAmountOfNotesPurchased Class of Warrant or Right, Principal Amount of Every Amount Of Notes Purchased Represents warrants to purchase common stock for every principle amount of notes. us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax asset Preferred stock, shares issued (in shares) Cash paid during period for interest Prepaid expenses and other current assets us-gaap_DeferredTaxAssetsOther Other us-gaap_DeferredTaxAssetsGross Deferred tax assets Preferred stock, shares authorized (in shares) Preferred stock, par value (in dollars per share) Cash flows from operating activities: us-gaap_WarrantsAndRightsOutstanding Warrants and Rights Outstanding Statement [Line Items] Options granted in exchange for release from contingent payment obligations The amount of options granted in exchange for release from contingent payment obligations. Additional paid-in capital us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Stock-based compensation AOCI Attributable to Parent [Member] Stockholders' equity: Other(expense) income us-gaap_NonoperatingIncomeExpense Total other expense us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Net operating loss carryforwards us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch Research credit carryforwards Current assets: Private Placement [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Exercise Price Range 1 [Member] Represents the first exercise price range. Sale of Stock [Axis] Sale of Stock [Domain] snbp_WarrantsIssuedWithConvertibleNotes Warrants issued with convertible notes The fair value of warrants issued with convertible notes in noncash financing activities. Exercise Price Range 2 [Member] Represents the second exercise price range. us-gaap_OperatingIncomeLoss Operating loss Exercise Price Range 3 [Member] Represents the third exercise price range. us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Other (expense) income: us-gaap_DeferredTaxLiabilities Deferrred tax liabilities Effect of exchange rate changes on cash us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Net change in cash Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block] Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization and tax credit carryforwards available to reduce future taxable income, including amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances. Permanent differences Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences. Schedule of Common Stock Reserved for Future Issuance [Table Text Block] Tabular disclosure for common stock reserved for future issuance. snbp_ClassOfWarrantOrRightIssuedDuringPeriod Class of Warrant or Right, Issued During Period (in shares) The number of warrants or rights issued during period. snbp_RoyaltyFeePercentageOfNetSales Royalty Fee Percentage of Net Sales Royalty payment percentage of net sales as per the agreement. snbp_RoyaltyTerm Royalty Term (Year) Royalties are to be paid in period of time lasting up to 10 years from the first commercial sale of licensed product. Licensing Agreement with University of Florida Research Foundation [Member] An exclusive license agreement entered into with the University of Florida Research Foundation (UFRF). us-gaap_InterestPayableCurrentAndNoncurrent Accrued interest at January 1, 2019 Accrued interest at December 31, 2019 us-gaap_PaymentsOfStockIssuanceCosts Proceeds from issuance of common stock and warrants, issuance costs Concentration Risk, Credit Risk, Policy [Policy Text Block] Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively Proceeds from Issuance of Private Placement Retained Earnings [Member] snbp_AnnualLicenseMaintenanceFee Annual License Maintenance Fee Amount per year the company is committed to pay for license maintenance fees. Title of Individual [Domain] Title of Individual [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_LongTermDebt Long-term Debt, Total us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Proceeds from the sale of convertible promissory notes, offering costs Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority [Axis] us-gaap_DeferredFinanceCostsCurrentNet Unamortized balance Income Tax Authority [Domain] Domestic Tax Authority [Member] Foreign Tax Authority [Member] us-gaap_RepaymentsOfLongTermDebt Repayments of Long-term Debt, Total Repayments of term debt Deferred Financing Costs us-gaap_AccumulatedAmortizationOfCurrentDeferredFinanceCosts Accumulated Amortization us-gaap_DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount, Total Exercise Price Range 4 [Member] Represents the fourth exercise price range. General and Administrative Expense [Member] us-gaap_DebtInstrumentCarryingAmount Balances at January 1, 2019 Balances at December 31, 2019 Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_OpenTaxYear Open Tax Year Basis of Accounting, Policy [Policy Text Block] us-gaap_ShortTermBorrowings Short-term Debt, Total Loan carrying amounts, net Entity Interactive Data Current Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7 Proceeds from Convertible Debt Research and Development Expense [Member] Tax Year 2018 [Member] Earliest Tax Year [Member] Income Statement Location [Axis] Income Statement Location [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Tax Period [Domain] Tax Period [Axis] Tax credits--federal Weighted average shares outstanding - basic and diluted (in shares) us-gaap_RepaymentsOfNotesPayable Repayment of demand note Common stock fair value (in dollars per share) us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Anti-dilutive securities (in shares) Basic and diluted net loss per share (in dollars per share) Net operating losses--federal snbp_UnamortizedDebtDiscountChargedToInterestExpense Unamortized Debt Discount Charged to Interest Expense Represents the amount of unamortized debt discount charged to interest expense upon conversion. snbp_ConvertibleDebtMandatoryConversionThresholdGrossProceedsFromSaleOfEquitySecurities Convertible Debt, Mandatory Conversion Threshold, Gross Proceeds from Sale of Equity Securities The amount of gross proceeds from sale of equity securities that represents a trigger amount for the mandatory conversion of convertible debt. Statement [Table] Statement of Financial Position [Abstract] Other Effective rate Change in effective tax rate Valuation allowance Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] snbp_WorkingCapital Working Capital Represents current assets less current liabilities. Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Cash flows from financing activities: Statutory rate Foreign research incentives Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to outside of the country research incentives. Deferred true-up Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred true-up. snbp_DeferredTaxLiabilitiesBeneficialConversionFeatureNet Beneficial conversion feature, net Amount, before allocation of valuation allowance, of deferred tax liabilities attributable to deductible temporary differences from the net amount of beneficial conversion feature. us-gaap_StockholdersEquity Stockholders' Equity Attributable to Parent, Ending Balance Total stockholders' equity Balances Balances Class of Stock [Axis] snbp_OperatingLossCarryforwardsExpirationYear Net operating losses--federal Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY format. snbp_TaxCreditCarryforwardExpirationYear Tax credits--federal Expiration year of the tax credit carryforward, in CCYY format. Options excercisable, weighted average remaining contractual life (Year) Options outstanding, weighted average exercise price (in dollars per share) Options outstanding, weighted average remaining contractual life (Year) Australian Taxation Office [Member] Options excercisable (in shares) Per share exercise price, upper limit (in dollars per share) Options outstanding (in shares) Stock options outstanding (in shares) Exercise Price Range [Axis] Exercise Price Range [Domain] Per share exercise price, lower limit (in dollars per share) EX-101.PRE 8 snbp-20200331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 image01.jpg begin 644 image01.jpg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image02.jpg begin 644 image02.jpg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end GRAPHIC 11 image03.jpg begin 644 image03.jpg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end GRAPHIC 12 image04a.jpg begin 644 image04a.jpg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end GRAPHIC 13 snbp20200630_s1img001.jpg begin 644 snbp20200630_s1img001.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document And Entity Information
3 Months Ended
Mar. 31, 2020
Document Information [Line Items]  
Entity Registrant Name Sun BioPharma, Inc.
Entity Central Index Key 0001029125
Entity Filer Category Non-accelerated Filer
Entity Emerging Growth Company false
Entity Small Business true
Document Type S-1
Document Fiscal Year Focus 2020
Document Fiscal Period Focus Q1
Amendment Flag false
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Current assets:          
Cash $ 1,296,000 $ 2,449,000 $ 1,379,000 $ 1,405,000 $ 152,000
Prepaid expenses and other current assets 389,000 283,000   110,000  
Income tax receivable 406,000 361,000   332,000  
Total current assets 2,091,000 3,093,000   1,847,000  
Other noncurrent assets 45,000 51,000   51,000  
Total assets 2,136,000 3,144,000   1,898,000  
Current liabilities:          
Accounts payable 271,000 597,000   1,064,000  
Accrued expenses 308,000 304,000   216,000  
Term debt, current portion 91,000 116,000   286,000  
Unsecured promissory note payable 742,000 742,000    
Total current liabilities 1,412,000 1,759,000   1,630,000  
Stockholders' equity:          
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2019 and December 31, 2018 0 0   0  
Common stock, $0.001 par value; 100,000,000 authorized; 6,631,308 and 5,077,483 shares issued and outstanding, as of December 31, 2019 and December 31, 2018, respectively 7,000 7,000   5,000  
Additional paid-in capital 42,671,000 42,331,000   35,038,000  
Accumulated deficit (43,056,000) (41,258,000)   (35,058,000)  
Accumulated comprehensive income 1,102,000 305,000   283,000  
Total stockholders' equity 724,000 1,385,000 $ (588,000) 268,000 $ (3,689,000)
Total liabilities and stockholders' equity $ 2,136,000 $ 3,144,000   $ 1,898,000  
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0 0
Preferred stock, shares outstanding (in shares) 0 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000 100,000,000
Common stock, shares issued (in shares) 6,631,308 6,631,308 5,077,483
Common stock, shares outstanding (in shares) 6,631,308 6,631,308 5,077,483
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended 108 Months Ended 111 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Mar. 31, 2020
Operating expenses:            
General and administrative $ 468 $ 303 $ 1,973 $ 2,108    
Research and development 598 350 2,349 1,783    
Operating loss (1,066) (653) (4,322) (3,891)    
Other (expense) income:            
Interest expense (4) (1,033) (2,194) (1,814)    
Other(expense) income (820) 34 (99) (508)    
Total other expense (824) (999) (2,293) (2,268)    
Loss before income tax benefit (1,890) (1,652) (6,615) (6,159)    
Income tax benefit 92 71 415 254    
Net loss (1,798) (1,581) (6,200) (5,905) $ (41,300) $ (42,600)
Foreign currency translation adjustment 797 (32) 22 448    
Comprehensive loss $ (1,001) $ (1,613) $ (6,178) $ (5,457)    
Basic and diluted net loss per share (in dollars per share) $ (0.27) $ (0.31) $ (1.09) $ (1.27)    
Weighted average shares outstanding - basic and diluted (in shares) 6,631,308 5,072,397 5,700,314 4,662,080    
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balances (in shares) at Dec. 31, 2017 3,842        
Balances at Dec. 31, 2017 $ 4 $ 25,625 $ (29,153) $ (165) $ (3,689)
Beneficial conversion feature 716 716
Warrants issued with sale of convertible notes payable 739 739
Common stock converted into convertible notes payable        
Stock-based compensation   2,373     2,373
Net loss     (5,905)   (5,905)
Foreign currency translation adjustment     448 448
Balances (in shares) at Dec. 31, 2018 5,078        
Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268
Beneficial conversion feature 353 353
Warrants issued with sale of convertible notes payable 419 419
Common stock converted into convertible notes payable (in shares) (7)        
Common stock converted into convertible notes payable (25) (25)
Stock-based compensation   10     10
Net loss     (1,581)   (1,581)
Foreign currency translation adjustment     (32) (32)
Balances (in shares) at Mar. 31, 2019 5,070        
Balances at Mar. 31, 2019 $ 5 35,795 (36,639) 251 (588)
Balances (in shares) at Dec. 31, 2018 5,078        
Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268
Beneficial conversion feature 353 353
Warrants issued with sale of convertible notes payable 419 419
Common stock converted into convertible notes payable (in shares) (7)        
Common stock converted into convertible notes payable (25) (25)
Stock-based compensation 1,093 1,093
Net loss (6,200) (6,200)
Foreign currency translation adjustment 22 22
Balances (in shares) at Dec. 31, 2019 6,631        
Balances at Dec. 31, 2019 $ 7 42,331 (41,258) 305 1,385
Common stock converted into convertible notes payable        
Stock-based compensation   112     112
Net loss     (1,798)   (1,798)
Foreign currency translation adjustment     797 797
Warrants issued for future services 228 228
Balances (in shares) at Mar. 31, 2020 6,631        
Balances at Mar. 31, 2020 $ 7 $ 42,671 $ (43,056) $ 1,102 $ 724
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net loss $ (1,798) $ (1,581)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 112 10
Amortization of debt discount 974
Amortization of debt issuance costs 6
Non-cash interest expense 48
Changes in operating assets and liabilities:    
Income tax receivable (97) (74)
Prepaid expenses and other current assets 97 38
Accounts payable 546 (193)
Accrued liabilities 20 (11)
Net cash used in operating activities (1,120) (783)
Cash flows from financing activities:    
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7 810
Repayment of demand note (25)
Repayments of term debt (26) (27)
Net cash provided by financing activities (26) 758
Effect of exchange rate changes on cash (7) (1)
Net change in cash (1,153) (26)
Cash at beginning of period 2,449 1,405
Cash at end of period 1,296 1,379
Supplemental disclosure of cash flow information:    
Cash paid during period for interest 2 5
Supplemental disclosure of non-cash transactions:    
Warrants issued for future services 228
Beneficial conversion feature on convertible notes 353
Warrants issued with convertible notes 419
Common stock converted into convertible notes payable $ 25
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash $ 2,449,000 $ 1,405,000
Prepaid expenses and other current assets 283,000 110,000
Income tax receivable 361,000 332,000
Total current assets 3,093,000 1,847,000
Other noncurrent assets 51,000 51,000
Total assets 3,144,000 1,898,000
Current liabilities:    
Accounts payable 597,000 1,064,000
Accrued expenses 304,000 216,000
Convertible notes payable, net of debt discounts 64,000
Term debt, current portion 116,000 286,000
Unsecured promissory note payable 742,000
Total current liabilities 1,759,000 1,630,000
Total liabilities 1,759,000 1,630,000
Stockholders' equity:    
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of December 31, 2019 and December 31, 2018 0 0
Common stock, $0.001 par value; 100,000,000 authorized; 6,631,308 and 5,077,483 shares issued and outstanding, as of December 31, 2019 and December 31, 2018, respectively 7,000 5,000
Additional paid-in capital 42,331,000 35,038,000
Accumulated deficit (41,258,000) (35,058,000)
Accumulated comprehensive income 305,000 283,000
Total stockholders' equity 1,385,000 268,000
Total liabilities and stockholders' equity $ 3,144,000 $ 1,898,000
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets (Parentheticals) - $ / shares
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000 10,000,000
Preferred stock, shares issued (in shares) 0 0 0
Preferred stock, shares outstanding (in shares) 0 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000 100,000,000
Common stock, shares issued (in shares) 6,631,308 6,631,308 5,077,483
Common stock, shares outstanding (in shares) 6,631,308 6,631,308 5,077,483
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:    
General and administrative $ 1,973 $ 2,108
Research and development 2,349 1,783
Operating loss (4,322) (3,891)
Other (expense) income:    
Grant income 54
Interest expense (2,194) (1,814)
Other(expense) income (99) (508)
Total other expense (2,293) (2,268)
Loss before income tax benefit (6,615) (6,159)
Income tax benefit 415 254
Net loss (6,200) (5,905)
Foreign currency translation adjustment 22 448
Comprehensive loss $ (6,178) $ (5,457)
Basic and diluted net loss per share (in dollars per share) $ (1.09) $ (1.27)
Weighted average shares outstanding - basic and diluted (in shares) 5,700,314 4,662,080
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balances (in shares) at Dec. 31, 2017 3,842        
Balances at Dec. 31, 2017 $ 4 $ 25,625 $ (29,153) $ (165) $ (3,689)
Sale of common stock and warrants (in shares) 485        
Sale of common stock and warrants 2,328 2,328
Beneficial conversion feature 716 716
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares) 751        
Conversion of convertible notes payable and accrued interest into common stock and warrants $ 1 3,257 3,258
Warrants issued with sale of convertible notes payable 739 739
Stock-based compensation   2,373     2,373
Net loss     (5,905)   (5,905)
Foreign currency translation adjustment     448 448
Common stock converted into convertible notes payable        
Balances (in shares) at Dec. 31, 2018 5,078        
Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268
Beneficial conversion feature 353 353
Warrants issued with sale of convertible notes payable 419 419
Stock-based compensation   10     10
Net loss     (1,581)   (1,581)
Foreign currency translation adjustment     (32) (32)
Common stock converted into convertible notes payable (in shares) (7)        
Common stock converted into convertible notes payable (25) (25)
Balances (in shares) at Mar. 31, 2019 5,070        
Balances at Mar. 31, 2019 $ 5 35,795 (36,639) 251 (588)
Balances (in shares) at Dec. 31, 2018 5,078        
Balances at Dec. 31, 2018 $ 5 35,038 (35,058) 283 268
Sale of common stock and warrants (in shares) 909        
Sale of common stock and warrants $ 1 3,159 3,160
Beneficial conversion feature 353 353
Warrants issued with sale of convertible notes payable 419 419
Stock-based compensation 1,093 1,093
Net loss (6,200) (6,200)
Foreign currency translation adjustment 22 22
Conversion of convertible notes payable and accrued interest into common stock (in shares) 651        
Conversion of convertible notes payable and accrued interest into common stock $ 1 2,280 2,281
Common stock converted into convertible notes payable (in shares) (7)        
Common stock converted into convertible notes payable (25) (25)
Warrants issued in exchange for modification of term debt 14 14
Balances (in shares) at Dec. 31, 2019 6,631        
Balances at Dec. 31, 2019 $ 7 42,331 (41,258) 305 1,385
Stock-based compensation   112     112
Net loss     (1,798)   (1,798)
Foreign currency translation adjustment     797 797
Common stock converted into convertible notes payable        
Balances (in shares) at Mar. 31, 2020 6,631        
Balances at Mar. 31, 2020 $ 7 $ 42,671 $ (43,056) $ 1,102 $ 724
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:    
Net loss $ (6,200) $ (5,905)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation 1,093 1,279
Amortization of debt discount 2,066 1,732
Amortization of debt issuance costs 12 9
Non-cash interest expense 102 4
Changes in operating assets and liabilities:    
Income tax receivable (31) 50
Prepaid expenses and other current assets (174) 25
Accounts payable 301 360
Accrued liabilities 92 59
Net cash used in operating activities (2,739) (2,387)
Cash flows from financing activities:    
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7 810 1,329
Proceeds from sale of common stock and warrants, net of offering costs of $16 and $27 respectively 3,160 2,328
Repayment of demand note (25)
Repayments of term debt (161) (14)
Net cash provided by financing activities 3,784 3,643
Effect of exchange rate changes on cash (1) (3)
Net change in cash 1,044 1,253
Cash at beginning of period 1,405 152
Cash at end of period 2,449 1,405
Supplemental disclosure of cash flow information:    
Cash paid during period for interest 14 67
Supplemental disclosure of non-cash transactions:    
Beneficial conversion feature on convertible notes 353 716
Warrants issued with convertible notes 419 739
Warrants issued in exchange for modification of term debt 14
Common stock converted into convertible notes payable (25)
Conversion of convertible notes payable and accrued interest into common stock and warrants 3,258
Conversion of convertible notes payable and accrued interest into common stock 2,281
Issuance of unsecured promissory note in exchange for vendor accounts payable 742
Options granted in exchange for release from contingent payment obligations $ 1,094
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Statements of Cash Flows (Parentheticals) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Proceeds from the sale of convertible promissory notes, offering costs $ 7 $ 5
Proceeds from issuance of common stock and warrants, issuance costs $ 16 $ 27
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Business
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
     Business
 
Sun BioPharma, Inc. and its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-
101,
from the University of Florida Research Foundation, Inc. (“UFRF”).
1.
Business
 
Sun BioPharma, Inc. and its wholly owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-
101,
from the University of Florida Research Foundation, Inc. (“UFRF”). Sun BioPharma, Inc. was incorporated under the laws of the State of Delaware on
September 
21,
2011.
Sun BioPharma Australia Pty Ltd was established on
May 24, 2013
and incorporated under the laws of Australian Securities and Investments Commission.
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Risks and Uncertainties
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Nature of Operations [Text Block]
2.
     Risks and Uncertainties
 
The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain,
may
take many years, and is normally expected to involve substantial expenditures.
 
We have incurred losses of
$42.6
million since our inception in
2011.
For the
three
months ended
March 31, 2020,
we incurred a net loss of
$1.8
million, which includes a foreign currency loss of
$0.8
million. We also incurred negative cash flows from operating activities of
$1.2
million for this period. As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-
101,
we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of
March 31, 2020,
we had cash of
$1.3
million, working capital of
$0.7
million, (current assets less current liabilities) and stockholders’ equity of
$0.7
 million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities.
 
The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed
consolidated financial statements do
not
include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our
2019
financial statements dated
March 24, 2020.
Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-
101
product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note
4
titled “Liquidity and Business Plan.”
 
On
March 11, 2020,
the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-
19”
) a global pandemic and continued widespread infection in the United States is a possibility. Actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-
19,
including through issuances of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations.  These measures, while intended to protect human life, have led to significantly reduced economic activity. The rapid development and uncertainty of the situation precludes any prediction as to the ultimate impact COVID-
19
will have on the Company's business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-
19
outbreak in the United States and Australia.  On
April 3, 2020,
we initiated a temporary pause in the enrollment of new patients in our ongoing clinical trial.  We anticipate resumption of new patient enrollment in
Q2
2020
once conditions allow.  We continue to treat patients already enrolled. 
2.
Risks and Uncertainties
 
The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain,
may
take many years, and is normally expected to involve substantial expenditures.
 
We have incurred losses of
$41.3
million since our inception in
2011.
For the year ended
December 31, 2019
we incurred a net loss and negative cash flows from operating activities of
$6.2
million and
$2.7
million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-
101.
As of
December 31, 2019,
we had cash of
$2.4
million, working capital of
$1.3
million and stockholders’ equity of
$1.4
million. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities.
 
The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do
not
include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-
101,
in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Basis of Presentation
3 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Basis of Presentation and Significant Accounting Policies [Text Block]
3.
     Basis of Presentation
 
We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 
10
-Q and Regulation S-
X
of the Securities and Exchange Commission (“SEC”). Accordingly, they do
not
include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on
December 31.
The condensed consolidated balance sheet as of
December 31, 2019
was derived from audited consolidated financial statements but does
not
include all disclosures required by U.S. GAAP. These interim condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included in our most recent filed Annual Report on Form
10
-K and our subsequent filings with the SEC. The nature of our business is such that the results of any interim period
may
not
be indicative of the results to be expected for the entire year.
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Liquidity and Business Plan
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Substantial Doubt about Going Concern [Text Block]
4.
     Liquidity and
Business
Plan
 
We need to obtain additional funds to continue our operations and execute our current business plans. We
may
seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give
no
assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or
not
positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.
 
If we are unable to obtain additional financing, we believe that we will need to reduce our operations by taking actions that
may
include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-
101
product candidate, licensing rights to
third
parties, including the right to commercialize our SBP-
101
product candidate for pancreatic cancer, or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.
 
Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-
101
product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are
not
successful or if we are unable to obtain marketing approval, we would
not
be able to continue as a going concern and would be forced to cease operations and liquidate our company.
 
There can be
no
assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.
3.
Liquidity and Management Plans
 
We will need to seek additional sources of funds to support our current business plans. We
may
seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give
no
assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is
not
positive or economic and market conditions deteriorate.
 
If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that
may
include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-
101
product candidate, license to
third
parties the rights to commercialize our SBP-
101
product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.
 
In closings occurring in
August,
September
and
October 2019
the Company sold
909,209
shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately
$3.2
million. The warrants are exercisable for a period of
five
years from the date of issuance at an initial exercise price of
$4.00.
 
In closings occurring in
December 2018
and
January 2019
the Company sold
$2.2
million principal amount of unsecured convertible promissory notes (the “Notes”) and warrants to purchase up to
1,243,498
shares of common stock in a private placement to certain investors. On
June 30, 2019
the entire principal balance and accrued interest of
$105,000
converted into
651,758
shares of common stock per the terms of the Notes at a conversion rate of
$3.50.
See Note
6
titled “Indebtedness” for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of
five
years from the date of issuance at an initial exercise price of
$4.50.
 
Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP-
101
product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are
not
successful, if we are unable to obtain marketing approval, we would
not
be able to continue as a going concern and would be forced to cease operations and liquidate our company.
 
There can be
no
assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Summary of Significant Accounting Policies
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Significant Accounting Policies [Text Block]
5.
     Summary of Significant Accounting Policies
 
Principles of consolidation
 
The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
 
Use of estimates
 
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
 
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our
second
Phase
1
human clinical trial, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
 
Stock
-based compensation
 
In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
 
Foreign currency translation adjustments
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity (deficit). During the
three
-month periods ended
March 31, 2020
and
2019,
any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.
 
Comprehensive loss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
 
Net loss per share
 
Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have
not
been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
 
The following table sets forth the potential shares of common stock that were
not
included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:
 
   
March 31,
 
   
2020
   
2019
 
Employee and non-employee stock options
   
1,745,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
636,234
 
Common stock issuable under common stock purchase warrants
   
3,497,099
     
2,509,477
 
     
5,242,910
     
4,177,922
 
   
5,242,910
     
4,177,922
 
4.
Summary of Significant Accounting Policies
 
Basis of
p
resentation
 
We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on
December 31.
 
Principles of consolidation
 
The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.
 
Use of estimates
 
The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
Concentration of
c
redit
r
isk
 
Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits
may
be in excess of insured limits. The Company has
not
experienced any losses on its deposits of cash.
 
Beneficial conversion feature
 
For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.
 
Debt issuance costs
 
Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.
 
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our Phase
1
human clinical trials, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
 
S
tock
-based compensation
 
In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
 
Income taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than
not
to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of
December 31, 2019
and
2018.
The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.
 
Foreign
c
urrency
t
ranslation
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended
December 31, 2019
and
2018,
any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.
 
Grant Income
 
Grant income is derived from a
one
-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the “Grant Agreement”). The total grant awarded under the Grant Agreement was
$225,000
and was used to fund studies of SBP-
101
as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of
December 31, 2018
the Company has been fully reimbursed under the Grant Agreement.
 
Comprehensive
l
oss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
 
Net
l
oss per
s
hare
 
We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.
 
The following outstanding potential common shares were
not
included in the diluted net loss per share calculations as their effects were
not
dilutive:
 
   
December 31,
 
   
2019
   
2018
 
Employee and non-employee stock options
   
1,744,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
383,947
 
Common stock issuable under common stock purchase warrants
   
3,422,099
     
2,035,197
 
     
5,166,910
     
3,451,355
 
 
Recently
Adopted
Accounting Pronouncement
s
 
In
June 2018,
the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
).” ASU
2018
-
07
simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning
January 1, 2019.
Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.
 
In
February 2016,
the FASB issued ASU
2016
-
02,
“Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic
842
and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.  For leases with a term of
12
months or less, a lessee is permitted to make an election under which such assets and liabilities would
not
be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.  This standard was adopted by the Company for the year beginning
January 1, 2019. 
The Company has evaluated the impact of this revised guidance on its financial statements and determined it had
no
material impact, as the Company has
no
leasing arrangements with terms greater than
one
year.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Debt Disclosure [Text Block]
6.
     
Indebtedness
 
Term debt
 
The terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) which was amended in
December
of
2019
to extend the maturity date from
December 31, 2019
to
December 31, 2020,
remain unchanged as of
March 31, 2020. 
The fair market value of the warrants issued in
2019
in exchange for modification of the terms is being amortized to interest expense over the remaining term of the loan. The amendment requires the continuation of monthly payments of principal and interest totaling
$10,000.
The unpaid principal balance at
March 31, 2020
was
$90,000.
 
Deferred financing costs
 
The following table summarizes the deferred financing costs which are presented as a direct reduction of the carrying amount of their related debt liabilities (in thousands):
 
   
March 31, 2020
   
December 31, 2019
 
   
Term Debt
   
Term Debt
 
Loan principal Amount
  $
97
    $
126
 
Deferred Financing Costs
   
51
     
51
 
Accumulated Amortization
   
(44
)    
(41
)
Unamortized balance
   
7
     
10
 
Discount on Debt
   
-
     
-
 
Accumulated Amortization
   
-
     
-
 
Unamortized balance
   
-
     
-
 
Loan carrying amounts, net
  $
90
    $
116
 
6.
Indebtedness
 
2018
Convertible notes payable
 
In
December
of
2018
and
January
of
2019,
we sold convertible promissory notes (the
“2018
Notes”) and warrants to purchase common stock for gross proceeds of
$2.2
million. The
2018
Notes were scheduled to matured on
June 30, 2019
and bore an interest at a rate of
10.0%
per year. The
2018
Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (
1
)
June 30, 2019
or (
2
) the date the Company receives gross proceeds of at least
$6.0
million from the sale of equity securities (subject to certain exclusions). The stated conversion rate was
$3.50
per share. In addition to the
2018
Notes, investors received a Warrant to purchase
two
shares of common stock for every
$3.50
principal amount of
2018
Notes purchased. In total, warrants to purchase up to
1,243,498
shares of common stock were issued in the
December
and
January
closings. The exercise price of each warrant is
$4.50
per share and they are exercisable until the
5
-year anniversary of the dates of issuance. The warrants had a fair market value of
$2.5
million upon issuance. After assigning the relative value of the warrants to the proceeds of the notes it was determined that the
2018
Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately
$0.9
million. Both the relative value of the warrants and the beneficial conversion feature were recorded as a debt discount which was fully amortized through interest expense over the life of the
2018
Notes. On
June 30, 2019,
all
$2.2
million aggregate principal balance of Notes outstanding plus
$105,000
of accrued interest was converted at a conversion rate of
$3.50
per share of common stock into
651,758
shares of common stock per the terms of the Notes.
 
2017
Convertible notes payable
 
In
2017
we sold convertible promissory notes (the
“2017
Notes”) raising gross proceeds of approximately
$3.1
million. The
2017
Notes had been scheduled to mature on
December 1, 2018
and bore an interest at a rate of
5.0%
per year. Principal and accrued interest on the
2017
Notes was payable at maturity. The
2017
Notes were convertible into shares of common stock or other securities of the Company upon the occurrence of a “qualified financing,” including the sale of equity securities or a strategic partnership, raising gross proceeds of at least
$2.0
million on or before the maturity of the
2017
Notes or upon the request of a holder of any
2017
Note at a fixed conversion rate of
$10.10
per share. The
2017
Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately
$3.0
million, which was recorded as a debt discount and is presented as a direct deduction from the carrying value of the
2017
Notes. The discount was amortized through interest expense over the life of the
2017
Notes.
 
On
May 16, 2018,
as the result of receiving aggregate gross proceeds exceeding
$2.0
million for the sale equity securities, under terms of the
2017
Notes, the Company completed the conversion of previously outstanding debt. Debt totaling approximately
$3.1
million and accrued interest totaling approximately
$183,000
was converted into
104,463
shares of common stock and
646,279
units (each consisting of a share of common stock and a warrant to purchase
one
additional share of common stock). The units were available through the
2018
Purchase Agreement. The shares were issued in reliance on the exemption from registration set forth in Section
3
(a)(
9
) of the Securities Act as securities exchanged by an issuer with existing security holders where
no
commission or other remuneration is paid or given directly or indirectly by the issuer for soliciting such exchange. As of the date of conversion an incremental beneficial conversion feature of
$121,000
was recorded as debt discount. Unamortized debt discount totaling
$1.0
million was charged to interest expense as of the date of conversion.
 
The following table sets forth the changes in convertible notes payable during the year ended
December 31, 2019 (
in thousands):
 
   
Convertible Notes Payable
 
   
Principal
   
Accrued Interest
 
Balances at January 1, 2019
  $
1,359
    $
2
 
Aggregate principal value of notes sold
   
816
     
-
 
Accrued Interest on notes
   
-
     
103
 
Aggregate principal value of notes and accrued interest converted into common stock
   
(2,175
)    
(105
)
      -       -  
Balances at December 31, 2019
  $
-
    $
-
 
 
Term debt
 
On
October 26, 2012,
we entered into an unsecured loan agreement (the “Agreement”) with the Institute for Commercialization of Public Research, Inc. (the “Institute”). Under the terms of the agreement, we borrowed
$300,000
at a fixed interest rate of
4.125%.
No
principal or interest payments were due until the maturity date,
October 26, 2017,
unless a mandatory repayment event occurred. Effective
October 26, 2017,
we entered into an amendment to our unsecured loan agreement with the Institute. Under the terms of the amendment, the maturity date of the note was extended to
May 1, 2019
with monthly payments of
$10,000
beginning on
May 1, 2018
with the remaining balance due in full on
May 1, 2019.
Effective
April 5, 2019
the terms of our unsecured loan (the “Term Debt”) payable to the Institute were amended again to extend the maturity date from
May 1, 2019
to
December 31, 2019.
The Institute agreed to the amendment in exchange for a warrant to purchase
5,555
shares of common stock at an exercise price of
$4.50.
The warrant expires
five
years from issuance. On
December 16, 2019
the Institute again modified the terms of repayment. In exchange for a payment
$50,000
payable on
December 31, 2019
and a warrant to purchase
5,000
shares of common stock at an exercise price of
$4.00
the maturity date of the loan was extended from
December 31, 2019
to
December 31, 2020.
The total fair market value of the warrants issued for both amendments was calculated at
$14,000
and was recorded as a discount to the debt, which will be amortized over the remaining period until maturity of the debt. The amendment requires the continuation of monthly payments of principal and interest totaling
$10,000
with monthly payments applied
first
to accrued and unpaid interest. The unpaid principal balance, net of unamortized debt discount, at
December 31, 2019
was
$116,000.
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Stockholders' Deficit
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Stockholders' Equity Note Disclosure [Text Block]
7
.     
S
tock
holders’
Deficit
 
Warrants to purchase common stock issued for future services
 
On
February 21, 2020,
the Company issued to a service provider a
five
-year warrant to purchase
75,000
shares of common stock at an exercise price of
$6.49
per share. The fair market value of the warrants issued of approximately
$228,000
was capitalized and will be charged against future proceeds.
 
Shares
of common stock reserved for future issuance were as follows as of
March 31,
20
20
:
 
Stock options outstanding
   
1,745,811
 
Shares available for grant under equity incentive plan
   
18,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,497,099
 
     
5,261,459
 
8
.
Stockholder
s’
Equity (
Deficit
)
 
2019
Private placement
 
On closings occurring in
August,
September
and
October
of
2019,
we issued an aggregate of
909,209
shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under
2019
Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately
$3.2
million, of which
$240,000
was received from directors and officers of the Company or its subsidiary. The warrants issued under the
2019
Purchase Agreement will be exercisable for a period of
five
years from the date of issuance at an exercise price of
$4.00
per share See Note
4,
titled “Liquidity and Management’s Plans”.
 
201
8
Private placement
 
On 
February 20, 2018,
we entered into a Securities Purchase Agreement (the
“2018
Purchase Agreement”) with certain accredited investors and completed an initial closing on the same date. Pursuant to the initial closing and
two
subsequent closings in
March
and
May
of
2018,
we sold a total of
468,200
shares of common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock. The warrants issued under the
2018
Purchase Agreement will be exercisable for a period of
three
years from the date of issuance at an exercise price of
$5.00
per share. We received aggregate gross proceeds totaling approximately
$2.3
million pursuant to private placements under the
2018
Purchase Agreement, of which
$125,000
was received from directors and officers of the Company or its subsidiary. As of
December 31, 2019,
468,200
warrants remained outstanding.
 
Shares
r
eserved
 
Shares of common stock reserved for future issuance were as follows as of
December 31, 2019:
 
Stock options outstanding
   
1,744,811
 
Shares available for grant under equity incentive plan
   
19,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,422,099
 
     
5,186,459
 
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Share-based Payment Arrangement [Text Block]
8
.
     
S
tock
-based
Compensation
 
2016
Omnibus Incentive Plan
 
The Sun BioPharma, Inc.
2016
Omnibus Incentive Plan (the
“2016
Plan”) was adopted by our Board of Directors in
March 2016
and approved by our stockholders in
May 2016.
The
2016
Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the
2016
Plan at
no
less than the fair market value of the underlying common stock as of the date of grant. Options granted under the
2016
Plan have a maximum term of
ten
years. Under the
2016
Plan, a total of
1,500,000
 shares of common stock were initially reserved for issuance. As of
March 31, 2020,
options to purchase
1,481,451shares
of common stock were outstanding under the
2016
Plan and
18,549
shares remained available for future awards.
 
2011
Stock Option Plan
 
Our Board of Directors ceased making awards under the Sun BioPharma, Inc.
2011
Stock Option Plan (the
“2011
Plan”) upon the receipt of stockholder approval for the
2016
Plan. Awards outstanding under the
2011
Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the
2011
Plan have a maximum term of
ten
years and generally vest over
zero
to
two
years for employees. As of
March 31, 2020,
options to purchase
264,360
shares of common stock remained outstanding under the
2011
Plan.
 
Stock
-based Compensation
Expense
 
General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through
March 31, 2020
vest based upon time-based and performance conditions. There was approximately
$229,000
unamortized stock-based compensation expense related to options granted to employees as of
March 31, 2020.
 
Stock-based compensation expense for each of the periods presented is as follows (in thousands):
 
   
Three Months Ended March 31,
 
   
2020
   
2019
 
General and Administrative
   
99
     
10
 
Research and Development
   
13
     
-
 
     
112
     
10
 
 
Details of options granted, exercised, cancelled or forfeited during the
three
months ended
March 31, 2020
follows:
 
   
Shares Available for Grant
   
Shares Underlying Options
 
Balance at January 1, 2020
   
19,549
     
1,744,811
 
Granted
   
(1,000
)    
1,000
 
Exercised
   
-
     
-
 
Cancelled
   
-
     
-
 
Forfeitures
   
-
     
-
 
                 
Balance at March 31, 2020
   
18,549
     
1,745,811
 
 
Information about stock options outstanding, vested and expected to vest as of
March 31, 2020,
is as follows:
 
          
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average Remaining Contractual Life (Years)
   
Weighted Average Exercise Price
   
Options Excercisable
   
Weighted Average Remaining Contractual Life (Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
2.75
    $
1.029
     
26,360
     
2.75
 
$2.275
-
$2.50
   
38,000
     
3.87
    $
2.464
     
38,000
     
3.87
 
$2.95
-
$3.70
   
774,100
     
8.07
    $
3.040
     
411,525
     
7.11
 
$4.95
-
$8.10
   
539,300
     
7.73
    $
6.739
     
506,500
     
7.67
 
$10.00
-
$10.10
   
54,000
     
7.30
    $
10.007
     
54,000
     
7.30
 
$15.10
 
 
   
314,051
     
6.16
    $
15.100
     
310,551
     
6.21
 
                                             
Totals
 
 
   
1,745,811
     
7.43
    $
6.525
     
1,346,936
     
6.94
 
9
.
Stock-
B
ased
Compensation
 
2016
Omnibus Incentive Plan
 
Stock-based awards are granted under the Sun BioPharma, Inc.
2016
Omnibus Incentive Plan (the
“2016
Plan”). The
2016
Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the
2016
Plan at
no
less than the fair market value of the underlying common stock as of the date of grant. Options granted under the
2016
Plan have a maximum term of
ten
years. A total of
1,500,000
 shares of common stock were initially reserved for issuance under the
2016
Plan. As of
December 31, 2019,
options to purchase
1,480,451
shares of common stock were outstanding under the
2016
Plan.
 
2011
Stock Option Plan
 
Prior to approval of the
2016
Plan, stock-based awards were granted under the Sun BioPharma, Inc.
2011
Stock Option Plan (the
“2011
Plan”). In conjunction with stockholder approval of the
2016
Plan, the Board terminated the
2011
Plan, although awards outstanding under the
2011
Plan will remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the
2011
Plan have a maximum term of
ten
years and generally vest over
zero
to
two
years for employees. As of
December 31, 2019,
options to purchase
264,360
shares of common stock remained outstanding under the
2011
Plan.
 
We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.
 
A summary of option activity is as follows:
 
   
Shares
Available for
Grant
   
Shares Underlying
Options
   
Weighted
Average
Exercise Price
Per Share
   
Aggregate
Intrinsic Value
 
Balance at January 1, 2018
   
1,060,400
     
733,960
    $
9.79
    $
169,495
 
Granted
   
(404,000
)    
404,000
     
7.49
     
 
 
Exercised
   
-
     
(30,000
)    
2.20
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
75,749
     
(75,749
)    
7.34
     
 
 
                                 
Balance at December 31, 2018
   
732,149
     
1,032,211
    $
8.90
    $
56,225
 
Granted
   
(733,400
)    
733,400
     
3.42
     
 
 
Exercised
   
-
     
-
     
-
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
20,800
     
(20,800
)    
15.10
     
 
 
                                 
Balance at December 31, 2019
   
19,549
     
1,744,811
    $
6.53
    $
1,030,547
 
 
A summary of the status of our unvested shares during the year ended and as of
December 31, 2019
is as follows:
 
   
Shares Under
Option
   
Weighted Average
Grant Date Fair Value
 
                 
Unvested at December 31, 2018
   
42,500
    $
4.83
 
Granted
   
733,400
     
2.09
 
Vested
   
(378,025
)    
2.41
 
Forefeitures
   
-
     
-
 
Unvested at December 31, 2019
   
397,875
    $
2.03
 
 
Information about stock options outstanding, vested and expected to vest as of
December 
31,
2019,
is as follows:
 
       
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise Price
   
Options
Excercisable
   
Weighted Average
Remaining
Contractual Life
(Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
3.00
    $
1.029
     
26,360
     
3.00
 
$2.275
-
$2.50
   
38,000
     
4.12
    $
2.464
     
38,000
     
4.12
 
$2.95
-
$3.70
   
774,100
     
8.32
    $
3.040
     
411,525
     
7.36
 
$4.50
-
$8.10
   
538,300
     
7.97
    $
6.742
     
506,500
     
7.92
 
$10.00
-
$10.10
   
54,000
     
7.55
    $
10.007
     
54,000
     
7.55
 
$15.10
 
 
   
314,051
     
6.41
    $
15.100
     
310,551
     
6.46
 
                                             
Totals
 
 
   
1,744,811
     
7.67
    $
6.526
     
1,346,936
     
7.19
 
 
As of
December 31, 2019,
total compensation expense related to unvested employee stock options
not
yet recognized was
$372,000
which is expected to be allocated to expenses over a weighted-average period of
2.4
years.
 
The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended
December 31, 2019
and
2018:
 
   
2019
   
2018
 
Common stock fair value  
$2.95
-
$5.00
   
$3.50
-
$8.10
 
Risk-free interest rate
 
 1.55%
-
2.25%
   
 2.30%
-
2.94%
 
Expected dividend yield
 
 
0
 
   
 
0
 
 
Expected Option life (in years)
 
 5.00
-
5.50
   
 1.25
-
5.75
 
Expected stock price volatility
 
 
72%
 
   
 
72%
 
 
 
Nonemployee
s
tock-
b
ased
c
ompensation
 
We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
). In connection with stock options granted to nonemployees, we recorded
$288,000
and
$263,000
for nonemployee stock-based compensation during the years ended
December 
31,
2019
and
2018,
respectively.
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Subsequent Events
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Subsequent Events [Text Block]
9.
Subsequent Event
 
On
May 1, 2020,
the Company the Company executed an unsecured promissory note with a lender as a part of the Payroll Protection Program (“PPP”) in the Coronavirus Aid, Relief, and Economic Security Act. Funds totaling approximately
$102,000
will be used to support Company payroll. The note
may
be forgiven in part and bears an interest rate of
1%
per annum after a
six
-month deferment period.
11
.
Subsequent Event
s
 
On
February 21, 2020
the company entered an agreement with an investment banking firm.  A portion of the retainer fee was paid via the issuance of
75,000
5
-year warrants.  The fair market value of the warrants issued of approximately
$148,000
will be capitalized and charged against future proceeds.
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Note 1 - Business
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
1.
     Business
 
Sun BioPharma, Inc. and its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for the treatment of patients with pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-
101,
from the University of Florida Research Foundation, Inc. (“UFRF”).
1.
Business
 
Sun BioPharma, Inc. and its wholly owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”) exist for the primary purpose of advancing the commercial development of a proprietary polyamine analogue for pancreatic cancer. We have exclusively licensed the worldwide rights to this compound, which has been designated as SBP-
101,
from the University of Florida Research Foundation, Inc. (“UFRF”). Sun BioPharma, Inc. was incorporated under the laws of the State of Delaware on
September 
21,
2011.
Sun BioPharma Australia Pty Ltd was established on
May 24, 2013
and incorporated under the laws of Australian Securities and Investments Commission.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Risks and Uncertainties
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Nature of Operations [Text Block]
2.
     Risks and Uncertainties
 
The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain,
may
take many years, and is normally expected to involve substantial expenditures.
 
We have incurred losses of
$42.6
million since our inception in
2011.
For the
three
months ended
March 31, 2020,
we incurred a net loss of
$1.8
million, which includes a foreign currency loss of
$0.8
million. We also incurred negative cash flows from operating activities of
$1.2
million for this period. As we continue to pursue development activities and seek commercialization of our initial product candidate, SBP-
101,
we expect to incur substantial losses, which are likely to generate negative net cash flows from operating activities. As of
March 31, 2020,
we had cash of
$1.3
million, working capital of
$0.7
million, (current assets less current liabilities) and stockholders’ equity of
$0.7
 million. The Company’s principal sources of cash have historically included the issuance of convertible debt and equity securities.
 
The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed
consolidated financial statements do
not
include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our current independent registered public accounting firm included a paragraph emphasizing this going concern uncertainty in their audit report regarding our
2019
financial statements dated
March 24, 2020.
Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-
101
product candidate in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern. See Note
4
titled “Liquidity and Business Plan.”
 
On
March 11, 2020,
the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-
19”
) a global pandemic and continued widespread infection in the United States is a possibility. Actions have been taken by federal, state and local governmental authorities to combat the spread of COVID-
19,
including through issuances of “stay-at-home” directives and similar mandates for many individuals to substantially restrict daily activities and for many businesses to curtail or cease normal operations.  These measures, while intended to protect human life, have led to significantly reduced economic activity. The rapid development and uncertainty of the situation precludes any prediction as to the ultimate impact COVID-
19
will have on the Company's business, financial condition, results of operation and cash flows, which will depend largely on future developments directly or indirectly relating to the duration and scope of the COVID-
19
outbreak in the United States and Australia.  On
April 3, 2020,
we initiated a temporary pause in the enrollment of new patients in our ongoing clinical trial.  We anticipate resumption of new patient enrollment in
Q2
2020
once conditions allow.  We continue to treat patients already enrolled. 
2.
Risks and Uncertainties
 
The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration (“TGA”) in Australia, the European Medicines Agency (“EMA”) in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain,
may
take many years, and is normally expected to involve substantial expenditures.
 
We have incurred losses of
$41.3
million since our inception in
2011.
For the year ended
December 31, 2019
we incurred a net loss and negative cash flows from operating activities of
$6.2
million and
$2.7
million, respectively. We expect to incur substantial losses for the foreseeable future, which will continue to generate negative net cash flows from operating activities, as we continue to pursue research and development activities and the clinical development of our primary product candidate, SBP-
101.
As of
December 31, 2019,
we had cash of
$2.4
million, working capital of
$1.3
million and stockholders’ equity of
$1.4
million. The Company’s principal sources of cash have included the issuance of convertible debt and equity securities.
 
The accompanying Consolidated Financial Statements have been prepared assuming that we will continue as a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business and do
not
include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties. Our ability to continue as a going concern, realize the carrying value of our assets and discharge our liabilities in the ordinary course of business is dependent upon a number of factors, including our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our initial product candidate, SBP-
101,
in the United States, Australia, the European Union or other markets and ultimately our ability to market and sell our initial product candidate. These factors, among others, raise substantial doubt about our ability to continue operations as a going concern.
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Liquidity and Business Plan
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Substantial Doubt about Going Concern [Text Block]
4.
     Liquidity and
Business
Plan
 
We need to obtain additional funds to continue our operations and execute our current business plans. We
may
seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give
no
assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is inconclusive or
not
positive or economic conditions worsen in the market as a whole or in the pharmaceutical or biotechnology markets individually.
 
If we are unable to obtain additional financing, we believe that we will need to reduce our operations by taking actions that
may
include, among other things, reducing use of outside professional service providers, reducing staff or further reducing staff compensation, significantly modifying or delaying the development of our SBP-
101
product candidate, licensing rights to
third
parties, including the right to commercialize our SBP-
101
product candidate for pancreatic cancer, or other applications that we would otherwise seek to pursue, or discontinuing operations entirely.
 
Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP-
101
product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are
not
successful or if we are unable to obtain marketing approval, we would
not
be able to continue as a going concern and would be forced to cease operations and liquidate our company.
 
There can be
no
assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.
3.
Liquidity and Management Plans
 
We will need to seek additional sources of funds to support our current business plans. We
may
seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give
no
assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This risk would increase if our clinical data is
not
positive or economic and market conditions deteriorate.
 
If we are unable to obtain additional financing when needed, we would need to scale back our operations taking actions that
may
include, among other things, reducing use of outside professional service providers, reducing staff or staff compensation, significantly modify or delay the development of our SBP-
101
product candidate, license to
third
parties the rights to commercialize our SBP-
101
product candidate for pancreatic cancer or other applications that we would otherwise seek to pursue, or cease operations.
 
In closings occurring in
August,
September
and
October 2019
the Company sold
909,209
shares of common stock and an equal number of warrants to purchase common stock in a private placement to certain accredited investors pursuant to a Securities Purchase Agreement. Net proceeds from these sales totaled approximately
$3.2
million. The warrants are exercisable for a period of
five
years from the date of issuance at an initial exercise price of
$4.00.
 
In closings occurring in
December 2018
and
January 2019
the Company sold
$2.2
million principal amount of unsecured convertible promissory notes (the “Notes”) and warrants to purchase up to
1,243,498
shares of common stock in a private placement to certain investors. On
June 30, 2019
the entire principal balance and accrued interest of
$105,000
converted into
651,758
shares of common stock per the terms of the Notes at a conversion rate of
$3.50.
See Note
6
titled “Indebtedness” for a detailed discussion of the material terms of the Notes. The warrants are exercisable for a period of
five
years from the date of issuance at an initial exercise price of
$4.50.
 
Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to demonstrate clinical progress for our SBP-
101
product candidate in the United States or other markets and ultimately our ability to market and sell our SBP-
101
product candidate. If we are unable to obtain additional financing when needed, if our clinical trials are
not
successful, if we are unable to obtain marketing approval, we would
not
be able to continue as a going concern and would be forced to cease operations and liquidate our company.
 
There can be
no
assurances that we will be able to obtain additional financing on commercially reasonable terms, or at all. The sale of additional convertible debt or equity securities would likely result in dilution to our current stockholders.
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Summary of Significant Accounting Policies
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Significant Accounting Policies [Text Block]
5.
     Summary of Significant Accounting Policies
 
Principles of consolidation
 
The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
 
Use of estimates
 
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
 
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our
second
Phase
1
human clinical trial, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
 
Stock
-based compensation
 
In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
 
Foreign currency translation adjustments
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity (deficit). During the
three
-month periods ended
March 31, 2020
and
2019,
any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.
 
Comprehensive loss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
 
Net loss per share
 
Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have
not
been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
 
The following table sets forth the potential shares of common stock that were
not
included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:
 
   
March 31,
 
   
2020
   
2019
 
Employee and non-employee stock options
   
1,745,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
636,234
 
Common stock issuable under common stock purchase warrants
   
3,497,099
     
2,509,477
 
     
5,242,910
     
4,177,922
 
   
5,242,910
     
4,177,922
 
4.
Summary of Significant Accounting Policies
 
Basis of
p
resentation
 
We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on
December 31.
 
Principles of consolidation
 
The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.
 
Use of estimates
 
The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
 
Concentration of
c
redit
r
isk
 
Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits
may
be in excess of insured limits. The Company has
not
experienced any losses on its deposits of cash.
 
Beneficial conversion feature
 
For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.
 
Debt issuance costs
 
Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.
 
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our Phase
1
human clinical trials, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
 
S
tock
-based compensation
 
In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
 
Income taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than
not
to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of
December 31, 2019
and
2018.
The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.
 
Foreign
c
urrency
t
ranslation
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended
December 31, 2019
and
2018,
any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.
 
Grant Income
 
Grant income is derived from a
one
-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the “Grant Agreement”). The total grant awarded under the Grant Agreement was
$225,000
and was used to fund studies of SBP-
101
as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of
December 31, 2018
the Company has been fully reimbursed under the Grant Agreement.
 
Comprehensive
l
oss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
 
Net
l
oss per
s
hare
 
We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.
 
The following outstanding potential common shares were
not
included in the diluted net loss per share calculations as their effects were
not
dilutive:
 
   
December 31,
 
   
2019
   
2018
 
Employee and non-employee stock options
   
1,744,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
383,947
 
Common stock issuable under common stock purchase warrants
   
3,422,099
     
2,035,197
 
     
5,166,910
     
3,451,355
 
 
Recently
Adopted
Accounting Pronouncement
s
 
In
June 2018,
the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
).” ASU
2018
-
07
simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning
January 1, 2019.
Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.
 
In
February 2016,
the FASB issued ASU
2016
-
02,
“Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic
842
and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.  For leases with a term of
12
months or less, a lessee is permitted to make an election under which such assets and liabilities would
not
be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.  This standard was adopted by the Company for the year beginning
January 1, 2019. 
The Company has evaluated the impact of this revised guidance on its financial statements and determined it had
no
material impact, as the Company has
no
leasing arrangements with terms greater than
one
year.
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Accrued Expenses
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Accrued Liabilities [Text Block]
5
.
Accrued
Expenses
 
Accrued expenses consisted of the following (in thousands):
 
   
December 31,
 
   
2019
   
2018
 
Clinical trial and related expenses
  $
147
    $
42
 
Professional services
   
125
     
157
 
Other
   
32
     
17
 
Total accrued liabilities
  $
304
    $
216
 
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness 2
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Debt Disclosure [Text Block]
6.
     
Indebtedness
 
Term debt
 
The terms of our unsecured loan (the “Term Debt”) payable to the Institute for Commercialization of Public Research, Inc. (the “Institute”) which was amended in
December
of
2019
to extend the maturity date from
December 31, 2019
to
December 31, 2020,
remain unchanged as of
March 31, 2020. 
The fair market value of the warrants issued in
2019
in exchange for modification of the terms is being amortized to interest expense over the remaining term of the loan. The amendment requires the continuation of monthly payments of principal and interest totaling
$10,000.
The unpaid principal balance at
March 31, 2020
was
$90,000.
 
Deferred financing costs
 
The following table summarizes the deferred financing costs which are presented as a direct reduction of the carrying amount of their related debt liabilities (in thousands):
 
   
March 31, 2020
   
December 31, 2019
 
   
Term Debt
   
Term Debt
 
Loan principal Amount
  $
97
    $
126
 
Deferred Financing Costs
   
51
     
51
 
Accumulated Amortization
   
(44
)    
(41
)
Unamortized balance
   
7
     
10
 
Discount on Debt
   
-
     
-
 
Accumulated Amortization
   
-
     
-
 
Unamortized balance
   
-
     
-
 
Loan carrying amounts, net
  $
90
    $
116
 
6.
Indebtedness
 
2018
Convertible notes payable
 
In
December
of
2018
and
January
of
2019,
we sold convertible promissory notes (the
“2018
Notes”) and warrants to purchase common stock for gross proceeds of
$2.2
million. The
2018
Notes were scheduled to matured on
June 30, 2019
and bore an interest at a rate of
10.0%
per year. The
2018
Notes had a mandatory conversion of all principal and interest into common stock on the earlier of (
1
)
June 30, 2019
or (
2
) the date the Company receives gross proceeds of at least
$6.0
million from the sale of equity securities (subject to certain exclusions). The stated conversion rate was
$3.50
per share. In addition to the
2018
Notes, investors received a Warrant to purchase
two
shares of common stock for every
$3.50
principal amount of
2018
Notes purchased. In total, warrants to purchase up to
1,243,498
shares of common stock were issued in the
December
and
January
closings. The exercise price of each warrant is
$4.50
per share and they are exercisable until the
5
-year anniversary of the dates of issuance. The warrants had a fair market value of
$2.5
million upon issuance. After assigning the relative value of the warrants to the proceeds of the notes it was determined that the
2018
Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately
$0.9
million. Both the relative value of the warrants and the beneficial conversion feature were recorded as a debt discount which was fully amortized through interest expense over the life of the
2018
Notes. On
June 30, 2019,
all
$2.2
million aggregate principal balance of Notes outstanding plus
$105,000
of accrued interest was converted at a conversion rate of
$3.50
per share of common stock into
651,758
shares of common stock per the terms of the Notes.
 
2017
Convertible notes payable
 
In
2017
we sold convertible promissory notes (the
“2017
Notes”) raising gross proceeds of approximately
$3.1
million. The
2017
Notes had been scheduled to mature on
December 1, 2018
and bore an interest at a rate of
5.0%
per year. Principal and accrued interest on the
2017
Notes was payable at maturity. The
2017
Notes were convertible into shares of common stock or other securities of the Company upon the occurrence of a “qualified financing,” including the sale of equity securities or a strategic partnership, raising gross proceeds of at least
$2.0
million on or before the maturity of the
2017
Notes or upon the request of a holder of any
2017
Note at a fixed conversion rate of
$10.10
per share. The
2017
Notes contained a beneficial conversion feature with an aggregate intrinsic value of approximately
$3.0
million, which was recorded as a debt discount and is presented as a direct deduction from the carrying value of the
2017
Notes. The discount was amortized through interest expense over the life of the
2017
Notes.
 
On
May 16, 2018,
as the result of receiving aggregate gross proceeds exceeding
$2.0
million for the sale equity securities, under terms of the
2017
Notes, the Company completed the conversion of previously outstanding debt. Debt totaling approximately
$3.1
million and accrued interest totaling approximately
$183,000
was converted into
104,463
shares of common stock and
646,279
units (each consisting of a share of common stock and a warrant to purchase
one
additional share of common stock). The units were available through the
2018
Purchase Agreement. The shares were issued in reliance on the exemption from registration set forth in Section
3
(a)(
9
) of the Securities Act as securities exchanged by an issuer with existing security holders where
no
commission or other remuneration is paid or given directly or indirectly by the issuer for soliciting such exchange. As of the date of conversion an incremental beneficial conversion feature of
$121,000
was recorded as debt discount. Unamortized debt discount totaling
$1.0
million was charged to interest expense as of the date of conversion.
 
The following table sets forth the changes in convertible notes payable during the year ended
December 31, 2019 (
in thousands):
 
   
Convertible Notes Payable
 
   
Principal
   
Accrued Interest
 
Balances at January 1, 2019
  $
1,359
    $
2
 
Aggregate principal value of notes sold
   
816
     
-
 
Accrued Interest on notes
   
-
     
103
 
Aggregate principal value of notes and accrued interest converted into common stock
   
(2,175
)    
(105
)
      -       -  
Balances at December 31, 2019
  $
-
    $
-
 
 
Term debt
 
On
October 26, 2012,
we entered into an unsecured loan agreement (the “Agreement”) with the Institute for Commercialization of Public Research, Inc. (the “Institute”). Under the terms of the agreement, we borrowed
$300,000
at a fixed interest rate of
4.125%.
No
principal or interest payments were due until the maturity date,
October 26, 2017,
unless a mandatory repayment event occurred. Effective
October 26, 2017,
we entered into an amendment to our unsecured loan agreement with the Institute. Under the terms of the amendment, the maturity date of the note was extended to
May 1, 2019
with monthly payments of
$10,000
beginning on
May 1, 2018
with the remaining balance due in full on
May 1, 2019.
Effective
April 5, 2019
the terms of our unsecured loan (the “Term Debt”) payable to the Institute were amended again to extend the maturity date from
May 1, 2019
to
December 31, 2019.
The Institute agreed to the amendment in exchange for a warrant to purchase
5,555
shares of common stock at an exercise price of
$4.50.
The warrant expires
five
years from issuance. On
December 16, 2019
the Institute again modified the terms of repayment. In exchange for a payment
$50,000
payable on
December 31, 2019
and a warrant to purchase
5,000
shares of common stock at an exercise price of
$4.00
the maturity date of the loan was extended from
December 31, 2019
to
December 31, 2020.
The total fair market value of the warrants issued for both amendments was calculated at
$14,000
and was recorded as a discount to the debt, which will be amortized over the remaining period until maturity of the debt. The amendment requires the continuation of monthly payments of principal and interest totaling
$10,000
with monthly payments applied
first
to accrued and unpaid interest. The unpaid principal balance, net of unamortized debt discount, at
December 31, 2019
was
$116,000.
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
7
.
Commitments and Contingencies
 
License agreement
 
On
December 22, 2011,
we entered into an exclusive license agreement with the University of Florida research Foundation (“UFRF”). This license agreement was amended on
first
of
December 12, 2016 (
“First Amendment”) and again on
October 3, 2019 (
“Second Amendment”). The license agreement requires the Company to pay royalties to UFRF ranging from
2.5%
to
5%
of net sales of licensed products developed from the licensed technology. The Second Amendment eliminated all minimum annual royalties and modified the duration of royalty payments to the shorter of (
1
)
ten
years from
first
commercial sale of licensed products or (
2
) the expiration of the period of regulatory exclusivity on a country by country basis. All future milestone payments contemplated in the original agreement were eliminated in the Second Amendment.
 
The amended license agreement remains subject to customary and usual termination provisions. The Company must also pay an annual license maintenance fee of
$10,000.
Accordingly, we recorded
$10,000
as a license expense in the accompanying
2019
and
2018
Consolidated Statements of Operations and Comprehensive Loss.
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity (Deficit)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Stockholders' Equity Note Disclosure [Text Block]
7
.     
S
tock
holders’
Deficit
 
Warrants to purchase common stock issued for future services
 
On
February 21, 2020,
the Company issued to a service provider a
five
-year warrant to purchase
75,000
shares of common stock at an exercise price of
$6.49
per share. The fair market value of the warrants issued of approximately
$228,000
was capitalized and will be charged against future proceeds.
 
Shares
of common stock reserved for future issuance were as follows as of
March 31,
20
20
:
 
Stock options outstanding
   
1,745,811
 
Shares available for grant under equity incentive plan
   
18,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,497,099
 
     
5,261,459
 
8
.
Stockholder
s’
Equity (
Deficit
)
 
2019
Private placement
 
On closings occurring in
August,
September
and
October
of
2019,
we issued an aggregate of
909,209
shares of our common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock pursuant to closings under
2019
Securities Purchase Agreements. Total proceeds from the sale of common stock and warrants was approximately
$3.2
million, of which
$240,000
was received from directors and officers of the Company or its subsidiary. The warrants issued under the
2019
Purchase Agreement will be exercisable for a period of
five
years from the date of issuance at an exercise price of
$4.00
per share See Note
4,
titled “Liquidity and Management’s Plans”.
 
201
8
Private placement
 
On 
February 20, 2018,
we entered into a Securities Purchase Agreement (the
“2018
Purchase Agreement”) with certain accredited investors and completed an initial closing on the same date. Pursuant to the initial closing and
two
subsequent closings in
March
and
May
of
2018,
we sold a total of
468,200
shares of common stock and warrants to purchase an aggregate of up to the same number of additional shares of common stock. The warrants issued under the
2018
Purchase Agreement will be exercisable for a period of
three
years from the date of issuance at an exercise price of
$5.00
per share. We received aggregate gross proceeds totaling approximately
$2.3
million pursuant to private placements under the
2018
Purchase Agreement, of which
$125,000
was received from directors and officers of the Company or its subsidiary. As of
December 31, 2019,
468,200
warrants remained outstanding.
 
Shares
r
eserved
 
Shares of common stock reserved for future issuance were as follows as of
December 31, 2019:
 
Stock options outstanding
   
1,744,811
 
Shares available for grant under equity incentive plan
   
19,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,422,099
 
     
5,186,459
 
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Share-based Payment Arrangement [Text Block]
8
.
     
S
tock
-based
Compensation
 
2016
Omnibus Incentive Plan
 
The Sun BioPharma, Inc.
2016
Omnibus Incentive Plan (the
“2016
Plan”) was adopted by our Board of Directors in
March 2016
and approved by our stockholders in
May 2016.
The
2016
Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the
2016
Plan at
no
less than the fair market value of the underlying common stock as of the date of grant. Options granted under the
2016
Plan have a maximum term of
ten
years. Under the
2016
Plan, a total of
1,500,000
 shares of common stock were initially reserved for issuance. As of
March 31, 2020,
options to purchase
1,481,451shares
of common stock were outstanding under the
2016
Plan and
18,549
shares remained available for future awards.
 
2011
Stock Option Plan
 
Our Board of Directors ceased making awards under the Sun BioPharma, Inc.
2011
Stock Option Plan (the
“2011
Plan”) upon the receipt of stockholder approval for the
2016
Plan. Awards outstanding under the
2011
Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the
2011
Plan have a maximum term of
ten
years and generally vest over
zero
to
two
years for employees. As of
March 31, 2020,
options to purchase
264,360
shares of common stock remained outstanding under the
2011
Plan.
 
Stock
-based Compensation
Expense
 
General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through
March 31, 2020
vest based upon time-based and performance conditions. There was approximately
$229,000
unamortized stock-based compensation expense related to options granted to employees as of
March 31, 2020.
 
Stock-based compensation expense for each of the periods presented is as follows (in thousands):
 
   
Three Months Ended March 31,
 
   
2020
   
2019
 
General and Administrative
   
99
     
10
 
Research and Development
   
13
     
-
 
     
112
     
10
 
 
Details of options granted, exercised, cancelled or forfeited during the
three
months ended
March 31, 2020
follows:
 
   
Shares Available for Grant
   
Shares Underlying Options
 
Balance at January 1, 2020
   
19,549
     
1,744,811
 
Granted
   
(1,000
)    
1,000
 
Exercised
   
-
     
-
 
Cancelled
   
-
     
-
 
Forfeitures
   
-
     
-
 
                 
Balance at March 31, 2020
   
18,549
     
1,745,811
 
 
Information about stock options outstanding, vested and expected to vest as of
March 31, 2020,
is as follows:
 
          
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average Remaining Contractual Life (Years)
   
Weighted Average Exercise Price
   
Options Excercisable
   
Weighted Average Remaining Contractual Life (Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
2.75
    $
1.029
     
26,360
     
2.75
 
$2.275
-
$2.50
   
38,000
     
3.87
    $
2.464
     
38,000
     
3.87
 
$2.95
-
$3.70
   
774,100
     
8.07
    $
3.040
     
411,525
     
7.11
 
$4.95
-
$8.10
   
539,300
     
7.73
    $
6.739
     
506,500
     
7.67
 
$10.00
-
$10.10
   
54,000
     
7.30
    $
10.007
     
54,000
     
7.30
 
$15.10
 
 
   
314,051
     
6.16
    $
15.100
     
310,551
     
6.21
 
                                             
Totals
 
 
   
1,745,811
     
7.43
    $
6.525
     
1,346,936
     
6.94
 
9
.
Stock-
B
ased
Compensation
 
2016
Omnibus Incentive Plan
 
Stock-based awards are granted under the Sun BioPharma, Inc.
2016
Omnibus Incentive Plan (the
“2016
Plan”). The
2016
Plan permits the granting of incentive and non-statutory stock options, restricted stock, stock appreciation rights, performance units, performance shares and other stock awards to eligible employees, directors and consultants. We grant options to purchase shares of common stock under the
2016
Plan at
no
less than the fair market value of the underlying common stock as of the date of grant. Options granted under the
2016
Plan have a maximum term of
ten
years. A total of
1,500,000
 shares of common stock were initially reserved for issuance under the
2016
Plan. As of
December 31, 2019,
options to purchase
1,480,451
shares of common stock were outstanding under the
2016
Plan.
 
2011
Stock Option Plan
 
Prior to approval of the
2016
Plan, stock-based awards were granted under the Sun BioPharma, Inc.
2011
Stock Option Plan (the
“2011
Plan”). In conjunction with stockholder approval of the
2016
Plan, the Board terminated the
2011
Plan, although awards outstanding under the
2011
Plan will remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the
2011
Plan have a maximum term of
ten
years and generally vest over
zero
to
two
years for employees. As of
December 31, 2019,
options to purchase
264,360
shares of common stock remained outstanding under the
2011
Plan.
 
We recognize stock-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.
 
A summary of option activity is as follows:
 
   
Shares
Available for
Grant
   
Shares Underlying
Options
   
Weighted
Average
Exercise Price
Per Share
   
Aggregate
Intrinsic Value
 
Balance at January 1, 2018
   
1,060,400
     
733,960
    $
9.79
    $
169,495
 
Granted
   
(404,000
)    
404,000
     
7.49
     
 
 
Exercised
   
-
     
(30,000
)    
2.20
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
75,749
     
(75,749
)    
7.34
     
 
 
                                 
Balance at December 31, 2018
   
732,149
     
1,032,211
    $
8.90
    $
56,225
 
Granted
   
(733,400
)    
733,400
     
3.42
     
 
 
Exercised
   
-
     
-
     
-
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
20,800
     
(20,800
)    
15.10
     
 
 
                                 
Balance at December 31, 2019
   
19,549
     
1,744,811
    $
6.53
    $
1,030,547
 
 
A summary of the status of our unvested shares during the year ended and as of
December 31, 2019
is as follows:
 
   
Shares Under
Option
   
Weighted Average
Grant Date Fair Value
 
                 
Unvested at December 31, 2018
   
42,500
    $
4.83
 
Granted
   
733,400
     
2.09
 
Vested
   
(378,025
)    
2.41
 
Forefeitures
   
-
     
-
 
Unvested at December 31, 2019
   
397,875
    $
2.03
 
 
Information about stock options outstanding, vested and expected to vest as of
December 
31,
2019,
is as follows:
 
       
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise Price
   
Options
Excercisable
   
Weighted Average
Remaining
Contractual Life
(Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
3.00
    $
1.029
     
26,360
     
3.00
 
$2.275
-
$2.50
   
38,000
     
4.12
    $
2.464
     
38,000
     
4.12
 
$2.95
-
$3.70
   
774,100
     
8.32
    $
3.040
     
411,525
     
7.36
 
$4.50
-
$8.10
   
538,300
     
7.97
    $
6.742
     
506,500
     
7.92
 
$10.00
-
$10.10
   
54,000
     
7.55
    $
10.007
     
54,000
     
7.55
 
$15.10
 
 
   
314,051
     
6.41
    $
15.100
     
310,551
     
6.46
 
                                             
Totals
 
 
   
1,744,811
     
7.67
    $
6.526
     
1,346,936
     
7.19
 
 
As of
December 31, 2019,
total compensation expense related to unvested employee stock options
not
yet recognized was
$372,000
which is expected to be allocated to expenses over a weighted-average period of
2.4
years.
 
The assumptions used in calculating the fair value under the Black-Scholes option valuation model are set forth in the following table for options issued by the Company for the years ended
December 31, 2019
and
2018:
 
   
2019
   
2018
 
Common stock fair value  
$2.95
-
$5.00
   
$3.50
-
$8.10
 
Risk-free interest rate
 
 1.55%
-
2.25%
   
 2.30%
-
2.94%
 
Expected dividend yield
 
 
0
 
   
 
0
 
 
Expected Option life (in years)
 
 5.00
-
5.50
   
 1.25
-
5.75
 
Expected stock price volatility
 
 
72%
 
   
 
72%
 
 
 
Nonemployee
s
tock-
b
ased
c
ompensation
 
We account for stock options granted to nonemployees in accordance with Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
). In connection with stock options granted to nonemployees, we recorded
$288,000
and
$263,000
for nonemployee stock-based compensation during the years ended
December 
31,
2019
and
2018,
respectively.
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes
12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
10
.
Income Taxes
 
We have incurred net operating losses since inception. We have
not
reflected the benefit of net operating loss carryforwards in the accompanying financial statements and have established a full valuation allowance against our deferred tax assets.
 
At
December 31, 2019
and
2018,
the Company had an income tax receivable of
$361,000
and
$332,000,
respectively, comprised of refundable tax incentives related to research and development activities of our subsidiary Sun BioPharma Australia Pty Ltd.
 
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes as well as operating losses and tax credit carryforwards.
 
The significant components of our deferred tax assets and liabilities are as follows (in thousands):
 
   
December 31,
 
Deferred tax assets (liabilities)
 
2019
   
2018
 
                 
Net operating loss carryforwards
  $
6,307
    $
4,807
 
Research credit carryforwards
   
235
     
235
 
Stock-based compensation
   
1,230
     
971
 
Other
   
72
     
71
 
Deferred tax assets
   
7,844
     
6,084
 
Valuation allowance
   
(7,844
)    
(5,801
)
Deferred tax assets, net of valuation allowance
   
-
     
283
 
Beneficial conversion feature, net
   
-
     
(283
)
Deferrred tax liabilities
   
-
     
(283
)
                 
Net deferred tax asset
  $
-
    $
-
 
 
Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carry-forward period. Because of our history of operating losses, management believes that the deferred tax assets arising from the above-mentioned future tax benefits are currently
not
likely to be realized and, accordingly, we have provided a full valuation allowance.
 
A reconciliation of the statutory tax rates and the effective tax rates is as follows:
 
   
Year Ended December 31,
 
   
2019
   
2018
 
Statutory rate
   
21.0
%    
21.0
%
Permanent differences
   
(5.9
)    
0.1
 
Change in effective tax rate
   
-
     
0.6
 
Valuation allowance
   
(32.4
)    
(22.6
)
Foreign research incentives
   
5.7
     
5.7
 
Deferred true-up
   
16.3
     
-
 
Other
   
1.0
     
0.9
 
Effective rate
   
5.7
%    
5.7
%
 
Net operating losses and tax credit carryforwards as of
December 
31,
2019,
are as follows:
 
   
Amount
(in thousands)
 
Expiration Years
Net operating losses--federal
   
12,958
 
Expires beginning 2031
2019 net operating loss -- federal
   
3,153
 
Never expires
Tax credits--federal
   
235
 
Beginning 2041
 
Utilization of the net operating loss carryforwards and credits
may
be subject to a substantial annual limitation due to the ownership change limitations provided by the IRC, and similar state provisions. We have
not
performed a detailed analysis to determine whether an ownership change under Section 
382
of the IRC has occurred. The effect of an ownership change would be the imposition of an annual limitation on the use of net operating loss carryforwards attributable to periods before the change.
 
The Company is subject to taxation in the United States and Australia. Tax returns for the year ended
December 31, 2015
and thereafter are subject to examinations by federal and state tax authorities. Tax returns of Sun BioPharma Australia Pty Ltd. for the year ended
December 
31,
2014
and thereafter are subject to examination by the Australian tax authorities.
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Subsequent Events
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes to Financial Statements    
Subsequent Events [Text Block]
9.
Subsequent Event
 
On
May 1, 2020,
the Company the Company executed an unsecured promissory note with a lender as a part of the Payroll Protection Program (“PPP”) in the Coronavirus Aid, Relief, and Economic Security Act. Funds totaling approximately
$102,000
will be used to support Company payroll. The note
may
be forgiven in part and bears an interest rate of
1%
per annum after a
six
-month deferment period.
11
.
Subsequent Event
s
 
On
February 21, 2020
the company entered an agreement with an investment banking firm.  A portion of the retainer fee was paid via the issuance of
75,000
5
-year warrants.  The fair market value of the warrants issued of approximately
$148,000
will be capitalized and charged against future proceeds.
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Significant Accounting Policies (Policies)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Accounting Policies [Abstract]    
Consolidation, Policy [Policy Text Block]
Principles of consolidation
 
The accompanying condensed consolidated financial statements include the assets, liabilities, and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Principles of consolidation
 
The accompanying Consolidated Financial Statements include the assets, liabilities and expenses of Sun BioPharma, Inc. and our wholly owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]
Use of estimates
 
The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
Use of estimates
 
The preparation of Consolidated Financial Statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Research and Development Expense, Policy [Policy Text Block]
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our
second
Phase
1
human clinical trial, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
Research and development costs
 
Research and development costs include expenses incurred in the conduct of our Phase
1
human clinical trials, for
third
-party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP-
101
compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP-
101
product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property.
 
We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO.
 
We expense costs associated with obtaining licenses for patented technologies when it is determined there is
no
alternative future use of the intellectual property subject to the license.
Share-based Payment Arrangement [Policy Text Block]
Stock
-based compensation
 
In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
S
tock
-based compensation
 
In accounting for stock-based incentive awards we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the grant date fair value of those awards. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. We record forfeitures in the periods in which they occur. The compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring.
 
The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do
not
expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term.
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Foreign currency translation adjustments
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the stockholders’ equity (deficit). During the
three
-month periods ended
March 31, 2020
and
2019,
any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential.
Foreign
c
urrency
t
ranslation
 
The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar (“AUD”). Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive gain (loss) in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended
December 31, 2019
and
2018,
any reclassification adjustments from accumulated other comprehensive gain to operations were inconsequential.
Comprehensive Income, Policy [Policy Text Block]
Comprehensive loss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Comprehensive
l
oss
 
Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]
Net loss per share
 
Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have
not
been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
 
The following table sets forth the potential shares of common stock that were
not
included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of:
 
   
March 31,
 
   
2020
   
2019
 
Employee and non-employee stock options
   
1,745,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
636,234
 
Common stock issuable under common stock purchase warrants
   
3,497,099
     
2,509,477
 
 
Net
l
oss per
s
hare
 
We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.
 
The following outstanding potential common shares were
not
included in the diluted net loss per share calculations as their effects were
not
dilutive:
 
   
December 31,
 
   
2019
   
2018
 
Employee and non-employee stock options
   
1,744,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
383,947
 
Common stock issuable under common stock purchase warrants
   
3,422,099
     
2,035,197
 
     
5,166,910
     
3,451,355
 
Basis of Accounting, Policy [Policy Text Block]  
Basis of
p
resentation
 
We have prepared the accompanying Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Our fiscal year ends on
December 31.
Concentration Risk, Credit Risk, Policy [Policy Text Block]  
Concentration of
c
redit
r
isk
 
Financial instruments that potentially subject the company to significant concentrations of credit risk consist primarily of cash. Cash is deposited in demand accounts at commercial banks. At times, such deposits
may
be in excess of insured limits. The Company has
not
experienced any losses on its deposits of cash.
Beneficial Conversion Feature, Policy [Policy Text Block]  
Beneficial conversion feature
 
For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a charge for the beneficial conversion feature (“BCF”) and related debt discount which is presented as a direct deduction from the carrying amount of the related debt. The discount is amortized to interest expense over the life of the debt.
Debt Issuance Costs [Policy Text Block]  
Debt issuance costs
 
Costs associated with the issuance of debt instruments are presented as a direct deduction from the carrying amount of the related debt. These costs are amortized on a straight-line basis, which approximates the effective interest method, over the term of the debt agreements and are included in interest expense.
Income Tax, Policy [Policy Text Block]  
Income taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the Consolidated Financial Statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted rates, for each of the jurisdictions in which the Company operates, expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. Valuation allowances are established when necessary to reduce deferred tax assets to the amount that is more likely than
not
to be realized. The Company has provided a full valuation allowance against the gross deferred tax assets as of
December 31, 2019
and
2018.
The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the Consolidated Statements of Operations and Comprehensive Loss.
Grant Income Policy [Policy Text Block]  
Grant Income
 
Grant income is derived from a
one
-time grant awarded to the Company by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (the “Grant Agreement”). The total grant awarded under the Grant Agreement was
$225,000
and was used to fund studies of SBP-
101
as a potential treatment for pancreatitis. Grant income is recognized as a non-operating income when the related research and development expenses are incurred, terms of the grant have been complied with and as of
December 31, 2018
the Company has been fully reimbursed under the Grant Agreement.
New Accounting Pronouncements, Policy [Policy Text Block]  
Recently
Adopted
Accounting Pronouncement
s
 
In
June 2018,
the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”)
2018
-
07,
“Compensation – Stock Compensation (Topic
718
).” ASU
2018
-
07
simplifies the accounting for nonemployee stock-based payment transactions. This ASU was adopted by the Company effective for the fiscal year beginning
January 1, 2019.
Historically, the ultimate stock-based compensation related to non-employee common stock options would fluctuate based on changes in the underlying option pricing model as the awards vest. Under the new guidance, the total compensation cost of non-employee options is determined at grant date. The Company has evaluated the impact of this new guidance on its financial statements and has determined that it will affect how the Company records stock-based compensation related to common stock options and other equity-based compensation, if any, granted to non-employees in the future.
 
In
February 2016,
the FASB issued ASU
2016
-
02,
“Leases,” which created a new Topic, Accounting Standards Codification (“ASC”) Topic
842
and established the core principle that a lessee should recognize the assets, representing rights-of-use, and liabilities to make lease payments, that arise from leases.  For leases with a term of
12
months or less, a lessee is permitted to make an election under which such assets and liabilities would
not
be recognized, and lease expense would be recognized generally on a straight-line basis over the lease term.  This standard was adopted by the Company for the year beginning
January 1, 2019. 
The Company has evaluated the impact of this revised guidance on its financial statements and determined it had
no
material impact, as the Company has
no
leasing arrangements with terms greater than
one
year.
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Summary of Significant Accounting Policies (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
March 31,
 
   
2020
   
2019
 
Employee and non-employee stock options
   
1,745,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
636,234
 
Common stock issuable under common stock purchase warrants
   
3,497,099
     
2,509,477
 
     
5,242,910
     
4,177,922
 
   
December 31,
 
   
2019
   
2018
 
Employee and non-employee stock options
   
1,744,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
383,947
 
Common stock issuable under common stock purchase warrants
   
3,422,099
     
2,035,197
 
     
5,166,910
     
3,451,355
 
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness (Tables)
3 Months Ended
Mar. 31, 2020
Notes Tables  
Schedule of Short-term Debt [Table Text Block]
   
March 31, 2020
   
December 31, 2019
 
   
Term Debt
   
Term Debt
 
Loan principal Amount
  $
97
    $
126
 
Deferred Financing Costs
   
51
     
51
 
Accumulated Amortization
   
(44
)    
(41
)
Unamortized balance
   
7
     
10
 
Discount on Debt
   
-
     
-
 
Accumulated Amortization
   
-
     
-
 
Unamortized balance
   
-
     
-
 
Loan carrying amounts, net
  $
90
    $
116
 
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Stockholders' Deficit (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]
Stock options outstanding
   
1,745,811
 
Shares available for grant under equity incentive plan
   
18,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,497,099
 
     
5,261,459
 
Stock options outstanding
   
1,744,811
 
Shares available for grant under equity incentive plan
   
19,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,422,099
 
     
5,186,459
 
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   
Three Months Ended March 31,
 
   
2020
   
2019
 
General and Administrative
   
99
     
10
 
Research and Development
   
13
     
-
 
     
112
     
10
 
 
Share-based Payment Arrangement, Option, Activity [Table Text Block]
   
Shares Available for Grant
   
Shares Underlying Options
 
Balance at January 1, 2020
   
19,549
     
1,744,811
 
Granted
   
(1,000
)    
1,000
 
Exercised
   
-
     
-
 
Cancelled
   
-
     
-
 
Forfeitures
   
-
     
-
 
                 
Balance at March 31, 2020
   
18,549
     
1,745,811
 
   
Shares
Available for
Grant
   
Shares Underlying
Options
   
Weighted
Average
Exercise Price
Per Share
   
Aggregate
Intrinsic Value
 
Balance at January 1, 2018
   
1,060,400
     
733,960
    $
9.79
    $
169,495
 
Granted
   
(404,000
)    
404,000
     
7.49
     
 
 
Exercised
   
-
     
(30,000
)    
2.20
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
75,749
     
(75,749
)    
7.34
     
 
 
                                 
Balance at December 31, 2018
   
732,149
     
1,032,211
    $
8.90
    $
56,225
 
Granted
   
(733,400
)    
733,400
     
3.42
     
 
 
Exercised
   
-
     
-
     
-
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
20,800
     
(20,800
)    
15.10
     
 
 
                                 
Balance at December 31, 2019
   
19,549
     
1,744,811
    $
6.53
    $
1,030,547
 
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
          
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average Remaining Contractual Life (Years)
   
Weighted Average Exercise Price
   
Options Excercisable
   
Weighted Average Remaining Contractual Life (Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
2.75
    $
1.029
     
26,360
     
2.75
 
$2.275
-
$2.50
   
38,000
     
3.87
    $
2.464
     
38,000
     
3.87
 
$2.95
-
$3.70
   
774,100
     
8.07
    $
3.040
     
411,525
     
7.11
 
$4.95
-
$8.10
   
539,300
     
7.73
    $
6.739
     
506,500
     
7.67
 
$10.00
-
$10.10
   
54,000
     
7.30
    $
10.007
     
54,000
     
7.30
 
$15.10
 
 
   
314,051
     
6.16
    $
15.100
     
310,551
     
6.21
 
                                             
Totals
 
 
   
1,745,811
     
7.43
    $
6.525
     
1,346,936
     
6.94
 
       
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise Price
   
Options
Excercisable
   
Weighted Average
Remaining
Contractual Life
(Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
3.00
    $
1.029
     
26,360
     
3.00
 
$2.275
-
$2.50
   
38,000
     
4.12
    $
2.464
     
38,000
     
4.12
 
$2.95
-
$3.70
   
774,100
     
8.32
    $
3.040
     
411,525
     
7.36
 
$4.50
-
$8.10
   
538,300
     
7.97
    $
6.742
     
506,500
     
7.92
 
$10.00
-
$10.10
   
54,000
     
7.55
    $
10.007
     
54,000
     
7.55
 
$15.10
 
 
   
314,051
     
6.41
    $
15.100
     
310,551
     
6.46
 
                                             
Totals
 
 
   
1,744,811
     
7.67
    $
6.526
     
1,346,936
     
7.19
 
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Summary of Significant Accounting Policies (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
   
March 31,
 
   
2020
   
2019
 
Employee and non-employee stock options
   
1,745,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
636,234
 
Common stock issuable under common stock purchase warrants
   
3,497,099
     
2,509,477
 
     
5,242,910
     
4,177,922
 
   
December 31,
 
   
2019
   
2018
 
Employee and non-employee stock options
   
1,744,811
     
1,032,211
 
Estimated common shares issuable upon conversion of notes payable and accrued interest
   
-
     
383,947
 
Common stock issuable under common stock purchase warrants
   
3,422,099
     
2,035,197
 
     
5,166,910
     
3,451,355
 
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2019
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   
December 31,
 
   
2019
   
2018
 
Clinical trial and related expenses
  $
147
    $
42
 
Professional services
   
125
     
157
 
Other
   
32
     
17
 
Total accrued liabilities
  $
304
    $
216
 
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness 2 (Tables)
12 Months Ended
Dec. 31, 2019
Notes Tables  
Schedule of Debt Activity [Table Text Block]
   
Convertible Notes Payable
 
   
Principal
   
Accrued Interest
 
Balances at January 1, 2019
  $
1,359
    $
2
 
Aggregate principal value of notes sold
   
816
     
-
 
Accrued Interest on notes
   
-
     
103
 
Aggregate principal value of notes and accrued interest converted into common stock
   
(2,175
)    
(105
)
      -       -  
Balances at December 31, 2019
  $
-
    $
-
 
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity (Deficit) (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]
Stock options outstanding
   
1,745,811
 
Shares available for grant under equity incentive plan
   
18,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,497,099
 
     
5,261,459
 
Stock options outstanding
   
1,744,811
 
Shares available for grant under equity incentive plan
   
19,549
 
Common shares issuable under outstanding common stock purchase warrants
   
3,422,099
 
     
5,186,459
 
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Notes Tables    
Share-based Payment Arrangement, Option, Activity [Table Text Block]
   
Shares Available for Grant
   
Shares Underlying Options
 
Balance at January 1, 2020
   
19,549
     
1,744,811
 
Granted
   
(1,000
)    
1,000
 
Exercised
   
-
     
-
 
Cancelled
   
-
     
-
 
Forfeitures
   
-
     
-
 
                 
Balance at March 31, 2020
   
18,549
     
1,745,811
 
   
Shares
Available for
Grant
   
Shares Underlying
Options
   
Weighted
Average
Exercise Price
Per Share
   
Aggregate
Intrinsic Value
 
Balance at January 1, 2018
   
1,060,400
     
733,960
    $
9.79
    $
169,495
 
Granted
   
(404,000
)    
404,000
     
7.49
     
 
 
Exercised
   
-
     
(30,000
)    
2.20
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
75,749
     
(75,749
)    
7.34
     
 
 
                                 
Balance at December 31, 2018
   
732,149
     
1,032,211
    $
8.90
    $
56,225
 
Granted
   
(733,400
)    
733,400
     
3.42
     
 
 
Exercised
   
-
     
-
     
-
     
 
 
Cancelled
   
-
     
-
     
-
     
 
 
Forfeitures
   
20,800
     
(20,800
)    
15.10
     
 
 
                                 
Balance at December 31, 2019
   
19,549
     
1,744,811
    $
6.53
    $
1,030,547
 
Schedule of Nonvested Share Activity [Table Text Block]  
   
Shares Under
Option
   
Weighted Average
Grant Date Fair Value
 
                 
Unvested at December 31, 2018
   
42,500
    $
4.83
 
Granted
   
733,400
     
2.09
 
Vested
   
(378,025
)    
2.41
 
Forefeitures
   
-
     
-
 
Unvested at December 31, 2019
   
397,875
    $
2.03
 
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
          
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average Remaining Contractual Life (Years)
   
Weighted Average Exercise Price
   
Options Excercisable
   
Weighted Average Remaining Contractual Life (Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
2.75
    $
1.029
     
26,360
     
2.75
 
$2.275
-
$2.50
   
38,000
     
3.87
    $
2.464
     
38,000
     
3.87
 
$2.95
-
$3.70
   
774,100
     
8.07
    $
3.040
     
411,525
     
7.11
 
$4.95
-
$8.10
   
539,300
     
7.73
    $
6.739
     
506,500
     
7.67
 
$10.00
-
$10.10
   
54,000
     
7.30
    $
10.007
     
54,000
     
7.30
 
$15.10
 
 
   
314,051
     
6.16
    $
15.100
     
310,551
     
6.21
 
                                             
Totals
 
 
   
1,745,811
     
7.43
    $
6.525
     
1,346,936
     
6.94
 
       
Outstanding, Vested and Expected to Vest
   
Options Vested and Excercisable
 
Per Share Exercise Price
 
Shares
   
Weighted Average
Remaining
Contractual Life
(Years)
   
Weighted
Average
Exercise Price
   
Options
Excercisable
   
Weighted Average
Remaining
Contractual Life
(Years)
 
                                             
$0.875
-
$1.10
   
26,360
     
3.00
    $
1.029
     
26,360
     
3.00
 
$2.275
-
$2.50
   
38,000
     
4.12
    $
2.464
     
38,000
     
4.12
 
$2.95
-
$3.70
   
774,100
     
8.32
    $
3.040
     
411,525
     
7.36
 
$4.50
-
$8.10
   
538,300
     
7.97
    $
6.742
     
506,500
     
7.92
 
$10.00
-
$10.10
   
54,000
     
7.55
    $
10.007
     
54,000
     
7.55
 
$15.10
 
 
   
314,051
     
6.41
    $
15.100
     
310,551
     
6.46
 
                                             
Totals
 
 
   
1,744,811
     
7.67
    $
6.526
     
1,346,936
     
7.19
 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]  
   
2019
   
2018
 
Common stock fair value  
$2.95
-
$5.00
   
$3.50
-
$8.10
 
Risk-free interest rate
 
 1.55%
-
2.25%
   
 2.30%
-
2.94%
 
Expected dividend yield
 
 
0
 
   
 
0
 
 
Expected Option life (in years)
 
 5.00
-
5.50
   
 1.25
-
5.75
 
Expected stock price volatility
 
 
72%
 
   
 
72%
 
 
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2019
Notes Tables  
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   
December 31,
 
Deferred tax assets (liabilities)
 
2019
   
2018
 
                 
Net operating loss carryforwards
  $
6,307
    $
4,807
 
Research credit carryforwards
   
235
     
235
 
Stock-based compensation
   
1,230
     
971
 
Other
   
72
     
71
 
Deferred tax assets
   
7,844
     
6,084
 
Valuation allowance
   
(7,844
)    
(5,801
)
Deferred tax assets, net of valuation allowance
   
-
     
283
 
Beneficial conversion feature, net
   
-
     
(283
)
Deferrred tax liabilities
   
-
     
(283
)
                 
Net deferred tax asset
  $
-
    $
-
 
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
Year Ended December 31,
 
   
2019
   
2018
 
Statutory rate
   
21.0
%    
21.0
%
Permanent differences
   
(5.9
)    
0.1
 
Change in effective tax rate
   
-
     
0.6
 
Valuation allowance
   
(32.4
)    
(22.6
)
Foreign research incentives
   
5.7
     
5.7
 
Deferred true-up
   
16.3
     
-
 
Other
   
1.0
     
0.9
 
Effective rate
   
5.7
%    
5.7
%
Summary of Operating Loss and Tax Credit Carryforwards [Table Text Block]
   
Amount
(in thousands)
 
Expiration Years
Net operating losses--federal
   
12,958
 
Expires beginning 2031
2019 net operating loss -- federal
   
3,153
 
Never expires
Tax credits--federal
   
235
 
Beginning 2041
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Risks and Uncertainties (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended 108 Months Ended 111 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Mar. 31, 2020
Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total $ (1,798) $ (1,581) $ (6,200) $ (5,905) $ (41,300) $ (42,600)  
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total 797 (32) 22 448      
Net Cash Provided by (Used in) Operating Activities, Total (1,120) (783) (2,739) (2,387)      
Cash and Cash Equivalents, at Carrying Value, Ending Balance 1,296 1,379 2,449 1,405 2,449 1,296 $ 152
Working Capital 700   1,300   1,300 700  
Stockholders' Equity Attributable to Parent, Ending Balance $ 724 $ (588) $ 1,385 $ 268 $ 1,385 $ 724 $ (3,689)
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Anti-dilutive securities (in shares) 5,242,910 4,177,922 5,166,910 3,451,355
Share-based Payment Arrangement [Member]        
Anti-dilutive securities (in shares) 1,745,811 1,032,211 1,744,811 1,032,211
Convertible Debt Securities [Member]        
Anti-dilutive securities (in shares) 636,234 383,947
Warrant [Member]        
Anti-dilutive securities (in shares) 3,497,099 2,509,477 3,422,099 2,035,197
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness (Details Textual) - Term Debt [Member] - USD ($)
3 Months Ended
Apr. 05, 2019
Mar. 31, 2020
Dec. 31, 2019
Debt Instrument, Periodic Payment, Total $ 10,000 $ 10,000  
Short-term Debt, Total   $ 90,000 $ 116,000
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness - Schedule of Debt (Details) - Term Debt [Member] - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Loan principal Amount $ 97,000 $ 126,000
Deferred Financing Costs 51,000 51,000
Accumulated Amortization (44,000) (41,000)
Unamortized balance 7,000 10,000
Loan carrying amounts, net $ 90,000 $ 116,000
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Stockholders' Deficit (Details Textual) - Warrants Issued for Future Services [Member]
Feb. 21, 2020
USD ($)
$ / shares
shares
Class of Warrant or Right, Expiration Term (Year) 5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares 75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares $ 6.49
Warrants and Rights Outstanding | $ $ 228,000
XML 62 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stock options outstanding (in shares) 1,745,811 1,744,811    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 18,549 19,549 732,149 1,060,400
Class of Warrant or Right, Outstanding (in shares) 3,497,099 3,422,099    
Common Stock, Capital Shares Reserved for Future Issuance 5,261,459 5,186,459    
XML 63 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 5,261,459 5,186,459    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 1,745,811 1,744,811 1,032,211 733,960
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 18,549 19,549 732,149 1,060,400
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 229,000      
Share-based Payment Arrangement, Option [Member]        
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount   $ 372,000    
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years 10 years    
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 1,500,000 1,480,451    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 1,481,451      
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]        
Common Stock, Capital Shares Reserved for Future Issuance (in shares)   1,500,000    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 18,549      
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years 10 years    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 264,360 264,360    
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 0 years 0 years    
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 2 years 2 years    
XML 64 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Share-based compensation expense $ 112 $ 10
General and Administrative Expense [Member]    
Share-based compensation expense 99 10
Research and Development Expense [Member]    
Share-based compensation expense $ 13
XML 65 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation - Summary of Option Activity (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Balance, shares available for grant (in shares) 19,549 732,149 1,060,400
Balance, shares underlying options (in shares) 1,744,811 1,032,211 733,960
Granted, shares available for grant (in shares) (1,000) (733,400) (404,000)
Granted, shares underlying options (in shares) 1,000 733,400 404,000
Balance, shares available for grant (in shares) 18,549 19,549 732,149
Balance, shares underlying options (in shares) 1,745,811 1,744,811 1,032,211
XML 66 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stock-based Compensation - Options Outstanding (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Options outstanding (in shares) 1,745,811 1,744,811
Options outstanding, weighted average remaining contractual life (Year) 7 years 156 days 7 years 244 days
Options outstanding, weighted average exercise price (in dollars per share) $ 6.525 $ 6.526
Options excercisable (in shares) 1,346,936 1,346,936
Options excercisable, weighted average remaining contractual life (Year) 6 years 343 days 7 years 69 days
Exercise Price Range 1 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 0.875 $ 0.875
Per share exercise price, upper limit (in dollars per share) $ 1.10 $ 1.10
Options outstanding (in shares) 26,360 26,360
Options outstanding, weighted average remaining contractual life (Year) 2 years 273 days 3 years
Options outstanding, weighted average exercise price (in dollars per share) $ 1.029 $ 1.029
Options excercisable (in shares) 26,360 26,360
Options excercisable, weighted average remaining contractual life (Year) 2 years 273 days 3 years
Exercise Price Range 2 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 2.275 $ 2.275
Per share exercise price, upper limit (in dollars per share) $ 2.50 $ 2.50
Options outstanding (in shares) 38,000 38,000
Options outstanding, weighted average remaining contractual life (Year) 3 years 317 days 4 years 43 days
Options outstanding, weighted average exercise price (in dollars per share) $ 2.464 $ 2.464
Options excercisable (in shares) 38,000 38,000
Options excercisable, weighted average remaining contractual life (Year) 3 years 317 days 4 years 43 days
Exercise Price Range 3 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 2.95 $ 2.95
Per share exercise price, upper limit (in dollars per share) $ 3.70 $ 3.70
Options outstanding (in shares) 774,100 774,100
Options outstanding, weighted average remaining contractual life (Year) 8 years 25 days 8 years 116 days
Options outstanding, weighted average exercise price (in dollars per share) $ 3.04 $ 3.04
Options excercisable (in shares) 411,525 411,525
Options excercisable, weighted average remaining contractual life (Year) 7 years 40 days 7 years 131 days
Exercise Price Range 4 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 4.95 $ 4.50
Per share exercise price, upper limit (in dollars per share) $ 8.10 $ 8.10
Options outstanding (in shares) 539,300 538,300
Options outstanding, weighted average remaining contractual life (Year) 7 years 266 days 7 years 354 days
Options outstanding, weighted average exercise price (in dollars per share) $ 6.739 $ 6.742
Options excercisable (in shares) 506,500 506,500
Options excercisable, weighted average remaining contractual life (Year) 7 years 244 days 7 years 335 days
Exercise Price Range 5 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 10 $ 10
Per share exercise price, upper limit (in dollars per share) $ 10.10 $ 10.10
Options outstanding (in shares) 54,000 54,000
Options outstanding, weighted average remaining contractual life (Year) 7 years 109 days 7 years 200 days
Options outstanding, weighted average exercise price (in dollars per share) $ 10.007 $ 10.007
Options excercisable (in shares) 54,000 54,000
Options excercisable, weighted average remaining contractual life (Year) 7 years 109 days 7 years 200 days
Exercise Price Range 6 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 15.10 $ 15.10
Options outstanding (in shares) 314,051 314,051
Options outstanding, weighted average remaining contractual life (Year) 6 years 58 days 6 years 149 days
Options outstanding, weighted average exercise price (in dollars per share) $ 15.10 $ 15.10
Options excercisable (in shares) 310,551 310,551
Options excercisable, weighted average remaining contractual life (Year) 6 years 76 days 6 years 167 days
XML 67 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Subsequent Events (Details Textual)
May 01, 2020
USD ($)
Subsequent Event [Member]  
Proceeds from Paycheck Protection Program Under CARES Act $ 102,000
XML 68 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Note 2 - Risks and Uncertainties (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended 108 Months Ended 111 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Mar. 31, 2020
Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total $ (1,798) $ (1,581) $ (6,200) $ (5,905) $ (41,300) $ (42,600)  
Net Cash Provided by (Used in) Operating Activities, Total (1,120) (783) (2,739) (2,387)      
Cash and Cash Equivalents, at Carrying Value, Ending Balance 1,296 1,379 2,449 1,405 2,449 1,296 $ 152
Working Capital 700   1,300   1,300 700  
Stockholders' Equity Attributable to Parent, Ending Balance $ 724 $ (588) $ 1,385 $ 268 $ 1,385 $ 724 $ (3,689)
XML 69 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Note 3 - Liquidity and Business Plan (Details Textual) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2019
Jan. 31, 2019
Mar. 31, 2020
Oct. 31, 2019
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Proceeds from Issuance of Private Placement           $ 3,160,000 $ 2,328,000
Proceeds from Convertible Debt       $ 810,000 $ 810,000 $ 1,329,000
Conversion from Debt Notes to Common Stock [Member]              
Debt Conversion, Accrued Interest, Amount $ 105,000            
Debt Conversion, Converted Instrument, Shares Issued (in shares) 651,758            
Debt Instrument, Convertible, Conversion Price (in dollars per share) $ 3.50            
Unsecured Convertible Promissory Notes [Member]              
Proceeds from Convertible Debt   $ 2,200,000          
Warrants in Connection with the Private Placement [Member]              
Class of Warrant or Right, Expiration Term (Year)       5 years      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)       $ 4      
Warrants In Connection with 2018 Convertible Notes Payable [Member]              
Class of Warrant or Right, Expiration Term (Year)   5 years          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)   $ 4.50          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)   1,243,498          
Warrants in Connection with Securities Purchase Agreement [Member]              
Class of Warrant or Right, Expiration Term (Year) 5 years            
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 4.50     $ 4     $ 5
Private Placement [Member]              
Stock Issued During Period, Shares, New Issues (in shares)       909,209     468,200
Proceeds from Issuance of Private Placement       $ 3,200,000     $ 2,300,000
XML 70 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Summary of Significant Accounting Policies (Details Textual)
Dec. 31, 2018
USD ($)
Grant Agreement, Total Grants $ 225,000
XML 71 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Anti-dilutive securities (in shares) 5,242,910 4,177,922 5,166,910 3,451,355
Share-based Payment Arrangement [Member]        
Anti-dilutive securities (in shares) 1,745,811 1,032,211 1,744,811 1,032,211
Convertible Debt Securities [Member]        
Anti-dilutive securities (in shares) 636,234 383,947
Warrant [Member]        
Anti-dilutive securities (in shares) 3,497,099 2,509,477 3,422,099 2,035,197
XML 72 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Note 5 - Accrued Expenses - Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Clinical trial and related expenses   $ 147 $ 42
Professional services   125 157
Other   32 17
Accrued liabilities $ 308 $ 304 $ 216
XML 73 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness 2 (Details Textual) - USD ($)
2 Months Ended 3 Months Ended 12 Months Ended
Dec. 16, 2019
Jun. 30, 2019
Apr. 05, 2019
May 16, 2018
May 01, 2018
Mar. 17, 2017
Jan. 31, 2019
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Oct. 26, 2012
Proceeds from Convertible Debt               $ 810,000 $ 810,000 $ 1,329,000  
Intrinsic Value of Convertible Debt with Conversion Feature               353,000 353,000 716,000  
Debt Instrument, Convertible, Gross Proceeds from Sale of Equity Trigger       $ 2,000,000                
Repayments of Long-term Debt, Total               26,000 $ 27,000 161,000 $ 14,000  
Institute [Member]                        
Debt Instrument, Interest Rate, Stated Percentage                       4.125%
Debt Instrument, Face Amount                       $ 300,000
Conversion from Debt to Common Stock [Member]                        
Debt Instrument, Convertible, Conversion Price (in dollars per share)   $ 3.50                    
Debt Conversion, Original Debt, Amount   $ 2,200,000   3,100,000                
Debt Conversion, Accrued Interest, Amount   $ 105,000   $ 183,000                
Debt Conversion, Converted Instrument, Shares Issued (in shares)   651,758   104,463                
Debt Conversion, Converted Instrument, Units Issued (in shares)       646,279                
Debt Instrument, Unamortized Discount, Total       $ 121,000                
Warrants In Connection with 2018 Convertible Notes Payable [Member]                        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)             2          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)             1,243,498          
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)             $ 4.50          
Class of Warrant or Right, Expiration Term (Year)             5 years          
Warrants Upon Issuance, Fair Value             $ 2,500,000          
Warrants in Connection with Debt Conversion [Member]                        
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)       1                
Warrants In Connection with Term Debt [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)     5,555                  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)     $ 4.50                  
Class of Warrant or Right, Expiration Term (Year)     5 years                  
Warrants Issued in Connection with Second Amended Unsecured Loan Agreement [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,000                      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 4                      
Warrants Issued for Both Amendments to the Unsecured Loan Agreement [Member]                        
Warrants and Rights Outstanding $ 14,000                      
Convertible Debt [Member]                        
Proceeds from Convertible Debt                   816,000    
Debt Conversion, Original Debt, Amount                   2,175,000    
The 2018 Notes [Member]                        
Proceeds from Convertible Debt             2,200,000          
Convertible Debt, Mandatory Conversion Threshold, Gross Proceeds from Sale of Equity Securities             6,000,000          
Class of Warrant or Right, Principal Amount of Every Amount Of Notes Purchased             3.50          
Intrinsic Value of Convertible Debt with Conversion Feature             $ 900,000          
The 2018 Notes [Member] | Convertible Debt [Member]                        
Debt Instrument, Interest Rate, Stated Percentage             10.00%          
Debt Instrument, Convertible, Conversion Price (in dollars per share)             $ 3.50          
The 2017 Notes [Member]                        
Proceeds from Convertible Debt, Gross           $ 3,100,000            
Unamortized Debt Discount Charged to Interest Expense       $ 1,000,000                
The 2017 Notes [Member] | Convertible Debt [Member]                        
Debt Instrument, Interest Rate, Stated Percentage           5.00%            
Debt Instrument, Convertible, Conversion Price (in dollars per share)           $ 10.10            
Debt Instrument, Qualified Financing, Minimum Proceeds           $ 2,000,000            
Debt Instrument, Convertible, Beneficial Conversion Feature           $ 3,000,000            
Amended Unsecured Loan Agreement [Member] | Institute [Member]                        
Debt Instrument, Periodic Payment, Total         $ 10,000              
Second Amended Unsecured Loan Agreement [Member] | Institute [Member]                        
Repayments of Long-term Debt, Total $ 50,000                      
Term Debt [Member]                        
Debt Instrument, Face Amount               97,000   126,000    
Debt Instrument, Periodic Payment, Total     $ 10,000         $ 10,000        
Long-term Debt, Total                   $ 116,000    
XML 74 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Note 6 - Indebtedness - Changes in Debt (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7 $ 810 $ 810 $ 1,329
Convertible Debt [Member]        
Balances at January 1, 2019 1,359 1,359  
Accrued interest at January 1, 2019 $ 2 2  
Proceeds from the sale of convertible promissory notes, net of debt issuance costs of $7     816  
Accrued Interest     103  
Aggregate principal value of notes converted into common stock     (2,175)  
Accrued interest converted into common stock and warrants     (105)  
Balances at December 31, 2019     1,359
Accrued interest at December 31, 2019     $ 2
XML 75 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Note 7 - Commitments and Contingencies (Details Textual) - Licensing Agreement with University of Florida Research Foundation [Member] - USD ($)
12 Months Ended
Dec. 22, 2011
Dec. 31, 2019
Royalty Term (Year) 10 years  
Annual License Maintenance Fee $ 10,000  
License Maintenance Fee [Member]    
Royalty Expense   $ 10,000
Minimum [Member]    
Royalty Fee Percentage of Net Sales 2.50%  
Maximum [Member]    
Royalty Fee Percentage of Net Sales 5.00%  
XML 76 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Equity (Deficit) (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Oct. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Mar. 31, 2020
Jun. 30, 2019
Proceeds from Issuance of Private Placement   $ 3,160,000 $ 2,328,000    
Class of Warrant or Right, Outstanding (in shares)   3,422,099   3,497,099  
Warrants in Connection with Securities Purchase Agreement [Member]          
Class of Warrant or Right, Expiration Term (Year) 5 years   3 years    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 4   $ 5   $ 4.50
Class of Warrant or Right, Outstanding (in shares)   468,200      
Directors and Officers [Member]          
Proceeds from Issuance of Private Placement $ 240,000   $ 125,000    
Private Placement [Member]          
Stock Issued During Period, Shares, New Issues (in shares) 909,209   468,200    
Proceeds from Issuance of Private Placement $ 3,200,000   $ 2,300,000    
XML 77 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Stock options outstanding (in shares) 1,745,811 1,744,811    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) 18,549 19,549 732,149 1,060,400
Class of Warrant or Right, Outstanding (in shares) 3,497,099 3,422,099    
Common Stock, Capital Shares Reserved for Future Issuance 5,261,459 5,186,459    
XML 78 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 5,261,459   5,186,459    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 1,745,811   1,744,811 1,032,211 733,960
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $ 229,000        
Share-based Payment Arrangement, Expense $ 112,000 $ 10,000      
Share-based Payment Arrangement, Option [Member]          
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount     $ 372,000    
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)     2 years 146 days    
Non-Employee Stock Option [Member]          
Share-based Payment Arrangement, Expense     $ 288,000 $ 263,000  
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years   10 years    
Common Stock, Capital Shares Reserved for Future Issuance (in shares) 1,500,000   1,480,451    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 1,481,451        
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]          
Common Stock, Capital Shares Reserved for Future Issuance (in shares)     1,500,000    
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) 10 years   10 years    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) 264,360   264,360    
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 0 years   0 years    
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) 2 years   2 years    
XML 79 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Balance, shares available for grant (in shares) 19,549 732,149 1,060,400  
Balance, shares underlying options (in shares) 1,744,811 1,032,211 733,960  
Balance, weighted average exercise price per share (in dollars per share)   $ 6.53 $ 8.90 $ 9.79
Aggregate intrinsic value   $ 1,030,547 $ 56,225 $ 169,495
Granted, shares available for grant (in shares) (1,000) (733,400) (404,000)  
Granted, shares underlying options (in shares) 1,000 733,400 404,000  
Granted, weighted average exercise price per share (in dollars per share)   $ 3.42 $ 7.49  
Forfeitures , shares available for grant (in shares)   20,800 75,749  
Forfeited, shares underlying options (in shares)   (20,800) (75,749)  
Forfeited, weighted average exercise price per share (in dollars per share)   $ 15.10 $ 7.34  
Balance, shares available for grant (in shares) 18,549 19,549 732,149  
Balance, shares underlying options (in shares) 1,745,811 1,744,811 1,032,211  
XML 80 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Unvested, shares under option (in shares) 397,875 42,500  
Unvested, weighted average grant-date fair value (in dollars per share) $ 2.03 $ 4.83  
Granted, shares under option (in shares) 1,000 733,400 404,000
Granted, weighted average grant-date fair value (in dollars per share)   $ 2.09  
Vested, shares under option (in shares)   (378,025)  
Vested, weighted average grant-date fair value (in dollars per share)   $ 2.41  
Forfeitures, shares under option (in shares)    
Forfeitures, weighted average grant-date fair value (in dollars per share)    
Unvested, shares under option (in shares)   397,875 42,500
Unvested, weighted average grant-date fair value (in dollars per share)   $ 2.03 $ 4.83
XML 81 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation - Options Outstanding (Details) - $ / shares
3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2019
Options outstanding (in shares) 1,745,811 1,744,811
Options outstanding, weighted average remaining contractual life (Year) 7 years 156 days 7 years 244 days
Options outstanding, weighted average exercise price (in dollars per share) $ 6.525 $ 6.526
Options excercisable (in shares) 1,346,936 1,346,936
Options excercisable, weighted average remaining contractual life (Year) 6 years 343 days 7 years 69 days
Exercise Price Range 1 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 0.875 $ 0.875
Per share exercise price, upper limit (in dollars per share) $ 1.10 $ 1.10
Options outstanding (in shares) 26,360 26,360
Options outstanding, weighted average remaining contractual life (Year) 2 years 273 days 3 years
Options outstanding, weighted average exercise price (in dollars per share) $ 1.029 $ 1.029
Options excercisable (in shares) 26,360 26,360
Options excercisable, weighted average remaining contractual life (Year) 2 years 273 days 3 years
Exercise Price Range 2 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 2.275 $ 2.275
Per share exercise price, upper limit (in dollars per share) $ 2.50 $ 2.50
Options outstanding (in shares) 38,000 38,000
Options outstanding, weighted average remaining contractual life (Year) 3 years 317 days 4 years 43 days
Options outstanding, weighted average exercise price (in dollars per share) $ 2.464 $ 2.464
Options excercisable (in shares) 38,000 38,000
Options excercisable, weighted average remaining contractual life (Year) 3 years 317 days 4 years 43 days
Exercise Price Range 3 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 2.95 $ 2.95
Per share exercise price, upper limit (in dollars per share) $ 3.70 $ 3.70
Options outstanding (in shares) 774,100 774,100
Options outstanding, weighted average remaining contractual life (Year) 8 years 25 days 8 years 116 days
Options outstanding, weighted average exercise price (in dollars per share) $ 3.04 $ 3.04
Options excercisable (in shares) 411,525 411,525
Options excercisable, weighted average remaining contractual life (Year) 7 years 40 days 7 years 131 days
Exercise Price Range 4 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 4.95 $ 4.50
Per share exercise price, upper limit (in dollars per share) $ 8.10 $ 8.10
Options outstanding (in shares) 539,300 538,300
Options outstanding, weighted average remaining contractual life (Year) 7 years 266 days 7 years 354 days
Options outstanding, weighted average exercise price (in dollars per share) $ 6.739 $ 6.742
Options excercisable (in shares) 506,500 506,500
Options excercisable, weighted average remaining contractual life (Year) 7 years 244 days 7 years 335 days
Exercise Price Range 5 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 10 $ 10
Per share exercise price, upper limit (in dollars per share) $ 10.10 $ 10.10
Options outstanding (in shares) 54,000 54,000
Options outstanding, weighted average remaining contractual life (Year) 7 years 109 days 7 years 200 days
Options outstanding, weighted average exercise price (in dollars per share) $ 10.007 $ 10.007
Options excercisable (in shares) 54,000 54,000
Options excercisable, weighted average remaining contractual life (Year) 7 years 109 days 7 years 200 days
Exercise Price Range 6 [Member]    
Per share exercise price, lower limit (in dollars per share) $ 15.10 $ 15.10
Options outstanding (in shares) 314,051 314,051
Options outstanding, weighted average remaining contractual life (Year) 6 years 58 days 6 years 149 days
Options outstanding, weighted average exercise price (in dollars per share) $ 15.10 $ 15.10
Options excercisable (in shares) 310,551 310,551
Options excercisable, weighted average remaining contractual life (Year) 6 years 76 days 6 years 167 days
XML 82 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) - $ / shares
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Expected dividend yield 0.00% 0.00%
Expected stock price volatility 72.00% 72.00%
Minimum [Member]    
Common stock fair value (in dollars per share) $ 2.95 $ 3.50
Risk-free interest rate 1.55% 2.30%
Expected option life (Year) 5 years 1 year 91 days
Maximum [Member]    
Common stock fair value (in dollars per share) $ 5 $ 8.10
Risk-free interest rate 2.25% 2.94%
Expected option life (Year) 5 years 182 days 5 years 273 days
XML 83 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes (Details Textual) - USD ($)
12 Months Ended
Dec. 31, 2019
Mar. 31, 2020
Dec. 31, 2018
Income Taxes Receivable, Current $ 361,000 $ 406,000 $ 332,000
Foreign Tax Authority [Member] | Australian Taxation Office [Member]      
Open Tax Year 2014 2015 2016 2017 2018 2019    
XML 84 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Net operating loss carryforwards $ 6,307 $ 4,807
Research credit carryforwards 235 235
Stock-based compensation 1,230 971
Other 72 71
Deferred tax assets 7,844 6,084
Valuation allowance (7,844) (5,801)
Deferred tax assets, net of valuation allowance 283
Beneficial conversion feature, net (283)
Deferrred tax liabilities (283)
Net deferred tax asset $ 0 $ 0
XML 85 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes - Income Tax Reconciliation (Details)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Statutory rate 21.00% 21.00%
Permanent differences (5.90%) 0.10%
Change in effective tax rate 0.60%
Valuation allowance (32.40%) (22.60%)
Foreign research incentives 5.70% 5.70%
Deferred true-up 16.30%
Other 1.00% 0.90%
Effective rate 5.70% 5.70%
XML 86 R73.htm IDEA: XBRL DOCUMENT v3.20.2
Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) - Domestic Tax Authority [Member]
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Net operating losses--federal $ 12,958
Tax credits--federal $ 235
Earliest Tax Year [Member]  
Net operating losses--federal 2031
Tax credits--federal 2041
Tax Year 2018 [Member]  
Net operating losses--federal $ 3,153
XML 87 R74.htm IDEA: XBRL DOCUMENT v3.20.2
Note 11 - Subsequent Events (Details Textual) - Subsequent Event [Member] - Warrants Issued as Partial Payment of Retainer Fee in Connection with Investment Banking Firm Agreement [Member]
Feb. 21, 2020
USD ($)
shares
Class of Warrant or Right, Issued During Period (in shares) | shares 75,000
Class of Warrant or Right, Expiration Term (Year) 5 years
Warrants and Rights Outstanding | $ $ 148,000
EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 167 322 1 false 50 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.sunbiopharma.com/20200331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.sunbiopharma.com/20200331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.sunbiopharma.com/20200331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.sunbiopharma.com/20200331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.sunbiopharma.com/20200331/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.sunbiopharma.com/20200331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Statement - Consolidated Balance Sheets Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 7 false false R8.htm 007 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 8 false false R9.htm 008 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-statements-of-operations-and-comprehensive-loss Consolidated Statements of Operations and Comprehensive Loss Statements 9 false false R10.htm 009 - Statement - Consolidated Statements of Stockholders' Equity (Deficit) Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-statements-of-stockholders-equity-deficit Consolidated Statements of Stockholders' Equity (Deficit) Statements 10 false false R11.htm 010 - Statement - Consolidated Statements of Cash Flows Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 11 false false R12.htm 011 - Statement - Consolidated Statements of Cash Flows (Parentheticals) Sheet http://www.sunbiopharma.com/20200331/role/statement-consolidated-statements-of-cash-flows-parentheticals Consolidated Statements of Cash Flows (Parentheticals) Statements 12 false false R13.htm 012 - Disclosure - Note 1 - Business Sheet http://www.sunbiopharma.com/20200331/role/statement-note-1-business Note 1 - Business Notes 13 false false R14.htm 013 - Disclosure - Note 2 - Risks and Uncertainties Sheet http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties Note 2 - Risks and Uncertainties Notes 14 false false R15.htm 014 - Disclosure - Note 3 - Basis of Presentation Sheet http://www.sunbiopharma.com/20200331/role/statement-note-3-basis-of-presentation Note 3 - Basis of Presentation Notes 15 false false R16.htm 015 - Disclosure - Note 4 - Liquidity and Business Plan Sheet http://www.sunbiopharma.com/20200331/role/statement-note-4-liquidity-and-business-plan Note 4 - Liquidity and Business Plan Notes 16 false false R17.htm 016 - Disclosure - Note 5 - Summary of Significant Accounting Policies Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-summary-of-significant-accounting-policies Note 5 - Summary of Significant Accounting Policies Notes 17 false false R18.htm 017 - Disclosure - Note 6 - Indebtedness Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness Note 6 - Indebtedness Notes 18 false false R19.htm 018 - Disclosure - Note 7 - Stockholders' Deficit Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit Note 7 - Stockholders' Deficit Notes 19 false false R20.htm 019 - Disclosure - Note 8 - Stock-based Compensation Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation Note 8 - Stock-based Compensation Notes 20 false false R21.htm 020 - Disclosure - Note 9 - Subsequent Events Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-subsequent-events Note 9 - Subsequent Events Notes 21 false false R22.htm 021 - Disclosure - Note 1 - Business Sheet http://www.sunbiopharma.com/20200331/role/statement-note-1-business83E463DE-CF7C-4591-B7FA-CE20017CA7FC Note 1 - Business Notes 22 false false R23.htm 022 - Disclosure - Note 2 - Risks and Uncertainties Sheet http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties77912DA6-94BC-420B-B6FC-D9BD9CD061E3 Note 2 - Risks and Uncertainties Notes 23 false false R24.htm 023 - Disclosure - Note 3 - Liquidity and Business Plan Sheet http://www.sunbiopharma.com/20200331/role/statement-note-3-liquidity-and-business-plan Note 3 - Liquidity and Business Plan Notes 24 false false R25.htm 024 - Disclosure - Note 4 - Summary of Significant Accounting Policies Sheet http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies Note 4 - Summary of Significant Accounting Policies Notes 25 false false R26.htm 025 - Disclosure - Note 5 - Accrued Expenses Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-accrued-expenses- Note 5 - Accrued Expenses Notes 26 false false R27.htm 026 - Disclosure - Note 6 - Indebtedness 2 Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-2 Note 6 - Indebtedness 2 Notes 27 false false R28.htm 027 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 28 false false R29.htm 028 - Disclosure - Note 8 - Stockholders' Equity (Deficit) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-equity-deficit Note 8 - Stockholders' Equity (Deficit) Notes 29 false false R30.htm 029 - Disclosure - Note 9 - Stock-based Compensation Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation Note 9 - Stock-based Compensation Notes 30 false false R31.htm 030 - Disclosure - Note 10 - Income Taxes Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes Note 10 - Income Taxes Notes 31 false false R32.htm 031 - Disclosure - Note 11 - Subsequent Events Sheet http://www.sunbiopharma.com/20200331/role/statement-note-11-subsequent-events Note 11 - Subsequent Events Notes 32 false false R33.htm 032 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.sunbiopharma.com/20200331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.sunbiopharma.com/20200331/role/statement-note-5-summary-of-significant-accounting-policies 33 false false R34.htm 033 - Disclosure - Note 5 - Summary of Significant Accounting Policies (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-summary-of-significant-accounting-policies-tables Note 5 - Summary of Significant Accounting Policies (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-5-summary-of-significant-accounting-policies 34 false false R35.htm 034 - Disclosure - Note 6 - Indebtedness (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-tables Note 6 - Indebtedness (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness 35 false false R36.htm 035 - Disclosure - Note 7 - Stockholders' Deficit (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit-tables Note 7 - Stockholders' Deficit (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit 36 false false R37.htm 036 - Disclosure - Note 8 - Stock-based Compensation (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-tables Note 8 - Stock-based Compensation (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation 37 false false R38.htm 037 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies-tables Note 4 - Summary of Significant Accounting Policies (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies 38 false false R39.htm 038 - Disclosure - Note 5 - Accrued Expenses (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-accrued-expenses-tables Note 5 - Accrued Expenses (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-5-accrued-expenses- 39 false false R40.htm 039 - Disclosure - Note 6 - Indebtedness 2 (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-2-tables Note 6 - Indebtedness 2 (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness 40 false false R41.htm 040 - Disclosure - Note 8 - Stockholders' Equity (Deficit) (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-equity-deficit-tables Note 8 - Stockholders' Equity (Deficit) (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-equity-deficit 41 false false R42.htm 041 - Disclosure - Note 9 - Stock-based Compensation (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-tables Note 9 - Stock-based Compensation (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation 42 false false R43.htm 042 - Disclosure - Note 10 - Income Taxes (Tables) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-tables Note 10 - Income Taxes (Tables) Tables http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes 43 false false R44.htm 043 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties-details-textual Note 2 - Risks and Uncertainties (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties 44 false false R45.htm 044 - Disclosure - Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-summary-of-significant-accounting-policies-antidilutive-securities-details Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 45 false false R46.htm 045 - Disclosure - Note 6 - Indebtedness (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-details-textual Note 6 - Indebtedness (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-tables 46 false false R47.htm 046 - Disclosure - Note 6 - Indebtedness - Schedule of Debt (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-schedule-of-debt-details Note 6 - Indebtedness - Schedule of Debt (Details) Details 47 false false R48.htm 047 - Disclosure - Note 7 - Stockholders' Deficit (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit-details-textual Note 7 - Stockholders' Deficit (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit-tables 48 false false R49.htm 048 - Disclosure - Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-stockholders-deficit-common-stock-reserved-for-future-issuance-details Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Details 49 false false R50.htm 049 - Disclosure - Note 8 - Stock-based Compensation (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-details-textual Note 8 - Stock-based Compensation (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-tables 50 false false R51.htm 050 - Disclosure - Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-stockbased-compensation-expense-details Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) Details 51 false false R52.htm 051 - Disclosure - Note 8 - Stock-based Compensation - Summary of Option Activity (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-summary-of-option-activity-details Note 8 - Stock-based Compensation - Summary of Option Activity (Details) Details 52 false false R53.htm 052 - Disclosure - Note 8 - Stock-based Compensation - Options Outstanding (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockbased-compensation-options-outstanding-details Note 8 - Stock-based Compensation - Options Outstanding (Details) Details 53 false false R54.htm 053 - Disclosure - Note 9 - Subsequent Events (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-subsequent-events-details-textual Note 9 - Subsequent Events (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-9-subsequent-events 54 false false R55.htm 054 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties-details-textualF5416276-F18D-40BC-A029-9804AB495C5D Note 2 - Risks and Uncertainties (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-2-risks-and-uncertainties 55 false false R56.htm 055 - Disclosure - Note 3 - Liquidity and Business Plan (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-3-liquidity-and-business-plan-details-textual Note 3 - Liquidity and Business Plan (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-3-liquidity-and-business-plan 56 false false R57.htm 056 - Disclosure - Note 4 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies-details-textual Note 4 - Summary of Significant Accounting Policies (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies-tables 57 false false R58.htm 057 - Disclosure - Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-4-summary-of-significant-accounting-policies-antidilutive-securities-details Note 4 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) Details 58 false false R59.htm 058 - Disclosure - Note 5 - Accrued Expenses - Accrued Expenses (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-5-accrued-expenses-accrued-expenses-details Note 5 - Accrued Expenses - Accrued Expenses (Details) Details 59 false false R60.htm 059 - Disclosure - Note 6 - Indebtedness 2 (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-2-details-textual Note 6 - Indebtedness 2 (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-tables 60 false false R61.htm 060 - Disclosure - Note 6 - Indebtedness - Changes in Debt (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-6-indebtedness-changes-in-debt-details Note 6 - Indebtedness - Changes in Debt (Details) Details 61 false false R62.htm 061 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-7-commitments-and-contingencies-details-textual Note 7 - Commitments and Contingencies (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-7-commitments-and-contingencies 62 false false R63.htm 062 - Disclosure - Note 8 - Stockholders' Equity (Deficit) (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-equity-deficit-details-textual Note 8 - Stockholders' Equity (Deficit) (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-equity-deficit-tables 63 false false R64.htm 063 - Disclosure - Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-8-stockholders-deficit-common-stock-reserved-for-future-issuance-details Note 8 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) Details 64 false false R65.htm 064 - Disclosure - Note 9 - Stock-based Compensation (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-details-textual Note 9 - Stock-based Compensation (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-tables 65 false false R66.htm 065 - Disclosure - Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-summary-of-option-activity-details Note 9 - Stock-based Compensation - Summary of Option Activity (Details) Details 66 false false R67.htm 066 - Disclosure - Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-nonvested-share-activity-details Note 9 - Stock-based Compensation - Nonvested Share Activity (Details) Details 67 false false R68.htm 067 - Disclosure - Note 9 - Stock-based Compensation - Options Outstanding (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-options-outstanding-details Note 9 - Stock-based Compensation - Options Outstanding (Details) Details 68 false false R69.htm 068 - Disclosure - Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-9-stockbased-compensation-assumptions-used-in-calculating-fair-value-of-options-details Note 9 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details) Details 69 false false R70.htm 069 - Disclosure - Note 10 - Income Taxes (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-details-textual Note 10 - Income Taxes (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-tables 70 false false R71.htm 070 - Disclosure - Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-deferred-tax-assets-and-liabilities-details Note 10 - Income Taxes - Deferred Tax Assets and Liabilities (Details) Details 71 false false R72.htm 071 - Disclosure - Note 10 - Income Taxes - Income Tax Reconciliation (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-income-tax-reconciliation-details Note 10 - Income Taxes - Income Tax Reconciliation (Details) Details 72 false false R73.htm 072 - Disclosure - Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-10-income-taxes-net-operating-losses-and-tax-credit-carryforwards-details Note 10 - Income Taxes - Net Operating Losses and Tax Credit Carryforwards (Details) Details 73 false false R74.htm 073 - Disclosure - Note 11 - Subsequent Events (Details Textual) Sheet http://www.sunbiopharma.com/20200331/role/statement-note-11-subsequent-events-details-textual Note 11 - Subsequent Events (Details Textual) Details http://www.sunbiopharma.com/20200331/role/statement-note-11-subsequent-events 74 false false All Reports Book All Reports snbp-20200331.xml snbp-20200331.xsd snbp-20200331_cal.xml snbp-20200331_def.xml snbp-20200331_lab.xml snbp-20200331_pre.xml http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 93 0001437749-20-014538-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-20-014538-xbrl.zip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end